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The presenilins are the catalytic component of the gamma-secretase protease 
complex, involved in the regulated intramembrane proteolysis of numerous type-1 
transmembrane proteins, including Amyloid precursor protein (APP) and Notch. In 
addition to their role in the γ-secretase complex the presenilins are involved in a 
number of γ-secretase independent functions such as calcium homeostasis, apoptosis, 
inflammation and protein trafficking. Presenilin function is known to be regulated 
through posttranslational modifications like endoproteolysis, phosphorylation and 
ubiquitination. Using a bioinformatics and protein sequence analysis approach this 
lab has identified a putative ubiquitin binding CUE domain in the presenilins.  
The aim of this project was to characterise the function of the presenilin CUE 
domains. Firstly, the presenilins are shown to contain a functional ubiquitin-binding 
CUE domain that preferentially binds to K63-linked polyubiquitin chains. The PS1 
CUE domain is shown to be dispensable for PS1 endoproteolysis and γ-secretase 
mediated cleavage of APP, Notch and IL-1R1. This suggests the PS1 CUE domain is 
involved in a γ-secretase independent PS1 function.  
Our hypothesis is that the PS1 CUE domain is involved in regulating PS1’s 
intermolecular protein-protein interactions or intramolecular PS1:PS1 interactions. 
Here the PS1 CUE domain is shown to be dispensable for the interaction of PS1 and 
the K63-linked polyubiquitinated PS1 interacting proteins P75
NTR
, IL-1R1, TRAF6, 
TRAF2 and RIP1. To further investigate PS1 CUE domain function a mass 
spectrometry proteomics based approach is used to identify PS1 CUE domain 
interacting proteins. This proteomics approach demonstrated that the PS1 CUE 
domain is not required for PS1 dimerization. Instead a number of proteins that 
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interact with the PS1 CUE domain are identified as well as proteins whose 
interaction with PS1 is downregulated by the presence of the PS1 CUE domain. 
Bioinformatic analysis of these proteins suggests possible roles for the PS1 CUE 
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Chapter 1 Introduction 
Part of this section has been previously published by Cellular Signalling [Duggan 
S.P. and McCarthy J.V. (2016)] “Beyond γ-secretase activity: The multifunctional 
nature of presenilins in cell signalling pathways.” Cell. Signal. 016 Jan;28(1):1-11. 
doi: 10.1016/j.cellsig.2015.10.006.  
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1.1 Regulated Intramembrane Proteolysis 
Presenilin 1 (PS1) and presenilin 2 (PS2) were discovered as part of genetic studies 
related to familial Alzheimer’s disease (FAD) and to date over 200 mutations in PS1 
and 10 mutations in PS2 have been associated with the disease [Zou et al 2014]. 
Alzheimer’s disease (AD) is characterised pathogenically by the formation of 
neurofibullar tangles arising from hyperphosphorylated Tau protein and by amyloid 
plaque deposits formed from aggregations of amyloid β (Aβ) peptides [Zou et al 
2014]. Aβ peptides are formed from the proteolytic cleavage of the transmembrane 
spanning amyloid precursor protein (APP) holoprotein. APP is sequentially cleaved: 
first by either α-secretase or β-secretase (BACE) and then by γ-secretase. PS1 and 
PS2 form part of the γ-secretase multi-protein complexes, consisting of the 
presenilins, anterior pharynx-defective 1 (Aph-1), presenilin enhancer 2 (Pen-2) and 
Nicastrin (Nct) [Spasic and Annaert 2008]. To date more than 100 γ-secretase 
substrates have been identified including APP and a large number of cell surface 
receptors including Notch [Haapasalo et al 2011; McCarthy et al 2009].  
The sequential proteolysis of APP culminating in intramembrane cleavage by γ-
secretase now serves as a model for the regulated intramembrane proteolysis of 
numerous transmembrane proteins (Figure 1.1) [Brown et al 2000; Medina and 
Dotti 2003]. Cleavage of APP by α-secretase or β-secretase results in the release of 
respective soluble ectodomains (sAPPα or sAPPβ), generation of the APP 
intracellular domain (AICD) and P3 or Aβ peptides that represent the remaining 
transmembrane domain of APP [Mills and Reiner 1999]. The sAPPα and sAPPβ 
fragments have been shown to promote neurite growth in cortical neurons in rats and 
mice and to regulate cell-signalling pathways [Hasebe et al 2013; Ohsawa et al 
1997; Hartl et al 2013]. The AICD fragment has been shown to interact with c-ABL 
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and Fe65 to regulate gene transcription [Vazquez et al 2009], in particular in 
regulating the transcription of neprilysin [Grimm et al 2015]. In addition the AICD 
is involved in cellular functions such as regulating Wnt signalling and apoptosis 
[Zhou et al 2012; Wang et al 2014].  
In general, substrates that undergo regulated intramembrane proteolysis are initially 
cleaved in the extracellular domain by sheddases such as TACE (TNFα converting 
enzyme) or ADAM (a disintegrin and metalloproteinase domain)/α-secretase, or by 
aspartyl proteases, such as BACE/β-secretase, before cleavage by the I-CLiP family 
of proteases [Mills and Reiner 1999; Langosch et al 2015]. Furthermore, it has been 
reported that prerequisite ectodomain shedding may not be required for subsequent 
cleavage by γ-secretase for some substrates [Laurent et al 2015]. 
 For several substrates γ-secretase cleavage plays an essential role in a signalling 
paradigm whereby generation of intracellular domains (ICDs) allows for the spatial 
segregation of divergent signalling pathways or as is the case for Notch, allows for 
the translocation of ICDs to the nucleus where they enable transcriptional activation 
activity [Jurisch-Yaksi et al 2013; Medina and Dotti 2003]. Indeed, Psen1 knockout 
animals display a predominant Notch loss of function phenotype resulting from loss 
of γ-secretase cleavage of Notch, highlighting the importance of γ-secretase in Notch 
signalling [De Strooper et al 1999; Geling et al 2002; Micchelli et al 2003]. Notch 
cleavage by γ-secretase has been shown to regulate diverse cellular functions 
including epithelial differentiation in the airway [Gomi et al 2015] and in memory 
formation in rats [Conboy et al 2007]. Similarly the γ-secretase mediated cleavage of 
ErbB4 has been to result in the creation of an ICD that translocates to the nucleus 
[Vidal et al 2005] and which regulates alveolar cell differentiation and lung 





 has been shown to negatively regulate cell invasiveness in glioblastoma cell 
lines [Berghoff et al 2015]. Cleavage can also be used as a signal for degradation of 
transmembrane protein fragments and the maintenance of so-called ‘membrane 
proteostasis’ [Lichtenthaler et al 2011].  
PS1 and PS2 are integral transmembrane proteins which both contain 9 
transmembrane (TMDs) and a large intracellular loop between TMDs 6 and 7 [Oh 
and Turner 2005] (Figure 1.2). PS1 has been shown to be both located and active 
within the endoplasmic reticulum (ER) and early stage of the Golgi of the cell 
[Annaert et al 1999] suggesting that this represents the location of the γ-secretase 
complexes. PS1 and PS2 undergo endoproteolysis in the loop domain before 
reaching maturity forming the N-terminal fragment (NTF) and C-terminal fragment 
(CTF) heterodimers and this process occurs in acidic cellular compartments after 
passing through the ER [Kim et al 2007]. The presenilin proteins are aspartyl 
proteases and act as the enzyme component of γ-secretase. Their active site is present 
in the sixth and seventh transmembrane at residues Asp257 and Asp385 in PS1 
[Wolfe et al 1999] and Asp263 and Asp366 in PS2 [Kimberly et al 2000]. Cysteine 
residues within TMD 1 and TMD 8 [Kornilova et al  2006] and a C-terminal PAL 
domain in TMD 9 of presenilin [Wang et al 2006] also contribute towards the 








Figure 1.1 Schematic of the Regulated Intramembrane Proteolysis of APP. This schematic shows 
the alternative cleavage of APP by either the α-secretase (left) or β-secretase (right) pathways. Firstly 
in the respective pathways the APP ectodomain is cleaved to release either sAPPα or sAPPβ into the 
lumen, leaving the APP C83 or APP C99 membrane bound C-terminal fragments. These membrane 
bound fragments are then cleaved by the γ-secretase complex to release the AICD into the cytoplasm 
and the P3 or Aβ fragments into the lumen by either the α-secretase or β-secretase pathways, 





1.2 Presenilins, Post-Translational Modification and Cell Signalling 
The presenilins undergo a number of post-translational modification including 
endoproteolysis, caspase cleavage [Walter et al 1999], phosphorylation 
[Kirschenbaum et al 2001; Fluhrer et al  2004; Kuo et al 2008; Lau et al 2002] and 
ubiquitination [Yan et al 2013; Gudey et al 2014; Li et al 2002] (Figure 1.2). PS1 
can be phosphorylated at a number of different serine or threonine residues by 
proteins such as protein kinase A (PKA) [Fluhrer et al 2004], protein kinase C 
(PKC) [Walter et al 1999],  glycogen synthase kinase 3β (GSK3β) [Kirschenbaum et 
al 2001], c-Jun N-terminal kinases (JNK) [Kuo et al 2008] and cyclin dependent 
kinase 5 (CDK5) [Lau et al 2002]. PS1 can be phosphorylated in the intracellular 
loop by both PKA (at Ser310) and by PKC (at Ser346) [Fluhrer et al 2004]. The 
phosphorylation of the presenilins by these kinases can result in alterations in γ-
secretase activity [Kuo et al 2008], β-catenin signalling [Uemura et al 2007] and 
presenilin stability [Lau et al 2002]. The PKC phosphorylation site is located near 
the caspase cleavage site in PS1 and pseudo-phosphorylation at this site inhibits 
caspase-3 related cleavage of PS1 in vitro and during induced apoptosis in HEK293T 
cells. Similarly, pseudo-phosphorylation near the caspase cleavage site, at residues 
Ser327 and Ser330, prevents caspase cleavage in PS2 [Walter et al 1999]. Tumour 
necrosis factor α (TNF-α) upregulates γ-secretase activity in a JNK dependent 
manner; JNK phosphorylates PS1 at residues Ser319 and Thr320 and mutations at 
these residues removes the ability of TNF-α to upregulate γ-secretase activity [Kuo 
et al 2008]. JNK phosphorylation at these residues also increases the stability of the 
PS1 CTF relative to that of the NTF. Similarly, CDK5 phosphorylation at Thr354 








Figure 1.2 Posttranslational Modifications of the Presenilin CUE and Intracellular Loop 
Domains. Schematic showing the CUE domains of the presenilins are highlighted in red and the 
remainder of the presenilin intracellular loop domains are highlighted in green. The area deleted in the 
PS1ΔE9 mutation is marked by ΔE9.  Previously described posttranslational modifications of the 
intracellular loop domains of human presenilins, PS1 and PS2 are also shown. PS1 contains three 
GSK3β phosphorylation sites [underlined] whereas PS2 contains none. PS1 and PS2 are subject to 
serine/threonine phosphorylation by PKA [●], PKC [○], CDK5 [■], GSK3β [□], JNK [◊] AND CK1/2 
[*] and mapped to specific individual residues. PS1 is also ubiquitinated by Fbw7/Sel-10 and TRAF6 
but the site(s) have not been mapped to individual residues. The TRAF6-binding domain (boxed in 
grey) and the endoproteolysis and caspase cleavage sites are also indicated [arrows]. Schematic 
showing known familial Alzheimer’s disease mutations within the CUE domains of the presenilins. 






PS1 is ubiquitinated by the E3 ligases SEL-10 [Li et al 2002] and tumour necrosis 
factor receptor associated factor 6 (TRAF6) [Yan et al 2013; Gudey et al 2014]. The 
ubiquitination of PS1 by SEL-10 reduces the level of PS1 by targeting PS1 for 
degradation through the ubiquitin-proteasome system [Li et al 2002]. However while 
the overexpression of SEL-10 in HEK293T cells caused a reduction in levels of PS1 
it also leads to an increase in the levels of Aβ detected. SEL-10 has also been shown 
to down regulate the signalling activity of the PS1 substrate Notch [Li et al 2002]. 
PS1 and Fbw7, the mammalian homolog of Sel10, have been shown to interact to 
regulate the stability and activity of the epidermal growth factor receptor (EGFR) 
and the Notch ICD (NICD) [Rocher-Ros et al 2010]. The authors suggest that PS1 
and Fbw7 interact with one another in a negative feedback loop to control the levels 
of EFGR and Notch respectively, which may play a role in skin carcinogenesis. 
Ubiquilin is a protein which contains both an ubiquitin like domain (UBL) and an 
ubiquitin associated (UBA) domain. The ubiquilin UBA domain has been shown 
bind to both PS1 and PS2 in GST pull down assays [Mah et al 2000]. 
Overexpression of ubiquilin has been shown to reduce the formation of the NTF and 
CTF of the presenilin proteins by stabilising the level of the full length presenilin 
proteins in the cell [Massey et al 2005]. Ubiquilin transcript variants (TV) 1 and 3 
have been shown to cause the accumulation of higher molecular weight forms of PS1 
(HMW-PS1) [Viswanathan et al 2011]. Ubiquilin is hypothesised to act as a shuttle 
between ubiquitinated proteins and the proteasome and it has been suggested that the 
accumulation of HMW-PS1 is a result of weak interactions between Ubiquilin-1 
TV3 and the proteasome [Viswanathan et al 2011].  
The presenilin proteins contain TRAF6-binding sequence which allows for the 
interaction between the E3 ligase TRAF6 and the presenilin proteins [Elzinga et al 
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2009; Powell et al 2009] and by doing so TRAF6 induces polyubiquitination of PS1 
[Yan et al 2013; Gudey et al 2014]. TRAF6 has been shown to extend the half-life of 
full length PS1 without having an effect on γ-secretase activity [Yan et al 2013]. The 
interaction between TRAF6 and PS1 promotes the cleavage of the γ-secretase 
substrates TGFβ Type 1 Receptor (TβR1) [Gudey et al 2014] and P75
NTR
 [Powell et 
al 2009] and the loss of the E3 ligase activity of TRAF6 abolishes the TRAF6 
mediated cleavage of P75
NTR
. These data suggest that the interaction between 
TRAF6, PS1 and γ-secretase substrates plays a role in modulating γ-secretase 
activity. However, as can be in the case of P75
NTR
, TRAF6 can ubiquitinate both PS1 
and some γ-secretase substrates, therefore the exact role played by TRAF6 mediated 
ubiquitination of PS1 remains to be fully elucidated [Gudey et al 2014]. All of this 
suggests that the interactions between presenilin, ubiquitin, E3 ligases such as 
TRAF6 and ubiquitin binding proteins such as ubiquilin play a role in regulating 
both the γ-secretase-dependent and –independent functions of presenilin. 
1.3 Ubiquitin, the Ubiquitin Proteasome System and Ubiquitin Binding 
Domains 
Ubiquitin is a 76 amino acid protein that is covalently bonded to target proteins at 
lysine residues as a post-translational modification [Komander and Rape 2012]. The 
transfer of ubiquitin to target proteins is controlled by a series of proteins known as 
the ubiquitin activating E1, the ubiquitin conjugating (Ubc) E2 and the ubiquitin 
ligase E3. Ubiquitin is first bound to the E1 protein before it is transferred to the E2 
protein; the E3 ligase then connects the E2 and the target protein thus binding 
ubiquitin to its target (Figure 1.3) [Welchman et al 2005]. There are estimated to be 
two E1, roughly forty E2 and over six hundred E3 proteins present in eukaryotes 
[Grabbe et al 2011]; the variety within these proteins is what allows ubiquitin to be 
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targeted to such a large range of proteins and for the diversity of uibiquitin linkages. 
There are a number of deubiquitylating enzymes (DUBs) found in eukaryotes, which 
play a role in down regulating ubiquitin signalling [Grabbe et al 2011]. Ubiquitin 
contains seven different lysine residues (K6, K11, K27, K29, K33, K48 and K63) 
[Chen and Sun 2009] all of which can be used to form polyubiquitin chains; these 
ubiquitin chains can be made up of mixed lysine linkages or form forked ubiquitin 
chains. The lysine residues of ubiquitin can covalently bond to the C-terminal 
glycine residue of another ubiquitin molecule to form polyubiquitin chains of 
varying lengths. Linear ubiquitin chains can also be formed between the N-terminal 
methionine and the C-terminal glycine residues [Grabbe et al 2011]. 
The ubiquitin proteasome system (UPS) is the cellular system in which ubiquitin 
proteins are bonded to proteins thus targeting them for degradation in the 
proteasome. The targeting of proteins to the UPS is determined by the binding of 
K48-linked polyubiquitin chains to UPS substrates [Pickart 2000]. Further research 
has provided insight into the formation and structure of polyubiquitin chains through 
the other lysine residues of ubiquitin [Komander and Rape 2012]. Unlike K48-linked 
ubiquitination the effects of K63-linked ubiquitination are more varied in outcome. 
Mutations at the K63 residue of ubiquitin in S. cerevisiae have been shown to have 
no negative affect on the degradative pathways in the yeast [Spence et al 1995]. 
However, S. cerevisiae strains containing this mutation were less resistant to 






Figure 1.3 Schematic of the E1/E2/E3 ubiquitination system. Firstly the ubiquitin activating E1 
enzyme binds to an ubiquitin molecule (Ub). Next the E1-Ub complex interacts with an E2 ubiquitin 
activating enzyme to transfers the Ub molecule to the E2 protein. Finally the E3 ubiquitin ligase 
interacts with both the E2-Ub complex and the substrate to transfer the Ub molecule to the substrate. 
The substrate can undergo both mono- and poly-ubiquitination with the closed confirmation of K48-
linked polyubiquitination and the open confirmation of K63-linked polyubiquitination shown here. 





play some role in DNA repair. K63-linked ubiquitination can also decrease the level 
of targeted protein via a non-proteasomal route. Activation of the interleukin-1 (IL-
1) receptor, type 1 (IL-1R1) leads to K63-linked polyubiquitination of IRAK1 
leading to a decrease in IRAK1 levels. However, this decrease in IRAK1 levels is 
not affected by proteasome inhibition but occurs via another cellular process 
[Windheim et al 2008]. K63-linked polyubiquitin of IκB Kinase has been shown to 
up-regulate the NFκB pathway [Deng et al 2000] and thus have an effect on 
regulating gene transcription. Additionally, TNF receptor associated factor 5 
(TRAF5) mediated K63-linked ubiquitination of retinoid-related orphan nuclear 
receptor γt has recently been shown to promote gene transcription [Wang et al 2015]. 
The linear ubiquitin chain assembly complex (LUBAC) has been shown to positively 
regulate NF-ĸB signalling through NEMO [Tokunaga et al 2009]. The LUBAC 
complex causes the formation of linear ubiquitin chains, where the primary 
methionine residue is bound to the terminal glycine residue, on to its substrates. A20 
has been shown to inhibit the interactions between NEMO and LUBAC to 
negatively regulate NF-ĸB signalling [Verhelst et al 2012]. This demonstrates how 
cellular signalling pathways can be affected through the ligation of differing 
polyubiquitin chains. These differences in the ubiquitination state of proteins can be 
detected through the presence of distinct ubiquitin binding domains within 
interacting proteins [Komander and Rape 2012].  
1.4 Ubiquitin Binding Domains 
Ubiquitin binding domains (UBDs) are the means through which a protein’s 
ubiquitination state can be recognised to regulate downstream cell signalling events 
[Chen and Sun 2009]. A number of UBDs have been found, including the ubiquitin 
interacting motif (UIM), the ubiquitin associated (UBA) and the coupling of 
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ubiquitin conjugation to endoplasmic reticulum degradation (CUE) domains 
amongst others (Table 1.1) [reviewed in Chen and Sun 2009]. The importance of 
UBDs in regulating cell signalling can be seen in the NFĸB pathway, where several 
proteins are known to contain UBDs required for signal propagation [Chen 2005]. 
The UBA and CUE domains are similar in size, roughly 40 residues, and show a 
structural homology. Both the UBA and CUE domains share a three helical 
secondary structure and both can interact with a hydrophobic patch on the surface of 
ubiquitin around the Ile44 residue [Hurley et al 2006]. Some UBA domains have 
shown an ability to bind both the K48- and K63-linked polyubiquitin chains [Matta-
Camacho et al 2009] while others, such as K63-linked polyubiquitin binding UBA 
domain of the sequestosome1/P62 protein [Seibenhener et al 2004], have shown a 
preference for binding to particular polyubiquitin chains. The UBA domain of P62 
has been shown to regulate the turnover of proteins via the ubiquitin-proteasome 
system. Mutations within the UBA domain of sequestosome1/P62 are associated 
with Paget’s disease [Seibenhener et al 2004] indicating that the ubiquitin binding 
properties of sequestosome1/P62 play an important physiological role. The CUE 
domain was discovered as part of a bioinformatics search for sequence homology 
with the yeast protein Cue1p, which recruits other proteins to the ER membrane 
[Ponting 2000]. This research showed a number of conserved residues, an invariant 
proline residue in particular, but also includes a number of semi-conserved 
sequences such as the phenylalanine-proline and di-leucine sequences that were 
shared amongst the examined proteins [Ponting 2000]. Studies of the CUE domain 
containing yeast protein Vps9 showed that the FP and LL motifs of the Vps9 CUE 
domain form part of the ubiquitin binding surface [Shih et al 2003]. In this study 
mutations at residues at F420 and P421 of the Vps9 CUE domain caused the loss or 
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reduction of the ubiquitin binding properties of the protein demonstrating the 
importance of this motif for the ubiquitin binding function of the Vps9 CUE domain. 
A structural study of the Vps9 CUE domain showed that the FP motif and the second 
leucine (L447) of the di-leucine motif directly interacted with the surface of 
ubiquitin molecules, while the first leucine (L446) residue of the Vps9 di-leucine 
motif played a role in stabilising the structure of the domain [Prag et al 2003]. 
Table 1.1 List of known ubiquitin binding domains. 
(Adapted from Dikic et al 2009) 
Ub-binding 
domain 
Protein Function Reference 
α-helical type    
CUE Vps9, 
Cue1p 
Trafficking, ERAD Shideler et al 2015; Bagola et 
al 2013 
GAT GGA3 Trafficking Bilodeau et al 2004 





Seibenhener et al 2004; 
Rothenburg et al 2010 




DNA replication Kannouche et al 2005 
UIM Eps15 Trafficking Gucwa et al 2014 
VHS STAM1 Lysosomal degradation  Lim et al 2011 
Zinc Finger   
A20 ZnF A20 cell signalling  Bellail et al 2012 
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DNA replication Kannouche et al 2005 
ZnF UBP isopeptidase
-T 
deubiquitinase activity Sokratous et al 2012 
Ubiquitin-conjugating like domain 
UEV Vps23  Trafficking Blanchin-Roland 2011 
Ubc UbcH5 Ubiquitin conjugation Yuhuang et al 2014 
Plekstrin Homology domain  
PRU Rpn13 Proteasomal degradation Aguileta et al 2015 
GLUE EAP45 Trafficking Alam et al 2006 
Other    
Jab1/MPN Prp8p Spliceosome Bellare et al 2006 
PFU Doa1 Trafficking Mullally et al 2006 
SH3 Sla1, CIN85 cell signalling Stamenova et al 2007 
 
UBDs have been shown to regulate protein function by competitive or non-
competitive binding with other interacting partners. The interaction between 
ubiquitin and different CUE domains can be involved in regulating the ubiquitination 
of other proteins or in regulating self-ubiquitination (Table 1.2). For example the 
CUE domain of the E3 ligase GP78 has been shown to be involved in regulating the 
length of polyubiquitin chains that GP78 builds up on its substrates [Liu et al 2014]. 
The GP78 CUE domain non-competitively binds to the incipient K48-linked 
polyubiquitin chain as it is synthesized onto the substrate thus stabilizing the chain 
and allowing further extension. Similarly, functional CUE domains have been shown 
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to be required for regulating a protein’s ubiquitination state. Mono-ubiquitination of 
Vps9 is eliminated by deletion of the proteins CUE domain [Shih et al 2003], 
suggesting that the Vps9 CUE domain interacts with components of the cell’s 
ubiquitination system. On the other hand in Tollip ubiquitin not only binds to the 
proteins CUE domain but also interacts with the protein’s lipid binding C2 domain 
[Mitra et al 2013], showing that there is competitive binding of ubiquitin or 
phosphoinositide to Tollip. This competition between the two protein domains 
regulates the association of Tollip with the membrane. These studies demonstrate 
that the ubiquitin binding function of the CUE domain is involved in self-
ubiquitination and the ubiquitination of other proteins. Additionally, these 
interactions can influence the cellular localization of the protein. Vps9 shows a 
preference for binding K48 linked polyubiquitin and both Vps9 and its human 
homolog Rabex-5 are involved in trafficking to the lysosome [Donaldson et al 
2003]. The CUE domain of CUEDC2 has been shown to be essential for the 
deactivation of the progesterone receptor via the ubiquitin-proteasome pathway 
[Zhang et al 2007]. As shown here CUE domains, and other ubiquitin binding 
domains, can confer a variety of functions upon a protein and be involved in diverse 




Table 1.2 List of known CUE domain containing proteins. 
Protein CUE domain function Reference 
Tollip Autophagy Lu et al 2014 
Vps9 Endocytosis Davies et al 2003 
Fun30 chromatin remodelling Bi et al 2015 
gp78 Ubiquitination Liu et al 2014 
Cue5 Autophagy Lu et al 2014 
AUP1 Lipid droplet formation Lohmann et al 2013 
Cue1p ERAD Bagola et al 2013 
FANCD2 Protein stability Rego et al 2012 
CUEDC2 Cell-cycle regulation Gao et al 2011 
TAB2 Cell signalling Kishida et al 2005 
 
1.5 Presenilin/γ-secretase Structure 
As membrane bound proteins the structures of the presenilin proteins and the γ-
secretase complex has been difficult to determine. However, in recent years these 
protein structures have begun to become clearer through a combination of 
mutagenesis studies, electron microscopy, NMR and x-ray crystallography [Lu et al 
2014; Takagi Niidome et al 2015; Sobhanifar et al 2010; Li et al 2012]. Analysis of 
the presenilins primary sequence showed that presence of the PAL motif in the C-
terminus of the proteins, which was shown to be required for complex formation and 
γ-secretase activity (Figure 1.4) [Tomita et al 2001; Wang et al 2005]. Using a 
method of cysteine substitution, allied with crosslinking the PAL domain of PS1 has 
been shown to be located near the active site of the protein [Tolia et al 2008]. NMR 
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analysis of the PS1 CTF has shown that of the 3 TMDs (relating to TMDs 7-9), only 
TMD 8 fully crosses the membrane. TMD 7 does not fully transverse the bilayer 
while TMD 9 is kinked such that it does not cross the bilayer but instead some of the 
helix lies perpendicular to the other TMDs [Sobhanifar et al 2010]. This study also 
showed that TMDs 7 and 9, which both play a role in the protease’s active site, are 
water accessible. Other studies, using the substituted cysteine accessibility method 
(SCAM), have shown that hydrophilic loop 1 and the C-terminal of PS1 also play an 
important role in substrate binding in the gamma secretase complex [Takagi 
Niidome et al 2015]. While all of these studies have illuminated some of the finer 
details of presenilin structure until recently the overall structure of the presenilins has 
remained elusive.  
There have been some significant advances in the use of x-ray crystallography to 
determine the structure of the presenilins in recent years. An archeal homolog of the 
presenilins called presenilin/SPP homolog (PSH) from Methanoculleus marisnigri 
was shown to have proteolytic activity [Li et al 2012]. PSH was subjected to a 
systemic program of mutagenesis that would promote protein crystallisation while 
retaining protease function. In the predicted PSH structural model the TMDs 1-6 
form an outer ring which surrounds TMDs 7-9, with two potential sites of substrate 
entry being possible between either TMDs 6 and 9 or between TMDs 6 and 2. The 
overall three-dimensional shape of PSH was found to be unlike the structure of any 
known protein so the authors have named the structure the ‘presenilin fold’ [Li et al 
2012]. Once the crystal structure of this presenilin homolog had been determined an 
in silico model of human PS1 was constructed. Using these models 12 different FAD 
mutations, that were present at conserved residues found in both PSH and human 
PS1, were analysed for their effect on protease activity. Two of the investigated FAD 
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mutations had no effect on protease activity and were found to be located away from 
the active site. Two of the other investigated residues were in direct contact with the 
proteolytic Asp162 residue of PSH and where mutation of this residue completely 
eliminated protease activity. Another group, which decreased proteolytic activity, 
were present near the proteolytic Asp residues of TMDs 6 and 7 [Li et al 2012]. This 
study provided great insight into both presenilin protein structure and γ-secretase 
activity, particularly in terms of the effects of presenilin FAD mutants, and could aid 
in the development of designed γ-secretase inhibitors and modulators. 
While the structure of the γ-secretase complex has yet to be determined by 
determined by x-ray crystallography, electron microscopy has been used with 
increasingly effective results in elucidating the three-dimensional structure of the 
complex. Firstly, intact γ-secretase complexes were purified from Chinese hamster 
ovary (CHO) cells and analysed by cryo-electron-microscopy (cryo-EM) with a 
resolution of about 15 A° [Lazarov et al 2006]. The γ-secretase complex was found 
to ~120 A° in length with a pore of 20-40 A° in size that was thought to represent the 
substrate cleavage site. Using tagged Nct expressing in CHO cells, the γ-secretase 
complex was purified and analysed by STEM to achieve a resolution of 12 A° 
[Osenkowki et al 2009]. Their analysis showed that the γ-secretase complex had a 
molecular weight of ~230 kDa with a proposed stoichiometry of 1:1:1:1 for each 
subunit. The extracellular portion of the complex showed a greater degree of 
heterogeneity than the relatively smooth cytosolic portion. Additionally they showed 
that there was an opening on the cytosolic side that extended about half way into the 
structure and two large holes that could represent pores.  Using a similar method, γ-







Figure 1.4 Schematic of the Structure of the Presenilin Proteins. The presenilins are membrane 
bound proteins that contain 9 transmembrane (TM) domains. The presenilins contain a large 
intracellular loop between TM domains 6 and 7 which contains the sites of presenilinase and caspase 
cleavage. The presenilins are aspartyl proteases where the protease active sites are found at the YD 






cryo-EM to obtain a resolution of 4.5 A° [Lu et al 2014]. In their model the whole γ-
secretase complex has a horseshoe shape and a horizontal wedge shape with one end 
thicker than the other. Nct extended 40 A° above the membrane; Pen-2 binds to 
TMD 4 of PS1 while Nct and Aph-1 interacted with PS1 CTF. TMDs 6 and 7, which 
contain the catalytic Asp residues, and TMD 9 of PS1 all face towards the central 
hollow of the complex representing their importance towards the proteolytic activity 
of the complex. An in silico model of PS1 was made by conflating the date retrieved 
from the previously described NMR structure of PS1 CTF and the x-ray 
crystallography model of PSH [Kong et al 2015]. In this model the substrate gate for 
presenilin/gamma secretase is formed by the gap between TMDs 2 and 6 of 
presenilin. The computer model also showed that TMD 9 and its PAL motif is highly 
mobile and flexible, backing up its suggested role in regulating substrate recognition 
and cleavage.  
The presenilin proteins have been suggested to act as passive calcium leak channels 
in the ER [Lu et al 2006]. Using the SCAM method residues within the TMDs 6, 7 
and 9 were found to be required for PS1 calcium pore function with TMDs 7 and 9 
seen to be most important [Nelson et al 2011]. In this study the residues within TMD 
9 were found throughout the entire domain, while in TMD 7 they were found to be 
present around the catalytically essential Asp385 residue. Analysis of the PSH 
protein showed the existence of a ‘hole’ that extends through the membrane that is 
separate to the substrate cleavage site [Li et al 2012]. This hole is big enough to 
allow the passage of small ions through the protein, though the authors suggest that it 
is probably filled with lipid molecules in vivo. A recent paper showed that the PSH 




 ions but not Ca
2+ 
ions 
[Kuo et al 2015]. This ion channel activity of PSH was removed when the 
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intracellular loop between TMDs 6 and 7, suggesting that this ion channel function 
of PSH is a function of the full length protein. These structural studies have added 
some weight to the controversial presenilin Ca
2+
 ER leak channel theory. The 
structure of PSH was only determined after the intracellular loop between TMDs 6 
and 7 had been removed [Li et al 2012]. The structure of the presenilins has mostly 
been studied in terms of the γ-secretase complex, where most of the work has been 
focused on the topology of the intramembrane domains and the structure of the 
catalytic active site. As such, the structure of the intracellular loop domain of the 
presenilins, which is a site of many protein-protein interactions and post-translational 
modifications [McCarthy et al 2009], remains to be resolved. 
 
1.6 Presenilins and Cell Signalling 
In addition to their role in the regulated intramembrane proteolysis as part of the γ-
secretase complex the presenilins are also known to be involved in a number of γ-
secretase independent functions (Table 1.3). The presenilins are involved in 
signalling pathways such as β–catenin [Zhang et al 1998], insulin signalling 
[Maesako et al 2011] and Akt signalling [Zhang et al 2008] in a γ-secretase 
independent manner. FAD mutants of PS1 have been shown to increase apoptosis by 
reducing Akt signalling [Weihl et al 1999]. Presenilin double knockout (PSDKO) 
cells have a much reduced level of Akt signalling which is rescued by γ-secretase 
redundant PS1 mutants suggesting that the presenilins have a γ-secretase 
independent role in regulating Akt signalling [Zhang et al 2008]. This reduction in 
Akt signalling always includes reductions in Erk signalling and is mediated by cell 
surface receptors such as Platelet-derived growth factor (PDGF) and the cadherins 
[Kang et al 2005]. Inhibition of the Akt downstream target GSK3β by insulin 
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treatment increases presenilin cell surface localisation and treatment with Akt 
inhibitors help reduce presenilin interactions with N-Cadherin and β-catenin 
suggesting that the presenilins play a role in Akt signalling [Maesako et al 2010]. 
Table 1.3 List of γ-secretase independent functions of the presenilin proteins 
γ-secretase Independent Presenilin Functions 
Regulation of beta-catenin/Wnt signalling 
Regulation of calcium homeostasis 




 The catenins are signalling protein that links transmembrane adhesion proteins, such 
as the γ-secretase substrate E-cadherin [Marambaud et al 2002], with intracellular 
signalling pathways and is involved in regulating transcription in a number of anti-
apoptotic/survival pathways [Rosenbluh et al 2014]. The presenilins have been 
shown to be involved in β-catenin signalling in two ways (Figure 1.5A). Firstly, 
cadherin proteins have been shown to be γ-secretase substrates causing the catenins 
to dissociate from the cell membrane [Marambaud et al 2002; Haas et al 2005] and 
secondly PS1 has been shown to interact with the catenins such as β-catenin 
[Murayama et al 1998], δ-catenin [Zhou et al 1997] and plakoglobin [Raurell et al 
2006]. PS1 FAD mutant has been shown to alter β-catenin signalling thus inducing 
apoptosis in neuronal cells [Zhang et al 2008]. FAD PS1 mutants inhibit Wnt 
signalling by increasing β-catenin phosphorylation [Kawamura et al 1998]. The 
serine residues Ser353 and Ser357, GSK3β phosphorylation sites located within the 
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intracellular loop domain of PS1, have been shown to regulate the interaction 
between PS1 and β-catenin in vivo [Kirschenbaum et al 2001] and to increase β-
catenin stability by reducing its ubiquitination and degradation [Prager et al 2007]. 
However, these mutations have no negative effects on cell survival, Wnt signalling 
or Aβ production in HEK293T cells. Similarly, the GSK3β mediated 
phosphorylation of residues Ser353 and Ser357 has been shown to reduce the 
association of PS1 and N-cadherin and β-catenin and a decrease in this association 
negatively affects Akt signalling [Uemura et al 2007]. PS1 is an unprimed substrate 
of GSK3β [Twomey and McCarthy 2006] and contains three consensus sites for 
GSK3β phosphorylation. Mutations at Ser397, located within another GSK3β 
binding site, increase the stability of the PS1 CTF; [Kirschenbaum et al 2001] this 
effect is also seen in cells treated with the GSK3β inhibitor lithium chloride. This 
increased stability is not repeated in the full-length protein or the NTF suggesting 
that GSK3β plays a role in targeting the CTF for degradation. The turnover of the 
PS1 binding protein δ-catenin is regulated by its GSK3β mediated phosphorylation, 
which induces its ubiquitination and proteosomal degradation [Oh et al 2009]. While 
in presenilin deficient cells an increase in Wnt signalling has been shown to be the 
result of sequestering of GSK3β to the endosome [Dobrowolski et al 2012]. PS1 has 
been shown to have both γ–secretase-dependent and -independent roles in β-catenin 
mediated transcription, where the PS1 holoprotein and the processed PS1 fragments 
have contrasting roles in modulating β-catenin/Tcf-4 gene transcription [Raurell et al 
2008]. Additionally, defects in neurite growth observed in FAD murine cells can be 
reduced by inhibiton of β-catenin mediated gene transcription [Teo et al 2005]. Thus 
PS1 is heavily implicated in the regulation of β-catenin/Wnt signalling through both 
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γ-secretase dependent- and -independent functions. These roles are regulated through 
the post-translational modification of both PS1 and the catenin proteins.  
1.7 Presenilins and Calcium Homeostasis 
Another proposed ancestral role for presenilins relates to the formation of calcium 
leak channels and the regulation of intracellular calcium homeostasis (Figure 1.5) 
[Zhang et al 2010; Zhang et al 2015]. Disrupted calcium signalling has been reported 
to precede the classic AD pathologies, neurofibrillary tangles and Aβ plaques, and is 
proposed to contribute to neuronal cell death during AD [Bezprozvanny et al 2008]. 
Similarly, in numerous mouse models of AD increased basal levels of Ca
2+
 have 
been observed and presenilin FAD mutations have been observed to cause changes 
in Ca
2+
 levels [Zhang et al 2010; Jung et al 2011; Nelson et al 2010; Tu et al 2006]. 
There are several lines of evidence supporting a role for presenilins in the regulation 
of calcium homeostasis of intracellular stores, which appears to be independent of γ-
secretase protease activities (Figure 1.5B). First, the presenilins interact with several 
proteins functionally involved in calcium signalling, including sorcin, calmodulin, 
calsenilin, calmyrin and calpain [Stabler et al 1999; Pack-Chung et al 2000; 
Shinozaki et al 1998]. It was next proposed that presenilin holoproteins act as 
passive Ca
2+
 channels in the ER and those PS FAD mutations alter channel 
conductance [Tu et al 2006]. In an elegant mutagenesis study it was subsequently 
demonstrated that the hydrophilic catalytic cavity of PS1 facilitates the formation of 
a calcium leak conductance pore [Nelson et al 2011]. In parallel, the presenilins have 
been shown to regulate Ca
2+
 levels through interactions with and activation of Ca
2+
 
channels such the sarco/ER Ca
2+
-ATPase (SERCA) pump [Green et al 2008], the 
inositol triphosphate receptor (InsP3R) [Cheung et al 2008], and the Ryanodine 
receptor (RyR) [Rybalchenko et al 2008; Hayrapetyan et al 2008]. More recently the 
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presenilins have also been reported to modulate phosphatidylinositol-4,5-
bisphosphate (PIP2)-mediated regulation of the transition receptor potential of 
melastatin related 7 (TRPM7) [Oh et al 2012]. Finally, the presenilins have also been 
proposed to increase the number of contact sites between the ER and mitochondria, 
thereby facilitating movement of Ca
2+
 from the ER to the mitochondria [Zampese et 
al 2011]. 
PS1 FAD mutations and an Alzheimer’s triple transgenic mouse model (3xTg) show 
increased Ca
2+
 signalling while use of a dominant negative allele of InsP3R has been 
shown to reduce AD-like symptoms in 3xTg mice, suggesting the importance of 
Ca
2+
 in AD progression [Shilling et al 2014]. Furthermore, presenilin-deficient 
MEFs show a decrease in ER Ca
2+
 concentration, which may be as a result of the 
presenilins regulating InsP3R levels [Kasri et al 2006] or SERCA pump levels 
leading to increased ER [Ca
2+
] [Green et al 2008], which in both cases normal Ca
2+
 
levels can be rescued by overexpression of presenilin holoproteins. Mouse models 
expressing PS1 FAD mutants show constitutive activation of cAMP response 
element binding (CREB) gene expression, which is eliminated by inhibition of 
InsP3R [Muller et al 2011]. PS1 FAD M146V mutant knock-in hippocampal cells 
showed reduced synaptic plasticity and defects in long-term potentiation (LTP), 
which can be rescued by inhibition of the RyR [Zhang et al 2015]. Overexpression 
of both PS1 and PS1 FAD mutants have been shown to increase dendritic density in 
murine cortical neurons in a Ca
2+
 signalling-mediated and γ-secretase-independent 
manner [Jung et al 2011] and PS1 FAD mutants have been shown to enhance [Ca
2+
] 
in human lymphoblasts [Nelson et al 2010]. PS1 FAD mutations have been shown to 
both decrease and increase PS1 mediated ER Ca
2+
 release [Nelson et al 2010; Tu et 
al 2006]. Conditional knockout of presenilins or expression of the PS1 FAD M146V 
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mutant in mouse hippocampal cells has been shown to increase ER Ca
2+
 levels and 
enhance susceptibility to induced Ca
2+
 release [Zhang et al 2010]. These cells also 
showed an increase in ER RyR levels, which the authors suggest, maybe a result of 
the decreased presenilin leak channel function, leading to the increased ER Ca
2+
 
levels and thus a need for an increase in ER Ca
2+
 channel expression.  
Down-regulation of PS1 via inhibition of JNK or P53 has been shown to decrease 
ER Ca
2+
 leakage without altering InsP3R expression [Das et al 2012]. TRAF6 has 
been shown to stabilize full length PS1 and both presenilin-deficient and TRAF6-
deficient MEFs have been shown to alter ER Ca
2+
 release [Yan et al 2013]. 
Consistent with mammalian studies and supportive of an evolutionary conserved 
function, X-ray crystallography studies of a presenilin archaeal homologue PSH 
have shown the presence of a hole that passes through the protein formed from 
TMD2, TMD3, TMD5 and TMD7, separate to the catalytic core of the enzyme, that 
is large enough to allow small ions to pass through. The authors suggest that rather 
than being a second channel this hole is probably filled by lipid molecules in vivo [Li 
et al 2012]. Despite all of these studies, some controversies have been raised by 
reports of the direct measurement of Ca
2+
 ER release from primary neurons, 
fibroblasts, B-cells and hippocampal neurons [Shilling et al 2012; Wu et al 2013], 
which showed no difference in ER Ca
2+
 dynamics between cells expressing PS1 WT 
and PS1 FAD mutants and that any change in ER [Ca
2+
] in presenilin-deficient cells 
was not due to increased ER filling [Shilling et al 2012]. Therefore, while the 
presenilins have been shown to be important in regulating intracellular Ca
2+
 via 
several proposed mechanisms, as it stands the Ca
2+
 leak channel function theory of 
the presenilins remains controversial. 
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1.8 Presenilins and Apoptosis 
Apoptosis is the process where external or internal cellular signals lead to a program 
of controlled cell death [Orrenius et al 2015]. In the extrinsic pathway ligands, such 
as tumour necrosis factor α (TNFα) or FasL, bind to cell surface death receptors 
(DRs), such as the TNFα receptor type 1 (TNFR1), to initiate a pro-apoptotic cell 
signalling pathway [Gonzalvez and Ashkenazi 2010]. The DRs contain death 
domains which can interact with death domain containing adaptor proteins, such as 
TNFR-associated death domain (TRADD), leading to the formation of a death-
inducing signalling complex (DISC) that activates the initiator caspase caspase-8. 
The activation of these initiator caspases leads to the cleavage and activation of the 
proteases caspase-3, -6 and -7, which ultimately carry out the apoptotic signal within 
the cell [Gonzalvez and Ashkenazi 2010]. In the intrinsic pathway internal signals 
such as reactive oxygen species, nutrient depletion or DNA damage lead to the 
activation of pro-apoptotic Bcl-2 family proteins, such as Bax, leading to the release 
of cytochrome c from the mitochondria and activation of the apoptotic initiator 
caspase-9 [Wu and Bratton 2013]. In AD abnormal levels of apoptotic associated 
proteins such as caspases-8 and -9, Bax and Bcl-2 proteins have been detected within 
the brain tissue of AD patients and accumulation of amyloidogenic Aβ40/42 peptides 
leads to the induction of apoptosis in cultured neurons [Calissano et al 2009]. The 
presenilins were first linked to apoptosis when cells expressing PS1 FAD mutants 
were shown to have increased susceptibility to apoptotic stimuli [Guo et al 1996; 
Yang et al 2008]. Both presenilin proteins are cleaved by caspase-3 during apoptosis 
to form alternative NTF and CTF fragments for each protein [Kim et al 1997]. 






Figure 1.5 Presenilin Involvement in β-Catenin Signalling and Calcium Homeostasis. (A) The γ-
secretase cleavage of E-cadherin causes the release β-catenin from the plasma membrane. PS1 
interacts with β-catenin, a signalling molecule that is involved in Wnt signalling and gene regulation, 
while PS1 FAD mutants have been shown to inhibit these signalling events. The interaction between 
PS1 and β-catenin is also inhibited by the phosphorylation of PS1 by GSK3β. (B) PS1 is known to be 
involved in regulating calcium homeostasis in the ER in a number of ways. Firstly, PS1 has been 
shown to interact with calcium channels InsP3R and SERCA. Secondly, PS1 has been hypothesised 
to act as a calcium leak channel within the ER. Additionally, PS1 FAD mutants have been shown to 





[Walter et al 1999]. Mouse B-cells deficient in PS1 or PS2 show an increased 
susceptibility to LPS induced apoptosis [Yagi et al 2008], while increased levels of 
neurodegeneration and apoptosis are observed in the brains of an Alzheimer’s 
PS/APP mouse model [Yang et al 2008]. Expression of the PS1 FAD mutants ΔE9 
and L250S lead to an increased susceptibility to apoptosis in neuroblastoma cells 
[Tanii et al 2000]. Expression of PS1 and PS2 in HeLa cells has been shown to cause 
cell cycle arrest and apoptosis and the expression of the FAD mutants of either 
presenilin protein leads to an increased level of apoptosis [Janicki et al 1997; Janicki 
et al 1999; Janicki et al 2000]. While both presenilins are involved in apoptosis they 
can sometimes play opposing roles in regulating apoptotic pathways. Overexpression 
of PS1 is able to reduce p53 mediated apoptosis in the LTR6 mouse leukaemia cell 
line [Amson et al 2000], whereas PS2 expression increases apoptosis via p53 where 
it increases Bax expression and reduces Bcl-2 expression [Alves da Costa et al 
2003]. PS1 has been shown to regulate apoptosis in both γ-secretase-dependent and –
independent ways via c-FLIP and the presenilin-1 associated protein (PSAP), 
respectively (Figure 1.6) [Zeng et al 2015]. PSAP is predominantly expressed 
within the brain and interacts with the PDZ interacting motif at the C-terminal of 
PS1 [Xu et al 1999] PSAP has been shown to regulate apoptosis via caspase 
signalling and by controlling the release of cytochrome C from the mitochondrial 
[Xu et al 2002]. Silencing of the pro-apoptotic Bcl-2 family Bax protein repressed 
this γ-secretase independent apoptotic pathway [Zeng et al 2015] suggesting that the 
interaction between PS1 and PSAP plays a γ-secretase independent role in regulating 
the mitochondrial apoptotic pathway. PS1 directly interacts with the Bcl-2 leading to 
alterations in apoptosis [Alberici et al 1999]. This presenilin mediated apoptosis is 






Figure 1.6 The presenilins play a γ-secretase-dependent and –independent role in the regulation 
of apoptosis. This schematic shows a representation of the extrinsic apoptotic pathway involving the 
induction of an apoptotic signal after the ligand binding to a death receptor leading to the downstream 
activation of the caspases and the initiation of apoptosis. Treatment with γ-secretase inhibitors can 
inhibit this pathway. PS1 promotes the interaction of PSAP and Bax via a γ-secretase independent 
pathway leading to mitochondrial membrane breakdown and release of cytochrome c into the 
cytoplasm and the activation of caspase 9 leading to the induction of apoptosis. This figure was taken 





localisation protecting them from presenilin mediated apoptosis [Wang et al 2005].  
Therefore, both presenilin proteins can be seen to play distinct roles in regulating 
apoptosis though due to the involvement of the presenilins in a variety of other 
cellular processes, the exact role played by the presenilins in apoptosis remains 
unclear. 
1.9 Presenilins and Inflammation 
Aβ deposits are known to induce inflammation within the brain, where both 
components of the complement system and the pro-inflammatory cytokine IL-1 are 
raised within the brains of AD patients [McGeer and McGeer 2013]. Alzheimer’s 
disease cases associated with FAD PS1 mutations are known to contain plaques that 
are enriched with microglial cells involved in the inflammatory response [Shepherd 
et al 2005]. Inhibition of γ-secretase activity leads to delayed CD8 T-cell 
development [Doerfler et al 2001] while conditional presenilin knockout mice show 
a deficit in CD4 thymocytes and a reduction in T-cell receptor signalling [Laky and 
Fowlkes 2007]. Mice with conditional knockout of presenilins have been shown to 
have alterations in their inflammatory response in both the neuronal system and the 
periphery [Jiang et al 2009]. There is an increase in TLR4 mediated cytokine 
expression in mice expressing the APP Swedish mutation and the PS1 ΔE9 FAD 
mutant [Jin et al 2008]. They have also been shown to have an autoimmune 
phenotype that is similar to systemic lupus erythematosus [Tournoy et al 2004]. 
These alterations included increased activation of glial cells and astrocytes, increased 
activation of the complement system and alterations in expression of pro-
inflammatory cytokines.  
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Mice overexpressing the PS1 M146V FAD mutation showed a significantly larger 
increase in TNF and IL-1β transcription and an increase in microglial activity 
following stimulation with LPS [Lee et al 2002]. LPS treatment is also known to 
downregulate PS2 expression in mice [Saban et al 2002] and bone marrow derived 
macrophages [Agrawal et al 2015].  By contrast PS1 expression increases in the 
brains of mice treated with LPS [Nadler et al 2008]. Presenilin deficient 
lymphocytes have been shown to have a reduced capability to differentiate after LPS 
treatment whilst also showing a reduction in signal transduction [Yagi et al 2008]. 
Presenilin deficient mice have also shown an upregulation in genes involved in the 
immune system such as the complement gene C1q and the glial marker GFAP 
[Beglopoulos et al 2004]. PS1 and PS2 have different effects in the inflammatory 
response where PS2KO cells show different responses to LPS stimulation compared 
to WT or PS1KO cells [Agrawal et al 2015]. This change in cytokine response to 
LPS in PS2KO cells is not affected by γ-secretase inhibitors suggesting that this PS2 
function in the inflammatory response is γ-secretase independent. PS2 has also been 
shown to upregulate the expression of the immune system modulating miRNA 
miR146 in microglial cells and this decrease in miR146 leads to increases NFĸB 
signalling [Jayadev et al 2013]. This suggests that the presenilin proteins may play 
conflicting roles in the regulation of inflammation though this process remains 
unclear at present. 
1.10 Presenilins in Protein Trafficking and Degradation 
A plant homologue of presenilin (PpPS) from Physcomitrella patens has been shown 
to be involved in regulating organelle movement and cytoskeleton remodelling 
within plant cells [Khandelwal et al 2007]. The PpPS protein does not show any 
protease activity and PpPS with mutations at the typical catalytic aspartate sites were 
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able to rescue defects in protein trafficking in PpPS null cells. This process was also 
rescued by human PS suggesting that this trafficking function is both γ-secretase 
independent and conserved through evolutionary time. Similarly in the amoeba 
Dictyostelium discoideum, the proteolytically active homologs of the presenilins 
have been shown to be required for both differentiation and for bacterial 
phagocytosis [McMains et al 2010]. The Dictyostelium presenilins have also been 
shown to play a γ-secretase independent role in development [Ludtmann et al 2014]. 
In mammalian cells the presenilins and γ-secretase were first shown to play an 
important role in protein trafficking within the cell and in regulating protein transport 
within the axons of neurons [Naruse et al 1998]. Presenilins have been shown to 
regulate axonal transport via interactions with GSK3β thus influencing kinesin-1 and 
dynein activity [Dolma et al 2014], and reduction in γ-secretase activity accelerates 
APP axonal transport via kinesin-1 and dynamin [Gunawardena et al 2013].  
Axons of mice expressing the PS1ΔE9 mutant also show reduced kinesin-1 activity 
and reduced fast axonal transport of type 1 transmembrane receptors such as APP 
and Trk [Lazarov et al 2007]. Presenilin conditional knockout (PScDKO) mice, 
where the presenilin genes are selectively knocked out in neuronal cells, show a 
reduction of the NMDAR regulating protein drebrin A at the synapse [Lee et al 
2012]. Overexpression of the PS1 FAD mutant M146L alters the distribution 
filamin, a protein that is involved in regulating neuronal migration, within the cell 
from the cell periphery to the cytoplasm; this alteration is not changed by treatment 
with a γ-secretase inhibitor (GSI) suggesting that PS1 regulates filamin localisation 
in a γ-secretase independent manner [Lu et al 2010]. These studies demonstrate that 
the presenilins play an important role in maintaining axonal transport within neurons 
and in regulating neuronal migration. 
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The presenilins regulate trafficking of proteins to the cell surface through both γ-
secretase dependent and independent functions. A number of sorting receptors, such 
as Sortilin, SorCS1b and SorLA, have been shown to be γ-secretase substrates 
[Nyborg et al 2006]. The presenilins are involved in regulating the trafficking of 
APP in neurons [Gandy et al 2007] and deletion of PS1 leads to an increased level of 
APP full length and CTF at the cell surface [Leem et al 2002]. MEFs expressing 
FAD PS1 mutants have abnormal APP trafficking leading to irregular APP 
glycosylation [Piccini et al 2004], and have also been shown to impair fast axonal 
transport (FAT) leading to changes in APP trafficking [Lazarov et al 2007]. While 
inhibition of γ-secretase can have a negative effect on trafficking [Weissmiller et al 
2015; Zhang et al 2006], the presenilins can also affect trafficking in γ-secretase 
independent ways.  PS1 trafficking to the cell surface is reduced and PS1 ER 
localisation is increased by overexpression of calsenilin and this in turn reduces the 
cleavage of N-Cadherin [Jang et al 2011; Jang et al 2011]. Presenilin deficient 
neurons have been shown to have a reduced level of trafficking of TrkB and EphB 
receptors to the plasma membrane [Naruse et al 1998; Barthet et al 2013] and that 
the neuro-protective qualities of the EphB ligand efnB are abrogated in presenilin 
deficient neurons. This neuroprotection is maintained in wild type cells treated with 
γ-secretase inhibitors suggesting that this is a γ-secretase independent function of the 
presenilins [Barthet et al 2013]. By contrast, PSDKO MEFs showed an increase in 
integrin β1 trafficking to the cell surface and an increase in integrin β1 post-
translational modification and maturation [Zou et al 2008]. The γ-secretase 
interacting protein CD147 translocation to the cell surface is reduced in PS2 
deficient cells [Nahalkova et al 2010]. These results suggest that the presenilins play 
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a role in chaperoning proteins through the ER to the Golgi which is independent of 
presenilin’s γ-secretase function.  
Presenilins have been shown to regulate the turnover of a number of proteins. The 
PS1 CTF has been shown to mediate EGFR turnover via the endosomal/lysosomal 
system and as such regulates EGFR signalling [Repetto et al 2007].  PS1 regulates 
EGFR turnover and signalling by down-regulating the E3 ligase Fbw7 via Fbw7 
interactions with the PS1 intracellular loop [Rocher-Ros et al 2010]. The neuronal 
cell adhesion protein telencephalin has been shown to interact with PS1 and been 
shown to increase in half-life and accumulate in autophagic vacuoles in PS deficient 
neurons [Esselens et al 2004]. There is an increased level of autophagic vacuoles 
(AVs) detected in neurons of human AD patients and in the neurons of AD mice 
models [Yu et al 2005]. Mice containing the FAD APPswe and PS1 ΔE9 mutations 
have shown decreased levels of the autophagy regulator mTOR and increased levels 
of AVs and increased levels of inflammation [Francois et al 2015]. Deletion of the 
presenilins, but not inhibition of γ-secretase activity, has been shown to cause a 
reduction in autophagy in both MEFs and in neuroblastoma cells [Neely et al 2011]. 
Treatment with the autophagy inducer rapamycin could not rescue autophagy in 
these presenilin deficient cell lines. Ubiquilin, a presenilin interacting protein, has 
been shown to regulate autophagy and thus rescue HeLa cells from cell death 
mediated by the PS2 N141I FAD mutant [Rothenburg et al 2010]. From this it is 
clear that the presenilins play an evolutionary conserved role in protein trafficking 
and they demonstrate both γ-secretase-dependent and -independent roles in protein 
trafficking and turnover. 
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1.11 Therapeutic Implications of γ-Secretase-Independent Functions of 
Presenilins 
Due to their role as the enzymatic core of the γ-secretase complex the presenilin 
proteins and the prevalence of presenilin mutations in the development of FAD, the 
presenilins have been an obvious drug target for many years. Therefore GSIs have 
principally been designed as a means of reducing the formation of toxic Aβ species. 
GSIs were first designed as transition-state peptide analogues of γ-secretase 
substrates before the development of non-transition state γ-secretase inhibitors which 
target the γ-secretase active site such as N-[N-(3,5-difluorophenacetyl)-1-alanyl]-s-
phenylglycine t-butyl ester (DAPT) or the structurally related Compound E [Wolfe 
2008]. The large number of γ-secretase substrates and the central importance of 
substrates such as Notch to cell differentiation has led to the search for γ-secretase 
modulators (GSMs), which would preferentially target toxic Aβ production without 
affecting other γ-secretase substrate cleavage [Weissmiller et al 2015; Liu et al 
2014]. There has also been some success in decreasing Aβ formation through 
modulating lipid raft formation and thus decreasing γ-secretase activity [Kang et al 
2013]. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen have 
been used as GSMs to shift the amyloid production from toxic Aβ40/42 species 
towards the longer Aβ peptides, while some more potent GSMs shift the production 
down towards shorter Aβ37/38 species [Golde et al 2013]. Targeting of γ-secretase 
activity is also a target in cancer treatment. The Notch1 gene is mutated in up to 50% 
of T-cell acute lymphoblastic leukemia/lymphoma while Notch 1 and 4 and the 
Notch ligands Delta and Jagged, which are also γ-secretase substrates, are highly 
expressed in endothelial cells [Takebe et al 2015]. Inhibition of Notch signalling 
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with the GSI MRK-003 lead to a decrease in cell growth and an increase in apoptosis 
in a number of glioblastoma cell lines [Chen et al 2010]. 
Alterations in presenilin mediated cell signalling have been shown by inhibiting γ-
secretase and by inhibiting other cell pathways. Treatment with a number of GSIs 
has been shown to induce caspase-3 mediated apoptosis in both normal and 
presenilin-deficient cells which suggests that treatment with GSIs may have off 
target effects other than inhibiting γ-secretase activity [Alves da Costa et al 2004]. 
On the other hand presenilin/ γ-secretase activity can be affected by targeting other 
signalling pathways, for example astroglial cells treated with cadmium induces the γ-
secretase cleavage of N-cadherin and this cleavage can be reduced by treatment with 
MEK1/2 inhibitors [Jo et al 2013]. Treatment with γ-secretase inhibitors has been 
shown to slow proliferation in multiple myeloma cells by lowering Notch signalling 
and stopping G0/G1 changeover [Hu et al 2013]. A combinational therapy of the 
GSI DAPT and the ERK inhibitor PD98059 has been shown to be effective in 
inducing apoptosis in gastric cancer cell lines [Yao et al 2013]. This effect is a result 
of DAPT inhibiting Notch leading to increased β-catenin signalling. Instead of a GSI 
the interaction between the presenilins and β-catenin can be modulated by treatment 
with LiCl, an inhibitor of GSK3β [Murayama et al 1998]. On the other hand, the 
interaction between PS1 and β-catenin and β-catenin signalling are not affected by 
treatment by another GSI compound E [Meredith et al 2002], suggesting that GSMs 
and GSIs may have different effects on the same signalling pathway. Treatment with 
compound E has no effect on cytoplasmic Ca
2+
 level in cells treated with the SERCA 
inhibitor thapsigargin [Das et al 2012]. However, treatment with DAPT has been 
shown to lead to an increase in InsP3R expression [Kasri et al 2006] suggesting that 
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Non-steroidal anti-inflammatory drugs (NSAID) have been used as a part of 
Alzheimer’s treatment for many years. Treatment with the NSAID ibuprofen has 
been shown to reduce expression of pro-inflammatory cytokines and prevent dental 
tissue damage in presenilin deficient mice [Su et al 2013]. Additionally treatment 
with intravenous immunoglobulin (IVIg) has been shown to reduce inflammation 
and reduce Aβ levels at a slower rate but for a long lasting period than treatment 
with an anti-APP antibody in APP/PS1 mice [Sudduth et al 2013]. Since the 
presenilin proteins, especially PS2, have been shown to have a γ-secretase 
independent role in regulating the immune system [Agrawal et al 2015] this could 
represent a novel drug target for inflammatory response in Alzheimer’s disease. 
Similarly given the autoimmune diseases-like phenotype present in some PS cDKO 
mice [Tournoy et al 2004] the presenilin proteins could represent a potential target 






1.12 Concluding remarks 
The presenilins are essential parts of the γ-secretase enzyme complex and as such 
control the regulated intramembrane proteolysis of over 100 transmembrane proteins 
including APP and Notch. These cleavage events play important roles in cellular 
differentiation, gene transcription and disease progression. In addition to its γ-
secretase-dependent functions the presenilins have a number of γ-secretase 
independent roles in cell signalling, calcium homeostasis and protein trafficking. 
These γ-secretase independent roles allow the presenilins another means to regulate 
cell signalling and gene transcription through pathways such as the β-catenin or Akt 
pathways and also to affect apoptosis and the inflammatory response. As such these 
γ-secretase independent functions of the presenilins represent an additional 
consideration when targeting the presenilins for drug treatment. On the other hand 
these γ-secretase independent functions of presenilins also represent a potential 
source of drug targeting for modulating diverse cellular systems. Ubiquitination is a 
post-translational modification that is important in controlling protein turnover and 
diverse cell signalling pathways. The ubiquitination status of a protein can be ‘read’ 
by a number of ubiquitin binding domains, which can then transmit this signal on to 
other proteins to regulate diverse cellular processes. The presenilins undergo a 
number of post-translational modifications, including ubiquitination by SEL-
10/Fbw7 and TRAF6, which can affect both γ-secretase dependent and independent 
functions of the proteins. In our studies we have identified a previously undescribed 
putative ubiquitin binding CUE domain in PS1 which is potentially important in 




The aims of this thesis are: 
1. To functionally characterise the ubiquitin binding CUE domains of presenilins. 
2. To investigate whether the presenilin CUE domains are involved in γ-secretase-
dependent or –independent function(s) of the presenilins. 
3. To develop and perform a mass spectrometry-based protein binding assay to 
identify ubiquitinated proteins that interact with the PS1 CUE domain and thereby 
elucidate the function of the PS1 CUE domain. 
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2 Materials and Methods 
2.1 Chemicals and Reagents 
All salts and reagents were purchased from Sigma-Aldrich (Dublin, Ireland) unless 
otherwise stated. Protein G-Sepharose beads were purchased from Invitrogen 
(Paisley, Scotland). Turbofect™ was obtained from Thermo Fisher Scientific via 
Medical Supply Company, Dublin, Ireland. Complete protease inhibitors were 
purchased from Roche (Boehringer-Mannheim, Indianapolis, USA). His-tagged 
recombinant human K48- and K63-linked polyubiquitin (chains of mixed length, 2-7 
ubiquitin molecules) were purchased from Boston Biochem (Boston, USA). Protein 
molecular weight marker was obtained from Biorad Laboratories (Munich, 
Germany). ECL chemiluminescent kit was purchased from GE Healthcare 
(Buckinghamshire, UK). Phorbol 12-myristate 13-acetate (PMA) was obtained from 
Calbiochem (Nottingham, UK) Protran Nitrocellulose membrane was obtained from 
Perkin Elmer. Bicinchoninic acid (BCA) protein concentration reagents were 
purchased from Pierce Biotechnology (Rockford, Illinois). 
2.2 Plasmid Sources 
HA-P62 was a gift from Prof Jorge Moscat (Sanford Burnham Medical Research 
Institute, California, USA). pcDNa3.1-IL-1R1, PRK5-RIP1 and the FLAG-tagged 
PRK5-TRAF2 and FLAG-tagged PRK5-TRAF6 constructs were a gift from Dr 
Vishva Dixit (Genentech, California, USA).pCAX-FLAG-APPCT100 was a gift 
from Scios Inc (California, USA). pCS2+deltaEMV-6mt/NEXT was a gift from 
Raphael Kopan (Washington University). HA-Ub WT, HA-Ub K48only, HA-UB 
K63only and HA-Ub K63R were a gift of Dr Ruaidhri Carmody (University of 
Glasgow). pKS-rat p75
NTR 
was a gift of Prof Eric Shooter (Stanford University 
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School of Medicine, California, USA). pcDNA3-PS1 and pcDNA3-PS2 were 
previously made by members of the lab [Ciara Twomey]. The pGex-6P1 vector was 
purchased from GE Healthcare (Buckinghamshire, UK). 
 
2.3 Molecular Biology Reagents 
Primers were obtained from Sigma-Aldrich (Dublin, Ireland) or Integrated DNA 
Technology (Leuvan, Belgium). KOD Polymerase Kit and KOD Hot Start DNA 
Polymerase Kit was obtained from Calbiochem (Nottingham, UK). All restriction 
enzymes and T4 Ligase were purchased from New England Biolabs (Ipswich, USA). 
Gel extraction kit (catalog number 28104) and PCR purification kit (catalog number 
28704) were obtained from Qiagen Ltd (West Sussex, UK). PureYield(TM) Plasmid 
Midiprep System kits were purchased from Promega through Millipore 
(Southampton, UK).  
2.4 Antibodies  
The 614.1 anti-PS1 NTF antibody was generated by Scios Inc. and has been 
previously described [Kirschenbaum et al 2001]. All other antibodies used in studies 
were obtained from commercial sources.  Anti-Rab11 and anti-RIP1 antibodies were 
obtained from BD Bioscience. Anti-cleaved Notch (Val 1744) and anti-PS2 
antibodies were purchased from Cell Signaling. Antibodies against PS1 CTF 
(MAB5232) and PS1 NTF (MAB1563) were obtained from Millipore; anti-HA 
antibody was obtained from Covance. Anti-mouse HRP and anti-rabbit HRP 
secondary antibodies were purchased from Dako Cytomation. IRDye 800CW anti-
mouse and IRDye 800CW anti-rabbit secondary antibodies were purchased from 
Licor. The P75
NTR
 antibody came from Promega. The IL-1R1 (C20), P4D1 anti-
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ubiquitin and anti-TRAF2 antibodies were purchased from Santa Cruz Technology. 
The anti-actin, anti-FLAG and anti APP C-terminus antibodies were purchased from 
Sigma-Aldrich.  
2.5 Chemical Competent Cell preparation of E. coli cells 
DH5-α or BL21 E. coli cells were streaked on a Luria broth (LB) agar plate and 
grown overnight at 37°C. From this plate a single colony was picked and grown 
overnight in 5 ml of LB broth at 37°C. For BL21 cells, the LB agar and the LB broth 
was supplemented with 25 μg/ml chloramphenicol. The following day, 3 ml of the 5 
ml DH5-α or BL21 cell cultures were added to 100 ml of LB broth and grown for 2-
3 hours until an OD595 reading of 0.6-1.0 was reached. The culture was then 
centrifuged at 3000 rpm for 15 mins at 4°C. The resulting pellet was resuspended in 
one third volume of pre-chilled 0.1 M MgSO4. This mixture was again centrifuged at 
3000 rpm for 15 mins at 4°C and the resulting pellet was resuspended in 0.1 M 
CaCl2 at 1/25
th
 of the volume of the original bacterial culture. This mixture was 
aliquoted, frozen on dry ice and stored at -80°C.  
2.6 Bacterial Transformation of Competent Cells 
The chemical competent DH5-α or BL21 E. coli cells were allowed to thaw on ice 
15-20 mins prior to transformation. For plasmid DNA, 100 ng of the vector were 
incubated with 100 μl of competent cell suspension for 20 mins on ice, and then heat 
shocked at 42°C for 60 seconds. The cells were then cooled for 5 mins on ice before 
900 μl of LB broth was added. The culture was then incubated for 60 mins whilst 
shaking at 37°C. 100 μl of this culture was then plated on LB-agar plates containing 
the appropriate antibiotic (50 μg/ml ampicillin or kanamycin; 25 μg/ml 
chloramphenicol) overnight at 37°C. For transformation of ligation or mutagenesis 
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reactions 5-20 μl of the reaction mix was incubated with 100 μl of competent cells 
and then were treated as described above. 
2.7 Cloning and Mutagenesis  
Site directed mutagenesis was carried out using KOD Hot Start as per the 
manufacturer’s protocol and the primer pairs listed in  Table 2.1. Primers for site-
directed mutagenesis studies were obtained from Sigma-Aldrich (Dublin, Ireland) or 
Integrated DNA Technology (Leuvan, Belgium). Following successful amplification, 
the PCR reaction was purified using a PCR purification kit and then digested with 
the Dpn1 restriction enzyme to remove the methylated parental supercoiled dsDNA. 
The purified Dpn1 treated DNA mix was subsequently heat inactivated and 5 μl of 
mix was transformed into DH5-α cells as described above. Mutagenesis was 
confirmed via DNA sequencing (GATC Biotech, Konstanz, Germany) and sequence 
alignment using Vector NTI (Invitrogen). 
Table 2.1 Paired Primers used in Cloning and Site-directed Mutagenesis 
Mutation Primer Sequence 
P62 F406V Forward 5’ CCATGGGCGTCTCTGATGAAGGC 3’  
Reverse 5’ GCCTTCATCAGAGACGCCCATGG 3’ 
PS1 ΔCUE Forward 5’ GATTTAGTGGCTTATAATGCAGAAAGCACAGAA 3’ 















Forward 5’ GGAAGCTCAAAGGAGAGCAGCCAAAAATTCCAAG 3’ 
Reverse 5’ CTTGGAATTTTTGGCTGCTCTCCTTTGAGCTTCC 3’ 
PS1 S310E Forward 5’ 
GCTCAAAGGAGAGTAGAGAAAAATTCCAAGTATAATGC 3’ 
Reverse 5’ GCATTATACTTGGAATTTTTCTCTACTCTCCTTTGAGC 3’ 
PS1 Loop  Forward 5’ CGGGGATCCGCCGTTTTGTGTCCGAAAGGT 3’ 
Reverse 5’ CCGGAATTCCTATTTTACTCCCCTTTCCTC 3’ 
PS2 
F289A/P290A 
Forward 5’ GAAATGAGCCCATAGCCGCTGCCCTGATATAC 3’ 
Reverse 5’ GTATATCAGGGCAGCGGCTATGGGCTCATTTC 3’ 
PS2 
L315A/Q316A 
Forward 5’ CTCAGGGTGCCGCCGCGCTCCCCTACGACCC 3’ 
Reverse 5’ GGGTCGTAGGGGAGCGCGGCGGCACCCTGAG 3’ 
 
 
2.8 Construction of GST-tagged Expression Vectors 
In order to generate a GST-tagged PS1 loop domain expression vector, the PS1 Loop 
primers (Table 2.1) were used to amplify the intracellular loop domain of human PS1 
(nucleotides 792-1140 of the coding sequence, corresponding to amino acids 265-
380,). The PCR products were digested with BamHI and EcoRI and then purified 
using the QiaQuick PCR purification kit. The pGex-6P1 GST expression vector was 
digested with BamHI and EcoRI, treated with alkaline phosphatase and gel purified 
using the QiaQuick gel extraction kit. The PCR products were ligated into the pGex-
6P1 vector using the T4 ligase kit and the resulting mix was transformed into DH5-α 
cells as described above. DNA sequencing (GATC Biotech, Konstanz, Germany) 
and sequence alignment using Vector NTI (Invitrogen) confirmed successful 
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cloning. Once a successful pGEX-6P1-PS1 Loop construct had been created this was 
used as a template to create the following pGEX-6P1-PS1 Loop point mutants: 
pGEX-6P1-PS1 Loop F283A/P284A (pGEX-6P1-PS1 Loop FP/AA), pGEX-6P1-
PS1 Loop V309A/S310A (pGEX-6P1-PS1 Loop VS/SS) and pGEX-6P1-PS1 Loop 
F283A/P284A/V309A/S310A (pGEX-6P1-PS1 Loop FP/VS/AA). 
2.9 Purification of GST-Tagged Recombinant Proteins 
The pGex 6P1-PS1 Loop, pGex 6P1-PS1 Loop FP/AA, pGex 6P1-PS1 Loop VS/AA 
and pGex 6P1-PS1 Loop FP/VS/AA expression vectors were transformed into BL21 
cells and plated on LB agar plates containing 50 μg/ml ampicillin and 25 μg/ml 
chloramphenicol. From each plate a single colony was picked and grown in 5 ml of 
LB broth containing 50 μg/ml ampicillin and 25 μg/ml chloramphenicol overnight at 
37°C. Three ml of each culture was inoculated into 500 ml of LB Broth containing 
50 μg/ml ampicillin and grown for 4-5 hours at 37°C until an OD595 reading of 1.0-
2.0 had been reached. The cells were induced using 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and grown overnight at 20°C. The cultures were 
subject to centrifugation at 4000 rpm for 20 mins at 4°C. The resulting pellets were 
then resuspended in a lysis buffer [50 mM Tris (pH 8.5), 150 mM NaCl, 1 mM DTT 
with Complete protease inhibitors] (1 tablet per 50 ml of buffer).  The cells were 
lysed through sonication in 10x1 minute cycles on ice using the Soniprep 150 
(MSE). The GST-tagged PS1 Loop recombinant proteins were purified using a 2 
hour incubation in a column containing glutathione agarose beads at 4°C. The 
column was washed with 2 L of washing buffer [50 mM Tris (pH 8.5), 500 mM 
NaCl, 1 mM DTT] and eluted from the column using elution buffer [50 mM Tris 
(pH 8.5), 150 mM NaCl, 10 mM Glutathione]. After the last of the wash buffer had 
passed through the column 25 ml off elution buffer was added to the beads. The 
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elution buffer was allowed to pass through the bead bed and was collected into 5 
elutions of 5 ml volume. These elutions were further aliquoted into 500 μl volumes, 
then frozen on dry ice and stored at -80°C. 
2.10 Cell Culture 
Human Embryonic Kidney 293T (HEK293T) cells were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM-21) containing 10% foetal bovine serum, 1% L-
glutamine, 50 units/ml penicillin and 50 μg/ml streptomycin. Murine embryonic 
fibroblasts (MEFs) were grown in Dulbecco’s Modified Eagle’s Medium (DMEM-
21) containing 10% foetal bovine serum, 1% L-glutamine, 50 units/ml penicillin, 50 
μg/ml streptomycin, non-essential amino acids, and sodium pyruvate. Cells were 
maintained in a humidified 37°C incubator with 5% CO2. MEFs, PS1 deficient 
MEFs and presenilin double knock out MEFs were a gift from Prof. Bart De 
Strooper (KU Leuven, Belgium). 
2.11 Calcium Phosphate Transfection of HEK293T Cells 
Transfections were carried out on HEK293T cell cultures using the calcium 
phosphate precipitation method. For a 10 cm dish HEK293T cells were grown to 
50% confluency before transfection. For each transfected 10 cm plate, 4 μg of DNA 
of each plasmid was used, to a maximum of 12 μg DNA. The transfection mixture 
consisted of the appropriate volume of DNA, the final volume was adjusted to 350 μl 
with autoclaved deionised water before 50 μl of filter sterilised 2 M CaCl2 was 
added. This mixture was added dropwise to 400 μl of 2x Hank’s Buffered Saline 
Solution (274 mM NaCl, 1.4 mM Na2HPO4, 42 mM HEPES pH 7.2). Then the DNA 
mixture was added dropwise over the entire surface of the 10 cm plate and put back 
into the incubator. After 12-16 hours the media was aspirated off and replaced with 
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fresh media. Cells were typically harvested 24-36 hours after transfection. For 
experiments with 6-well plates HEK293T cells were grown to 50% confluency 
before transfection. The reaction mixture was scaled down to a total volume of 200 
μl, with 1 μg of each plasmid used per transfection up to a maximum of 2 μg DNA 
per well. 
2.12 Transfection of Murine Embryonic Fibroblasts 
Transfections in MEFs were carried out with Turbofect™. Twenty-four hours prior 
to transfection the cells were plated at 2x10
5
 in 6-well plates. For the transfection, 1 
μg of plasmid DNA was mixed with 200 μl of serum free DMEM and allowed to 
stand for 5 mins. Then 3 μl of Turbofect was added and allowed to stand at room 
temperature for 20 mins. This mixture was then added dropwise over the entire 
surface of the well. The media was aspirated after 8-12 hours and replaced with fresh 
media. The cells were harvested 36 hours after transfection. 
 
2.13 Western Blotting 
When harvesting cells firstly the media was aspirated off and then the cells were 
washed twice in ice cold Phosphate buffered Saline (PBS) and then detached from 
plates by scraping with ice cold PBS supplemented with 5 mM 
Ethylenediaminetetraacetic acid (PBS-EDTA). The samples were then centrifuged at 
2000 rpm for 5 minutes at 4°C. The supernatant was aspirated off and the cell pellets 
were re-suspended in RIPA buffer [10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM 
EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl] 
supplemented with 1 mM sodium orthovanadate and Complete protease inhibitor 
cocktail (1 tablet was sufficient for 50 ml of buffer). The cells were lysed on ice for 
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50 minutes, centrifuged at 13000 rpm for 20 minutes at 4°C and then the supernatant 
was transferred to a fresh tube. The protein concentration of the lysate was 
determined using the BCA method. Proteins samples were diluted 1/10, mixed with 
200 μl of BCA reaction mix (196 μl of BCA buffer A and 4 μl of BCA buffer B) and 
after 30 minute incubation at 37°C  the samples were then read at 562 nm. To 
demonstrate equal efficiency of transfection, equivalent masses of proteins (50-80 
μg) were resolved on 12% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels before being transferred to nitrocellulose 
membrane. The membranes were blocked for an hour in 5% Marvel Milk in Tris-
buffered saline (TBS) with 0.1% Tween (TBS-T). The membranes were incubated in 
the indicated primary antibody either overnight at 4°C or 2 hours at room 
temperature. After incubation in primary antibody the blots underwent 3x5 min 
washes with TBS-T before the blots were incubated with either ECL or Licor 
Odyssey secondary antibodies for 1-2 hours at room temperature.  After incubation 
with the secondary antibody the blots were subjected to 3x5 min washes in TBS-T 
and then the proteins were detected using either the ECL method, according to 
manufacturers protocol, or using the Licor Odyssey CLx Imager system.  
 
Table 2.2 Antibodies used for Western Blot Analysis and Immunoprecipitation. 
Antibody  Supplier Concentration Species 
Actin Sigma-Aldrich 1/3000 Mouse 
Anti-cleaved Notch (Val 
1744) 
Cell Signalling 1/1000 Rabbit 




Anti-HA Covance 1/1000 WB; 1/250 
IP 
Mouse 
APP Sigma-Aldrich 1/4000 Rabbit 
IL-1R1 C20 Santa Cruz 1/250 Rabbit 
IRDye 800CW anti-mouse LiCor 1/10000 Goat 
IRDye 800CW anti-rabbit LiCor 1/10000 Goat 
P4D1 anti-ubiquitin Santa Cruz 1/1000 Mouse 
P75NTR Promega 1/1000 Rabbit 










PS1 CTF Chemicon 1/1000 Mouse 
PS1 NTF   Chemicon 1/300 IP Rat 
PS1 NTF 614.1 Scios 1/1000 WB; 1/250 
IP 
Mouse 
PS2  Cell Signalling 1/1000 WB; 1/250 
IP 
Rabbit 
RAB11 BD Bioscience 1/3000 Mouse 
RIP1 BD Bioscience 1/1000 Mouse 




2.14 Ubiquitination Assay 
HEK293T cells were transiently transfected using the calcium phosphate method 
with the appropriate constructs. Thirty six hours post transfection the cells were 
washed with ice cold PBS and detached from plates by scraping in 1 ml PBS-EDTA 
(0.5 mM). Cells were pelleted by spinning at 2000 rpm for 5 min at 4°C. The cells 
were lysed in 250 μl of 1% SDS supplemented with protease inhibitors (Complete 
Roche Life Sciences) and then boiled for 5 min. Equal volume covalent buffer (50 
mM Tris (pH 8), 150 mM NaCl, 1% Triton, 0.5% sodium deoxycholate and protease 
inhibitors) was added, the lysates were mixed and then spun at 13000 rpm for 30 min 
at 4°C. The pellets were removed and the lysates were normalised using the BCA 
method. Samples were immunoprecipitated by incubating the lysates with the 
appropriate antibody overnight at 4°C before protein-G sepharose beads (Roche Life 
Sciences) were added and the samples were incubated for a further 3 hours at 4°C. 
The beads were washed 3 times in covalent buffer before boiling in 2x SDS sample 
buffer. Precipitated proteins were resolved by SDS-PAGE and detected using the 
Licor Odyssey Infrared Imaging System. 
2.15 Co-Immunoprecipitation Assay 
HEK293T cells were transiently transfected 36 hours before harvesting. The media 
was aspirated from the cells, the plate was washed twice with ice cold PBS and then 
detached from the plate surface in 1 ml PBS-EDTA. The cells were pelleted by 
centrifugation at 2000 rpm for 5 mins at 4°C. The cell pellet was resuspended in 
lysis buffer [50 mM HEPES (pH 7.0), 150 mM NaCl, 1 mM EDTA supplemented 
with Complete protease inhibitors (1 tablet per 50 ml of buffer) and 1 mM sodium 
orthovanadate]. Cells were lysed for 45 mins on ice, then centrifuged for 20 mins at 
4°C. After centrifugation protein concentration was determined using the BCA 
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assay. After protein overexpression had been confirmed by western blotting, an 
equal mass of total protein from each sample were brought up to 1 ml volume with 
lysis buffer and then pre-cleared with 20 μg of protein-G sepharose beads for 1 hour 
at 4°C on the rotator. The beads were pelleted by centrifugation at 2000 rpm for 5 
mins; the supernatants were transferred to a fresh tube and then subjected to 
immunoprecipitation (IP) with 3-4 μg of the specific antibody required. The IP 
samples were then incubated at 4°C overnight on the rotator. The following morning 
30 μl of protein-G sepharose beads were added to each sample and incubated at 4°C 
on the rotator for 3 hours. The samples were then centrifuged for at 3000 rpm 2 
mins, The supernatant was aspirated off and the beads were washed twice with 500 
mM NaCl lysis buffer and once with 150 mM NaCl lysis buffer. After the final wash 
40 μl of 2X Laemmli sample buffer [4% SDS, 20% glycerol, 120 mM Tris-HCl (pH 
6.8), bromophenol blue 0.02% (w/v), 2% β-mercaptoethanol] was added to the beads 
and the samples were boiled for 5 mins. The beads were pelleted by centrifuging the 
samples at 13000 rpm for 0.5 mins and then the samples were resolved by SDS-
PAGE on 12% gels. The co-immunoprecipitation of proteins was then detected by 
western blotting.  
2.16 Ubiquitin Binding Assay 
HEK293T cells were transiently transfected using the calcium phosphate method 
with the appropriate constructs. Thirty-six hours post transfection the cells were 
washed with ice cold PBS and detached from plates by scraping in 1 ml PBS-EDTA. 
Cells were pelleted by centrifugation at 2000 rpm for 5 min at 4°C. The cells were 
lysed in 250 μl of 1% SDS supplemented with protease inhibitors (1 tablet per 50 ml 
of buffer) and then boiled for 5 min. An equal volume of covalent buffer [50 mM 
Tris (pH 8), 150 mM NaCl, 1% Triton, 0.5% sodium deoxycholate, 1 mM sodium 
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orthovanadate and protease inhibitors] was added, the lysates were mixed and then 
centrifuged at 13000 rpm for 30 min at 4°C. The pellets were removed and the 
lysates were normalised using the BCA method. Samples were immunoprecipitated 
by incubating the lysates with the appropriate antibody overnight at 4°C before 30 μl 
of 50% protein-G sepharose beads were added and the samples were incubated for a 
further 3 hours at 4°C. The beads were washed 3 times in covalent buffer before 
boiling in 2X SDS sample buffer. At this stage the beads were washed once with 
binding buffer [20 mM Tris-HCl (pH 7.6), 50 mM NaCl, 0.1% Nonidet P-40, 0.5 
mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF)]. Then 1 ml of 
binding buffer and 5 μg of recombinant (K-48 or K-63 linked) polyubiquitin were 
added to each sample and incubated on a rotator overnight at 4°C. The samples were 
centrifuged at 3000 rpm for 2 minutes and then washed 3 times with binding buffer. 
30 μl of 2x sample buffer was added; the samples were boiled for 5 minutes and then 
centrifuged at 13000 rpm for 0.5 minutes. The samples were then resolved on a 12% 
SDS-PAGE gel and detected via western blotting. 
2.17 Ubiquitin Pulldown Assay 
HEK293T cells were transiently transfected with either HA-tagged K48only or 
K63only ubiquitin and then lysed in 1 ml of binding buffer [20 mM Tris-HCl (pH 
7.6), 50 mM NaCl, 0.1% Nonidet P-40, 0.5 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride (PMSF)]. The GST-tagged PS1 Loop proteins were 
bound to 30 μl of glutathione agarose beads in binding buffer on a rotator for 3 
hours. The glutathione agarose bound GST-PS1 Loop proteins were washed three 
times in binding buffer and then incubated with 800 μg of cell lysates from the 
HEK293T cells expressing either HA-tagged K48only or K63only ubiquitin. The 
samples were washed three times in binding buffer, 30 μl of 2x sample buffer was 
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added to the beads and then boiled for 5 minutes. The samples were then resolved on 
12% SDS-PAGE gels. The gels were transferred to nitrocellulose paper and then 
ubiquitin binding was analysed by western blotting. 
2.18 GST-Pulldown of Endogenous Mammalian Proteins for Mass Spec 
Analysis 
10 x 15 cm dishes of HEK293T cells were grown to 100% confluency. The media 
was aspirated off and the cells were washed with 3 ml of ice cold PBS. The cells 
were harvested from the plates by scraping in PBS-EDTA and then pelleted at 4°C 
before aspirating off the PBS-EDTA. The cells were resuspended in 1.5 ml of 
binding buffer (with or without 8 mM phenanthroline) per plate used. The cells were 
then sonicated for 5x10 second cycles on ice before centrifuging at 15000 rpm for 30 
min  at 4°C and then protein concentration was determined using the BCA method. 
For the pull-down, 30 μl of 50% glutathione agarose slurry per 1 mg of protein was 
incubated with 30 mg with either GST-PS1 Loop or GST-PS1 FP/VS/AA Loop for 1 
hour at room temperature. The GST recombinant protein buffer was then allowed to 
flow through. The HEK293T lysate was then added to the column and then 
incubated at 4°C overnight on the shaker. After the unbound lysate was allowed to 
flow through the beads were washed in 10 x bed volume of ice cold binding buffer. 
This step was repeated four times. Bound protein was eluted from the column by 
elution with 300 μl of an elution buffer (50mM Tris pH 8.5, 150 mM NaCl, 50 mM 
Glutathione) or by boiling the beads with 250 μL of 2X Laemmli Sample Buffer 
followed by centrifugation for 5 mins at 2000 rpm at 4°C. Protein binding was 
determined via separation on 12% SDS-PAGE followed by Coomassie staining.  
Gels were soaked in fixing solution (50% methanol, 10% glacial acetic acid, 40% 
H2O) for 30 mins before 5 mins staining in Coomassie stain (50% methanol, 10% 
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glacial acetic acid, 40% H2O, 0.25% Coomassie blue R-250). Gels were then washed 
in destaining solution (40% methanol, 10% glacial acetic acid, 50% H2O) for 2-24 
hours prior to scanning. 
2.19 Mass Spectrometry  
The mass spectrometry (MS) analysis was carried out by Fingerprints Proteomics 
(University of Dundee, UK) [Mutsaers et al 2013]. A one dimensional Liquid 
chromatography-MS-MS reverse phase chromatography approach was used to 
analyse the proteins on a 4000 QTRAP machine. 28 μl of each sample was mixed 
with 4 μl of N-Ethylmaleimide and 8 μl of 5X Laemmli sample buffer and loaded on 
to premade SDS-PAGE gels in a laminar flow. The protein bands were excised from 
the gel, gel purified and then digested with trypsin before analysis by MS [Walsh et 





3 Characterisation of the Presenilin CUE Domains 
Some of these data was previously published in FEBS Letters [Stephen P. Duggan, 
Run Yan, and Justin V. McCarthy (2015)] “A ubiquitin-binding CUE domain in 
presenilin-1 enables interaction with K63-linked polyubiquitin chains” FEBS Letters 




PS1 and PS2 both contain a large hydrophilic intracellular loop domain between 
transmembrane domains 6 and 7. The intracellular loop domains are the regions that 
show the greatest difference between the sequences of the two presenilin proteins. 
While the overall ammino acid sequences of the human presenilins are 65% 
identical, the intracellular loop domain of PS2 is 19 residues shorter with the 
remainder of the loop being only 59% identical in sequence to that of PS1.The 
intracellular loop domains contain the sites of  endoproteolysis where the 
catalytically inactive presenilin holoproteins are cleaved into their mature NTF and 
CTF fragments, which facilitate assembly and formation of the γ-secretase protease 
complexes. This intracellular loop domain has also been shown to be the site of 
protein-protein interactions between the presenilins and other proteins such as Rab11 
[Dunmanchin et al 1999], syntaxin 5 [Smith et al 2000], β-catenin and δ-catenin 
[Zhou et al 1997] [reviewed in McCarthy et al 2009]. The interaction between PS1 
and β-catenin and δ-catenin regulates Wnt signalling, demonstrating that the 
intracellular loop domain of PS1 is also involved in the γ-secretase independent roles 
of PS1. The PS1 intracellular loop domain is the site of a number of phosphorylation 
events driven by kinases such as PKA, PKC, GSK3β, JNK and CDK5, which 
regulate proteolysis of the presenilins and interactions with other intracellular 
proteins [Fluhrer et al 2004, Walter et al 1999, Kirschenbaum et al 2001, Kuo et al 
2008, Lau et al 2002]. Furthermore, studies in our lab have shown that the 
intracellular loop domain of PS1 contains a TRAF6 interaction motif (PEERGV) at 
residues 374-379 [Elzinga et al 2009]. This interaction has been shown to influence 
the γ-secretase mediated cleavage of P75
NTR
 [Powell et al 2009]. TRAF6 has also 
been shown to facilitate the K63-linked polyubiquitination of PS1 [Yan et al 2013; 
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Gudey et al 2014], though this ubiquitination has not been attributed to a particular 
lysine residue and TRAF6 seems to be able to ubiquitinate PS1 at multiple residues 
[Yan unpublished data]. This suggests that the large intracellular loops of the 
presenilins are involved in both γ-secretase dependent and independent roles of the 
presenilins and that they are the site of both post-translational modifications and 
protein-protein interactions. As such, studying and characterising conserved and 
divergent regions within the hydrophilic loop domains of PS1 and PS2 present an 
opportunity to investigate established and novel presenilin functions.  
Previous members of our lab have used a bioinformatics approach to investigate the 
function of the intracellular domains of the presenilin proteins [Powell et al 2009]. 
Using this approach they showed that the presenilin proteins exhibited some 
sequence homology with proteins containing ubiquitin binding CUE domains. CUE 
domains from different proteins have been reported to facilitate binding to different 
types of ubiquitin, mono-, di- and polyubiquitin. For example, CUE domains have 
been shown to interact with both monoubiquitin, in the case of Vps9 [Davies et al 
2003] and polyubiquitin chains in the case of Cue1p [Bagola et al 2013]. On the 
other hand the CUE domain of gp78 has been shown to have no preference in 
binding to monoubiquitin, K48- or K63 -inked polyubiquitin chains [Liu et al 2012]. 
The ubiquitination state of some proteins, such as Vps9 and gp78, is controlled by 
their CUE domains [Davies et al 2003, Chen et al 2005]. Similarly CUE domains 
can also regulate the ubiquitination of other proteins, such as the CUE domain of 
Tollip which has been shown to influence β-catenin ubiquitination and Wnt 
signalling [Torun et al 2015]. The CUE domain of Cue1p has been shown to regulate 
the formation of K48-linked polyubiquitin chains. In Tollip binding of ubiquitin to 
its CUE domain causes Tollip to have a lower affinity for phosphoinositide and as 
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such the Tollip CUE domain acts a switch that regulates Tollip’s interaction with 
plasma membranes [Mitra et la 2013]. Collectively, the findings from these research 
studies proposes that the presence of CUE domains does not confer a single function 
upon proteins. Additionally different CUE domains are involved in diverse 
signalling pathways such as Wnt signaling [Torun et al 2015], NFĸB signaling 
[Kishida et al 2005] and in ER associated degradation (ERAD) [Bagola et al 2013]. 
In this chapter the presenilins will be shown to contain a functional ubiquitin binding 
CUE domain. The presenilin CUE domain shows a preference in binding to K63-
linked over K48-linked polyubiquitin chains. The VS motif, but not the FP motif, of 
the PS1 CUE domain are required for PS1 CUE domain function. In addition, this 
chapter will show that the PS1 CUE domain is dispensable for a number of γ-
secretase related PS1 roles. Mutation of the conserved CUE domain motifs had no 
effect on PS1 endoproteolysis, though deletion of the CUE domain eliminated this 
function. The PS1 CUE domain was shown to be dispensable for the γ-secretase 




3.1 Identification of a putative CUE domain in presenilin proteins 
Previous members of our lab discovered sequence homology between a region of the 
intracellular loop of the presenilin proteins and proteins which contain an ubiquitin 
binding CUE domain (James Powell) (Figure 3.1A). The CUE domain is 
approximately 40 amino acids in length, has a three-helix tertiary structure and 
contains two well-conserved motifs [Hurley et al 2006]. These motifs are the 
strongly conserved phenylalanine-proline (FP) motif and the less well conserved di-
leucine motif. In human presenilins the putative CUE domain is found at amino 
acids 271-314 in PS1 (Figure 3.1B) and between amino acids 277-320 in PS2 
(Figure 3.1C). Both presenilin proteins contain the FP motif at residues F283/P284 
for human PS1 and F289/P290 for human PS2; instead of the di-leucine motif human 
PS1 has the residues V309/S310 and human PS2 has the residues L315/Q316 
(Figure 3.1A). To study the tertiary structure of the putative presenilin CUE 
domains these sequences were analysed using the Jnet Structure predicting software 
[www.compbio.dundee.ac.uk]. This software predicted that these sequences would 
form the typical 3-helix structure that is attributed to other CUE domains [Hurley et 
al 2006]. To further investigate the putative CUE domains of both PS1 (Figure 
3.1A) and PS2 (Figure 3.1C) were aligned with the amino acid sequences of 
presenilin proteins across a number of species. These alignments show that the 
putative CUE domains of both presenilin proteins are well conserved across 
evolutionary time. The FP-motif is strongly conserved across all species examined 
for both PS1 and PS2 while the VS- and LQ-motifs are less strongly conserved for 
both proteins. Residues with the presenilin CUE domains associated with FAD are 





Figure 3.1 Alignment of the putative CUE domains of Presenilin proteins. (A) Shows an 
alignment of the putative CUE domains of the presenilin proteins with the sequence of known CUE 
domains. Residues highlighted in black are identical, residues highlighted in grey are similar and 
residues in boxes are weakly similar. Above the sequence alignment shows the position of the 3 
helices predicted by the Jnet secondary structure prediction software. Below the alignment is the 
consensus sequence of the CUE domains present with the important FP and di-leucine motifs 
highlighted with stars. (B) and (C) show that the putative CUE domains of PS1 and PS2, respectively, 
are conserved across different species with the important CUE domain motifs highlighted in black. 
All alignments were done using AlignX software. (D) Schematic showing known familial 





3.2 Validation of an Ubiquitin Binding Assay Using P62/Sequestosome 1 
To investigate the ability of PS1 to bind to ubiquitin through its potential CUE 
domain an ubiquitin binding assay was first designed and optimised. It has previouly 
been shown that P62/sequestosome-1 contains a functional UBA domain that binds 
to K63-linked polyubiquitin chains [Seibenhener et al 2004], and a single point 
mutation within the UBA domain of P62, P62 F406V, abolishes ubiquitin binding to 
the P62 UBA domain. Using this information, first HEK293T cells were transiently 
transfected with pcDNA3.1 empty vector (EV), pcDNA3.1-HA-P62 or pcDNA3.1-
HA-P62 F406V mutant. 236 hours post-transfection cell lysates were 
immunoprecipitated with an anti-HA antibody. Immunoprecipitates were 
subsequently incubated with equal concentrations (5 μg) of recombinant His-tagged 
lysine 63 (K63)-linked polyubiquitin chains. Ubiquitin binding was subsequently 
determined by SDS-PAGE and immunoblotting with an anti-polyubiquitin (P4D1) 
antibody.  Consistent with previous studies, after immunoprecipitation wild type P62 
but not P62 F406V bound to K63-linked polyubiquitin (Figure 3.2). Loading control 
for recombinant lysine 63 (K63)-linked polyubiquitin used in experiment is indicated 
in the right hand side panel. These results demonstrate that this ubiquitin binding 
assay is able to differentiate between functional and dysfunctional ubiquitin binding 
domains and so can be used to test whether PS1 has a functional ubiquitin binding 
CUE domain. 
3.3 PS1 Contains an Ubiquitin Binding CUE Domain 
Having shown the validity of the ubiquitin binding assay, next this assay was used to 
investigate the ability of the PS1 CUE domain to bind to ubiquitin. To do this a PS1 
mutant, called pcDNA3.1-PS1 ΔCUE, in which the entire CUE domain (residues 






Figure 3.2 Validation of ubiquitin binding assay. HEK293T cells were transiently transfected with 
pcDNA3 (EV), pcDNA3.1-HA-P62 or the ubiquitin binding defective mutant pcDNA3.1-HA-P62 
F406V and lysed under strict denaturing conditions. The lysates were subject to immunoprecipitation 
and then incubated with 5 μg of recombinant K63-linked polyubiquitin and bound ubiquitin was 
detected following SDS-PAGE and western blotting with P4D1 anti-ubiquitin antibody. The 
immunoprecipitation and expression of HA-P62 and HA-P62 F406V were confirmed by 
immunoblotting with anti-HA antibody. A β-actin blot is included to show loading control. The right 
panel shows a loading control with 1μg of recombinant K63-linked polyubiquitin used. IP: 
immunoprecipitation; WB: western blot; Ub: ubiquitin; HC: IgG heavy chain: IgG LC light chain; 




endoproteolysis at residue  M292. HEK293T cells were transfected with pcDNA3.1, 
pcDNA3.1-PS1 or pcDNA3.1-PS1ΔCUE, and thirty six hours post-transfection cells 
were harvested under denaturing conditions and the cell lysates were 
immunoprecipitated with an anti-PS1 NTF antibody. The immunoprecipitates were 
then incubated overnight with equal quantities of recombinant His-taggedK63-linked 
or lysine 48 (K48)-linked polyubiquitin and after stringent washing ubiquitin-
binding was determined by western blotting with an anti-polyubiquitin (P4D1) 
antibody. Equal amounts of PS1 full length protein were immunoprecipitated in this 
assay, whether it was PS1 FL or PS1 ΔCUE (lower panel of Figure 3.3). The upper 
panel on left of Figure 3.3 demonstrates that PS1 has a preference for binding K63-
linked over K48-linked polyubiquitin chains, as can be seen when you compare lane 
2 to lane 4. In contrast, no binding to K63-linked polyubiquitin to PS1 was observed 
in the PS1 ΔCUE mutant. Loading control for recombinant lysine 63 (K63)-linked or 
lysine 48 (K48)-linked polyubiquitin used in experiment is indicated (Figure 3.3, 
right panel).  
3.4 Characterisation of the PS1 CUE Domain 
Having shown that the human PS1 CUE domain contains a highly conserved FP and 
a less well-conserved VS motif that is shared with other CUE domains, it was 
decided to use a site-directed mutagenesis approach to generate mammalian 
expression constructs of the PS1 CUE missense mutants PS1 F283A/P284A and PS1 
V309A/S310A to investigate PS1 CUE domain function. Previous studies 
demonstrated that mutation of the conserved methionine-phenylalanine-proline and 
di-leucine motifs reduce the ability of the CUE domain of Vps9 to interact with 







Figure 3.3 PS1 CUE domain selectively binds to K63-linked polyubiquitin chains. HEK293T 
cells were transiently transfected with pcDNA3, pcDNA3-PS1 WT or pcDNA3-PS1ΔCUE and lysed 
under strict denaturing conditions. The lysates were subject to immunoprecipitation and then 
incubated with 5 μg of either K63 or K48 recombinant polyubiquitin, as indicated above, and bound 
ubiquitin was detected following SDS-PAGE and western blotting with P4D1 anti-ubiquitin antibody. 
Equal immunoprecipitation was confirmed by immunoblotting with anti-PS1 CTF antibody. The right 
panel shows a loading control with 1ug of recombinant K63 and K48 polyubiquitin used. IP: 
immunoprecipitation; WB: western blot; Ub: ubiquitin; HC: IgG heavy chain: IgG LC light chain; 




be a site of PKA phosphorylation [Fluhrer 2004] and to investigate whether this 
could have any effect on PS1 CUE domain function a pseudo-phosphorylated PS1 
S310E mutant was generated. HEK293T cells were transiently transfected with equal 
quantities of pcDNA3, pcDNA3-PS1, pcDNA3-PS1 ΔCUE, pcDNA3-PS1 
F283A/P284A, pcDNA3-PS1 V309A/S310A or pcDNA3-PS1 S310E. The PS1 
proteins were isolated using immunoprecipitation and were then incubated with 5μg 
of recombinant His-tagged K63-linked polyubiquitin (Figure. 3.4A). Western 
blotting analysis revealed that wild-type PS1 and the PS1 F283A/P284A and PS1 
S310E mutants bound to ubiquitin, while in contrast the PS1ΔCUE and 
PS1V309A/S310A mutants had reduced interaction with K63-linked polyubiquitin 
(compare lanes 4 and 6 with lane 3). These results suggest that the K63-linked 
polyubiquitin binding capability of the putative CUE of PS1 is not regulated by PKA 
activity but is mediated by the V309/S310 sequence. The F283/P284 motif does not 
appear to be as important in PS1 binding to K63-linked polyubiquitin as it shows a 
similar level of ubiquitin-binding to wild-type PS1. Figure 3.4B shows the 
overexpression of  the pcDNA3-PS1, pcDNA3-PS1 ΔCUE, pcDNA3-PS1 
F283A/P284A, pcDNA3-PS1 V309A/S310A and pcDNA3-PS1 S310E constructs in 
HEK293T cells that were used in the ubiquitin binding assay.  
3.5 PS2 Contains a Functional Ubiquitin Binding CUE Domain 
To investigate the functionality of the putative PS2 CUE domain a pcDNA3-PS2 
ΔCUE mutant was created, where residues 277-320 of PS2 were deleted. HEK293T 
cells were transiently transfected with pcDNA3, pcDNA3-PS2 WT or pcDN3-PS2 
ΔCUE (Figure 3.5). Thirty-six hours after transfection the cells were harvested and 
lysed under strict denaturing conditions. Once transfection had been determined 
through western blotting (see Figure 3.5B) the lysates were subject to 
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immunoprecipitation with an anti-PS2 antibody. Once the immunoprecipitated 
proteins had been washed 3 times with covalent buffer and once with binding buffer 
the immunoprecipitated proteins were incubated overnight with either 5 μg of His-
tagged K48- or 5 μg of His-tagged K63-linked polyubiquitin chains. After 3 washes 
with binding buffer the samples were boiled for 5 mins and then resolved on a 10% 
SDS-PAGE gel and the resulting blot was incubated with P4D1 anti-ubiquitin 
antibody. PS2 WT binds to K63 linked polyubiquitin but not K48 linked 
polyubiquitin chains (compare lanes 2 and 4 in Figure 3.5). However, deletion of 
the PS2 CUE domain causes a reduction in binding to K63-linked polyubiquitin 
chains. The lower panel of Figure 3.5 shows that the PS2 ΔCUE proteins were not 
immunoprecipitated at a similar level to that of PS2 WT. However, the difference in 
ubiquitin binding to PS2 WT and PS2 Δ is greater than the difference in the 
immunoprecipitation of PS2 WT and PS2 ΔCUE. This ubiquitin binding assay also 
demonstrates that the PS2 CUE domain shows a preference for binding to K63-
linked over K48-linked polyubiquitin chains. This shows that PS2 like PS1, contains 
a functional ubiquitin binding CUE domain that shows a preference for binding to 
K63-linked polyubiquitin over K48-linked polyubiquitin. 
 
3.6 Characterisation of the PS2 CUE Domain 
To further investigate the PS2 CUE domain a series of point mutants was created to 
replicate the mutants used in the PS1 in vivo ubiquitin binding assay. The mutants 
created were pcDNA3-PS2 F289A/P290A, and pcDNA-PS2 L315A/Q316A. 
HEK293T cells were transiently transfected with pcDNA3 (vector), pcDNA3-PS2 




Figure 3.4 Characterisation of PS1 CUE domain mutants. HEK293T cells were transiently 
transfected with pcDNA3, pcDNA3-PS1 WT, pcDNA3-PS1ΔCUE, pcDNA3-PS1 F283A/P284A, 
pcDNA3-PS1 V309A/S310A or pcDNA3-PS1 S310E and lysed under strict denaturing conditions. 
(A) The lysates were subject to immunoprecipitation and then incubated with 5 μg of recombinant 
K63 polyubiquitin and bound ubiquitin was detected following SDS-PAGE and western blotting with 
P4D1 and anti-PS1 CTF. (B) The overexpression of pcDNA3-PS1 WT, pcDNA3-PS1ΔCUE, 
pcDNA3-PS1 F283A/P284A, pcDNA3-PS1 V309A/S310A or pcDNA3-PS1 S310E was confirmed 
by western blotting with anti-PS1 CTF antibody.  A β-actin blot is included to show loading control. 
IP: immunoprecipitation; WB: western blot; Ub: ubiquitin; HC: IgG heavy chain: IgG LC light chain; 




cells were lysed under strict denaturing conditions and overexpression was examined 
by western blotting (Figure. 3.6). Unlike the other plasmids used, the pcDNA-PS2 
L315A/Q316A plasmid did not express in the HEK293T cells (lane 6 of Figure 3.6). 
As a result of the poor expression of the pcDNA-PS2 L315A/Q316A plasmid, which 
is the PS2 equivalent of the ubiquitin binding defective PS1 V309A/S310A mutant, 
it was decided to focus more on the function of the PS1 CUE domain. 
3.7 Generation of Recombinant GST-tagged PS1 Proteins 
To further validate PS1 CUE domain function a GST-tagged recombinant protein 
containing the intracellular loop domain of PS1 was created. This protein contained 
residues 265-380 of PS1, contained within this sequence is the CUE domain of PS1 
(residues 271-314). This recombinant protein was then used in an ubiquitin pulldown 
assay where the recombinant GST-tagged presenilin loop protein was incubated with 
lysates from HEK293T cells overexpressing ubiquitin constructs that can only form 
K48- or K63-linked polyubiquitin chains. Figure 3.7 shows a schematic 
representation of this approach, where the GST tag is on the N-terminal of each 
recombinant protein and the PS1 loop domain is at the C-terminal. In addition to the 
creation of a GST-PS1 Loop protein it was decided to use a mutagenesis approach to 
create a series of point mutants within the CUE domain to replicate the CUE domain 
mutants used in previous experiments. The F283/P284 and V309/S310 motifs of the 
PS1 CUE domain were either mutated singly or in tandem to create the following 
mutants: GST-PS1 FP/AA Loop (the recombinant version of the PS1 F283A/P284A 
mutant), GST-PS1 VS/AA (the recombinant version of the PS1 V309A/S310A 





Figure 3.5 PS2 CUE domain selectively binds to K63 polyubiquitin chains. HEK293T cells were 
transiently transfected with pcDNA3, pcDNA3-PS2 WT or pcDNA3-PS2ΔCUE and lysed under strict 
denaturing conditions. (A) The lysates were subject to immunoprecipitation and then incubated with 5 
μg of either K63 or K48 recombinant polyubiquitin, as indicated above, and bound ubiquitin was 
detected following SDS-PAGE and western blotting with P4D1 anti-ubiquitin antibody. Equal 
immunoprecipitation was confirmed by immunoblotting with anti-PS2 CTF antibody. (B) The 
overexpression of pcDNA3-PS2 WT and pcDNA3-PS2 ΔCUE was confirmed by western blotting 
with anti-PS2 CTF antibody.  A β-actin blot is included to show loading control. IP: 
immunoprecipitation; WB: western blot; Ub: ubiquitin; HC: IgG heavy chain: IgG LC light chain; 








Figure 3.6 Characterisation of PS2 CUE domain. HEK293T cells were transiently transfected with 
pcDNA3, pcDNA3-PS2 WT, pcDNA3-PS2 ΔCUE, pcDNA3-PS2 F289A/P290A, or pcDNA3-PS2 
L315A/Q316A and lysed under strict denaturing conditions.  The overexpression of pcDNA3-PS2 
WT, pcDNA3-PS2ΔCUE, pcDNA3-PS2 F289A/P290A, pcDNA3-PS2 F289S/P290S or pcDNA3-
PS2 L315A/Q316A was confirmed by western blotting with anti-PS2 CTF antibody.  A β-actin blot is 
included to show loading control.. WB: western blot; WT: wild type; FL: full length. Data are 




3.8 Purification of GST and recombinant GST-PS1 Loop Proteins 
As outlined above (section 3.7) a series of GST-tagged human PS1 Loop constructs 
were generated. The pGEX-6P1 vector contains the gene for a bacterial GST protein 
and this protein was used as a negative control for any experiment that used these 
GST-tagged PS1 Loop recombinant proteins. pGEX-6P1 and pGEX-6P1-PS1 Loop 
plasmids were transformed into BL21 E. coli cells, a single colony was picked from 
either plate and grown in a 5 ml culture. This culture was expanded to a 500 ml 
culture before being induced with 0.5 mM IPTG and grown overnight. The cultures 
were centrifuged and the pellets lysed using sonication and the recombinant proteins 
were purified using a glutathione-agarose column. To demonstrate protein 
purification, samples taken during the purification process were separated on a 12% 
SDS-PAGE gel and then stained with Coomassie dye. The bacterial GST protein was 
expressed and was resolved at a size of 25 kDa on the SDS-PAGE gel (Figure 
3.8A). The five GST elutions can be seen in lanes 8-12 of the gel. The GST-PS1 
Loop protein resolved at a size of 40 kDa (Figure 3.8B) and the six GST-PS1 Loop 
protein elutions can be seen in lanes 8-13. The ~15 kDa size difference between the 
two proteins represents the size of the inserted human PS1 loop domain. 
 
3.9 Purification of GST tagged PS1 Loop CUE Domain Mutants 
Once the pGEX-6P1-PS1 Loop plasmid had been created and the GST-PS1 Loop 
protein was successfully purified it was decided to make a series of recombinant PS1 
CUE domain mutants. The pGEX-6P1-PS1 Loop plasmid was used as a template for 






Figure 3.7 Schematic representation of recombinant GST- PS1 Loop proteins. The intracellular 
Loop domain (residues 265-380) of human PS1 was amplified by PCR and cloned into the pGEX-6P1 
expression vector to give it a N-terminal GST tag (blue highlighted region). Within the intracellular 
loop domain (purple highlighted region) of PS1 is the 44 amino acid long CUE domain (red 
highlighted region). Using site-directed mutagenesis the two key motifs within the PS1 CUE domain 
(positions marked above) were mutated singly or in tandem to create the following mutant proteins: 





F283A/P284A (GST-PS1 Loop FP/AA), GST-PS1 Loop V309A/S310A (GST-PS1 
Loop VS/AA) and GST-PS1 Loop F283A/P284A/V309A/S310A (GST-PS1 Loop 
FP/VS/AA). These plasmids were transformed into BL21 E. coli cells, a single 
colony was picked from each plate and grown in 5 ml of LB broth. This culture was 
expanded into a 500 ml culture before being induced with 0.5 mM IPTG and the 
culture was grown overnight. The culture was centrifuged, lysed by sonication and 
the GST-tagged recombinant proteins were purified on a glutathione-agarose 
column. The recombinant proteins were eluted with an elution buffer containing 10 
mM glutathione. Samples were taken during the purification process of each 
recombinant protein and resolved using a 12% SDS-PAGE gel. After separation the 
gel was stained with coomassie dye. The gel of the GST-PS1 Loop purification 
process from Figure 3.8B was repeated here to show equivalency of protein 
purification of the recombinant proteins. Figure 3.9B shows the purification process 
of the GST-PS1 Loop FP/AA protein, the induced recombinant protein can be seen 
at 40 kDa as before and the 4 elutions of the GST-PS1 Loop FP/AA protein can be 
seen in lanes 8-11. The recombinant proteins present in these elutions were later used 
in an ubiquitin pulldown assay. The purification of GST-PS1 Loop VS/AA protein 
can be seen in Figure 3.9C and the 5 elutions can be seen in lanes 8-12. The 
purification of the doubly mutated GST-PS1 Loop FP/VS/AA protein can be seen in 
Figure 3.9D and the elutions can be seen in lanes 8-12. Each elution of the 
recombinant GST-PS1 loop proteins were broadly similar to one another (Figure 
3.9). To demonstrate the equivalency of the elutions to one another 10 μl volumes of 
elution 2 of the GST, GST-PS1 Loop, GST-PS1 Loop FP/AA and GST- PS1 Loop 





Figure 3.8 Purification of recombinant GST and GST-PS1 Loop proteins. pGEX-6P1 and pGEX-
6P1-PS1 Loop were transformed into BL21 E.coli cells and the culture expanded to 500 ml before 
induction for 16 hrs with IPTG. The cultures were lysed through sonication and the recombinant 
proteins were purified using a glutathione-agarose column.  Samples were taken during the different 
purification stages and protein purification was demonstrated following separation through SDS-
PAGE. Purification of (A) recombinant GST and (B) recombinant GST-PS1 Loop were shown 
through staining with a Coomassie dye.. kDa: kilodaltons; Un: uninduced; In: induced; Ins: insoluble; 




GST-PS1 Loop and GST-PS1 Loop FP/AA were purified at roughly similar levels, 
which was roughly double the amount of purified GST-PS1 Loop VS/AA (Figure 
3.9E). There was roughly 4 times as much GST protein purified as compared to 
GST-PS1 Loop. Figure 3.9F shows the comparison between elution 2 of GST-PS1 
Loop and all elutions of GST-PS1 Loop FP/VS/AA. This demonstrates that elutions 
1, 2 and 4 are roughly 1/3 the intensity while elution 3 is roughly 1/2 intensity of 
GST-PS1 Loop. 
3.10 Recombinant GST-PS1 Loop and GST-PS1 Loop FP/AA but not 
GST-PS1 Loop VS/AA Mutant Binds to K63-Linked Polyubiquitin  
Having created that series of recombinant GST proteins (GST, GST-PS1 Loop, 
GST-PS1 Loop FP/AA, GST-PS1 Loop VS/AA  and GST-PS1 loop FP/VS/AA), 
they were next used to further demonstrate the functionality of the PS1 CUE domain. 
Instead of using the His-tagged recombinant proteins that were used in the in vivo 
ubiquitin binding assay (Figure 3.3), it was decided to use ubiquitin proteins 
expressed in HEK293T cells. Firstly, GST, GST-PS1 Loop, GST-PS1 Loop FP/AA 
and GST-PS1 Loop VS/AA recombinant proteins were immobilized with 30 μl of 
glutathione agarose beads, following incubation for 2 hours at 4°C. Next the 
immobilized recombinant GST-PS1 proteins were incubated with lysates from 
HEK293T cells that were over expressing HA-tagged K63only ubiquitin (HA-Ub 
K63only). This ubiquitin mutant has every lysine residue mutated to arginine except 
for the lysine 63 (K63) residue and so it can only form K63-linked polyubiquitin 
chains. GST protein was used as negative control for this experiment. The resulting 
samples were run on a 12% SDS-PAGE gel and the presence of bound HA-tagged 
ubiquitin was detected by immunoblotting for HA. Consistent with data presented in 
Figure 3.4A, the GST-PS1 Loop domain fusion protein and GST-PS1 Loop FP/AA 
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mutant bound to K63-linked polyubiquitin, while the GST-PS1 Loop VS/AA domain 
mutant lost the ability to bind K63-linked polyubiquitin (Figure 3.10A). To verify 
PS1 selectivity for binding to K63-linked ubiquitin in our pull-down assay, 
recombinant GST-PS1 Loop domain protein and GST-PS1 Loop VS/AA mutant 
were immobilized on glutathione agarose beads and then incubated with cell lysate 
from HEK293T cells overexpressing HA-tagged K63only ubiquitin (HA-Ub K63only) 
or HA-tagged K48only ubiquitin (HA-Ub K48only) (Figure 3.10B). The GST-PS1 
Loop domain fusion protein selectively bound to K63-linked polyubiquitin and not 
K48-linked polyubiquitin, while the GST-PS1 VS/AA mutant was again shown to 
have lost its ability to bind K63-linked polyubiquitin (Figure 3.10B). 
3.11 PS1 CUE Mutation Has No Effect On PS1 Endoproteolysis 
Having shown that PS1 contains a functional ubiquitin binding CUE domain next it 
was determined whether the CUE domain was required for presenilin 
endoproteolysis and γ-secretase activity. Given that the CUE domain (residues 271–
314) of PS1 is located within the large hydrophilic loop domain and spans the sites 
of presenilin endoproteolysis (PS1 Met292/Val293) [Jacobsen et al 1999; 
Thinakaran et al 1996], we examined the possible involvement of the putative CUE 
domain in endoproteolysis of PS1 by deletion of the entire CUE domain from PS1 
(PS1 ΔCUE) and mutagenesis of the two conserved motifs within the PS1 CUE 
domain (PS1F283A/P284A and PS1V309A/S310A). Presenilin double knockout 
murine embryonic fibroblasts (PSDKO MEFs) were transfected with pcDNA3, 
pcDNA3-PS1 WT, the catalytically inactive pcDNA3-PS1D257A/D385A 
(PS1ΔAsp) mutant, pcDNA3-PS1 ΔCUE, or CUE domain point mutants pcDNA3-
PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A. Cell lysates were separated by 





Figure 3.9 Purification of recombinant PS1 CUE domain mutant proteins. pGEX-6P1-PS1 Loop, 
pGEX-6P1-PS1 Loop FP/AA , pGEX-6P1-PS1 Loop VS/AA  and pGEX-6P1-PS1 Loop FP/VS/AA  
were transformed into BL21 E.coli cells and the cultures expanded to 500 ml before induction for 16 
hrs with IPTG. The cultures were lysed and the recombinant proteins were purified using a 
glutathione-agarose column.  Samples were taken during the different purification stages and protein 
purification was demonstrated following separation through SDS-PAGE. Purification of (A) GST-
PS1 Loop, (B) GST-PS1 FP/AA Loop, (C) GST-PS1 VS/AA Loop and (D) GST-PS1 FP/VS/AA 
Loop were shown through staining with a coomassie dye. The purified proteins are indicated by the 
arrows in the above gels. Elutions 2 of GST, GST-PS1 Loop, GST-PS1 Loop FP/AA and GST-PS1 
Loop Vs/AA proteins are compared in (E). All GST-PS1 Loop FP/VS/AA are compared to GST-PS1 





endoproteolysis was determined by immunoblotting with anti-PS1 NTF antibody 
(Figure 3.11). As anticipated, expression of the catalytically inactive 
PS1D257A/D385A (PS1ΔAsp) mutant, or deletion of PS1 CUE domain prevented 
the endoproteolysis of PS1, and abolished the formation of PS1 NTF fragment 
(Figure 3.11). However, expression of the PS1 CUE domain point mutants PS 
1F283A/P284A and PS1 V309A/S310A had no effect on PS1 endoproteolysis and 
formation of PS1 NTF fragment. 
3.12 PS1 CUE Domain Is Dispensable For γ-Secretase Cleavage of APP 
The presenilin proteins are predominantly studied as a component of the γ-secretase 
protease complex involved in the regulated intramembrane proteolysis of APP, 
Notch and several other type I integral membrane proteins [McCarthy et al 2009].  
To measure the effect of PS1 CUE domain deletion or mutation of the conserved 
PS1 CUE domain motifs on γ-secretase activity in cells PS1 CUE mutants were co-
expressed with a truncated APP mutation (APP CT100-FLAG), which corresponds 
to the β-secretase generated APP C99 C-terminus fragment, which is a constitutive 
substrate for γ-secretase protease. First, HEK293T cells, were transiently transfected 
with APP CT100-FLAG plasmid and co-transfected with pcDNA3, PS1, PS1ΔCUE 
PS1 F283A/P284A or PS1 V309A/S310A and cell lysates were subjected to Western 
blot analysis with an anti-APP C-terminus-specific antibody (Figure 3.12A). In cells 
expressing PS1, overexpressed APP C99-FLAG fragment is clearly detected (Figure 
3.12A, lane 3). In cells expressing PS1 and treated with the γ-secretase inhibitor, 
Compound E, accumulation of overexpressed APP C99-FLAG and endogenous APP 





Figure 3.10 Recombinant GST-PS1 selectively binds to K63 polyubiquitin while the GST-PS1 
VS/AA mutant does not. (A) Recombinant GST, GST-PS1 Loop, GST-PS1 FP/AA Loop and GST-
PS1 VS/AA Loop were bound to glutathione-agarose beads and incubated with lysates from 
HEK293T cells overexpressing K63only HA-Ub. Bound protein was resolved by SDS-PAGE and 
ubiquitin binding was detected by western blotting with anti-HA antibody. Pulldown of GST-PS1 
Loop, GST-PS1 FP/AA Loop and GST-PS1 VS/AA Loop was confirmed by western blotting with 
anti-PS1 CTF antibody. (B) GST, GST-PS1 Loop and GST-PS1 VS/AA Loop were bound to 
glutathione-agarose beads and incubated with lysates from HEK293T cells overexpressing K48only 
or K63only HA-Ub. Bound protein was separated via SDS-PAGE and bound protein was detected by 
western blotting with anti-HA antibody. Pulldown of GST-PS1 Loop and GST-PS1 VS/AA Loop was 
confirmed by western blotting with anti-PS1 CTF antibody. WB: western blot; Ub: ubiquitin. Data are 







Figure 3.11 Mutation of  PS1 CUE domain  does not affect PS1 endoproteolysis. Presenilin 
double knock out MEFs were transiently transfected with pcDNA3, pcDNA3-PS1 WT, pcDNA3-PS1 
ΔAsp, pcDNA3-PS1 ΔCUE, pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A 
expression vectors. Thirty six hours after transfection the cells were harvested, lysed with RIPA 
buffer and proteins were resolved by SDS-PAGE. PS1 endoproteolysis was detected by western 
blotting with 614.1 anti-PS1 NTF antibody. Equal loading was confirmed by western blotting with an 




PS1 CUE mutants did not alter levels of exogenous APP C99-FLAG nor endogenous 
APP C99 C-terminal fragment, which indicates that deletion of the CUE domain nor 
mutation of key residues does not induce a major change in γ-secretase activity 
(Figure 3.12A). To further confirm the result with a more sensitive method, cell 
culture medium was collected after transfection and tested using ELISA to measure 
the concentration of the γ-secretase cleavage products Aβ40 and Aβ42 (Figure 
3.12B). Results showed that CUE domain deletion or mutagenesis does not induce 
significant change in the generation of soluble Aβ40 and Aβ42. 
3.13 PS1 CUE domain is dispensable for γ-secretase cleavage of APP in 
MEFs 
To further validate this observation (Section 3.12), PS1-deficient MEFs were 
transiently transfected with pcDNA3, pcDNA3-PS1, pcDNA3-PS1ΔCUE, pcDNA-
PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A and cell lysates were analysed 
for endogenous APP C99, by Western blotting with an APP C-terminus-specific 
antibody (Figure 3.13). Again, expression of the CUE mutants had no effect on 
levels of endogenous APP C99, whereas treatment with the γ-secretase inhibitor 
Compound E (lane 3) caused the accumulation of the APP C99 fragment, therefore 
demonstrating that loss of or mutagenesis of the PS1 CUE domain does not 
significantly alter γ-secretase cleavage of APP. 
3.14 PS1 CUE domain is dispensable for γ-secretase cleavage of Notch 
Notch is another major γ-secretase substrate that is essential for development [Geling 
et al 2002]. To further examine the functionality of the PS1 CUE domain in the 
cleavage of γ-secretase substrates, HEK293T cells were transiently transfected with 




Figure 3.12 PS1 CUE domain is dispensable for γ-secretase cleavage of APP. (A) HEK293T cells 
were transiently co-transfected with FLAG-APP CT100 and pcDNA3-PS1 WT, pcDNA3-PS1 ΔCUE, 
pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A expression vectors. Twenty four hours 
after transfection cells were treated with the γ-secretase inhibitor compound E (Cpd E) (50 nM) as 
indicated. After 12 hours treatment with Cpd E the cells were harvested, lysed with RIPA buffer and 
the lysates were separated by SDS-PAGE. Cleavage of APP was detected by immunoblotting with an 
anti-APP CTF antibody; expression of the PS1 constructs was confirmed by immunoblotting with 
614.1 anti-PS1 NTF antibody. A β-actin blot was included as a loading control. Data are 
representative of experiments (n=3). (B) Media from HEK293T cells co-transfected with FLAG-APP 
CT100 and pcDNA3-PS1 WT, pcDNA3-PS1 ΔCUE, pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 
V309A/S310A was collected and used in ELISAs for Aβ40 and Aβ42. Data shown are the mean 
(SEM) of 3 independent experiments and p < 0.05 is considered significant.  
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transfected with pcDNA3 (Vector), pcDNA3-PS1 WT, pcDNA3-PS1 ΔCUE, 
pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A. Twenty-four hours 
post-transfection cell were treated with the γ-secretase inhibitor Compound E. After 
12 hours treatment with Compound E the cells were lysed and subjected to Western 
blot analysis with an anti-cleaved Notch 1 specific antibody (Figure. 3.14). In cells 
expressing PS1, generation of NICD was evident (Figure 3.14, lane 3), while in 
cells treated with the γ-secretase inhibitor, compound E (Figure 3.14, lane 4) 
formation of NICD was inhibited. In contrast, in cells expressing PS1 ΔCUE, PS1 
F283A/P284A or PS1 V309A/S310A, NICD formation is still observed. However, 
co-expression of NEXT with the pcDNA-PS1 ΔCUE mutant does cause a reduction 
in the formation of cleaved notch suggesting that deletion of the PS1 CUE domain 
may have an effect on modulating γ-secretase cleavage of Notch. These data shows 
that mutagenesisof key motifs within the CUE domain of PS1 has no effect on the γ-
secretase mediated cleavage of Notch. 
3.15 PS1 CUE domain has no effect on γ-secretase cleavage of IL-1R1  
There are over 100 known γ-secretase substrates known [McCarthy et al 2009] with 
APP and Notch being the most examined. As shown above deletion or mutation of 
the PS1 CUE domain has no effect on the cleavage of these two γ-secretase 
substrates. However, ubiquitination has been shown to regulate the γ-secretase 
mediated cleavage of some substrates [Gudey et al 2014, Twomey et al 2009]. 
Previous work in our lab has shown that IL-1R1 is a γ-secretase substrate and that 
this cleavage event is mediated by the E3 ligase TRAF6 [Elzinga et al 2009]. 
TRAF6 has also been shown to cause the K63-linked polyubiquitination of IL-1R1, 
which positively influences its cleavage by the γ-secretase complex [Twomey et al 







Figure 3.13 PS1 CUE domain function is dispensable for γ-secretase of APP cleavage in PS1KO 
MEFs. PS1KO MEF cells were transiently transfected with pcDNA3, pcDNA3-PS1 WT, pcDNA3-
PS1 ΔCUE, pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A expression vectors. 
Twenty four hours after transfection cells were treated with the γ-secretase inhibitor compound E 
(Cpd E) (50 nM) as indicated. After 12 hours treatment with Cpd E the cells were harvested, lysed 
with RIPA buffer and the lysates were separated by SDS-PAGE. Cleavage of endogenous APP was 
detected by immunoblotting with an anti-APP CTF antibody; expression of the PS1 constructs was 
confirmed by immunoblotting with 614.1 anti-PS1 NTF antibody. A β-actin blot was included as a 








Figure 3.14 PS1 CUE domain function is dispensable for γ-secretase cleavage of Notch. 
HEK293T cells were transiently co-transfected with NEXT and pcDNA3-PS1 WT, pcDNA3-PS1 
ΔCUE, pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A expression vectors as indicated. 
Twenty four hours after transfection cells were treated with the γ-secretase inhibitor compound E 
(Cpd E) (50 nM) as indicated. After 12 hours treatment with Cpd E the cells were harvested, lysed 
with RIPA buffer and the lysates were separated by SDS-PAGE. Cleavage of NEXT was detected by 
immunoblotting with an anti-cleaved Notch antibody; expression of the PS1 constructs was confirmed 
by immunoblotting with 614.1 anti-PS1 NTF antibody. A β-actin blot was included as a loading 




polyubiquitin chains it was decided to investigate whether the PS1 CUE domain had 
any effect on the regulation of this γ-secretase substrate. HEK293T cells were 
transiently transfected with pcDNA3-IL-1R1 WT and with either pcDNA-PS1 WT, 
pcDNA-PS1 ΔCUE, pcDNA-PS1 F283A/P284A or pcDNA-PS1 V309A/S310A. To 
act as a negative control cells expressing both pcDNA-IL-1R1 and pcDNA-PS1 were 
pre-treated for 12 hours with γ-secretase inhibitor Compound E. To stimulate 
ectodomain shedding, cells were treated with PMA as indicated for 2 hours before 
harvesting. Treatment with PMA stimulates formation of the IL-1R1 ICD (compare 
lanes 3 and 5 of Figure. 3.15) in cells coexpressing pcDNA3-IL-1R1 and pcDNA3-
PS1. However, as can be seen in lane 4 (Figure 3.15) that treatment with Cpd E 
inhibits formation of the IL-1R1 ICD fragment even when the cells are also treated 
with PMA. In cells coexpressing pcDNA3-IL-1R1 and the PS1 CUE mutants 
pcDNA-PS1 ΔCUE, pcDNA-PS1 F283A/P284A or pcDNA-PS1 V309A/S310A pre-
treatment with PMA also caused the formation of the IL-1R1 ICD fragment (see 
lanes 6-8 of Figure. 3.15). The level of IL-1R1 ICD was at a comparable level to the 
IL-1R1 ICD found in PMA treated cells expressing pcDNA3-PS1 WT (lane 5). This 
shows that deletion or mutation of the PS1 CUE domain has no effect on the γ-







Figure 3.15 PS1 CUE domain function is dispensable for γ-secretase cleavage of IL-1R1. 
HEK293T cells were transiently co-transfected with pcDNA3-IL-1R1 and either pcDNA3-PS1 WT, 
pcDNA3-PS1 ΔCUE, pcDNA3-PS1 F283A/P284A or pcDNA3-PS1 V309A/S310A expression 
vectors. Twenty four hours after transfection cells were treated with the γ-secretase inhibitor 
compound E (Cpd E) (50 nM) as indicated. After 10 hours pre-treatment with Cpd E ectodomain 
shedding was induced by a 2 hr treatment with PMA (200 ng/ml). After harvesting, cells lysed with 
RIPA buffer and the lysates were separated by SDS-PAGE. Cleavage of IL-1R1 was detected by 
immunoblotting with an anti-IL-1R1 C20 antibody; expression of the PS1 constructs was confirmed 
by immunoblotting with 614.1 anti-PS1 NTF antibody. A β-actin blot was included as a loading 





The presenilin proteins are typically seen as the protease found at the heart of the γ-
secretase complexes.  In addition to that, the presenilin proteins are involved in a 
number of γ-secretase independent functions such as regulating calcium homeostasis 
[Tu et al 2006], β-catenin signalling [Soriano et al 2001], protein trafficking 
[Esselens et al 2004] and apoptosis [Zeng et al 2015]. The presenilin proteins 
undergo a number of post translational modifications, such as ubiquitination, 
phosphorylation and caspase cleavage, within the large intracellular loop domain that 
exists between TMDs 6 and 7 of both proteins (see Fig. 1.2). This intracellular loop 
has also been shown to be the site of protein-protein interactions that are involved in 
γ-secretase independent roles of the presenilins, e.g. β-catenin/δ-catenin and Rab11 
[Zhou et al 1997, Dunmanchin et al 1999]. As such this intracellular loop domain 
represents an important region in investigating γ-secretase independent roles of 
presenilin proteins. 
Previous work in our lab identified an area of homology between a region of the 
intracellular loop domains of the presenilins (residues 271-314 in human PS1 and 
277-320 of human PS2) and the sequence of proteins containing an ubiquitin binding 
CUE domain (Figure 3.1A)  [James Powell]. Both presenilins contained the highly 
conserved FP motif (residues F283/P284 for human PS1 and residues F289/P290 for 
human PS2) and a less well conserved di-leucine motif (residues V309/S310 for 
human PS1 and L315/Q316 for human PS2). These putative CUE domains in the 
presenilins were well conserved across different species and evolutionary time 
(Figure 3.1B). To investigate the function of the presenilin CUE domains the CUE 
domain of both PS1 and PS2 were deleted, and the key FP and VS or LQ motifs 
were mutated in PS1 and PS2, respectively. Using an ubiquitin binding assay using 
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immunopurified presenilin proteins and recombinant polyubiquitin molecules it was 
shown that the presenilin CUE domains bind preferentially to K63-linked 
polyubiquitin chains over K48-linked polyubiquitin (Figure 3.3 and 3.5). 
Additionally we have shown that the V309/S310 motif, but not the F283/P284 motif, 
is required for K63 polyubiquitin binding to the PS1 CUE domain (Figure 3.4A). 
The effect of point mutations within the PS2 CUE domain remains to be explored 
(Figure 3.5B) To strengthen this observation a series of GST-tagged proteins 
containing the intracellular loop domain of PS1 were created (Figure 3.7), which 
contained either the WT PS1 CUE domain or PS1 CUE domains with the conserved 
FP and VS motifs mutated either singly or in tandem. These recombinant proteins 
were then used in an ubiquitin pulldown assay to demonstrate PS1 CUE domain 
function. These experiments further demonstrate that the PS1 CUE domain 
preferentially binds to K63-linked polyubiquitin and that residues V309/S310 are 
required for this interaction (Figure 3.10). Therefore, using both cell based and 
recombinant protein based approaches we have shown that PS1 contains a functional 
ubiquitin binding CUE domain within its intracellular loop domain and that the 
conserved V309/S310 motif is required for PS1 CUE domain function. 
The Jnet secondary structure prediction software to analyse the structures of the 
putative CUE domains of the presenilins and those of known CUE domains (Figure 
3.1A). This analysis predicted a three helical structure of the examined CUE 
domains, where the conserved FP motif was found at the C-terminal end of the first 
helix and the semi-conserved di-leucine motif was found within the third helix. The 
structure of the CUE domains of Vps9 [Prag et al 2003] and Tollip [Azurmendi et al 
2010] have been determined using X-ray crystallography and NMR, respectively. In 
the Vps9 CUE domain the FP motif directly interacts with the surface of ubiquitin 
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and the proline residue represents the end point of the first helix of the domain [Prag 
et al 2003]. However, in the Tollip CUE domain the first helix ends prior to the FP 
motif [Azurmendi et al 2010]. This discrepancy may help explain the reason why 
mutation of the F283/P284 motif of PS1 does not affect PS1 CUE domain function, 
that there is some variability in the structures of CUE domains. In Vps9 the di-
leucine motif is present in the third helix of the CUE domain where the first leucine 
residue (L446) plays a role in stabilising the Vps9 CUE domain structure and the 
second lysine residue (L447) interacts with the surface of ubiquitin, including the 
K48 residue of ubiquitin [Prag et al 2003]. Applying this model to the PS1 CUE 
domain the PS1 V309 residue would be required for PS1 CUE domain secondary 
structure and the PS1 S310 residue would interact with the surface of ubiquitin 
proteins. This proposed interaction between S310 and ubiquitin may explain the 
importance of the V309/S310 motif to the binding of K63 polyubiquitin. This motif 
may represent the region that specifies the binding of K63 polyubiquitin to the PS1 
CUE domain. 
After showing that the presenilin CUE domains bind to K63-linked polyubiquitin it 
was decided to investigate whether the PS1 CUE domain had no role to play in more 
established presenilin functions. Firstly, it was shown that mutation of the 
F283/P284 and V309/S310 sites had no effect on PS1 endoproteolysis (Figure 3.11) 
in PS double knockout MEFs. Deletion of the PS1 CUE domain also deleted the site 
of PS1 endoproteolysis [Steiner et al 1999] so as expected this mutated protein does 
not undergo endoproteolysis.  Next, the effect of PS1 CUE domain deletion or 
mutation of conserved CUE domain motifs on γ-secretase function was investigated 
using the PS1 ΔCUE, PS1 F283A/P284A and PS1 V309A/S310A mutants. The PS1 
CUE domain was shown to be dispensable for APP cleavage in both HEK293T cells 
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(Figure 3.12A) and PS1 deficient MEFs (Figure 3.13). Formation of the γ-secretase 
APP cleavage products Aβ40 and Aβ42 was also examined through ELISA, showing 
that CUE domain deletion or mutation of conserved motifs had no significant effect 
on levels of Aβ40/42 (Figure 3.12B). Similarly the PS1 F283A/P284A and PS1 
V309A/S310A mutations had no effect on cleavage of NEXT, a constitutively 
cleaved Notch construct, when co-expressed in HEK293T cells (Figure 3.14). 
Finally, the γ-secretase cleavage of IL-1R1 was examined using these PS1 CUE 
domain mutants.  Co-expression of the PS1 ΔCUE, PS1 F283A/P284A or PS1 
V309A/S310A mutants with IL-1R1 WT had no effect on PMA induced IL-1R1 
ICD formation in HEK293T (Figure 3.15). These data demonstrate that mutation of 
the CUE domain of PS1 has no effect on either presenilin endoproteolysis or of the 
γ-secretase mediated cleavage of the γ-secretase substrates APP, Notch and IL-1R1.  
However, when the PS1 ΔCUE mutant was co-expressed with the NEXT construct 
in HEK293T cells there was a reduction in NICD formation was compared to PS1 
WT or to the PS1 F283A/P284A or PS1 V309A/S310A CUE domain point mutants 
(Figure 3.14). Additionally, there was a reduction in formation of both Aβ40 and 
Aβ42 in HEK293T cells overexpressing the PS1 ΔCUE mutant, though this 
reduction was not found to be statistically significant. These data raise the possibility 
that the non-endoproteolytically cleaved PS1 ΔCUE mutant may have a reduced γ-
secretase function compared to PS1 proteins which undergo endoproteolysis. The 
PS1 ΔE9 mutation causes the formation of a non-cleavable PS1 protein, missing 
residues 290-319 of PS1, which contains the site of endoproteolysis [Rovelet-Lecrux 
et al 2015]. Expression of the PS1 ΔE9 mutant in presenilin null MEFs has been 
shown to cause a reduction in the formation of AICD and Aβ40 and Aβ42 as 
compared to expression of PS1 WT [Cacquevel et al 2012]. Neurons formed from 
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induced pluripotent stem cells expressing the PS1 ΔE9 mutation show a greater 
expression of APP CTF while also showing an increase in the Aβ42 to Aβ40 ratio. 
These data suggest that the formation of a non-endoproteolytically cleavable PS1 
holoprotein can have an effect on γ-secretase function within cells. This may suggest 
a reason for the differences in γ-secretase function within cells expressing the PS1 
ΔCUE mutant.  
The intracellular loop domains of the presenilins represent a region with numerous 
protein-protein interactions [McCarthy et al 2009] and post translational 
modifications [see Figure 1.2]. The presence of ubiquitin binding CUE domains in 
the presenilin proteins therefore represents a novel way in which presenilin function 
can be regulated. The serine residue of the conserved V309/S310 motif of the PS1 
CUE domain has previously been shown to be a site of PKA phosphorylation 
[Fluhrer et al 2004]. To investigate whether PKA phosphorylation regulates PS1 
CUE domain function a pseudo-phosphorylated PS1 S310E mutant was created and 
used in an ubiquitin binding assay (Figure 3.4). This pseudo-phosphorylated PS1 
S310E mutant showed no difference in K63-linked polyubiquitin binding compared 
to PS1 WT, suggesting that PS1 CUE domain function is not regulated by PKA 
phosphorylation. 
The CUE domain of the presenilins spans the sites of endoproteolysis, suggesting 
that the presenilin CUE domains are only functional in the immature holoproteins. 
Having shown that the presenilins can interact with K63-linked polyubiquitin chains, 
next we need to explain the function of this novel presenilin domain.  While K48-
linked polyubiquitination is primarily associated with protein degradation via the 
ubiquitin proteasome system, K63 ubiquitination is known to be involved in a 
number of other pathways including DNA repair and cell signalling pathways [Ge et 
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al 2015, Wang et al 2015]. The presenilins are known to interact with over 50 
proteins that cover a number of cellular pathways and functions [reviewed in 
McCarthy et al 2009]. The presenilins are also known to be involved in a number of 
γ-secretase independent roles, including those that are associated with the 
holoprotein. In the next chapter we will begin to explore the function of the PS1 
CUE domain by investigating the effect of the PS1 CUE domain on a number of PS1 




4 PS1 Interacting Proteins and the PS1 CUE Domain 
Introduction 
In chapter 3 it was demonstrated that the presenilins contain functional CUE 
domains that selectively bind to K63-linked polyubiquitin chains. It was further 
demonstrated that the PS1 CUE domain is dispensable for PS1 endoproteolysis and 
the γ-secretase mediated cleavage of APP, Notch and IL-1R1. Having shown that 
PS1 contains an ubiquitin binding CUE domain within its intracellular loop domain, 
the possible function(s) of this domain was next considered. We hypothesised that 
the PS1 CUE domain is involved in regulating intermolecular or intramolecular 
presenilin protein-protein interactions. By this we mean that the PS1 CUE domain 
could be involved in interacting with K63-linked polyubiquitinated PS1 interacting 
proteins or the PS1 CUE domain interacts with K63-linked polyubiquitinated PS1 
proteins. Therefore, we reasoned that through the identification of the PS1 CUE 
domain interacting protein(s) it would be possible to begin to elucidate the 
function(s) of this novel ubiquitin binding domain within PS1. 
The presenilins were first discovered through research into genetic linkages in 
familial Alzheimer’s disease and much early research was focused on discovering 
presenilin interacting proteins as a means of investigating presenilin function. The γ-
secretase protease complex is comprised of presenilins, Nicastrin [Yu et al 2000], 
Aph1 and Pen-2 [Hebert et al 2004]. While the identity of the members of the γ-
secretase complex had been determined, further research into the presenilins 
demonstrated that the presenilins had a number of γ-secretase independent functions 
such as involvement in calcium homeostasis [Tu et al 2006], apoptosis [Guo et al 
1996] and protein trafficking [Naruse et al 1998]. As such identifying presenilin 
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interacting proteins remained a research priority, leading to the discovery of an ever 
increasing number of presenilin interacting proteins such as the catenins [Zhou et al 
1997], GSK3β [Takashima et al 1998] and calsenilin [Buxbaum et al 1998] amongst 
many others [McCarthy et al 2009; Soler-Lopez et al 2011]. The involvement of the 
presenilins in diverse cell signalling pathways has been shown through the 
identification of presenilin interacting proteins. For example, expression of PS1 and 
PS2 FAD mutants was observed to lead to an increase in apoptosis [Guo et al 1997; 
Janicki et al 1997] which lead to the discovery that the presenilins interact directly 
with the apoptotic proteins such as Bcl-2 [Alberici et al 1999], Bcl-2L1 [Passer et al 
1999] or the presenilin-associated protein (PSAP) [Xu et al 2002]. Conversely 
identification of presenilin interacting proteins has also suggested novel signalling 
for the presenilins, e.g. once the presenilins were shown to interact with the catenin 
proteins [Zhou et al 1997] it lead to the discovery that the presenilin were involved 
in the regulation of Wnt signalling [Kawamura et al 1998] and β-catenin mediated 
apoptosis [Zhang et al 2008].  
Apart from the proteins that make up the γ-secretase complex, PS1 and PS2 share a 
number of common interacting proteins including the γ-secretase substrate APP, 
glutaryl-CoA dehydrogenase (GCDH), the E3 ligase F-box/LRR-repeat protein 12 
(FBXL12), the adaptor protein ECSIT and programmed cell death 4 (PDCD4) have 
all been shown to directly interact with both PS1 and PS2 [Soler-Lopez et al 2011]. 
Calsenilin [Buxbaum et al 1998] calmyrin [Stabler et al 1999], KCNIP4 [Morohashi 
et al 2002] and the calcium channels SERCA [Green et al 2008] and InsP3R [Cai et 
al 2006; Cheung et al 2008], which all interact with both presenilins, are all involved 
in the regulation of calcium homeostasis. This supports the observation that both PS1 
and PS2 are involved in calcium regulation [Muller et al 2011; Kipanyula et al 
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2012]. The adhesion protein ICAM5 [Annaert et al 2001], the glial fibrillary acidic 
protein (GFAP) [Nielsen et al 2002] and the cytoskeleton protein filamin B [Zhang 
et al 1998] are structural proteins that also interact with both proteins. The armadillo 
proteins β-catenin and δ-catenin, which associate with the cadherin adhesion 
proteins, interact with the intracellular loops of PS1 and PS2 [Levesque et al 1999]. 
FAD mutations within both presenilin proteins inhibit the translocation of β-catenin 
to the nucleus [Nishimura et al 1999] suggesting that both presenilin proteins are 
involved in the regulation of β-catenin signalling. The E3 ligase TRAF6 interacts 
and ubiquitinates both presenilin proteins [Elzinga et al 2009; Yan et al 2013] and 
the UBA domain containing protein ubiquilin also interacts with PS1 and PS2 [Mah 
et al 2000]. The Bcl-2 family member Bcl-2L1 interacts with both presenilins 
[Passer et al 1999] while only PS1 has been shown to interact with Bcl-2 [Alberici et 
al 1999]. Similarly, PSAP interacts solely with PS1 [Xu et al 2002] and upregulates 
apoptosis through its interaction with Bax [Zeng et al 2015]. These differences in 
protein-protein interactions between the presenilin proteins may explain the 
differences in apoptosis observed between PS1 and PS2 [Amson et al 2000; Alves da 
Costa et al 2003]. 
CUE domains have been shown to be involved in a number of pathways such as 
autophagy [Lu et al 2014], protein turnover [Bagola et al 2013], endocytosis [Davies 
et al 2014] and cell signalling [Kishida et al 2005]. CUE domains have also been 
shown to be involved in the regulation of proteins turnover and stability within the 
cell in a number of discrete ways. The yeast protein Cue5 and its mammalian 
homolog Tollip are involved in the autophagic turnover of Poly-Q proteins, such as 
huntingtin [Lu et al 2014]. Similarly the CUE domain of Cue1p is involved in 
regulating the turnover of proteins through ERAD [Bagola et al 2013. Conversely, 
99 
 
the CUE domain of FANCD2 prevents the polyubiquitination and proteasomal 
degradation of FANCD2 through its binding to monoubiquitin [Rego et al 2012]. 
The CUE domain of Vps9 has been shown to be essential for endocytosis in yeast 
cells [Davies et al 2003]. CUE domains have also been shown to be involved in the 
regulation of cell signalling pathways. The CUE domain of TAB2 is required for the 
ubiquitination of TRAF6 and for the propagation of IL-1 signalling in human 293 
cells [Kishida et al 2005] while the CUE domain of CUEDC2 is involved regulating 
progesterone receptor signalling [Zhang et al 2007] and mitotic regulation [Gao et al 
2011]. Given that the presenilins and ubiquitin binding CUE domains can be 
involved in multiple cellular functions and pathways, it was decided to first focus the 
search for PS1 CUE domain interacting proteins on known PS1 interacting proteins 
that undergo K63-linked polyubiquitination. 
In this chapter a list of published presenilin-interacting proteins are compiled and 
their published ubiquitination states are identified. This list is then narrowed down to 
include K63-linked polyubiquitinated proteins which also interact with PS1. Then 
using a bioinformatics based approach the sites of potential ubiquitination within 
these proteins are identified. The TRAFs are a family of E3 RING domain 
containing proteins that are involved regulating cell signalling pathways [Silke and 
Melino 2009]. TRAF6 has previously been shown to promote the K63-linked 
polyubiquitination of PS1 [Yan et al 2013; Gudey et al 2014]. In this study, using 
co-immunoprecipitation assays the E3 ligase activity of TRA6 was shown to be 
required for the interaction between TRAF6 and PS1. The PS1 CUE domain was 
also shown to be dispensable for this interaction with TRAF6, but mutation of 
conserved residues within the PS1 CUE domain was shown to be required for the 
interaction between PS1 and TRAF6. However, mutation of these conserved PS1 
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CUE domain residues had no effect on the TRAF6 mediated increased stability of 
the PS1 holoprotein. Additionally, previous studies in our lab have shown that PS1 
interacts with TRAF2 [Powell unpublished]. In this study, using an ubiquitination 
assay we showed that PS1 is a target for TRAF2 mediated K63-linked 
polyubiquitination but the PS1 CUE domain is dispensable for this interaction 





4.1 Presenilin Interacting Proteins 
In addition to their interactions with Aph1, nicastrin and Pen-2 as part of the γ-
secretase complex the presenilins are known to interact with a large number of 
additional proteins [McCarthy et al 2009; Soler-Lopez et al 2011]. As a way of 
investigating the function of the PS1 CUE domain it was decided to analyse known 
PS1 interacting proteins to look for proteins which are subject to K63-linked 
polyubiquitination. Any PS1 interacting protein that is subject to K63-linked 
polyubiquitination could represent a protein that interacts with the K63-linked 
polyubiquitin binding PS1 CUE domain. To construct the PS1 interactome a list of 
PS1 interacting proteins was compiled from conflating a previously published source 
[McCarthy et al 2009] and an online database of published human PS1 interacting 
proteins obtained from the BioGRID [http://thebiogrid.org/111642/summary/homo-
sapiens/psen1.html]. The BioGRID (http://thebiogrid.org/) is an online database that 
records published protein-protein interactions and known sites of posttranslational 
modification.  Therefore, once the list of PS1 interacting proteins was generated the 
potential for ubiquitination of these proteins was investigated using the BioGRID. 
These data were compiled (Table 4.1) providing the gene symbol, protein name, 
type of ubiquitination and citations for both the interaction with PS1 and for the 
proteins ubiquitination. For many of these proteins, for example CD147 [Beltrao et 
al 2012], FKBP38, GDI1 [Udeshi et al 2013] etc., their ubiquitination was 
determined using high throughput screening using mass spectrometry. Using this 
high throughput approach CD147 was shown to be ubiquitinated at 13 different 
lysine residues [Beltrao et al 2012], FKBP38 at 9 different lysine residues and GDI1 
at 12 lysine residues [Udeshi et al 2013]. For these proteins the high throughput 
analysis would give the site of ubiquitination but would not be able to determine 
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whether this was a site of monoubiquitin or polyubiquitination nor would it provide 
the type of polyubiquitin chains that could be bound to that site. For all proteins 
whose ubiquitination was determined in this manner the type of ubiquitination is 
recorded as ‘screen’. For some proteins that undergo ubiquitination the type of 
ubiquitination is determined through ubiquitination assays but the type of 
polyubiquitination is not determined so these are recorded as ‘not specified’. In other 
cases the type of ubiquitination is not determined but the proteins ubiquitination is 
involved in determining protein turnover so these are recorded as ‘not specified 
UPS’. If the type of protein ubiquitination is known it is recorded e.g. mono, K48, 
K63, etc.  
From the data provided in (Table 4.1), all reported PS1 interacting protein that are 
known to undergo K63-linked polyubiquitination are summarized in (Table 4.2). 
This table provides the gene symbol, protein name and a citation for the K63-linked 
polyubiquitination of these PS1 interacting proteins. The proteins (Table 4.2) 
provided a start-point from which it was possible to begin investigating the 
function(s) of the PS1 CUE domain. 
These K63-linked polyubiquitinated PS1-interacting proteins are involved in a 
variety of cell signalling pathways. BACE and Tau are proteins that are associated 
with the β-amyloid and neurofibrillary tangle pathologies of AD, respectively [Zou 
et al 2014]. Meanwhile, Fe65 is a protein that interacts with the AICD to regulate 
gene transcription [Vazquez et al 2009]. BACE1 is ubiquitinated at residue K501 by 
either monoubiquitin or K63-linked polyubiquitination [Kang et al 2008]. Fe65 
turnover is regulated by its K63-linked polyubiquitination by the E3 ligase RNF157 
[Matz et al 2015] and similarly K63-linked polyubiquitination of Tau causes the 
p62-mediated proteasomal degradation of the protein [Babu et al 2005]. Best 
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Table 4.1 Presenilin-1 Interacting Proteins and their known ubiquitination type  
Protein name Protein Name Type Interaction citation Ubiquitination 
Citation 
ACHE acetylcholinesterase  Silveyra et al 2008  
ACTN1 actinin, alpha 1 screen Soler-Lopez et al 2011 Povlsen et al 
2012 
AP1M2 adaptor-related protein complex 
1, mu 2 subunit 
screen Soler-Lopez et al 2011 Beltrao et al 
2012 
APBA1 amyloid beta (A4) precursor 
protein-binding, family A 
 Lau et al 2000 
 
APBB1 amyloid beta (A4) precursor 
protein-binding, family B 
K63 Lau et al 2000 Matz et al 2015 
APH1A APH1A gamma secretase subunit screen Hebert et al 2004 Beltrao et al 
2012 
APH1B APH1B gamma secretase subunit screen Hebert et al 2004 Beltrao et al 
2012 
APOE apolipoprotein E not specified Soler-Lopez et al 2011 Wenner et al 
2001 
APP amyloid beta (A4) precursor 
protein 
K48  Soler-Lopez et al 2011 Beltrao et al 
2012 
BACE BACE mono/k63 Hebert et al 2003 Kang et al 
2008 
BCL2  B-cell CLL/lymphoma 2 mono Alberici et al 1999 Chen et al 
2010 
BCL2L1 BCL2-like 1 K48  Passer et al 1999 Wagner et al 
2011 
CAPN1 Calpain  Shinozaki et al 1998 Beltrao et al 
2012 
CD147 CD147  Zhou et al  2005 Beltrao et al 
2012 
CDC37 cell division cycle 37 screen Soler-Lopez et al 2011 Beltrao et al 
2012 
CDH1 cadherin 1, type 1, E-cadherin 
(epithelial) 
K48  Georgakopoulos et al 
1999 
Yang et al 
2006 
CDK5 cyclin-dependent kinase 5 K48  Soler-Lopez et al 2011 Udeshi et al 
2013 
CFL1 cofilin 1 (non-muscle) screen Soler-Lopez et al 2011 Danielsen et al 
2011 
CIB1 calcium and integrin binding 1 
(calmyrin) 
screen Stabler et al 1999 Kim et al 2011 
CLIP1 CLIP1/CLIP170 screen Johnsingh et al 2000 Stes et al 2014 
CLSTN1 calsyntenin 1 screen Araki et al 2004 Beltrao et al 
2012 
CTNNA1 catenin (cadherin-associated 
protein), alpha 1, 102kDa 
screen Georgakopoulos et al 
1999 
Povlsen et al 
2012 
CTNNB1 catenin (cadherin-associated 
protein), beta 1, 88kDa 
K11, K48, 
K63 
Raurell et al 2006 Dao et al 2012 
CTNND1 catenin (cadherin-associated 
protein), delta 1 
screen Tanahashi et al 1999 Kim et al 2011 
CYP2C18 cytochrome P450, family 2, 
subfamily C, polypeptide 18 
 Soler-Lopez et al 2011 
 
CYP2C8 cytochrome P450, family 2, 
subfamily C, polypeptide 8 
 Soler-Lopez et al 2011 
 
DHX9 DEAH (Asp-Glu-Ala-His) box 
helicase 9 
screen Havugimama et al 
2012 




DOCK3 dedicator of cytokinesis 3 screen Kashiwa et al 2000 Danielsen et al 
2011 
DSP desmoplakin screen Raurell et al 2006 Beltrao et al 
2012 
DTNA dystrobrevin, alpha  Havugimama et al 
2012 
 
ECSIT ECSIT signalling integrator k63 Soler-Lopez et al 2011 Mi Wi et al 
2015 
EFHD1 EF-hand domain family, member 
D1 
screen Soler-Lopez et al 2011 Oshikawa et al 
2012 
ENSA endosulfine alpha screen Soler-Lopez et al 2011 Stes et al 2014 
EPB41L3 erythrocyte membrane protein 
band 4.1-like 3 
screen Soler-Lopez et al 2011 Povlsen et al 
2012 
ERLIN2 ER lipid raft associated 2 screen Teranishi et al 2012 Beltrao et al 
2012 
ERN1 endoplasmic reticulum to nucleus 
signaling 1 
K63 Katayama et al 1999 Zhu et al 2014 
ETFA electron-transfer-flavoprotein, 
alpha polypeptide 
screen Van Gassen et al 1999 Beltrao et al 
2012 
FBXL12 F-box and leucine-rich repeat 
protein 12 
screen Soler-Lopez et al 2011 Beltrao et al 
2012 
FBXW7 F-box and WD repeat domain  
containing 7, E3 ubiquitin protein 
 ligase 
Li et al 2002 Udeshi et al 
2013 
FGF13 fibroblast growth factor 13  Soler-Lopez et al 2011  
FKBP38 FKBP38 screen Wang et al 2005 Povlsen et al 
2012 




screen Soler-Lopez et al 2011 Kim et al 2011 
GCDH glutaryl-CoA dehydrogenase screen Soler-Lopez et al 2011 Udeshi et al 
2013 
GDI1 GDP dissociation inhibitor 1 screen Scheper et al 2000 Udeshi et al 
2013 
GFAP glial fibrillary acidic protein not specified Nielsen et al 2002 Beltrao et al 
2012 
GNAO1 guanine nucleotide binding 
protein (G protein), alpha 
screen Smine et al 1998 Udeshi et al 
2013 
GRB2 growth factor receptor bound 
protein 2 
screen Nizzari et al 2007 Beltrao et al 
2012 
GRIN1 glutamate receptor, ionotropic, 
NMDA1 (zeta 1) 
 Saura et al 2004 
 
GSAP gamma-secretase activating 
protein 
 He et al 2010 
 
GSK3B glycogen synthase kinase 3 beta mono/not 
specified 
Takashima et al 1998 Gao et al 2014 
HERPUD1 homocysteine-inducible, 
endoplasmic reticulum stress-
inducible, ubiquitin-like domain 
member 1 
screen Sai et al 2002 Beltrao et al 
2012 
HMGB1 high mobility group box 1 screen Soler-Lopez et al 2011 Beltrao et al 
2012 
HTRA2 HtrA serine peptidase 2 screen Gupta et al 2004 Beltrao et al 
2012 
ICAM5 intercellular adhesion molecule 5, 
telencephalin 
 Annaert et al 2001 
IRAK2 interleukin-1 receptor-associated 
kinase 2 
screen Elzinga et al 2009 Lee et al 2011 
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ITPR1 inositol 1,4,5-trisphosphate 
receptor, type 1 
not specified 
UPS 
Cheung et al 2008 Sarraf et al 
2013 
ITSN2 intersectin 2 screen Soler-Lopez et al 2011 Stes et al 2014 
JUP junction plakoglobin screen Raurell et al 2006 Beltrao et al 
2012 
KANK2 KN motif and ankyrin repeat 
domains 2 
screen Soler-Lopez et al 2011 Kim et al 2011 
KCNIP3 Calsenilin not specified 
UPS 
Buxbaum et al 1998 Jang et al 2011 
KCNIP4 Kv channel interacting protein 4  Morohashi et al 2002 
MAPT microtubule-associated protein 
tau 
K63 Takashima et al 1998 Babu et al 
2005 
MET1 Met1 methyltransferase  Zhang et al 2001  
NCSTN nicastrin screen Yu et al 2000 Udeshi et al 
2013 
NDUFS8 NADH dehydrogenase 
(ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q 
reductase) 
screen Havugimana et al 2012 Beltrao et al 
2012 
NOS3 nitric oxide synthase 3 
(endothelial cell) 
screen Soler-Lopez et al 2011 Beltrao et al 
2012 
NOTCH1 notch 1 k29/mono Ray et al 1999 Chastagner et 
al 2008 
OXCT1 3-oxoacid CoA transferase 1 screen Soler-Lopez et al 2011 Stes et al 2014 
PARL presenilin associated, rhomboid-
like 
screen Pellegrini et al 2001 Beltrao et al 
2012 





Soler-Lopez et al 2011 Beltrao et al 
2012 
PIK3R1 phosphoinositide-3-kinase, 
regulatory subunit 1 (alpha) 
 Baki et al 2004 
PKP4 plakophilin 4 screen Stahl et al 1999 Beltrao et al 
2012 
PLD1 phospholipase D1 mono-multi Cai et al 2006 Yin et al 2010 
PRAM1 PML-RARA regulated adaptor 
molecule 1 
 Soler-lopez et al 2011 
PRDX1 Peroxiredoxin 1 PAG k48 Zhou et al 2002 Nasu et al 2010 
PRDX2 peroxiredoxin 2 screen Soler-Lopez et al 2011 Beltrao et al 
2012 
PRKACB protein kinase, cAMP-dependent, 
catalytic, beta 
screen Kang et al 2002 Beltrao et al 
2012 
PSEN1 presenilin 1 K63 Hebert et al 2004 Yan et al 2013 
PSEN2 presenilin 2 K63 Hebert et al 2004 Yan et al 2013 
PSENEN presenilin enhancer gamma 
secretase subunit 
 Hebert et al 2004 
PSMA5 proteasome (prosome, 
macropain) subunit, alpha type, 5 
screen Van Gassen et al 1999 Beltrao et al 
2012 
PSMB1 proteasome (prosome, 
macropain) subunit, beta type, 1 
screen Van Gassen et al 1999 Beltrao et al 
2012 
RAB11A RAB11A screen Dumanchin et al 1999 Udeshi et al 
2013 
RAB3A RAB3A, member RAS oncogene 
family 
 Soler-lopez et al 2011 
RAD23A RAD23 homolog A (S. 
cerevisiae) 
 Soler-Lopez et al 2011 
RHEB Ras homolog enriched in brain screen Soler-Lopez et al 2011 Beltrao et al 
2012 
RIPK1 receptor (TNFRSF)-interacting K63 Unpublished data Ea et al 2006 
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serine-threonine kinase 1 
RMDN3 regulator of microtubule 
dynamics 3 
screen Soler-Lopez et al 2011 Danielsen et al 
2011 
RNF32 ring finger protein 32  Soler-Lopez et al 2011  
RYR2 ryanodine receptor 2  screen Takeda et al 2005 Sarraf et al 
2013 
SCN1A sodium channel, voltage-gated, 
type I, alpha subunit 
 Soler-Lopez et al 2011 
SRI Sorcin screen Pack-Chung et al 2000 Stes et al 2014 
ST13 suppression of tumorigenicity 13 
(colon carcinoma) (Hsp70 
interacting protein) 
screen Soler-Lopez et al 2011 Beltrao et al 
2012 
STAMBPL1 STAM binding protein-like 1 screen Soler-Lopez et al 2011 Udeshi et al 
2013 
STX1A Syntaxin 1A  smith et al 2000  
STX5 Syntaxin 5 screen Suga et al 2004 Povlsen et al 
2012 
TCF4 transcription factor 4 not specified Raurell et al 2006 Yamada et al 
2006 
TCF7L2 transcription factor 7-like 2 (T-
cell specific, HMG-box) 
screen Palacino et al 2001 Udeshi et al 
2013 
TDP2 tyrosyl-DNA phosphodiesterase 
2 
screen Wang et al 2011 Danielsen et al 
2011 
TGFBR1 transforming growth factor, beta 
receptor 1 
K63 Gudey et al 2014 Mu et al 2011 
TMED10 TMP21 screen Chen et al 2006 Beltrao et al 
2012 
TPTE2 transmembrane phosphoinositide  
-phosphatase and tensin homolog 2 
Prihar et al 1999  
TRAF2 TNF receptor-associated factor 2, 
E3 ubiquitin protein ligase 
K63 Unpublished data Li et al 2009 
TRAF6 TNF receptor-associated factor 6, 
E3 ubiquitin protein ligase 
k63 Elzinga et al 2009 Wooten et al 
2005 
TUBA1B tubulin, alpha 1b screen Soler-Lopez et al 2011 Danielsen et al 
2011 
UBC ubiquitin C  Yan et al 2013 Danielsen et al 
2011 
UBQLN1 ubiquilin 1  Mah et al 2000 Beltrao et al 
2012 
UMPS uridine monophosphate 
synthetase 
screen Soler-Lopez et al 2011 Stes et al 2014 
YME1L1 YME1-like 1 ATPase screen Pellegrini et al 2001 Kim et al 2011 
 
characterised as a signalling molecule that links transmembrane adhesion proteins 
with Wnt signalling and gene transcription [Rosenbluh et al 2014], β-catenin is 
regulated by K11- and K63-linked polyubiquitination by FANCL [Dao et al 2012]. 
ECSIT, RIP1, TRAF2 and TRAF6 are adaptor proteins that are involved in signal 
transduction [Wi et al 2014; De et al 2014; Park et al 2015; Lamothe et al 2007]. 
The K63-linked polyubiquitin of ECSIT at K372 [Mi Wi et al 2015] and RIP1 at 
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K377 [Ea et al 2006] are required for ECSIT- and RIP1-mediated NFĸB activation, 
respectively. TRAF2 is K63-linked polyubiquitinated at residue K31, which 
regulates TRAF2 binding to TAB2/3, and is required for TRAF2 activation of IKK 
and JNK [Li et al 2009]. TRAF6 undergoes K63-linked autoubiquitination at K124 
and ubiquitination at this site is required for NFĸB signalling [Lamothe et al 2007]. 
ERN1/IRE1 is involved in monitoring the unfolded protein response in the ER; IRE1 
is K63-linked polyubiquitinated at residues K545 and K828. K63-linked 
polyubiquitination at K828 was shown to be essential for the interaction between 
IRE1 and TRAF2 under stress conditions [Zhu et al 2014].  
Previous work in our lab has identified RIP1, TRAF2 and TRAF6 as PS1 interactng 
proteins. While RIP1 was shown to interact with PS1, the site of the interaction has 
not been mapped [Frances Harte unpublished work]. Therefore the PS1 CUE domain 
mutants will be used to determine whether the PS1 CUE domain is required for the 
interaction between RIP1 and PS1. The major interaction site for TRAF2 
(P/S/T/A)X(Q/E)E has been identified in the intracellular loops of both PS1 and PS2 
[James Powell unpublished work]. Additionally a TRAF6 interaction motif 
PxExxAr/Ac hass been mapped to the intracellular loop of PS1 [Powell et al 2009]. 
The TRAF2 and TRAF6 interaction sites are shown in Figure 4.1. Thus, both 
TRAF2 and TRAF6 are known to undergo K63-linked polyubiquitination and 
interact with PS1 within the intracellular loop domain and represent strong targets 
for investigating possible PS1 CUE domain interacting proteins.  
4.2 Ubiquitination Site Prediction for Presenilin-1 Interacting Proteins 
Using bioinformatic tools, an analysis of the potential for ubiquitination amongst the 
list of known PS1 interacting proteins (Table 4.1) was also conducted. An 
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ubiquitination prediction tool called Ubpred (www.ubpred.org) was used for this 
purpose. Ubpred analyses the primary structure of submitted proteins and determines 
the likelihood of any lysine residues to be sites of ubiquitination. These sites are 
scored on a scale of 0 to 1 where 1 is the highest likelihood for a lysine residue to be 
a site of ubiquitination. A residue with an Ubpred score of 0.62-0.69 is given a low 
confidence rating as an ubiquitination site, while scores of 0.69-0.84 and 0.84-1 are 
given medium confidence and high confidence ratings, respectively. The primary 
sequences of the PS1 interacting proteins (Table 4.1) were analysed by Upred and 
the number of potential ubiquitination sites was split into low, medium and high 
confidence ratings. These data were compiled (Table 4.3) providing the gene 
symbol, protein name and number of potential ubiquitination sites for each protein 
examined. 
Table 4.2 PS-1 interacting proteins that undergo K63-linked polyubiquitination 
Gene  Protein Citation 
APBB1 amyloid beta (A4) precursor protein-binding, family B, member 1 
(Fe65) 
Matz et al 2015 
BACE BACE Kang et al 2008 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa Dao et al 2012 
ECSIT ECSIT signalling integrator Mi Wi et al 2015 
ERN1 endoplasmic reticulum to nucleus signaling 1 Zhu et al 2014 
MAPT microtubule-associated protein tau Babu et al 2005 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 Ea et al 2006 
TGFBR1 transforming growth factor, beta receptor 1 Mu et al 2011 
TRAF2 TNF receptor-associated factor 2, E3 ubiquitin protein ligase Li et al 2009 










Figure 4.1 Schematic of Presenilin Intracellular Loop Domains including TRAF2 and TRAF6 
Interaction Sites. Schematic shows the CUE domains of PS1 and PS2 (highlighted in red and 
bookended by ‘CUE’) and the remainder of the intracellular loop domains of the presenilins 
(highlighted in green and bookended by the symbol *). The sites of presenilin endoproteolysis are 
marked by arrows. The TRAF2 interaction sites (highlighted in blue) and the TRAF6 interaction site 




Table 4.3 Ubpred predicted ubiquitination sites in PS-1 interacting proteins 
gene Protein Name Number of Potential Ubiquitination 
Sites 
  low medium high 
ACHE acetylcholinesterase                      0                   1               0 
ACTN1 actinin, alpha 1 4 1 0 
AP1M2 adaptor-related protein complex 1, mu 2 subunit 2 3 0 
APBA1 amyloid beta (A4) precursor protein-binding, family A 1 7 5 
APBB1 amyloid beta (A4) precursor protein-binding, family B 3 6 2 
APH1A APH1A gamma secretase subunit 0 0 0 
APH1B APH1B gamma secretase subunit 1 0 0 
APOE apolipoprotein E 1 3 3 
APP amyloid beta (A4) precursor protein 3 8 5 
BACE BACE 0 3 0 
BCL2  B-cell CLL/lymphoma 2 0 0 0 
BCL2L1 BCL2-like 1 0 0 0 
CAPN1 Calpain 1 0 0 
CD147 CD147 2 3 0 
CDC37 cell division cycle 37 7 4 11 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) 5 0 1 
CDK5 cyclin-dependent kinase 5 1 0 0 
CFL1 cofilin 1 (non-muscle) 2 2 0 
CIB1 calcium and integrin binding 1 (calmyrin) 0 1 0 
CLIP1 CLIP1/CLIP170 20 58 42 
CLSTN1 calsyntenin 1 3 4 0 
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa 4 9 0 
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 4 2 0 
CTNND1 catenin (cadherin-associated protein), delta 1 7 5 3 
CYP2C18 cytochrome P450, family 2, subfamily C, polypeptide 18 0 1 0 
CYP2C8 cytochrome P450, family 2, subfamily C, polypeptide 8 1 0 0 
DHX9 DEAH (Asp-Glu-Ala-His) box helicase 9 4 4 1 
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DOCK3 dedicator of cytokinesis 3 14 10 1 
DSP desmoplakin 40 68 16 
DTNA dystrobrevin, alpha 2 8 4 
ECSIT ECSIT signalling integrator 0 1 1 
EFHD1 EF-hand domain family, member D1 1 5 0 
ENSA endosulfine alpha 0 3 1 
EPB41L3 erythrocyte membrane protein band 4.1-like 3 5 17 16 
ERLIN2 ER lipid raft associated 2 6 2 1 
ERN1 endoplasmic reticulum to nucleus signaling 1 5 9 1 
ETFA electron-transfer-flavoprotein, alpha polypeptide 1 2 0 
FBXL12 F-box and leucine-rich repeat protein 12 0 0 0 
FBXW7 F-box and WD repeat domain containing 7 1 0 0 
FGF13 fibroblast growth factor 13 2 1 1 
FHL2 FHL2/DRAL/SLIM-3 0 0 0 
FKBP38 FKBP38 0 1 0 
FLNB filamin B, beta 19 16 0 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 1 0 0 
GCDH glutaryl-CoA dehydrogenase 1 2 0 
GDI1 GDP dissociation inhibitor 1 0 3 0 
GFAP glial fibrillary acidic protein 4 2 0 
GNAO1 guanine nucleotide binding protein (G protein) 3 2 0 
GRB2 growth factor receptor bound protein 2 0 0 0 
GRIN1 glutamate receptor, ionotropic, NMDA1 (zeta 1) 2 3 0 
GSAP gamma-secretase activating protein 0 0 0 
GSK3B glycogen synthase kinase 3 beta 0 3 0 
HERPUD
1 
homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member 1 
0 2 1 
HMGB1 high mobility group box 1 2 3 0 
HTRA2 HtrA serine peptidase 2 0 0 0 
ICAM5 intercellular adhesion molecule 5, telencephalin 0 0 0 
IRAK2 interleukin-1 receptor-associated kinase 2 2 1 5 
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ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 17 19 4 
ITSN2 intersectin 2 18 26 8 
JUP junction plakoglobin 5 1 0 
KANK2 KN motif and ankyrin repeat domains 2 3 4 2 
KCNIP3 Kv channel interacting protein 3, calsenilin 0 1 1 
KCNIP4 Kv channel interacting protein 4 0 1 0 
MAPT microtubule-associated protein tau 7 11 7 
METL Met1 methyltransferase 3 0 1 
NCSTN nicastrin 3 3 0 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 1 1 0 
NOS3 nitric oxide synthase 3 (endothelial cell) 1 1 2 
NOTCH1 notch 1 6 5 2 
OXCT1 3-oxoacid CoA transferase 1 2 3 0 
PARL presenilin associated, rhomboid-like 1 0 1 
PDCD4 programmed cell death 4 1 2 1 
PEN2 presenilin enhancer gamma secretase subunit 1 0 0 
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha) 7 7 3 
PKP4 plakophilin 4 6 7 6 
PLD1 phospholipase D1 4 3 0 
PRAM1 PML-RARA regulated adaptor molecule 1 9 30 4 
PRDX1  peroxiredoxin 1 PAG 1 0 0 
PRDX2 peroxiredoxin 2 0 2 0 
PRKACB protein kinase, cAMP-dependent, catalytic, beta 2 2 2 
PSEN1 presenilin 1 0 0 2 
PSEN2 presenilin 2 1 0 0 
PSMA5 proteasome (prosome, macropain) subunit, alpha type, 
5 
1 1 0 
PSMB1 proteasome (prosome, macropain) subunit, beta type, 
1 
1 0 0 
RAB11A RAB11A 1 3 0 
RAB3A RAB3A, member RAS oncogene family 0 0 2 
RAD23A RAD23 homolog A (S. cerevisiae) 1 3 0 
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RHEB Ras homolog enriched in brain 1 2 0 
RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 5 5 2 
RMDN3 regulator of microtubule dynamics 3 0 5 2 
RNF32 ring finger protein 32 1 4 4 
RYR2 ryanodine receptor 2 (cardiac) 13 24 11 
SCN1A sodium channel, voltage-gated, type I, alpha subunit 7 17 9 
SRI Sorcin 0 0 0 
ST13 suppression of tumorigenicity 13 2 7 1 
STAMBP
L1 
STAM binding protein-like 1 1 3 0 
STX1A Syntaxin 1A 0 3 4 
STX5 Syntaxin 5 2 6 0 
TCF4 transcription factor 4 0 6 4 
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 1 6 8 
TDP2 tyrosyl-DNA phosphodiesterase 2 0 0 4 
TGFBR1 transforming growth factor, beta receptor 1 1 3 0 
TMED10 TMP21 1 3 0 
TPTE2 TM phosphoinositide 3-phosphatase and tensin 
homolog 2 
3 0 3 
TRAF2 TNF receptor-associated factor 2 7 2 0 
TRAF6 TNF receptor-associated factor 6 1 3 0 
TUBA1B tubulin, alpha 1b 2 1 1 
UBC ubiquitin C 5 0 0 
UBQLN1 ubiquilin 1 0 2 0 
UMPS uridine monophosphate synthetase 1 2 0 
YME1L1 YME1-like 1 ATPase 6 1 0 
 
By comparing the Ubpred predicted sites of ubiquitination with published sites of 
ubiquitination the effectiveness of the Ubpred software can be analysed. The K377 
residue of RIP1 was given a high confidence rating for ubiquitination and is a known 
target of K63-linked polyubiquitination [Ea et al 2006]. However, Ubpred gave a 
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low confidence rating for ubiquitination of TRAF6 at residue K124, which is the site 
of TRAF6 autoubiquitination [Lamothe et al 2007]. Meanwhile the site of TRAF2 
K63-linked polyubiquitination at K31 [Li et al 2009] was not predicted to be a site of 
ubiquitination.  Dystrobrevin was predicated to have 14 possible sites of 
ubiquitination (2 with low (L) confidence, 8 with medium (M) and 4 with a high (H) 
confidence) using Ubpred analysis but there are no published sites of dystrobrevin 
ubiquitination according to the BioGRID. Ubpred analysis of isoform A of APP 
predicts the APP contains 16 possible sites of ubiquitination (3L, 8M, 5H). This APP 
isoform has been shown to be ubiquitinated at residues K751 and K763 [Beltrao et al 
2012]; both of these sites were given a medium confidence of ubiquitination. UMPS 
was predicted to have 3 potential sites of ubiquitination at residues K219, K223 and 
K314 by Ubpred and these sites of have been shown to undergo ubiquitination 
[Beltrao et al 2012]. However, another 18 sites have been published to undergo 
ubiquitination [Beltrao et al 2012; Stes et al 2014; Udeshi et al 2013; Kim et al 
2013]. GCDH was predicted to have 3 lysine residues that are sites of ubiquitination 
(K32, K42 and K361). Two of these sites (K31 and K361), plus an additional 5 
residues (K163, K202. K240, K371 and K377), are published site of GCDH 
ubiquitination [Udeshi et al 2013; Stes et al 2014]. CYP2C18 and CYP2C8 were 
both predicted to a solitary potential site of ubiquitination and there are no published 
sites of ubiquitination for either protein while ICAM5, which had no predicted sites 
of ubiquitination, is also not known to undergo ubiquitination. These data 
demonstrates that the complexity of the ubiquitination system within a cell cannot 
easily be replicated using in silico methods. The Ubpred system has some success in 
predicting sites of protein ubiquitination but Ubpred can both over- and under-





 Does Not Interact With PS1 Holoprotein or PS1 ΔCUE 
Mutant 
The cleavage of some γ-secretase substrates is known to be regulated by K63-linked 
polyubiquitination including P75
NTR
, IL-1R1 and TGFβR1 [Powell et al 2009; 
Twomey et al 2009; Gudey et al 2014]. Given that the PS1 CUE domain interacts 
with K63-linked polyubiquitin chains it was decided to investigate whether the CUE 
domain was required for the interaction between PS1 and interact with any of these 
γ-secretase substrates. To investigate this interaction HEK293T cells were transiently 
co-transfected with pRK5-P75
NTR
 and pcDNA3.1-PS1 WT, pcDNA3.1-PS1 ΔCUE 
or pcDNA3.1-PS1 F283A/P284A/V309A/S310A (Figure 4.1). PS1 has previously 
been shown to interact with the P75
NTR
 after pre-treatment with the P75
NTR
 ligand 
NGF [Powell et al 2009] so the cells were treated with NGF (100 ng/ml) for 20 mins 
prior to harvesting. Expression of P75
NTR
 and the PS1 constructs was confirmed by 
western blotting and anti-β-actin was used as a loading control (lower panels of 
Figure 4.1) before an equivalent amount of each lysate was subject to 
immunoprecipitation with an anti-P75
NTR
 antibody. After separation by SDS-PAGE 
the co-immunoprecipitation of PS1 with P75
NTR
 was confirmed by western blotting 
with 614.1 anti-PS1 NTF and anti-PS1 CTF antibodies; equal immunoprecipitation 
of P75
NTR
 was confirmed by immunoblotting with an anti-P75
NTR
 antibody. Bands 
equivalent to both the PS1 NTF and PS1 CTF fragments were immunoprecipitated 
with P75
NTR
 (upper panels of Figure 4.1). However, no bands equivalent to the PS1 
holoprotein or the PS1 ΔCUE mutant could be seen on the blot, which suggests that 
P75
NTR 
does not interact with full length PS1 and as such deletion of the PS1 CUE 





4.4 IL-1R1 Does Not Interact with PS1 Holoprotein nor PS1 ΔCUE 
Mutant 
IL-1R1 is another γ-secretase substrate which is known to undergo K63-linked 
polyubiquitination [Twomey et al 2009]. While we have previously shown that the 
PS1 CUE domain is dispensable for the γ-secretase mediated cleavage of IL-1R1 
(Figure 3.15) it was decided to investigate whether the PS1 CUE domain had any 
effect on regulating the interaction between PS1 and IL-1R1. HEK293T cells were 
transiently transfected with pcDNA3-IL-1R1 and either pcDNA3.1-PS1 WT, 
pcDNA3.1-PS1 ΔCUE or pcDNA3.1-PS1 F283A/P284A/V309A/S310A (Figure 
4.2). Cells were pre-treated with IL1 (10 ng/ml) for 15 mins prior to lysing. The cell 
lysates were subject to SDS-PAGE and expression of IL-1R1 and the PS1 constructs 
was demonstrated by western blotting with anti-IL-1R1 C20 and anti-PS1 CTF 
antibodies; anti-β-actin was used as a loading control (lower panels Figure 4.2). 
After expression had been confirmed an equal amount of each cell lysate was subject 
to immunoprecipitation with anti-IL-1R1 C20 antibody, the immunipurified proteins 
were separated on a 12% gel by SDS-PAGE and co-immunoprecipitation of PS1 and 
IL-1R1 was demonstrated by western blotting with anti-PS1 CTF antibody; equal 
immunoprecipitation of IL-1R1 was shown by probing with anti-IL-1R1 antibody  
(upper panels Figure 4.2). There are no bands equivalent to either the PS1 
holoproteins, or to the PS1 ΔCUE mutant present (Figure 4.2). These data suggest 
that IL1-R1 does not strongly interact with PS1 holoprotein and as such deletion of 
the PS1 CUE domain does not play a role in regulating the interaction between PS1 
and IL1-R1. Therefore, it was concluded that the PS1 CUE domain is not required 
for regulating the interaction between PS1 and the K63-linked polyubiquitinated γ-
secretase substrates P75
NTR 
or IL-1R1. As the PS1 CUE domain has previously been 
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shown to be dispensable for the γ-secretase cleavage of APP, Notch and IL-1R1, 
these data reinforce the theory that the PS1 CUE domain is involved in γ-secretase 
independent PS1 function(s). 
4.5 TRAF6 E3 Ligase activity is Required For interaction between 
TRAF6 and PS1  
TRAF6 has been shown to interact with and ubiquitinate PS1, allowing it to regulate 
the cleavage of γ-secretases substrates such as TGFBR1, IL-1R1 and P75
NTR
. 
[Elzinga et al 2009; Powell et al 2009; Gudey et al 2014]. TRAF6 is an E3 ligase 
that facilitates K63-linked polyubiquitination of its substrates, which requires residue 
C70; in addition to this TRAF6 undergoes auto-ubiquitination at its K124 residue 
[Lamothe et al 2007]. Since the CUE domain of PS1 selectively binds to K63-linked 
polyubiquitin chains it was next decided to investigate whether the PS1 CUE domain 
is responsible for the interaction between PS1 and TRAF6. To achieve this pRK5-
FLAG-TRAF6, the E3 ligase defective mutant pRK5-FLAG-TRAF6 C70A and the 
auto-ubiquitination mutant pRK5-FLAG-TRAF6 K124R were co-expressed in 
HEK293T cells with either pcDNA3.1-PS1 WT or pcDNA3.1-PS1 ΔCUE. After 
overexpression was confirmed through western blotting (lower panels of Figure 
4.8) the cell lysates were immunoprecipitated using anti-FLAG antibody and after 
SDS-PAGE the co-immunoprecipitation of PS1 was determined by immunoblotting 
with an anti-PS1 NTF antibody. Both PS1 (lanes 3 and 5 of upper panel of Figure 
4.3) and PS1 ΔCUE (lanes 5 and 8 of upper panel of Figure 4.3) co-
immunoprecipitated with TRAF6 and TRAF6 K124R. However, neither PS1 nor 
PS1 ΔCUE were co-immunoprecipitated with the TRAF6 C70A mutant (lanes 4 and 
7 of upper panel Figure 4.3).  This result suggests that neither TRAF6 auto-






 does not interact with PS1 nor do PS1 CUE domain mutants. HEK293T cells 
were transiently co-transfected with pRK5-P75
NTR
 and pcDNA3.1-PS1 WT, pcDNA3.1-PS1 ΔCUE 
or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 36 hours after transfection the cells were treated 
with 100 ng/ml NGF for 20 mins before the cells were harvested. The cells were lysed in lysis buffer 
and proteins were separated by SDS-PAGE in 12% gels. Overexpression was determined by 
immunoblotting with anti-P75
NTR
 and anti-PS1 CTF antibodies, anti-β-actin antibody was used to 
show equal loading (lower panels). Once overexpression had been shown, equivalent amounts of cell 
lysate were subjected to immunoprecipitation with anti-P75
NTR
 antibody, the immunopurified proteins 
were separated by SDS-PAGE on 12% gels. Co-immunoprecipitation was determined by western 
blotting with anti-PS1 NTF and anti-PS1 CTF antibodies; immunoprecipitation of P75
NTR
 was shown 
by western blotting with anti-P75
NTR
 antibody. FL: full length; HC: IgG heavy chain; CTF: C-
terminal fragment; NTF: N-terminal fragment; IP: immunoprecipitation; NGF: nerve growth factor; 






Figure 4.3 IL-1R1 does not interact with PS1  and PS1 CUE domain mutants. HEK293T cells 
were transiently co-transfected with pcDNA3-IL-1R1 and pcDNA3.1-PS1 WT, pcDNA3.1-PS1 
ΔCUE or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 36 hours after transfection the cells were 
treated with 10 ng/ml IL1 for 15 mins before the cells were harvested. The cells were lysed in lysis 
buffer and proteins were separated by SDS-PAGE in 12% gels. Overexpression was determined by 
immunoblotting with anti-IL-1R1 C20 and anti-PS1 CTF antibodies, anti-β-actin antibody was used 
to show equal loading (lower panels). Once overexpression had been shown, equivalent amounts of 
cell lysate were subjected to immunoprecipitation with anti-IL-1R1 C20 antibody, the 
immunopurified proteins were separated by SDS-PAGE on 12% gels. Co-immunoprecipitation was 
determined by western blotting with anti-PS1 CTF antibody; immunoprecipitation of IL1-R1 was 
shown by western blotting with anti-IL-1R1 C20 antibody. FL: full length; HC: IgG heavy chain; 
CTF: C-terminal fragment; IP: immunoprecipitation; WB: western blot; WT: wild type. Data are from 
a representative experiment (n=3).  
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interaction between PS1 and TRAF6. It does suggest that TRAF6 E3 ligase activity 
is required for the interaction between TRAF6 and PS1. 
4.6 Mutation of Conserved PS1 CUE Domain Motifs Affect PS1-TRAF6 
Interaction 
To further investigate the interaction between TRAF6 and PS1 it was decided to co-
express TRAF6 with three PS1 CUE domain point mutants: PS1 F283A/P284A, PS1 
V309A/S310A and PS1 F283A/P284A/V309A/S310A.  In these mutants the main 
motifs in the PS1 CUE domain are either mutated single or together. As the TRAF6 
C70A mutation has been shown to prevent the interaction between PS1 and TRAF6 
this was used as a negative control for this co-immunoprecipitation experiment. 
HEK293T cells were transiently transfected with pRK5-FLAG-TRAF6 or pRK5-
FLAG-TRAF6 C70A and co-transfected with either PS1 WT, PS1 F283A/P284A, 
PS1 V309A/S310A or PS1 F283A/P284A/V309A/S310A. After overexpression was 
confirmed via western blotting (Lower panels of Figure 4.4) the cell lysates were 
immunoprecipitated with an anti-FLAG antibody. PS1 and TRAF6 co-
immunoprecipitated together and the TRAF6 C70A mutation again disrupted this 
interaction (upper panel of Figure 4.4). Both PS1 F283A/P284A and PS1 
V309A/S310A CUE domain mutants were co-immunoprecipitated with TRAF6 to a 
similar level as PS1 (compare lanes 5 and 6 to lane 3 of upper panel of Figure 
4.4), though there was variability between the different experiments. This result is 
unusual as removal of the entire CUE domain had no effect on the PS1-TRAF6 
interaction (Figure 4.3) but mutation of the two CUE domain motifs caused a 
reduction in this interaction. This suggests that the interaction between PS1 and 
TRAF6 may be regulated by an intermediate protein or proteins.  
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4.7 TRAF6 Interacts With PS1 N-Terminal and C-Terminal Fragments 
TRAF6 is known to interact with PS1 and the intracellular loop domain of PS1 is 
known to contain a TRAF6 interacting motif (PEERGV) at residues 374-379 [Powell 
et al 2009]. To further investigate the site of the interaction between PS1 and 
TRAF6, plasmids that express the PS1 NTF or the PS1 CTF domains were used 
(NSE-PS1 NTF and NSE-PS1 CTF, respectively). In addition, a PS1 mutant which 
had residues 305-372 from the intracellular loop domain of PS1 were removed 
(pCDNA3.1-PS1 ΔLoop) was used. This mutant removes the final 10 residues from 
the PS1 CUE domain including the essential V309/S310 motif of the CUE domain. 
In HEK293T cells pRK5-FLAG-TRAF6 was co-expressed with these PS1 mutants, 
pcDNA3.1-PS1 and pRK5-FLAG-TRAF6 C70A were used as positive and negative 
controls for the experiment. The NSE-PS1 NTF and NSE-PS1 CTF constructs did 
not overexpress as well as the pcDNA3.1-PS1 WT or pcDNA3.1-PS1 ΔLoop 
constructs (Figure 4.5). These lysates were used in a co-immunoprecipitation assay 
using anti-FLAG antibody and after separation by SDS-PAGE the co-
immunoprecipitation of TRAF6 and PS1 was detected by western blotting with both 
PS1 NTF and PS1 CTF antibodies. Both PS1 NTF and PS1 CTF weakly co-
immunoprecipitated with TRAF6, however, these constructs were also weakly 
overexpressed (input panels of Figure 4.5). This result suggests that TRAF6 can 
interact with both the PS1 NTF and CTF fragments at a similar level to one another 
The PS1 ΔLoop protein strongly co-immunoprecipitated with TRAF6 (Figure 4.5, 
lane 5 upper panel). This result suggests that deletion of this part of the PS1 
intracellular loop domain may cause an increased interaction between PS1 and 
TRAF6. This deleted region of the protein includes a part of the PS1 CUE domain 
and mutation of the two motifs within the PS1 CUE domain has been shown to cause 
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a reduction in the binding of PS1 to TRAF6 (Figure 4.4). The deletion of part of the 
PS1 intracellular loop ends two residues before the TRAF6 interaction motif 
[Elzinga et al 2009; Powell et al 2009] which may explain the increased interaction 
between the PS1 ΔLoop mutant and TRAF6. This PS1 intracellular loop domain 
deletion may make the TRAF6 interaction motif more available for TRAF6 or 
deletion of the V309/S310 motif of the PS1 CUE domain may reduce the interaction 
of PS1 with another protein which regulates the interaction between PS1 and 
TRAF6. 
4.8 Mutation of Conserved PS1 CUE Domain Motifs Has No Effect On 
TRAF6 Mediated Stability of PS1 
Overexpression of TRAF6 with PS1 has previously been shown to help increase the 
stability of the PS1 holoprotein [Yan et al 2013] and deletion of the PS1 CUE 
domain has no effect on the TRAF6-mediated increase in stability of the PS1 
holoprotein [Yan unpublished material]. However, since mutation of both PS1 CUE 
domain motifs caused a reduction in the interaction with PS1 and TRAF6 it was 
decided to investigate whether these mutations would have any effect on PS1 
stability. HEK293T cells were transfected with pRK5-FLAG-TRAF6 and co-
transfected with   pcDNA3.1-PS1 or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 
Cell cultures were treated with the translation inhibitor cycloheximide (CHX) at 
differing time points. When expressed alone PS1 holoprotein was mostly turned over 
by 8 hours but when co-expressed with TRAF6 PS1 holoprotein was still present at 
high levels even after 24 hours of treatment with CHX. Similarly expression of the 
PS1 F283A/P284A/V309A/S310A was still present at 24 hours when co-expressed 
with TRAF6 suggesting that mutation of these residues had no effect on PS1 





Figure 4.4 TRAF6 C70 residue is required for TRAF6-PS1 interaction. HEK293T cells were 
transiently co-transfected with pRK5-FLAG-TRAF6WT, pRK5-FLAG-TRAF6C70A or pRK5-
FLAG-TRAF6K124R- and with either pcDNA3.1-PS1 WT or pcDNA3.1-PS1 ΔCUE. 36 hours after 
transfection the cells were lysed in Lysis buffer. The lysates were run on 12% SDS-PAGE gels and 
overexpression was detected with anti-FLAG or 614.1 anti-PS1 NTF antibodies, equal loading was 
confirmed by blotting with anti-β-actin antibody (input panels). After expression was confirmed an 
equivalent amount of protein (1000 μg) was subject to immunoprecipitation with anti-FLAG 
antibody. Immunoprecipitated proteins were separated on 12% SDS-PAGE gels and co-
immunoprecipitation was detected by probing with 614.1 anti-PS1 NTF antibody. 
Immunoprecipitation of TRAF6 was detected by immunoblotting with anti-FLAG antibody. FL: full 
length; HC: IgG heavy chain; IP: immunoprecipitation; WB: western blot; WT: wild type. Data are 
from a representative experiment  (n=3).  
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TRAF6 when these CUE domain residues are mutated that it has no effect on the 
TRAF6-mediated PS1 holoprotein stability. 
4.9 TRAF2 Promotes K63-linked Polyubiquitination of Presenilin-1 
Previous work in our lab has shown that PS1 interacts with TRAF2 and TRAF6 
[unpublished data; Powell et al 2009]. Like TRAF6, TRAF2 is an E3 ligase that 
catalyses K63-linked polyubiquitin of its substrates. TRAF6 has previously been 
shown to promote the K63-linked polyubiquitination of PS1 [Yan et al 2013; Gudey 
et al 2014]. To investigate whether the interaction of TRAF2 with PS1 would also 
lead to the TRAF2 mediated ubiquitination of PS1, HEK293T cells expressing 
pcDNA3.1-PS1 WT were co-transfected with HA-ubiquitin or a K63R ubiquitin 
mutant, which cannot form K63-linked polyubiquitin chains, and with pRK5-FLAG-
TRAF2 WT or a dominant negative mutant pRK5-FLAG-TRAF2DN, in which the 
RING domain and the Zinc Finger domains of TRAF2 (residues 1-289) have been 
deleted. The cells were lysed under denaturing conditions, the lysates were separated 
by SDS-PAGE and protein overexpression was confirmed by western blotting with 
anti-FLAG and anti-PS1 NTF antibody (Figure 4.7 lower panels). Once 
overexpression was demonstrated the lysates were used in an ubiquitination assay. 
The equivalent amounts of cell lysate were immunoprecipitated with anti-PS1 NTF 
antibody and separation by SDS-PAGE. PS1 ubiquitination was detected by 
immunoblotting with an anti-HA antibody. Co-expression of pcDNA3.1-PS1 with 
pRK5-FLAG-TRAF2 and HA-Ub increased the formation of polyubiquitinated 
forms of PS1 (Figure 4.7), however when co-expressed with either pRK5-
TRAF2DN or HA-Ub K63R mutant there was a dramatic reduction in PS1 
ubiquitination. These data show that like TRAF6, TRAF2 is able to promote K-63-




Figure 4.5 The PS1 F283A/P284A/V309A/S310A mutant shows reduced interaction with 
TRAF6. HEK293T cells were transiently co-transfected with either pRK5-FLAG-TRAF6WT or 
pRK5-FLAG-TRAF6C70A and with pcDNA3.1-PS1 WT, pcDNA3.1-PS1 F283A/P284A, 
pcDNA3.1-PS1 V309A/S310A or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 36 hours after 
transfection the cells were lysed in Lysis buffer. The lysates were run on 12% SDS-PAGE gels and 
overexpression was detected with anti-FLAG or 614.1 anti-PS1 NTF antibodies, equal loading was 
confirmed by blotting with anti-β-actin antibody (input panels). After expression was confirmed an 
equivalent amount of protein (1000 μg) was subject to immunoprecipitation with anti-FLAG 
antibody. Immunoprecipitated proteins were separated on 12% SDS-PAGE gels and co-
immunoprecipitation was detected by probing with 614.1 anti-PS1 NTF antibody. 
Immunoprecipitation of TRAF6 was detected by immunoblotting with anti-FLAG antibody. FL: full 
length; HC: IgG heavy chain; IP: immunoprecipitation; WB: western blot; WT: wild type. Data are 





Figure 4.6 PS1 N-terminal and C-terminal fragments interact with TRAF6; PS1 ΔLoop mutant 
interacts with TRAF6. HEK293T cells were transiently co-transfected with either pRK5-FLAG-
TRAF6WT or pRK5-FLAG-TRAF6C70A and with pcDNA3.1-PS1 WT, pcDNA3.1-PS1 ΔLoop, 
NSE-PS1 NTF or NSE-PS1 CTF. 36 hours after transfection the cells were lysed in Lysis buffer. The 
lysates were run on 12% SDS-PAGE gels and overexpression was detected with anti-FLAG, anti-PS1 
CTF or 614.1 anti-PS1 NTF antibodies, equal loading was confirmed by blotting with anti-β-actin 
antibody (input panels). After expression was confirmed an equivalent amount of protein (1000 μg) 
was subject to immunoprecipitation with anti-FLAG antibody. Immunoprecipitated proteins were 
separated on 12% SDS-PAGE gels and co-immunoprecipitation was detected by probing with anti-
PS1 CTF and 614.1 anti-PS1 NTF antibodies. Immunoprecipitation of TRAF6 was detected by 
immunoblotting with anti-FLAG antibody. FL: full length; HC: IgG heavy chain; IP: 
immunoprecipitation; NTF: N-terminal fragment; CTF: C-terminal fragment; WB: western blot; WT: 










Figure 4.7 Mutation of conserved PS1 CUE domain motifs does not affect the TRAF6 mediated 
increase in PS1 FL stability. HEK293T cells were transiently transfected with pcDNA3.1-PS1 WT 
or co-transfected with pcDNA3.1-PS1 WT or pcDNA3.1-PS1 F283A/P284A/V309A/S310A and 
pRK5-FLAG-TRAF6WT. Cells were treated with 20 μg/ml cycloheximide (CHX) for the indicated 
time period. Cells were harvested 36 hours post-transfection, separated on 12% SDS-PAGE gels and 
immunoblotted with anti-FLAG or 614.1 anti-PS1 NTF antibodies. Equal loading was detected by 
probing with anti-β-actin antibody. CHX: cycloheximide; FL: full length; hrs: hours; NTF: N-terminal 




4.10 Deletion of the PS-1 CUE Domain Does Not Affect binding to TRAF2 
As well as acting as an E3 ligase that can add K63-linked polyubiquitin chains to 
substrates, TRAF2 itself undergoes ubiquitination in both a K48- and K63-linked 
manner [Li et al 2009]. As TRAF2 has been shown to interact with PS1 [Powell 
unpublished material], it was decided to investigate whether this interaction requires 
the CUE domain of PS1. In HEK293T cells either pRK5-FLAG-TRAF2 or pRK5-
FLAG-TRAF2DN were co-expressed with pcDNA3.1-PS1, pcDNA3.1-PS1 ΔCUE 
or pcDNA3.1-PS1 F283A/P284A/V309A/S310A (Figure 4.8). The cells were lysed 
and lysates were separated by SDS-PAGE and overexpression was confirmed by 
western blotting with anti-FLAG and anti-PS1 CTF antibodies. After protein 
expression was confirmed the lysates were subject to a co-immunoprecipitation 
experiment using an anti-PS1 NTF antibody. The samples were separated via SDS-
PAGE and the co-immunoprecipitation of TRAF2 with PS1 was confirmed by 
immunoblotting with an anti-TRAF2 antibody (lower panels of Figure 4.8). In 
addition to this TRAF2 WT was immunoprecipitated with both the PS1 ΔCUE and 
PS1 F283A/P284A/V309A/S310A CUE domain mutants. Similarly to TRAF2DN, 
there does appear to be less TRAF2WT co-immunoprecipitated with the PS1 
F283A/P284A/V309A/S310A mutant but also less PS1 
F283A/P284A/V309A/S310A protein was immunoprecipitated. This result shows 
that the interaction of PS1 with TRAF2 is not controlled by the activity of the PS1 
CUE domain. 
4.11 Presenilin-1 CUE Domain Not Required For RIP1 Interaction 
RIP1 is an adaptor protein that is involved in the transmission of tumour necrosis 
factor (TNF) signalling from TNF Receptors (TNFR) but is also involved in other 




Figure 4.8 TRAF2 promotes K63-linked polyubiquitination of PS1. HEK293T cells were 
transiently co-transfected with pcDNA3.1-PS1 WT, either pRK5-FLAG-TRAF2 or pRK5-FLAG-
TRAF2DN and with HA-Ub or HA-Ub K63R. 36 hours post-transfection the cells were lysed under 
strict denaturing conditions, equivalent amounts of lysate were separated on 12% SDS-PAGE gels 
and overexpression was detected with anti-FLAG and 614.1 anti-PS1NTF antibodies; equal loading 
was demonstrated with anti-β-actin antibody (input panels). After overexpression had been 
demonstrated an equivalent amount of each lysate (1000 μg) was subjected to immunoprecipitation 
with 614.1 anti-PS1 antibody. PS1 ubiquitination was detected with immunoblotting with anti-HA 
antibody, PS1 immunoprecipitation was detected with probing with 614.1 anti-PS1 NTF antibody. 
DN: dominant negative; IP: immunoprecipitation; WB: western blot; Ub: ubiquitin. Data are from a 
representative experiment (n=2).  
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and K63-linked polyubiquitination, and K63-linked ubiquitination of RIP1 at residue 
K377 has been shown to be essential for RIP1 function in signal transduction [Ea et 
al 2006]. Previous work in our lab has shown that RIP1 interacts with PS1 
[unpublished data] and as RIP1 is known to undergo K63-linked polyubiquitination 
it was decided to investigate whether this ubiquitination event was required for the 
PS1-RIP1 interaction. HEK293T cells were transfected with either pRK5-RIP1 or 
the ubiquitination mutant pRK5-RIP1 K377R and co-transfected with pcDNA3.1-
PS1, pcDNA3.1-PS1 ΔCUE or pcDNA3.1-PS1 F283A/P284A/V309A/S310A 
(Figure 4.9). Overexpression of the various constructs was confirmed via western 
blotting and then the lysates were immunoprecipitated using anti-PS1 NTF antibody. 
After separation by SDS-PAGE the co-immunoprecipitation of RIP1 with PS1 was 
determined by immunoblotting for RIP1. Wild type RIP1 interacts with PS1 WT, 
PS1 ΔCUE and PS1 F283A/P284A/V309A/S310A (Figure 4.9). In addition to this 
the RIP1 K377R mutant, which does not undergo K63 linked polyubiquitination, 
was also shown to interact with PS1 WT. These data shows that the interaction of 
RIP1 and PS1 is not mediated by the ubiquitination state of RIP1 or the functionality 





Figure 4.9 PS1 CUE domain is not required for PS1-TRAF2 interaction. HEK293T cells were 
transiently co-transfected with either pRK5-FLAG-TRAF2WT or pRK5-FLAG-TRAF2DN and with 
pcDNA3.1-PS1 WT, pcDNA3.1-PS1 ΔCUE or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 36 
hours after transfection the cells were lysed in Lysis buffer. The lysates were run on 12% SDS-PAGE 
gels and overexpression was detected with anti-FLAG or anti-PS1 CTF antibodies, equal loading was 
confirmed by blotting with anti-β-actin antibody (input panels). After expression was confirmed an 
equivalent amount of protein (1000 μg) was subject to immunoprecipitation with anti-PS1 NTF 
antibody. Immunoprecipitated proteins were separated on 12% SDS-PAGE gels and co-
immunoprecipitation was detected by probing with anti-TRAF2 antibody. Immunoprecipitation of 
PS1 was detected by immunoblotting with anti-PS1 CTF antibody. DN: dominant negative; FL: full 
length; HC: IgG heavy chain; IP: immunoprecipitation; WB: western blot; WT: wild type. Data are 




Figure 4.10 PS1 CUE domain is not required for PS1-RIP1 interaction. HEK293T cells were 
transiently co-transfected with either pRK5-RIP1 or pRK5-RIP1 K377R and with pcDNA3.1-PS1 
WT, pcDNA3.1-PS1 ΔCUE or pcDNA3.1-PS1 F283A/P284A/V309A/S310A. 36 hours after 
transfection the cells were lysed in Lysis buffer. The lysates were run on 12% SDS-PAGE gels and 
overexpression was detected with anti-RIP1 or anti-PS1 CTF antibodies, equal loading was confirmed 
by blotting with anti-β-actin antibody (input panels). After expression was confirmed an equivalent 
amount of protein (1000 μg) was subject to immunoprecipitation with anti-PS1 NTF antibody. 
Immunoprecipitated proteins were separated on 12% SDS-PAGE gels and co-immunoprecipitation 
was detected by probing with anti-RIP1 antibody. Immunoprecipitation of PS1 was detected by 
immunoblotting with anti-PS1 CTF antibody. FL: full length; HC: IgG heavy chain; IP: 






Having shown that the presenilins contain K63-linked polyubiquitin chain binding 
CUE domains, in this chapter we began to investigate the function of the PS1 CUE 
domain. In the previous chapter it was shown that PS1 CUE domain function was 
not involved in PS1 endoproteolysis (Figure 3.11) or the γ-secretase cleavage of 
APP, IL-1R1 and Notch. In this chapter a list of known PS1 interacting proteins was 
compiled from previously published reviews [McCarthy et al 2009] and from the 
online database BioGRID (www.thebiogrid.org), which resulted in a list of 110 
different proteins. The BioGRID, which also contains details of published 
posttranslational modifications, was then used to determine which of these PS1 
interacting proteins are substrates of K63-linked polyubiquitination (Table 4.1). Of 
these 110 PS1 interacting proteins 25 are not known to be ubiquitinated and 58 
proteins were found to be ubiquitinated through high throughput mass spectrometric 
analysis. This analysis demonstrates that a lysine residue is ubiquitinated but does 
not show the type of ubiquitination that occurs there. Of the remaining proteins from 
this list 10 proteins were found to undergo K63-linked polyubiquitination (Table 
4.2) and were considered to be potential PS1 CUE domain interacting proteins. 
Additionally, an ubiquitination site prediction tool (www.ubpred.org) was used to 
determine the number of potential sites of ubiquitination amongst these PS1 
interacting proteins (Table 4.3). Of the 110 proteins examined only 10 proteins were 
predicted to have no likely sites of ubiquitination. 
Next to investigate the function of the PS1 CUE domain we used co-
immunoprecipitation assays to determine whether deletion of the PS1 CUE domain 
or mutation of conserved PS1 CUE domain residues had any effect on regulating 
PS1 protein-protein interactions. There are 10 known PS1 interacting proteins that 
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are known to be K63-linked polyubiquitinated (Table 4.2). From this list of 10 
proteins we investigated whether the PS1 CUE domain is involved in regulating the 
interaction of PS1 with TRAF6, TRAF2 and RIP1. TRAF6 has previously been 
shown to interact with PS1 [Elzinga et al 2009; Powell et al 2009] and to promote 
the K63-linked polyubiquitination of PS1 [Yan et al 2013; Gudey et al 2014]. This 
interaction has been shown to be involved in regulating the γ-secretase cleavage of 
IL-1R1, P75
NTR
 and TGFβR1 [Powell et al 2009; Powell et al 2009; Gudey et al 
2014]. Co-expression of PS1 and TRAF6 has been shown to promote the K63-linked 
polyubiquitination of PS1 and also to increase the stability of the PS1 holoprotein 
[Yan et al 2013]. In this chapter we demonstrated that deletion of the PS1 CUE 
domain nor mutation of residue K124 of TRAF6, the site of K63-linked TRAF6 
autoubiquitination, did not affect the interaction between PS1 and TRAF6 (Figure 
4.8). However, mutation of the C70 residue of TRAF6, which is essential for TRAF6 
E3 function, caused a reduction in the binding of TRAF6 to both PS1 WT and the 
PS1 ΔCUE mutant (Figure 4.8). Additionally we showed that single mutation of the 
F283/P284 or the V309/S310 CUE domain motifs did not cause a reduction in the 
interaction between PS1 and TRAF6 but mutation of both motifs in tandem (the PS1 
F283A/P284A/V309A/S310A mutant) caused a reduction in this interaction (Figure 
4.9). Both the PS1 NTF and CTF fragments could be co-immunoprecipitated with 
TRAF6 (lanes 6 and 7 of Figure 4.10). Deletion of residues 305-372 from the 
intracellular loop of PS1 caused an increased affinity of PS1 for TRAF6 (lane 5 of 
Figure 4.10). This partial deletion of the PS1 intracellular loop domain ends only 2 
residues before the PS1 TRAF6 interacting motif (residues 374-379), which may 
explain the increased affinity of this PS1 mutant for TRAF6. 
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 Mutation of the FANCD2 CUE domain leads to an increase in FANCD2 
proteasomal degradation [Rego et al 2012]. Co-expression of TRAF6 with PS1 has 
been shown to promote the stability of the PS1 holoprotein [Yan et al 2013] and 
deletion of the PS1 CUE domain has previously been shown to have no effect on this 
process [Yan unpublished material]. However, since we have demonstrated here that 
the PS1 F283A/P284A/V309A/S310A CUE domain mutant shows a reduced 
interaction with TRAF6 it was decided to investigate whether TRAF6 could still 
promote an increase in holoprotein stability for this PS1 mutant. TRAF6 
overexpression promoted an increased stability for both the PS1 WT and the PS1 
F283A/P284A/V309A/S310A holoproteins (Figure 4.13), suggesting that the 
decreased interaction between TRAF6 and the PS1 F283A/P284A/V309A/S310A 
mutant had no effect on this TRAF6 function. 
The interaction between RIP1 and PS1 was not affected by PS1 CUE domain 
deletion or by mutation of the conserved PS1 CUE domain motifs (Figure 4.3). 
Similarly, mutation of residue K377 within RIP1, a previously published site of 
RIP1 K63-linked polyubiquitination [Ea et al 2006], had no effect on the interaction 
between RIP1 and PS1. These data suggest that the interaction between PS1 and 
RIP1 is not determined by the ubiquitination state of RIP1. PS1 has previously been 
shown to be a substrate for TRAF6 mediated ubiquitination [Yan et al 2013; Gudey 
et al 2014]. Therefore, we next showed that PS1 is a substrate for TRAF2 mediated 
K63-linked polyubiquitination (Figure 4.6). Next we showed that the PS1 CUE 
domain is dispensable for the interaction between PS1 and TRAF2 (Figure 4.7). 
TRAF2 co-immunoprecipitated with PS1 WT and the PS1 ΔCUE and PS1 
F283A/P284A/V309A/S310A CUE domain mutants and the TRAF2DN mutant 
(which is missing the RING and Zinc finger domains at the N-terminus of TRAF2) 
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was co-immunopurified with PS1 WT. These data suggest that the PS1 CUE domain 
is not involved in the interactions of PS1 with RIP1 or TRAF2. 
Tollip negatively regulates β-catenin/Wnt signalling but deletion of the Tollip CUE 
domain abrogates this inhibition [Torún et al 2015]. Deletion of the TAB2 CUE 
domain causes a reduction in NFĸB activity [Kishida et al 2005]. In CUEDC2 
deletion of the CUE domain does not affect the binding of CUEDC2 with Cdc20 but 
instead this interaction is mediated by the Cdk1 phosphorylation of CUEDC2 [Gao 
et al 2011]. However, in this study both CUEDC2 and the presence of the CUEDC2 
CUE domain were still required for dissociation of Mad2 from Cdc20. The CUE 
domain of CUEDC2 is required for the interaction of CUEDC2 and the progesterone 
receptor (PR) [Zhang et al 2007]. However, the CUE domain is not sufficient for the 
CUEDC2 mediated inhibition of progesterone receptor signalling [Zhang et al 2007]. 
These data suggest that the CUEDC2 CUE domain may affect function as a mediator 
of CUEDC2’s protein-protein interactions. Deletion of the entire PS1 CUE domain 
did not affect the interaction of PS1 and TRAF6 (Figure 4.8) but mutation of the 
two conserved CUE domain motifs in tandem caused a reduction in this interaction 
(Figure 4.9). From this unusual result we hypothesised that a PS1 CUE domain 
interacting protein may act as an intermediate in the interaction between PS1 and 
TRAF6. From these data the identity of PS1 CUE domain interacting protein or 
proteins remains unknown. Some unknown PS1 interacting protein may regulate the 
interaction between PS1 and TRAF6. This interaction could be unaffected by 
deletion of the PS1 CUE domain but the presence of a non-functional CUE domain 
may allow the interaction of other unidentified protein(s) with PS1 which negatively 
affect the PS1-TRAF6 interaction. This result suggests that the interaction between 
PS1 and TRAF6 may be mediated by a more complex system than a simple protein-
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protein interaction. The Tollip CUE domain plays a role in modulating Tollip’s 
interaction with the cell membrane as the competitive binding of ubiquitin to the 
Tollip CUE domain prevents the Tollip C2 domain from interacting with 
phosphoinositides [Mitra et al 2013]. Human isoT protein contains one inactive 
UBA domain (UBA1) and one active ubiquitin binding domain (UBA2) [Raasi et al 
2005]. However, an isoT mutant which replaces the UBA2 domain with an 
additional UBA1 domain retains ubiquitin binding ability suggesting that isoT UBA 
function is dependent on non-UBA regions of the protein. These data demonstrate 
how the function of ubiquitin binding domains can be modulated by intra-protein or 
protein-protein interactions. 
Of the proteins examined here only TRAF6 showed any change in its interaction 
with PS1 WT or with PS1 CUE domain mutants. However, the proteins studied here 
were PS1 interacting proteins that had been identified within our lab. Ten different 
PS1 interacting proteins were identified as undergoing K63-linked 
polyubiquitination (Table 4.2) and of these proteins a few are known to be involved 
in both γ-secretase –dependent and –independent functions of PS1. The interaction 
of PS1 and β-catenin is involved in γ-secretase independent PS1 functions [Raurell 
et al 2008] and should represent a target for future investigation of PS1 CUE domain 
function. BACE1 is a protease that is involved in ectodomain shedding in regulated 
intramembrane proteolysis [Kang et al 2008] and is thought of as the rate-limiting 
step in APP cleavage [Cole and Vassar 2007]. Fe65 is known to interact with the γ-
secretase APP cleavage product AICD to regulate Neprilysin gene regulation 
[Vazquez et al 2009]. Tau is a protein that is found in the neurofibrillary tangles that 
are present in the brains of AD patients which also undergoes K63-linked 
polyubiquitination [Babu et al 2005]. The UBA domain containing protein p62 is 
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known to be required for correct turnover of K63-polyubiquitinated Tau [Babu et al 
2008]. As these 3 proteins are involved in regulated intramembrane proteolysis, APP 
signalling and AD disease they represent strong targets for future investigation of 
PS1 CUE domain function.  
The data shown here did not identify any PS1 CUE domain interacting proteins. To 
determine the identity of potential PS1 CUE domain interacting proteins it was 
decided to next use a high throughput proteomic approach. In the next chapter we 
will present proteomics data attained from mass spectrometry that we will use to 
investigate whether the PS1 CUE domain is involved in regulating intermolecular or 
intramolecular interactions of PS1. 
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5 Mass Spectrometry Analysis of PS1 Interacting Proteins 
Introduction 
Having first shown that the PS1 CUE domain selectively binds to K63-linked 
polyubiquitin chains, the PS1 CUE domain was shown to be dispensable for the 
interaction of PS1 with a number of PS1 interacting proteins which are known to 
undergo K63-linked polyubiquitination. While the interaction between PS1 and 
TRAF6 has been shown to be somewhat regulated by the PS1 CUE domain, this 
approach has not helped identify PS1-binding partners nor demonstrate the function 
of the PS1 CUE domain. To identify PS1 CUE domain binding proteins and to 
elucidate PS1 CUE domain function(s) it was decided to utilise a mass spectrometry-
based proteomics approach. The purpose of this experiment was to isolate PS1 CUE 
domain interacting proteins from whole cell lysate using a recombinant bait protein 
which would include the PS1 CUE domain. After isolation of these PS1 CUE 
domain interacting proteins, mass spectrometry would be used to identify these 
interacting proteins. A further aim of the experiment was to determine whether the 
PS1 CUE domain is involved in the intermolecular or intramolecular interactions of 
PS1.  
Mass spectrometry-based proteomic approaches typically involve the use of a bait 
protein that is either singly- [Shi et al 2011] or doubly-tagged [Tagwerker et al 
2006]. Tandem affinity-purification (TAP) tags have often been used in the 
identification of interacting proteins [Tagwerker et al 2006; Guerrero et al 2006; 
Golebiowski et al 2010]. In these approaches the bait protein contains two different 
protein tags that are separated by a protease cleavage site. The bait protein and any 
bound proteins are first purified using one tag before this tag is removed by 
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treatment with the appropriate protease. The remainder of the bait protein can then 
be re-purified using the second epitope tag [Rigaut et al 1999]. The benefit of this 
sequential purification method is that it allows for a reduction in non-specific 
binding of proteins as it uses two different purification systems in tandem. There is a 
variation of this method has been used to aid in discovering ubiquitinated proteins 
where both the target protein(s) and ubiquitin are tagged with differing epitope tags 
[Maine et al 2010]. This approach allows for a protein sample to be enriched with 
ubiquitinated proteins and then ubiquitinated forms of the protein(s) of interest can 
be purified. This also allows for better identification of sites of ubiquitination within 
a protein of interest. Identification of general sites of ubiquitination within the 
proteome of cells have also been investigated through a tag-based mass spectrometry 
approach. In this approach GST-tagged repeats of different UBA domains have been 
incubated with whole cell lysate to enrich for ubiquitinated proteins prior to mass 
spectrometry analysis [Shi et al 2011]. Since a number of GST-tagged recombinant 
PS1 Loop containing proteins had already been created in our lab, it was decided to 
use this approach to attempt to identify PS1 CUE interacting proteins. 
In this chapter an endogenous GST pulldown assay was validated, which uses the 
previously described recombinant GST-PS1-Loop and GST-PS1-Loop FP/VS/AA 
CUE domain mutant proteins. The GST-tagged proteins were first shown to bind to 
unknown proteins using Coomassie staining and the assay was validated by showing 
an interaction between recombinant GST-PS1-Loop and Rab11. Further validation of 
the methodology ruled out the need to use the DUB inhibitor, phenanthroline when 
lysing the HEK293T cells and the use of a glutathione elution buffer when removing 
bound proteins from the purification column. Three different samples were sent for 
mass spectrometry analysis: the negative control GST, the positive control GST-
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PS1-Loop and the test sample CUE domain mutant GST-PS1-Loop FP/VS/AA. 
Once the mass spectrometry results were returned and analysed, it was concluded 
that the PS1 loop and CUE domains are not involved in regulating PS1-PS1 
intramolecular interactions. The lists of proteins identified by mass spectrometry 
were analysed and broken down to show the proteins that interact with either the 
GST-PS1-Loop or the GST-PS1-Loop FP/VS/AA recombinant proteins. The 
molecular and biological functions of the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA interacting proteins were then investigated using a number of 
bioinformatics approaches to help elucidate the function of the PS1 CUE domain. 
   
142 
 
5.1 Validation of GST-Pulldown Assay 
To determine the identity of PS1 CUE domain interacting proteins a GST-pulldown 
assay utilizing endogenous human proteins was first developed. This assay involved 
the use of the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA recombinant proteins 
that have been previously described in Section 3.7. These recombinant proteins 
contain the entire intracellular PS1 loop domain (residues 265-380) including the 
PS1 CUE domain; the GST-PS1-Loop-FP/VS/AA protein contains mutations at 
conserved CUE domain residues. For these experiments recombinant GST, GST-
PS1-Loop and GST-PS1-Loop FP/VS/AA were purified as previously described in 
Sections 3.8 and 3.9. The elutions of both GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA proteins were separated by SDS-PAGE on a 12% gel and stained with a 
coomassie stain to compare the amount of recombinant protein present in each 
elution;  the elutions of both GST-PS1-Loop and GST-PS1-Loop FP/VS/AA were 
comparable in protein concentration (Figure 5.1A). Next, the GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA recombinant proteins were used in the GST-pulldown 
assay using endogenous human protein. In this assay, recombinant GST-PS1-Loop 
or GST-PS1-Loop FP/VS/AA proteins were incubated with glutathione agarose 
beads, the binding buffer was allowed to flow through the column before an 
equivalent amount of protein from HEK293T cell lysate (50 mg) was added to the 
columns. The columns were incubated overnight at 4°C with the cell lysate. The 
following morning the unbound lysate was allowed to flow through the column and 
the beads were then washed 4 times in binding buffer. After washing the beads were 
collected in an Eppendorf tube and boiled in 500 ml of 2X Laemmli sample buffer. 
Samples taken at each stage of the pulldown assay were separated by SDS-PAGE 
and proteins were detected by coomassie staining (Figures 5.1B and 5.1C) showing 
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the intensity and size-diversity of proteins that bound to the GST-PS1-Loop (Figure 
5.1B lane 9) and GST-PS1-Loop-FP/VS/AA recombinant proteins (Figure 5.1C 
lane 9). These gels demonstrate that this experimental approach can be used to 
investigate PS1 CUE domain function as it demonstrates that the recombinant 
proteins interact with a range of proteins of different sizes. 
5.2 Endogenous Rab11 is purified by recombinant GST-PS1 Loop 
Proteins 
To validate this pulldown assay it was decided to determine if any known PS1 
intracellular loop domain interacting proteins were pulled out of HEK293T lysate by 
the GST-PS1 Loop and GST-PS1 Loop FP/VS/AA recombinant proteins. Rab11 is a 
known PS1 interacting protein that interacts with the intracellular loop domain of 
PS1 [Dumanchin et al 1999] and this protein was used to validate the assay. Protein 
samples taken during the GST-pulldown assay were separated by SDS-PAGE and 
then immunoblotted with an anti-Rab11 antibody. Rab11 can be seen to be pulled 
down by the recombinant GST-PS1 Loop (Figure 5.2A) and GST-PS1 Loop 
FP/VS/AA proteins (Figure 5.2B). The blot was also probed with anti-PS1 CTF 
antibody to show the presence of the recombinant GST-tagged proteins. These data 
further validates the GST-pulldown assay for the purpose of investigating PS1 
intracellular loop interacting proteins. 
5.3 The Deubiquitinase Inhibitor Phenanthroline Prevents GST Binding 
To Glutathione Agarose Beads 
Sites of ubiquitination can be identified through mass spectrometry by the presence 




Figure 5.1 GST-PS1 Loop pulldown from endogenous HEK293T cells. (A) GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA proteins were purified from BL21 E. coli cells. The purified proteins were 
collected into 5 elutions and indicated above with an arrow. Equivalent protein purification was 
demonstrated by separation by SDS-PAGE and coomassie staining. Cell lsyates from HEK293T cells 
were incubated with (B) GST-PS1 Loop or (C) GST-PS1 Loop FP/VS/AA recombinant proteins 
bound to glutathione-agarose beads. The unbound proteins were allowed to flow through the column 
before the beads were washed 4 times. Bound proteins were removed from the bead bed through 
boiling. Protein samples were separated by SDS-PAGE on 12% gels and proteins were detected by 










Figure 5.2 Western blot analysis of GST-PS1 Loop pulldown from HEK293T cells. Cell lsyates 
from HEK293T cells were incubated with (A) GST-PS1 Loop or (B) GST-PS1 Loop FP/VS/AA 
recombinant proteins bound to glutathione-agarose beads. The unbound proteins were allowed to flow 
through the column before the beads were washed 4 times. Bound proteins were removed from the 
bead bed through boiling. Protein samples taken at different stages through the assay were separated 
by SDS-PAGE on 12% gels and were subject to immunoblotting with either anti-Rab11 or anti-PS1 





the final two glycine residues of ubiquitin and the lysine residue on which they are 
covalently bound. To find these sites of ubiquitination it is necessary to inhibit 
deubiquitinase (DUB) proteins when lysing the cells that will be analysed. As 
iodoacetamide has been known to cause the formation of pseudo-ubiquitinated sites 
it was decided to test the DUB inhibitor phenanthroline (Phen) on the GST-pulldown 
assay [Shi et al 2011]. GST, GST-PS1-Loop or GST-PS1-Loop FP/VS/AA proteins 
were incubated with glutathione agarose beads, the binding buffer was allowed to 
flow through the column before an equivalent amount of protein from HEK293T 
cells lysed in binding buffer supplemented with 8 mM phenanthroline was added to 
the column. The column was incubated overnight at 4°C with the cell lysate. The 
following morning the unbound lysate was allowed to flow through the column and 
the beads were then washed 4 times in binding buffer. After washing the bound 
protein was eluted from the column with 50 μM glutathione elution buffer. The 
bound proteins were eluted from the beads in this assay rather than boiled to try and 
minimise non-specific protein binding. Samples were retained at each stage of the 
assay, then separated by SDS-PAGE and protein binding was detected by coomassie 
staining of each gel. The recombinant GST protein is not clearly visible after the 
binding process suggesting that the phenanthroline may cause GST to detach from 
the glutathione-agarose beads (lane 9 of Figure 5.3A). To test this hypothesis the 
experiment was repeated using GST-PS1-Loop and GST-PS1-Loop FP/VS/AA 
proteins. Unbound GST-PS1-Loop and GST-PS1-Loop FP/VS/AA proteins and 
samples of the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA bound beads were 
retained prior to the addition of the HEK293T lysate. The HEK293T cells were still 
lysed in binding buffer supplemented with the DUB inhibitor phenanthroline (8 
mM). The GST-PS1-Loop and GST-PS1-Loop FP/VS/AA proteins were bound to 
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the glutathione agarose beads prior to incubation with the HEK293T cell lysate 
(Lanes 1 of Figures 5.3B and 5.3C). However, no equivalent bands to these 
recombinant proteins can be seen on the gels after incubation with the 
phenanthroline supplemented binding buffer. As the phenanthroline appeared to be 
causing the GST-tagged proteins to detach from the glutathione agarose beads it was 
decided to leave the DUB inhibitor out of the GST-pulldown of endogenous human 
protein assay. 
5.4 GST-Pulldown of Endogenous Human Proteins for Mass 
spectrometry Analysis 
Once the GST-pulldown assay had been optimised the samples for mass 
spectrometry analysis were prepared. Recombinant GST, GST-PS1-Loop or GST-
PS1-Loop FP/VS/AA proteins were incubated with glutathione agarose beads prior 
to incubation with an equivalent amount of HEK293T lysate (50 mg per 
experiment). The recombinant proteins were incubated with the HEK293T lysate 
overnight at 4°C, unbound protein was allowed to flow through the column and the 
bead bed was washed 4 times with binding buffer. For the GST sample (Figure 
5.4A) the bound proteins were first eluted from the beads using a 50 mM elution 
buffer but as can be seen in lane 10 of the gel (marked ‘GST’)  that the recombinant 
GST protein is not clearly visible after elution. After consultation with Fingerprints 
Proteomics (Dundee, UK), who performed our mass spectrometry analysis, it was 
decided to remove bound protein from the beads through boiling in 2X Laemmli 
sample buffer as a means of increasing protein concentration in the sample. Here the 
GST protein appears as a much stronger band (marked ‘GST’) and other bound 
proteins can also be seen clearly on the gel (Figure 5.4B). For the GST-PS1-Loop 




Figure 5.3 Phenanthroline inhibits binding of recombinant GST-tagged proteins to glutathione 
agarose beads. HEK293T cells were lysed in binding buffer supplemented with 8 mM 
phenanthroline (PTL). The HEK293T lysates were incubated with (A) GST, (B) GST-PS1 Loop or 
(C) GST-PS1 Loop FP/VS/AA recombinant proteins bound to glutathione-agarose beads. The 
unbound proteins were allowed to flow through the column before the beads were washed 4 times. 
Bound proteins were removed from the bead bed through elution with 50 mM glutathione elution 
buffer. Protein samples were separated by SDS-PAGE and bound proteins were detected by 
Coomassie staining.  El: elution; kDa: kilodaltons; Ly: lysate; FT: flow through; W: wash; Un: 




process was repeated and bound proteins were removed from the beads by boiling in 
2X Laemmli sample buffer andhere the recombinant proteins are marked as ‘GST-
PS1-Loop’ and ‘GST-PS1-Loop FP/VS/AA’ (the final lanes of Figures 5.4C and 
5.4D). These samples were adjudged to be of sufficient quality and concentration to 
be used for mass spectrometry analysis. 
5.5 Mass Spec Identification of Pulled Down Proteins 
Three samples; GST, GST-PS1-Loop and GST-PS1-Loop FP/VS/AA were sent for 
mass spectrometry analysis. The GST sample was acting as a negative control for the 
experiment; proteins that were identified in this sample would be excluded from 
consideration if also present either of the other two samples. Bound proteins were 
separated by SDS-PAGE under laminar air flow conditions to reduce contamination 
(see Figure 5.5 for image of sample separation), gel purified and then subject to 
tryptic digestion as previously described [Walsh et al 2002]. Tryptic peptides from 
the samples were analysed using matrix–assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry. The analysed tryptic peptides were 
identified and scored using the Mascot server (www.matrixscience.com). In the 
Mascot server each analysed peptide will be assigned an ion score based on the 
probability that that the calculated mass of a peptide matches that of a queried 
protein in the Mascot database. The Mascot score represents the sum of the ion 
scores that a protein identified through a mass spectrometry analysis accrues i.e. a 
protein will achieve a higher Mascot score when there is a greater number of unique 
peptides analysed by the mass spectrometry machine. Therefore, the higher the 
Mascot score that an identified protein achieves the more confident you can be that 
this is a correctly identified protein. The proteins identified in each of the three 






Figure 5.4 GST-pulldown of endogenous HEK293T proteins for mass spectrometry analysis. 
HEK293T lysates were incubated with (A) and (B) GST, (C) GST-PS1-Loop or (D) GST-PS1-Loop 
FP/VS/AA recombinant proteins bound to glutathione-agarose beads. The unbound proteins were 
allowed to flow through the column before the beads were washed 4 times. Bound proteins were 
removed from the bead bed through either (A) elution with 50 mM glutathione buffer or (B-D) 
through boiling. Bound proteins were separated by SDS-PAGE on 12% gels and proteins were 
detected by Coomassie staining. Bl: Boil El: elution; kDa: kilodaltons; Ly: lysate; FT: flow through; 




identified and the total number of proteins through mass spectrometry analysis and 
the number of proteins remaining after the cutoff was applied. 
 
Table 5.1 Total number of proteins identified in mass spectrometry analysis of 
GST, GST-PS1 Loop and GST-PS1 Loop FP/VS/AA samples and number of 
proteins remaining after application of cut-off. 
Data Set Total No. of proteins No. of Proteins after  
Cut-off 
GST 584 264 
GST-PS1 Loop 380 162 




The identified proteins from the GST, GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA samples are presented in full in Appendices 7.1-7.3. The mass 
spectrometry results for the three samples are presented in Table 5.1 showing the 
total amount of proteins identified per sample and the amount of proteins remaining 
after a cut-off had been applied to each sample list. The cut-off was applied to any 
protein that had only 1 unique peptide identified through the mass spectrometry 
analysis [Atrih et al 2014]. This removed 320 proteins from the GST dataset, 218 










Figure 5.5 Separation of samples for mass spec analysis. Prior to mass spectrometry analysis 
protein samples were separated by SDS-PAGE under laminar airflow conditions and proteins were 
detected by coomassie staining. The GST (GST), GST-PS1 Loop (PS1 WT) and GST-PS Loop 
FP/VS/AA (PS1 FP/VS/AA) samples are highlighted on top of the panel. The GST and GST-PS1 





5.6 Alignment of Mass spectrometry PS1 Tryptic Peptides 
Our hypothesis for the function of the PS1 CUE domain was that it was involved in 
regulating either intermolecular PS1 protein-protein interactions or intramolecular 
PS1-PS1 interactions. The GST-PS1-Loop recombinant proteins contain the 
intracellular loop domain of PS1 that is present between residues 265 and 380 of 
PS1. By aligning the sequences of the PS1 tryptic peptides identified with the 
primary sequence of the PS1 holoprotein the presence of any tryptic peptides that 
originate from endogenous PS1 protein can be detected. Endogenous proteins can be 
detected if any tryptic PS1 peptides that align with PS1 sequences outside of the 
intracellular loop of PS1. The unique PS1 peptides identified in the GST-PS1-Loop 
and GST-PS1-Loop FP/VS/AA samples were aligned with the primary sequence of 
PS1 using AlignX. All peptides examined aligned between residues 270 and 380 of 
the PS1 primary sequence (Figure 5.6). As all PS1 tryptic peptides aligned with the 
intracellular loop domain of PS1 these data suggests that the intracellular loop 
domain of PS1, and by extension the PS1 CUE domain, is not involved in 
intramolecular PS1-PS1 interactions. This suggests that the PS1 CUE domain is 





Presenilin 1 (270-319)  MLVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSKYNAES 
GST-PS1 peptide 1      -------------------------------------------------- 
GST-PS1 peptide 2      -------------------------------------------------- 
GST-PS1 peptide 3      ---------------------------------------------YNAES 
GST-PS1 peptide 4      MLVETAQER----------------------------------------- 
GST-PS1 peptide 5      -------------------------------------------------- 
GST-PS1-peptide 6      -------------------------------------------------- 
GST-PS1 peptide 7      ---------------------------------------------YNAES 
GST-PS1 peptide 8      MLVETAQER----------------------------------------- 
GST-PS1 peptide 9      ---------------------------------------------YNAES 
GST-PS1 FPVSAA peptide 1   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 2   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 3   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 5  MLVETAQER----------------------------------------- 
GST-PS1 FPVSAA peptide 4   ---------------------------------------------YNAES 
GST-PS1 FPVSAA peptide 6   ---------------------------------------------YNAES 
GST-PS1 FPVSAA peptide 7   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 8   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 9   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 10  ------------------------------------------NSKYNAES 
 
Presenilin 1 (320-369)  TERESQDTVAENDDGGFSEEWEAQRDSHLGPHRSTPESRAAVQELSSSIL 
GST-PS1 peptide 1       ---------------------------------------AAVQELSSSIL 
GST-PS1 peptide 2       ---ESQDTVAENDDGGFSEEWEAQR------------------------- 
GST-PS1 peptide 3       TERESQDTVAENDDGGFSEEWEAQR------------------------- 
GST-PS1 peptide 4      -------------------------------------------------- 
GST-PS1 peptide 5       ---------------------------------------AAVQELSSSIL 
GST-PS1 peptide 6       ---ESQDTVAENDDGGFSEEWEAQRDSHLGPHR----------------- 
GST-PS1 peptide 7       TER----------------------------------------------- 
GST-PS1 peptide 8      -------------------------------------------------- 
GST-PS1 peptide 9       TERESQDTVAENDDGGFSEEWEAQRDSHLGPHR----------------- 
GST-PS1 FPVSAA peptide 1   ---------------------------------------AAVQELSSSIL 
GST-PS1 FPVSAA peptide 2   ---ESQDTVAENDDGGFSEEWEAQR------------------------- 
GST-PS1 FPVSAA peptide 3   ---------------------------------------AAVQELSSSIL 
GST-PS1 FPVSAA peptide 5   -------------------------------------------------- 
GST-PS1 FPVSAA peptide 4  TERESQDTVAENDDGGFSEEWEAQR------------------------- 
GST-PS1 FPVSAA peptide 6   TER----------------------------------------------- 
GST-PS1 FPVSAA peptide 7   ---ESQDTVAENDDGGFSEEWEAQRDSHLGPHR----------------- 
GST-PS1 FPVSAA peptide 8   ---------------------------------STPESRAAVQELSSSIL 
GST-PS1 FPVSAA peptide 9   ---------------------------------------AAVQELSSSIL 
GST-PS1 FPVSAA peptide 10  TER----------------------------------------------- 
                
Presenilin 1 (370-380)   AGEDPEERGVK 
GST-PS1 peptide 1      AGEDPEER--- 
GST-PS1 peptide 2      ----------- 
GST-PS1 peptide 3      ----------- 
GST-PS1 peptide 4      ----------- 
GST-PS1 peptide 5      AGEDPEERGVK 
GST-PS1 peptide 6      ----------- 
GST-PS1 peptide 7      ----------- 
GST-PS1 peptide 8      ----------- 
GST-PS1 peptide 9      ----------- 
GST-PS1 FPVSAA peptide 1  AGEDPEER--- 
GST-PS1 FPVSAA peptide 2   ----------- 
GST-PS1 FPVSAA peptide 3   AGEDPEER--- 
GST-PS1 FPVSAA peptide 5   ----------- 
GST-PS1 FPVSAA peptide 4   ----------- 
GST-PS1 FPVSAA peptide 6   ----------- 
GST-PS1 FPVSAA peptide 7   ----------- 
GST-PS1 FPVSAA peptide 8  AGEDPEER--- 
GST-PS1 FPVSAA peptide 9   AGEDPEERGVK 
GST-PS1 FPVSAA peptide 10  ----------- 
 
Figure 5.6 Alignment of PS1 tryptic peptides with the primary sequence of PS1 holoprotein. The 
tryptic peptides identified by the mass spectrometry analysis of the GST-PS1-Loop and GST-Ps1-
Loop FP/VS/AA samples were aligned with the primary sequence of PS1 using AlignX. All peptides 
examined aligned with PS1 between residues 270-280. 
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5.7 Analysis of Proteins Identified Through Mass spectrometry Analysis 
After the cut-off had been applied to all three datasets, next the proteins identified in 
the negative control GST dataset were removed from both the GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA datatsets. Any proteins identified in the negative control 
sample are likely to bind to either the glutathione-agarose beads or the GST protein 
and as such represent non-specific binding in either the GST-PS1-Loop or GST-PS1-
Loop FP/VS/AA samples. While PS1 was the highest scoring protein for both the 
GST-PS1-Loop (13124.15) and GST-PS1-Loop FP/VS/AA datasets (23106.01), it 
also received a Mascot score in the GST dataset (370.42) suggesting that a small 
amount of endogenous PS1 interacted with the negative control sample. The highest 
Mascot scoring protein that remained after removal of the negative control dataset 
was δ-catenin for both the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA samples. 
Plakophilin-4 also received a high Mascot score in both protein samples. Both 
proteins have previously been shown to interact with PS1 which demonstrates the 
validity of these results [Tanahashi et al 1999; Stahl et al 1999]. The other identified 
proteins remaining after removal of the negative control have been tabulated into 
three separate tables. Table 5.2 records the bound proteins that were identified in 
both the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA samples. The table gives 
the accession code and name of the proteins, the percentage of the proteins sequence 
covered by the examined peptides, the Mascot score received and the number of 
proteins, peptides and unique peptides recorded by the mass spectrometry analysis. 
The same details are presented for proteins unique to the GST-PS1-Loop sample in 




Table 5.2 Common bound proteins identified through mass spectrometry 
analysis of GST-PS1 Loop and GST-PS1 Loop FP/VS/AA sample.     
Proteins from GST-PS1 Loop sample are highlighted, while proteins from GST-PS1 
Loop FP/VS/AA are unhighlighted.  







O60716 Catenin delta-1 OS=Homo 
sapiens GN=CTNND1  
3890.51 47.93 1 38 38 
 Catenin delta-1 OS=Homo 
sapiens GN=CTNND1  
3953.12 55.06 1 41 41 
Q99569 Plakophilin-4 OS=Homo 
sapiens GN=PKP4  
670.78 18.20 2 18 18 
 Plakophilin-4 OS=Homo 
sapiens GN=PKP4  
692.53 20.30 2 17 17 
P68371 Tubulin beta-4B chain 
OS=Homo sapiens 
GN=TUBB4B  
1269.99 42.70 4 2 14 
 Tubulin beta-4B chain 
OS=Homo sapiens 
GN=TUBB4B  
1194.15 48.09 5 2 18 
P35579 Myosin-9 OS=Homo sapiens 
GN=MYH9  
322.08 5.71 3 8 8 
 Myosin-9 OS=Homo sapiens 
GN=MYH9 
172.57 3.32 3 4 5 
Q9BUF5 Tubulin beta-6 chain 
OS=Homo sapiens 
GN=TUBB6  
491.59 14.35 2 1 6 
 Tubulin beta-6 chain 
OS=Homo sapiens 
GN=TUBB6  
539.27 22.87 2 3 10 





192.54 8.06 1 4 4 





321.58 20.22 1 9 9 
Q96EY1 DnaJ homolog subfamily A 
member 3, mitochondrial 
OS=Homo sapiens 
GN=DNAJA3 
172.14 10.21 1 4 4 
 DnaJ homolog subfamily A 
member 3, mitochondrial 
OS=Homo sapiens 
GN=DNAJA3 
132.15 14.79 1 5 5 




143.90 7.57 1 4 4 




139.88 7.73 1 4 4 





 Leucine--tRNA ligase, 
cytoplasmic OS=Homo 
sapiens GN=LARS 
146.02 2.38 1 2 2 
P35580 Myosin-10 OS=Homo sapiens 
GN=MYH10  
179.70 2.23 1 3 3 
 Myosin-10 OS=Homo sapiens 
GN=MYH10  
112.09 1.77 1 2 3 




117.07 8.31 1 3 3 




291.92 16.39 1 5 5 
P62424 60S ribosomal protein L7a 
OS=Homo sapiens 
GN=RPL7A 
115.40 12.41 1 3 3 
 60S ribosomal protein L7a 
OS=Homo sapiens 
GN=RPL7A 
98.25 9.02 1 2 2 
P33993 DNA replication licensing 
factor MCM7 OS=Homo 
sapiens GN=MCM7 
106.36 6.68 1 3 3 
 DNA replication licensing 
factor MCM7 OS=Homo 
sapiens GN=MCM7 
173.67 11.27 1 6 6 
P40429 60S ribosomal protein L13a 
OS=Homo sapiens 
GN=RPL13A 
99.78 14.29 2 3 3 
 60S ribosomal protein L13a 
OS=Homo sapiens 
GN=RPL13A 
102.39 14.29 2 3 3 
Q9Y2S7 Polymerase delta-interacting 
protein 2 OS=Homo sapiens 
GN=POLDIP2 
94.87 10.87 1 3 3 
 Polymerase delta-interacting 
protein 2 OS=Homo sapiens 
GN=POLDIP2 
227.43 18.21 1 5 5 
P12236 ADP/ATP translocase 3 
OS=Homo sapiens 
GN=SLC25A6 
91.61 10.40 3 1 3 
 ADP/ATP translocase 3 
OS=Homo sapiens 
GN=SLC25A6 
70.71 5.70 3 1 2 
P31689 DnaJ homolog subfamily A 
member 1 OS=Homo sapiens 
GN=DNAJA1 
91.06 11.59 3 3 3 
 DnaJ homolog subfamily A 
member 1 OS=Homo sapiens 
GN=DNAJA1 
185.04 17.88 6 4 5 
P48047 ATP synthase subunit O, 
mitochondrial OS=Homo 
sapiens GN=ATP5O 
175.95 13.15 1 2 2 
 ATP synthase subunit O, 
mitochondrial OS=Homo 
sapiens GN=ATP5O 
127.51 18.31 1 3 3 
P84098 60S ribosomal protein L19 
OS=Homo sapiens 
GN=RPL19 
143.49 13.27 1 2 2 
 60S ribosomal protein L19 
OS=Homo sapiens 
GN=RPL19 
106.96 13.27 1 2 2 
P13674 Prolyl 4-hydroxylase subunit 
alpha-1 OS=Homo sapiens 




 Prolyl 4-hydroxylase subunit 
alpha-1 OS=Homo sapiens 
GN=P4HA1 
161.05 8.05 1 3 3 
P40938 Replication factor C subunit 3 
OS=Homo sapiens GN=RFC3 
102.17 7.87 1 2 2 
 Replication factor C subunit 3 
OS=Homo sapiens GN=RFC3 
114.73 7.87 1 2 2 




87.16 6.33 1 2 2 




70.69 6.33 1 2 2 
Q9Y3Z3 Deoxynucleoside triphosphate 
triphosphohydrolase 
SAMHD1 OS=Homo sapiens 
GN=SAMHD1 
82.07 3.99 1 2 2 
 Deoxynucleoside triphosphate 
triphosphohydrolase 
SAMHD1 OS=Homo sapiens 
GN=SAMHD1 
154.00 10.86 1 5 5 
Q96I99 Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial OS=Homo 
sapiens GN=SUCLG2 
81.43 3.94 1 2 2 
 Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial OS=Homo 
sapiens GN=SUCLG2 
249.84 15.28 1 6 6 
Q96C36 Pyrroline-5-carboxylate 
reductase 2 OS=Homo 
sapiens GN=PYCR2 
70.43 6.56 1 2 2 
 Pyrroline-5-carboxylate 
reductase 2 OS=Homo 
sapiens GN=PYCR2 





Table 5.3 Proteins identified through mass spectrometry analysis unique to the 
GST-PS1 Loop dataset. 
Accessi
on 










P04259 Keratin, type II cytoskeletal 6B 
OS=Homo sapiens GN=KRT6B  
619.71 32.09 6 1 16 
P63261 Actin, cytoplasmic 2 OS=Homo sapiens 
GN=ACTG1 
909.76 44.53 7 1 13 
P09488 Glutathione S-transferase Mu 1 
OS=Homo sapiens GN=GSTM1  
809.33 24.31 2 1 7 
P63267 Actin, gamma-enteric smooth muscle 
OS=Homo sapiens GN=ACTG2 
212.41 19.41 5 1 7 
P13646 Keratin, type I cytoskeletal 13 
OS=Homo sapiens GN=KRT13  
160.66 9.39 4 1 5 
O75828 Carbonyl reductase [NADPH] 3 
OS=Homo sapiens GN=CBR3 
1112.77 19.86 1 1 4 
Q9NR3
0 
Nucleolar RNA helicase 2 OS=Homo 
sapiens GN=DDX21  
150.55 7.02 1 4 4 
Q86Y4
6 
Keratin, type II cytoskeletal 73 
OS=Homo sapiens GN=KRT73  
127.99 6.48 4 1 4 
Q86V8
1 
THO complex subunit 4 OS=Homo 
sapiens GN=ALYREF 
225.81 21.40 1 3 3 
P12277 Creatine kinase B-type OS=Homo 
sapiens GN=CKB 
153.35 12.34 1 3 3 
P05386 60S acidic ribosomal protein P1 
OS=Homo sapiens GN=RPLP1  
118.58 20.18 2 2 2 
P13637 Sodium/potassium-transporting ATPase 
subunit alpha-3 OS=Homo sapiens 
GN=ATP1A3 
115.31 3.26 4 2 2 
P62750 60S ribosomal protein L23a OS=Homo 95.35 14.10 1 2 2 
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sapiens GN=RPL23A  
Q8N1N
4 
Keratin, type II cytoskeletal 78 
OS=Homo sapiens GN=KRT78  
95.04 3.85 2 1 2 
Q9UL
V4 
Coronin-1C OS=Homo sapiens 
GN=CORO1C 
90.15 5.70 1 2 2 
O00483 NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 4 OS=Homo 
sapiens GN=NDUFA4  
85.65 27.16 1 2 2 
P62826 GTP-binding nuclear protein Ran 
OS=Homo sapiens GN=RAN 
81.61 10.19 1 2 2 
P08621 U1 small nuclear ribonucleoprotein 70 
kDa OS=Homo sapiens GN=SNRNP70 
80.54 4.35 1 2 2 
P68431 Histone H3.1 OS=Homo sapiens 
GN=HIST1H3A 
74.48 11.76 5 2 2 
P27348 14-3-3 protein theta OS=Homo sapiens 
GN=YWHAQ 
71.43 7.35 7 2 2 
Q9BU
Q8 
Probable ATP-dependent RNA helicase 
DDX23 OS=Homo sapiens 
GN=DDX23 
62.71 2.80 1 2 2 
Q8IX1
2 
Cell division cycle and apoptosis 
regulator protein 1 OS=Homo sapiens 
GN=CCAR1 






Table 5.4 Proteins identified through mass spectrometry analysis unique to the 
GST-PS1 Loop FP/VS/AA dataset. 
Accessi
on 










P46459 Vesicle-fusing ATPase OS=Homo 
sapiens GN=NSF 
243.78 10.75 1 7 7 
Q9UK
B1 
F-box/WD repeat-containing protein 11 
OS=Homo sapiens GN=FBXW11 
240.52 18.27 2 6 6 
Q92947 Glutaryl-CoA dehydrogenase, 
mitochondrial OS=Homo sapiens 
GN=GCDH 
199.93 18.95 1 4 4 
O60762 Dolichol-phosphate 
mannosyltransferase subunit 1 
OS=Homo sapiens GN=DPM1  
150.18 23.08 1 4 4 
Q7Z7L
1 
Schlafen family member 11 OS=Homo 
sapiens GN=SLFN11  
134.32 5.88 1 4 4 
P30837 Aldehyde dehydrogenase X, 
mitochondrial OS=Homo sapiens 
GN=ALDH1B1 
130.82 8.51 1 4 4 
P11172 Uridine 5'-monophosphate synthase 
OS=Homo sapiens GN=UMPS  
148.10 7.92 1 3 3 
P32322 Pyrroline-5-carboxylate reductase 1, 
mitochondrial OS=Homo sapiens 
GN=PYCR1 
113.06 14.42 1 3 3 
P0C0S
5 
Histone H2A.Z OS=Homo sapiens 
GN=H2AFZ 
112.94 20.31 5 1 3 
P53597 Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, mitochondrial 
OS=Homo sapiens GN=SUCLG1 
148.30 3.76 1 2 2 
P22695 Cytochrome b-c1 complex subunit 2, 
mitochondrial OS=Homo sapiens 
GN=UQCRC2 
131.37 6.62 1 2 2 
Q9HA
V7 
GrpE protein homolog 1, mitochondrial 
OS=Homo sapiens GN=GRPEL1 
113.90 12.44 1 2 2 
Q99714 3-hydroxyacyl-CoA dehydrogenase 
type-2 OS=Homo sapiens 
GN=HSD17B10 
107.86 9.58 1 2 2 
Q7Z3Y
8 
Keratin, type I cytoskeletal 27 
OS=Homo sapiens GN=KRT27  
106.48 4.58 4 1 2 
Q14203 Dynactin subunit 1 OS=Homo sapiens 
GN=DCTN1 
105.87 1.41 4 1 2 
Q8NE7
1 
ATP-binding cassette sub-family F 
member 1 OS=Homo sapiens 
GN=ABCF1 
103.95 3.08 1 2 2 
P07686 Beta-hexosaminidase subunit beta 
OS=Homo sapiens GN=HEXB  
92.49 4.32 1 2 2 
Q16531 DNA damage-binding protein 1 
OS=Homo sapiens GN=DDB1 
90.68 1.75 1 2 2 
P23258 Tubulin gamma-1 chain OS=Homo 
sapiens GN=TUBG1 
90.25 11.09 2 2 2 
Q8N4T
8 
Carbonyl reductase family member 4 
OS=Homo sapiens GN=CBR4 
86.74 10.13 1 2 2 
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P34897 Serine hydroxymethyltransferase, 
mitochondrial OS=Homo sapiens 
GN=SHMT2 
82.59 4.37 1 2 2 
Q5JPH
6 
Probable glutamate--tRNA ligase, 
mitochondrial OS=Homo sapiens 
GN=EARS2 
77.55 4.21 1 2 2 
P15924 Desmoplakin OS=Homo sapiens 
GN=DSP 
76.92 0.77 1 2 2 
Q16775 Hydroxyacylglutathione hydrolase, 
mitochondrial OS=Homo sapiens 
GN=HAGH 
74.71 7.79 1 2 2 
P81605 Dermcidin OS=Homo sapiens 
GN=DCD 
73.48 22.73 1 2 2 
Q15120 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 3, 
mitochondrial OS=Homo sapiens 
GN=PDK3 
72.91 4.93 1 2 2 
Q9UN3
7 
Vacuolar protein sorting-associated 
protein 4A OS=Homo sapiens 
GN=VPS4A 
72.87 4.35 3 2 2 
Q9NTJ
3 
Structural maintenance of 
chromosomes protein 4 OS=Homo 
sapiens GN=SMC4 
72.65 1.71 1 2 2 
O60884 DnaJ homolog subfamily A member 2 
OS=Homo sapiens GN=DNAJA2  
67.93 7.77 1 2 2 
Q53H9
6 
Pyrroline-5-carboxylate reductase 3 
OS=Homo sapiens GN=PYCRL  
65.76 8.03 1 2 2 
Q9UL0
3 
Integrator complex subunit 6 
OS=Homo sapiens GN=INTS6  





5.8 PANTHER System of Protein Classification 
The lists of proteins identified in both the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA samples were first reduced in size by the application of a cut-off with the 
removal of proteins that were identified by a single peptide. After this the lists were 
further reduced by the removal of any protein that was also contained with the 
negative control GST sample. This reduced the number of proteins identified in the 
GST-PS1-Loop sample to 48 from the initial size of 380 and reduced the GST-PS1-
Loop FP/VS/AA sample to 57 from an initial size of 353. These proteins are 
compiled into the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets that are 
presented in Table 5.5. These datasets were then used to investigate the function of 
PS1 CUE domain using bioinformatics tools. These bioinformatics tools were used 
to look for any relevant differences in the biological function of proteins contained in 
either dataset. 
To do this protein analysis through evolutionary relationships (PANTHER) 
classification system was used (www.pantherdb.org) [Mi et al 2012]. PANTHER 
analyses submitted lists of protein accession numbers or gene names and categorises 
them using the Gene Ontology annotations molecular function, biological process or 
pathway [The Gene Ontology Consortium 2011]. The molecular function category, 
defines proteins by their direct function e.g. kinases, phosphatases etc.; over 9000 
different molecular function terms were used as of 2011. The GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA datasets were split into 6 different molecular function 
categories: translation regulator activity, binding, enzyme regulator activity, 
structural molecule activity, catalytic activity and transporter activity. The molecular 




Table 5.5 List of gene and proteins names contained within the GST-PS1-Loop 
or GST-PS1-Loop FP/VS/AA datasets. 
GST-PS1-Loop Dataset GST-PS1-Loop FP/VS/AA Dataset 
Gene 
Name 
Protein name Gene Name Protein name 
PSEN1 Presenilin-1 PSEN1 Presenilin-1 
CTNND1 Catenin delta-1  CTNND1 Catenin delta-1 
TUBB4B Tubulin beta-4B chain  TUBB4B Tubulin beta-4B chain 
CBR3 Carbonyl reductase [NADPH] 3  PKP4 Plakophilin-4 
ACTG1 Actin, cytoplasmic 2  TUBB6 Tubulin beta-6 chain 
GSTM1 Glutathione S-transferase Mu 1  CLPX ATP-dependent Clp protease ATP-binding 
subunit clpX-like, mitochondrial 
PKP4 Plakophilin-4  ACADM Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
KRT6B Keratin, type II cytoskeletal 6B  SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit 
beta, mitochondrial 
TUBB6 Tubulin beta-6 chain  NSF Vesicle-fusing ATPase/NSF 
MYH9 Myosin-9 FBXW11 F-box/WD repeat-containing protein 11 
ALYREF THO complex subunit 4  POLDIP2 Polymerase delta-interacting protein 2 
ACTG2 Actin, gamma-enteric smooth 
muscle  
GCDH Glutaryl-CoA dehydrogenase, mitochondrial 
CLPX ATP-dependent Clp protease 
ATP-binding subunit clpX-like, 
mitochondrial  
DNAJA1 DnaJ homolog subfamily A member 1 
LARS Leucine--tRNA ligase, cytoplasmic  MCM7 DNA replication licensing factor MCM7 
MYH10 Myosin-10  MYH9 Myosin-9  
ATP5O ATP synthase subunit O, 
mitochondrial  
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 
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DNAJA3 DnaJ homolog subfamily A 
member 3, mitochondrial  
SAMHD1 Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
KRT13 Keratin, type I cytoskeletal 13  DPM1 Dolichol-phosphate mannosyltransferase 
subunit 1 
CKB Creatine kinase B-type  SUCLG1 Succinyl-CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial 
DDX21 Nucleolar RNA helicase 2  UMPS Uridine 5'-monophosphate synthase 
ADCK3 Chaperone activity of bc1 
complex-like, mitochondrial 
LARS Leucine--tRNA ligase, cytoplasmic 
RPL19 60S ribosomal protein L19  ADCK3 Chaperone activity of bc1 complex-like, 
mitochondrial 
P4HA1 Prolyl 4-hydroxylase subunit 
alpha-1 
SLFN11 Schlafen family member 11 
KRT73 Keratin, type II cytoskeletal 73  DNAJA3 DnaJ homolog subfamily A member 3, 
mitochondrial 
RPLP1 60S acidic ribosomal protein P1  UQCRC2 Cytochrome b-c1 complex subunit 2, 
mitochondrial 
ACADM Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial  
ALDH1B1 Aldehyde dehydrogenase X, mitochondrial 
RPL7A 60S ribosomal protein L7a ATP5O ATP synthase subunit O, mitochondrial 
ATP1A3 Sodium/potassium-transporting 
ATPase subunit alpha-3 
PYCR2 Pyrroline-5-carboxylate reductase 2 
MCM7 DNA replication licensing factor 
MCM7  
RFC3 Replication factor C subunit 3 
RFC3 Replication factor C subunit 3 GRPEL1 GrpE protein homolog 1, mitochondrial 
RPL13A 60S ribosomal protein L13a  PYCR1 Pyrroline-5-carboxylate reductase 1, 
mitochondrial 
RPL23A 60S ribosomal protein L23a  H2AFZ Histone H2A.Z 
KRT78 Keratin, type II cytoskeletal 78  MYH10 Myosin-10 
POLDIP2 Polymerase delta-interacting HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2 
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protein 2  
SLC25A6 ADP/ATP translocase 3 RPL19 60S ribosomal protein L19 
DNAJA1 DnaJ homolog subfamily A 
member 1 
KRT27 Keratin, type I cytoskeletal 27 
CORO1C Coronin-1C  DCTN1 Dynactin subunit 1 
HNRNPAB Heterogeneous nuclear 
ribonucleoprotein A/B 
ABCF1 ATP-binding cassette sub-family F member 1 
NDUFA4 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 4  
RPL13A 60S ribosomal protein L13a 
SAMHD1 Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
RPL7A 60S ribosomal protein L7a 
RAN GTP-binding nuclear protein Ran  HEXB Beta-hexosaminidase subunit beta 
SUCLG2 Succinyl-CoA ligase [GDP-
forming] subunit beta, 
mitochondrial 
DDB1 DNA damage-binding protein 1 
SNRNP70 U1 small nuclear 
ribonucleoprotein 70 kDa  
TUBG1 Tubulin gamma-1 chain 
HIST1H3A Histone H3.1 CBR4 Carbonyl reductase family member 4 




EARS2 Probable glutamate--tRNA ligase, 
mitochondrial 
DDX23 Probable ATP-dependent RNA 
helicase DDX23 
DSP Desmoplakin 
CCAR1 Cell division cycle and apoptosis 
regulator protein 1 
HAGH Hydroxyacylglutathione hydrolase, 
mitochondrial 
 DCD Dermcidin 
PDK3 [Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 3, mitochondrial 
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VPS4A Vacuolar protein sorting-associated protein 
4A 
SMC4 Structural maintenance of chromosomes 
protein 4 
SLC25A6 ADP/ATP translocase 3 
HNRNPAB Heterogeneous nuclear ribonucleoprotein 
A/B 
DNAJA2 DnaJ homolog subfamily A member 2 
PYCRL Pyrroline-5-carboxylate reductase 3 





5.7A) and in percentage terms for both GST-PS1-Loop (Figure 5.7B) and GST-PS1-
Loop FP/VS/AA (Figure 5.7C). The GST-PS1-Loop dataset contained more 
proteins involved in both binding activities and structural activities; the GST-PS1-
Loop FP/VS/AA dataset contained more proteins with a catalytic activity (Figure 
5.7A). These differences are also represented in the bar charts  (Figures 5.7B and 
5.7C) where the structural activity represents the biggest function in the GST-PS1-
Loop dataset and catalytic activity is the biggest function in the GST-PS1-Loop 
FP/VS/AA dataset. 
 
5.9 PANTHER Biological Processes of GST-PS1-Loop and GST-PS1-
Loop FP/VS/AA datasets 
The PANTHER classification system was again used to investigate the biological 
processes involved in the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets. 
The PANTHER system again uses the GO terms for this classification system; as of 
2011 the GO uses over 20000 different biological process terms when classifying 
proteins/genes [The Gene Ontology Consortium 2011]. The GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA datasets are compared in absolute terms (Figure 5.8A). 
The GST-PS1-Loop dataset is over-represented by the cellular component 
organisation and developmental processes and the GST-PS1-Loop FP/VS/AA 
dataset is overrepresented by the response to stimulus, metabolic and immune 
system processes. These over-representations can also be seen in relative terms by 
comparing the pie charts seen (Figures 5.8B and 5.8C). The presence of two 




Figure 5.7 Molecular function analysis of GST-PS1-Loop and GST-PS1-Loop FP/VS/AA using 
PANTHER. The molecular functions of the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets 
were analysed using the PANTHER clsasification system. (A) The molecular function data was first 
compared in absolute terms in a bar chart. The percentage breakdown for the (B) GST-PS1-Loop and 
(C) GST-PS1-Loop FP/VS/AA datasets are also shown using pie charts. The key for the colour 
scheme used is shown on the right. 
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representation of the cellular component organisation and developmental processes 
in these dataset. Schlafen family member 11 (SLFN11) was a protein identified 
solely in the GST-PS1-Loop FP/VS/AA dataset, as can be seen in Table 5.4. This 
protein represented an important difference in terms of the response to stimulus and 
immune system processes that exist between the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA datasets. Schlafen genes are upregulated in response to interferon and 
SLFN11 is a protein that has been shown to block HIV-1 replication inside host cells 
by selectively interacting with viral tRNA [Li et al 2012]. The other biological 
processes (cellular process, localisation, biological regulation, multicellular 
organismal and biological adhesion) were at similar levels to another across both 
datasets. 
 
5.10 PANTHER Pathway Analysis of GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA Datasets 
Following the analysis of the biological process involvement of the GST-PS1-Loop 
and GST-PS1-Loop FP/VS/AA datasets the PANTHER classification system was 
used to analyse the involvement of proteins within the different pathways. The GST-
PS1-Loop dataset was found to be involved in 17 different pathways while the GST-
PS1-Loop FP/VS/AA dataset was found to be involved in 21 different pathways 
(Table 5.6).  Fourteen pathways were represented in both datasets and for each 
dataset there were a number of unique pathways. As these unique pathways were 
each represented by a single protein they will be listed here. For the GST-PS1-Loop 
dataset there were 3 unique pathways represented: integrin signalling pathway 




Figure 5.8 GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets analysed by biological 
processes using PANTHER. (A) The biological processes of the GST-PS1-Loop and GST-PS1-
Loop FP/VS/AA datasets were examined using the PANTHER classification system and the resulting 
data was compared in absolute terms using a bar chart. The breakdown for biological processes were 
also shown in percentage terms for (B) the GST-PS1-Loop dataset or (C) GST-PS1-Loop dataset. The 
key for the colour scheme used is shown on the right. 
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receptor signalling pathways represented: (14-3-3 protein theta). For the GST-PS1-
Loop FP/VS/AA dataset there were 7 unique pathways represented were ionotropic 
glutamate receptor pathway (Vesicle fusing ATPase/NSF), heme biosynthesis 
(Probable glutamate-tRNA ligase, mitochondrial), serine glycine biosynthesis 
(Serine hydroxymethyltransferase, mitochondrial), de novo pyrmidine 
riobonucleotide sysnthesis (Uridine 5'-monophosphate synthase), synaptic vesicle 
trafficking (Vesicle fusing ATPase/NSF), hedgehog signalling pathway (F-box/WD 
repeat-containing protein 11) and the Krebs cycle (Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, mitochondrial). Table 5.6 shows that the AD-associated 
presenilin pathway, the cytoskeletal regulation by Rho pathway and Inflammation-
mediated by chemokine and cytokine signaling pathway showed a greater than 50% 
increase in number of pathway hits in the GST-PS1-Loop dataset as compared to the 
GST-PS1-Loop FP/VS/AA dataset. All other pathways showed a lesser than 50% 











Table 5.6. List of pathways identified through PANTHER pathway analysis of 
the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets.  























1 1.80% 2.50% Alzheimer disease-amyloid 
secretase pathway 
1 1.80% 3.00% 
Alzheimer disease-presenilin 
pathway 
3 5.30% 7.50% Alzheimer disease-presenilin 
pathway 
1 1.80% 3.00% 
Angiotensin II-stimulated 
signaling through G proteins and 
beta-arrestin 
1 1.80% 2.50% Angiotensin II-stimulated 
signaling through G proteins and 
beta-arrestin 
1 1.80% 3.00% 
Cadherin signaling pathway 3 5.30% 7.50% Cadherin signaling pathway 1 1.80% 3.00% 




15.00% Cytoskeletal regulation by Rho 
GTPase 
4 7.00% 12.10% 
DNA replication 2 3.50% 5.00% De novo pyrmidine 
ribonucleotides biosythesis 
1 1.80% 3.00% 
EGF receptor signaling pathway 1 1.80% 2.50% DNA replication 1 1.80% 3.00% 
FGF signaling pathway 1 1.80% 2.50% Hedgehog signaling pathway 1 1.80% 3.00% 
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway 
1 1.80% 2.50% Heme biosynthesis 1 1.80% 3.00% 
Huntington disease 5 8.80% 12.50% Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway 
1 1.80% 3.00% 
Inflammation mediated by 
chemokine and cytokine signaling 
pathway 
5 8.80% 12.50% Huntington disease 4 7.00% 12.10% 
Integrin signalling pathway 1 1.80% 2.50% Inflammation mediated by 
chemokine and cytokine signaling 
pathway 
3 5.30% 9.10% 
Nicotinic acetylcholine receptor 
signaling pathway 
4 7.00% 10.00% Ionotropic glutamate receptor 
pathway 
1 1.80% 3.00% 
Notch signaling pathway 1 1.80% 2.50% Nicotinic acetylcholine receptor 
signaling pathway 
2 3.50% 6.10% 
Parkinson disease 2 3.50% 5.00% Notch signaling pathway 1 1.80% 3.00% 
Proline biosynthesis 1 1.80% 2.50% Parkinson disease 1 1.80% 3.00% 
Wnt signaling pathway 2 3.50% 5.00% Proline biosynthesis 3 5.30% 9.10% 
 Serine glycine biosynthesis 1 1.80% 3.00% 
Synaptic_vesicle_trafficking 1 1.80% 3.00% 
TCA cycle 1 1.80% 3.00% 
Wnt signaling pathway 2 3.50% 6.10% 
 
5.11 Mentha Interactome Mapping of GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA datasets 
The GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets contain lists of that 
were bound by the GST pulldown assay and identified through mass spectrometry 
The molecular functions, biological processes and cellular pathways of these 
174 
 
proteins have been characterised using the PANTHER classification system. Since 
these proteins are involved in multiple pathways and biological processes it was 
decided to look for pre-existing protein-protein interactions within the proteins found 
in these databases. By doing this it was hoped to reveal the presence of different 
protein-protein interaction nodes between the GST-PS1-Loop and the GST-PS1-
Loop FP/VS/AA datasets, which could help reveal the function of the PS1 CUE 
domain. To do this the Mentha Interactome Browser was used (mentha.uniroma2.it/) 
[Calderone et al 2013], which contains protein interaction databases of published 
protein-protein interactions for 8 different species including humans. Each 
interaction is given a reliability score (between 0 and 1) that measures the reliability 
of the interaction based on both the interaction type and interaction method recorded 
in the published data. The gene names for both the GST-PS1-Loop and GST-PS1-
Loop FP/VS/AA databases compiled in Table 5.6 were entered into the Mentha 
browser to provide a network map where each node is represented by a gene name 
and each link represents a known protein interaction. A reliability score of 0.5 was 
assigned for both datasets to provide a clear picture of these known protein-protein 
interactions. The GST-PS1-Loop dataset is shown in Figure 5.9A while the GST-
PS1-Loop FP/VS/AA dataset is represented in Figure 5.9B. In both network maps 
queried genes are represented by purple nodes while green nodes represent genes 
that interact with queried genes with a reliability score of  >0.5. Protein-protein 
interactions between nodes are represented by black lines while protein-protein 
interactions between queried genes are represented by yellow lines. PS1 itself, DNA 
replication licensing factor MCM7 and δ-catenin are present as major nodes in both 
datasets. RAN (GTP-binding nuclear protein Ran) and YWHAQ (14-3-3 protein θ) 
represent major nodes of protein-protein interaction that are unique to the GST-PS1-
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Loop dataset. While the DDB1 (DNA damage-binding protein 1) and the E3 ligase 
FBXW11 (F-box/WD repeat-containing protein 11) represent the major nodes 
unique to the GST-PS1-Loop FP/VS/AA dataset. The GST-PS1-Loop FP/VS/AA 
dataset contains a greater number of known PS1 interacting proteins (plakophilin-4, 
desmoplakin, δ-catenin and Glutaryl-CoA dehydrogenase) than the GST-PS1-Loop 
dataset (plakophilin-4 and δ-catenin). In the GST-PS1-Loop dataset 16 proteins do 
not show protein-protein interactions with a reliability score of <0.5 while in the 
GST-PS1-Loop dataset 8 proteins have a reliability score of <0.5. These interaction 
maps (Figure 5.9A/B) demonstrate that PS1 was previously known to interact with 
two proteins (plakophilin-4 and δ-catenin) in the GST-PS1-Loop sample and four 
proteins [glutaryl-CoA dehydrogenase (GCDH), desmoplakin, plakophilin-4 and δ-
catenin] in the GST-PS1-Loop FP/VS/AA dataset. As the interaction maps shows 
known interactions between the proteins present in both datasets. The interaction 
maps also show published interactions between identified proteins and other 
proteins. This can provide some links between different proteins identified in the 
datasets for example EGFR connects to both 14-3-3-θ and δ-catenin (Figure 5.9A) 
or β-catenin that connects to both PS1 and FBXW11 (Figure 5.9B). These protein-










Figure 5.9 Mentha alignment of known protein-protein interactions of GST-PS1-Loop dataset. 
The proteins from the (A) GST-PS1-Loop dataset or the (B) GST-PS1-Loop FP/VS/AA dataset were 
analysed for protein-protein interactions using the Mentha search engine. A cut-off was applied such 
that any protein-protein with a reliability score under 0.50 was excluded from view. All proteins 
searched for are highlighted in purple and any protein-protein interactions between proteins searched 





The aim of this chapter was to identify PS1 CUE domain binding proteins and to 
determine whether the PS1 CUE domain is involved in the intermolecular or 
intramolecular interactions of PS1. We hypothesised that the PS1 CUE domain was 
involved in regulating either intramolecular PS1:PS1 interactions or PS1 
intermolecular protein-protein interactions. To test this hypothesis a GST-pulldown 
assay was devised, validated and used for a mass spectrometry-based proteomics 
assay. Using a recombinant PS1 loop domain that contains the CUE domain and a 
recombinant PS1 CUE domain mutant protein, we anticipated that it would be 
possible to distinguish between ubiquitinated proteins that bound to the PS1 
intracellular loop domain and the PS1 CUE domain. Through the identification of 
PS1 CUE domain binding proteins we further hypothesised that it would be possible 
to determine whether the PS1 CUE domain was involved in γ-secretase-dependent or  
γ-secretase-independent PS1 function(s).  
PS1 is known to form homo- and heterodimers, where dimers have been shown to 
form between the PS1 holoprotein, N-terminal and C-terminal fragments using a 
two-hybrid yeast assay [Hebert et al 2004]. In this study, no PS1 tryptic peptides 
corresponding to peptide sequences from outside the PS1 intracellular loop were 
identified in the mass spectrometry-based analysis (Figure 5.6). This demonstrated 
that the intramolecular PS1:PS1 interaction is not regulated by either the intracellular 
loop or the CUE domain of PS1. This also strongly suggests that the function of the 




In chapter 3 deletion of the PS1 CUE domain and mutation of conserved CUE 
domain residues were shown to be dispensable for the γ-secretase mediated cleavage 
of APP (Figure 3.12), Notch (Figure 3.14) and IL-1R1 (Figure 3.15). To further 
investigate whether the PS1 CUE domain was involved in γ-secretase function the 
proteins identified through mass spectrometry were analysed to look for other 
members of the γ-secretase complex, γ-secretase substrates or other type-1 
transmembrane proteins. The γ-secretase protease complex is comprised of 
presenilins, Nicastrin [Yu et al 2000], Aph1 and Pen-2 [Hebert et al 2004]. None of 
these proteins were identified in either the GST-PS1-Loop or the GST-PS1-Loop 
FP/VS/AA samples which suggests that the PS1 CUE domain is not involved in the 
formation of the γ-secretase complex. In addition to the γ-secretase substrates that 
were examined here (APP, Notch and IL-1R1) there are over 100 known γ-secretase 
substrates [Haapasalo and Kovacs 2011]. No known γ-secretase substrates were 
identified through the mass spectrometry analysis of the GST-PS1-Loop or the GST-
PS1-Loop FPVSAA samples. Only three type 1 transmembrane proteins were 
identified in either sample: the small integral membrane protein 4 (SMIM4), 
dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (RPN1) 
and mitochondrial import inner membrane translocase subunit (TIM50). However, 
both RPN1 and TIM50 were also identified in the GST negative control sample so is 
most likely a result of non-specific binding. The SMIM4 is an uncharacterised 
protein of 70 residues in length that was discovered through the analysis of human 
cDNA [Mammalian Gene Collection (MGC) Program Team 2002]. These data 
further supports the conclusion that the PS1 CUE domain is not involved in γ-




To investigate the involvement of the PS1 CUE in the intermolecular protein-protein 
interactions of PS1 the lists of mass spectrometry identified proteins from the GST, 
GST-PS1-Loop and GST-PS1-Loop FP/VS/AA samples were analysed and broken 
down to identify proteins that interacted with just the GST-PS1-Loop or the GST-
PS1-Loop FP/VS/AA recombinant proteins. There 22 proteins that were shown to 
uniquely interact with the GST-PS1-Loop protein (Table 5.3), 31 proteins that 
uniquely interacted with the GST-PS1-Loop FP/VS/AA mutant (Table 5.4) and 26 
proteins were identified in both samples (Table 5.2). In the GST-PS1-Loop sample 
only δ-catenin and plakophilin-4 proteins have been previously shown to interact 
with PS1 [Tanahashi et al 1999; Stahl et al 1999] (Figure 5.9A), while 4 proteins 
identified in the GST-PS1-Loop FP/VS/AA sample were previously known to 
interact with PS1 [δ-catenin, plakophilin-4, desmoplakin and Glutaryl-CoA 
dehydrogenase (GCDH)] [Raurell et al 2006; Soler-lopez et al 2011] (Figure 5.9B). 
Desmoplakin was also identified in both the GST and GST-PS1-Loop samples but 
was present at a low level, below the applied cutoff. 
The armadillo proteins plakophilin-4 and δ-catenin were two of the highest Mascot 
scoring proteins that were present in both the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA datasets. Both α-catenin and JUP were identified in the GST-PS1-Loop 
sample and β-catenin was identified in the GST-PS1-Loop FP/VS/AA sample. All of 
these proteins were identified through one peptide and so were below the cut-off 
level. With the exception of JUP, all of these armadillo proteins have previously 
been shown to interact with PS1 [Georgakopoulos et al 1999; Tanahashi et al 1999; 
Stahl et al 1999; Tesco et al 1998] (Table 4.1). The armadillo proteins are involved 
in cell signalling, gene transcription and the cytoskeletal structure [Dusek and 
Attardi 2011]. The armadillo protein α-catenin can interact with both the E-
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cadherin/β-catenin complex and with actin filaments where it acts to inhibit actin 
polymerisation [Drees et al 2005]. Overexpression of α-catenin leads to down 
regulation of Wnt signalling and developmental defects in Xenopus laevis [Sehgal et 
al 1997]. JUP, also known as γ-catenin, is involved in both desmosome and adherens 
junctions which can interact with the cytoskeleton [Dusek and Attardi 2011].  
Adherens junctions are the transmembrane protein complexes that are involved in 
maintaining cell-cell contact and while desmosomes also form cell to cell linkages, 
they are also bound to the cells cytoskeleton [Dusek and Attardi 2011]. JUP is 
required during development but can also act as a negative regulator of β-
catenin/Wnt signalling in zebrafish [Martin et al 2009]. Transport of JUP to 
desmosomes is controlled by 14-3-3-γ, where knockout of 14-3-3-γ leads to a 
decrease in desmosomes and adherens junctions between cells which can lead to 
male sterility in mice [Sehgel et al 2014]. Many non-small cell lung cancer cell lines 
show a reduction in JUP expression and restoration of JUP expression in these cells 
leads to a reduction in cancer cell migration [Sechler et al 2015]. 
 Both δ-catenin and plakophilin-4 have previously been shown to interact with PS1 
and are involved in cadherin signalling pathways [Tanahashi et al 1999; Stahl et al 
1999]. Plakophilin-4 and δ-catenin are members of the plakophilin subcategory of 
armadillo proteins [Bass-Zubek et al 2009] and δ-catenin has previously been shown 
to interact with proteins involved in protein trafficking and the cytoskeleton [Koutras 
and Lévesque 2011]. δ-catenin knockout mice have deficits in synaptic plasticity 
[Israely et al 2004] and co-expression of PS1 with δ-catenin has been shown to 
reduce dendrite branching in HIH 3T3 cells [Kim et al 2006]. Plakophilin-4 and δ-
catenin were the highest Mascot scoring proteins identified in both the GST-PS1-
Loop and GST-PS1-Loop FP/VS/AA samples. However, as these proteins were 
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identified in both samples it demonstrates that these proteins interact with the PS1 
intracellular loop domain rather than the PS1 CUE domain.  
The BioGRID was used to investigate the ubiquitination status of the proteins that 
were only contained within the GST-PS1-Loop dataset (Table 5.3) to determine 
whether any of these proteins undergo K63-linked polyubiquitination. Ubiquitination 
of the histone H3 protein was previously demonstrated, though the specific type of 
ubiquitination was not determined [Karagianni et al 2008]. The published 
ubiquitination status of the remaining proteins had been determined through high 
throughput screening of ubiquitination sites so the type of ubiquitination was also 
not determined. 14-3-3-θ, which was identified solely in the GST-PS1-Loop sample 
(Table 5.3), is known to interact with a large number of other proteins (Figure 
5.9A).  
No 14-3-3 isoform has previously been shown to interact with the presenilins so the 
interaction between PS1 and 14-3-3-θ represents a novel interaction. 14-3-3-θ has 
been shown to undergo ubiquitination through a number of mass throughput 
ubiquitination screens [Danielsen et al 2011; Wagner et al 2011; Stes et al 2014]. 
These studies unfortunately do not determine the type of ubiquitination that occur at 
these sites so it is not currently known if 14-3-3-θ undergoes K63-linked 
polyubiquitination. 14-3-3 proteins can bind to phosphorylated serine and threonine 
residues and are involved in many cellular pathways including TLR signalling 
[Schuster et al 2011], apoptosis [Nomura et al 2003] and trafficking [Sehgal et al 
2014]. 14-3-3 proteins are also able to bind to non-phosphorylated proteins [Obsil 
and Obsilova 2011]. There are seven 14-3-3 isoforms found in mammals (β, ε, η, γ, 
τ, ζ and θ) which show high sequence homology between the different isoforms 
[Obsil and Obsilova 2011]. While the 14-3-3 proteins have not previously been 
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shown to interact with the presenilins, the 14-3-3 proteins and the presenilins are 
known to be involved in some of the same cell signalling pathways such as apoptosis 
[Nomura et al 2003; Yagi et al 2008], trafficking [Nakamura et al 2010; Khandelwal 
et al 2007] and β-catenin/Wnt signalling [Nava et al 2014; Kawamura et al 1998].  
14-3-3-θ has been shown to interact with proteins involved in TLR signalling such as 
IRAK4 and ILF2 [Schuster et al 2011]. A number of different 14-3-3 isoforms are 
known to be involved in the regulation of trafficking within the cell. 14-3-3-θ 
interacts with PKC-γ leading to the phosphorylation of the GABAAγ2 receptor. This 
phosphorylation is required for the sorting of the GABAAγ2 receptor to the cell 
membrane in Purkinje cells [Qian et al 2013]. The presenilins are involved in the 
regulation of apoptosis through both γ-secretase-dependent and -independent 
functions [Zeng et al 2015]. 14-3-3 proteins are also involved in the regulation of 
apoptosis through protein-protein interactions. The pro-apoptotic Bcl-2 protein Bax 
has been shown to interact with 14-3-3-θ and this interaction downregulates the 
incorporation of Bax into the mitochondria [Nomura et al 2003]. The presenilins also 
known to upregulate Bax mediated apoptosis via P53 and PSAP [Alves da Costa et 
al 2003; Zeng et al 2015].  
The presenilins are known to interact with the β-catenin and other armadillo proteins 
[Levesque et al 1999] and are able to regulate β-catenin/Wnt signalling [Kawamura 
et al 1998; Zhang et al 2008]. The functions of these armadillo proteins are known to 
be regulated by their interaction with different 14-3-3 isoforms and 14-3-3-θ in 
particular is required for the dynein-dynactin mediated transport of N-cadherin/β-
catenin complex from the ER [Nakamura et al 2010]. The presenilins have not 
previously been shown to interact with any 14-3-3 proteins but as has been described 
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here, the presenilins and 14-3-3 are involved in the same signalling pathways and are 
known to interact with similar proteins. 
There were 31 identified proteins that solely interacted with the GST-PS1-Loop 
recombinant protein (Table 5.4). These proteins bind to the intracellular loop 
domain of PS1 when the PS1 CUE domain is disrupted and represent proteins whose 
interaction with PS1 is downregulated by a functional PS1 CUE domain. One such 
protein, FBXW11, which is also known as β-transducin repeat protein 2 (βTrCP2), 
got the
 
second highest Mascot score of the proteins identified only in the GST-PS1-
Loop FP/VS/AA mutant dataset. Mammals have two different genes for βTrCP, 
BTRC and FBXW11 in humans, and the two βTrCP proteins are 88% similar in 
primary sequence [Nakagawa et al 2015]. The βTrCP proteins, which are both F-box 
containing proteins, can form part of the SKP1-CUL1-F-box (SCF) E3 ubiquitin 
ligase complex which targets substrates for proteasomal degradation [Kim et al 
2015]. βTrCP itself is known to be ubiquitinated leading to its degradation by the 
UPS [Li et al 2004]. There are no published interactions between the βTrCP proteins 
and the presenilins. However the C. elegans presenilin homolog SEL-12 is known to 
interact with and be ubiquitinated by the F-box protein SEL-10 E3 ligase via the 
SCF complex [Li et al 2002]. Transcription of Fbxw7, the human homolog of SEL-
10, is regulated by the presenilins and this genetic relationship in turn regulates 
EGFR stability [Rocher-Ros et al 2010]. Due to their high sequence similarity the 
βTrCP proteins do have some overlapping roles in promoting protein turnover and 
regulating cell signalling pathways, but βTrCP2 does also have some unique 
functions. While both βTrCP proteins may be found in the nucleus only βTrCP2 is 
observed within the cytoplasm [Lassot et al 2001]. The βTrCP proteins are known to 
interact with β-catenin leading to reduction in β-catenin levels and a reduction in β-
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catenin induced gene transcription [Hart et al 1998]. Both βTrCP proteins upregulate 
NFĸB signalling by promoting the ubiquitination and proteasomal degradation of 
IRAK1 and IĸBα [Cui et al 2012; Suzuki et al 2000]. βTrCP2, but not βTrCP1, 
promotes the proteasomal degradation p19
ARF
 to promote proliferation in MEFs 
[Nakagawa et al 2015]. βTrCP2 also regulates the proteasomal degradation of the 
prolactin-receptor [Li et al 2004]. Knockout of βTrCP2 was shown to be 
embryonically lethal in mice, whereas knockout of βTrCP1 has no major phenotypic 
effect [Nakagawa et al 2015; Nakayama et al 2003]. The differences in binding to 
14-3-3-θ and βTrCP2 between the WT GST-PS1-Loop and the GST-PS1-Loop 
FP/VS/AA CUE domain mutant may represent an important difference if the PS1 
CUE domain is involved in regulating cell signalling pathways. 
A number of proteins found in both the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA datasets are involved in cellular transport and the cytoskeleton (Figure 
5.7 and Figure 5.8). The plakophilins are known to interact with Rho GTPase to 
regulate actin structures to affect cell morphology [Anastasiadis 2007], while the 2 
actin proteins identified in the GST-PS1-Loop dataset (Actin, cytoplasmic 2 and 
Actin, gamma-enteric smooth muscle) are involved in the Rho cytoskeleton pathway 
(Table 5.6). Myosin and tubulin proteins are present in the GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA datasets (Figure 5.5). All of these data suggest a role for 
the PS1 intracellular loop domain in the regulation of the cytoskeleton. Plakophilin-
4, δ-catenin and the tubulin proteins were identified in both the GST-PS1-Loop and 
GST-PS1-Loop FP/VS/AA datasets, which could suggest that any role played by 
PS1 in cytoskeleton regulation is a function of the PS1 intracellular loop rather than 
the PS1 CUE domain. Proteins involved in protein trafficking were also identified in 
both datasets. The GTPase Ran was identified only in the GST-PS1-Loop dataset 
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and is an important node in terms of protein-protein interactions (Figure 5.9A). Ran 
is known to undergo ubiquitination at K134, though the type of ubiquitination is 
unknown [Udeshi et al 2012]. Ran is involved in nuclear transport, microtubule 
formation and cellular mitosis [Sato and Toda 2010], and Ran is known to interact 
with the actin gene ACTG1 that was also identified in the GST-PS1-Loop sample 
(Figure 5.9A). Ran is also known to be required for the translocation of β-catenin to 
the nucleus [Fagotto et al 1998]. The transcription factor TCF-4, which binds to β-
catenin to co-regulate β-catenin induced gene transcription, also interacts with Ran 
and other nuclear pore complex proteins transport TCF-4 into the nucleus to 
upregulate TCF-4 gene transcription [Shitashige et al 2008]. The Vesicle-fusing 
ATPase, also known as NSF, which was identified only in the GST-PS1-Loop 
FP/VS/AA sample, is involved in vesicle trafficking within the cell where it interacts 
with SNARE proteins to promote membrane fusion [Zhao et al 2012]. NSF is 
involved in the transport of AMPA receptors to the post-synapse during long term 
potentiation in primary rat neurons [Yao et al 2008]. Expression of a dominant 
negative NSF mutant leads to a decrease in synaptic vesicle transport and alterations 
in actin structure in Drosophila neurons [Nunes et al 2006]. Expression of a 
truncated NSF mutant leads to alterations in synaptic formation in Zebrafish neurons 
and in a reduction in brain-derived neurotrophic factor from the synapse [Mo and 
Nicolson 2011]. Dynactin subunit 1, which was also only present in the GST-PS1-
Loop FP/VS/AA sample, is part of the dynactin complex that is also known to be 
involved in microtubule related vesicle trafficking [Fu and Holzbaur 2014]. Dynactin 
regulates the sorting of phosphorylated Akt (p-Akt) to the microtubule network and 
knockdown of dynactin in cells leads to an increased susceptibility to apoptosis 
caused by a reduction in p-Akt levels and microtubule dysregulation [Jo et al 2014]. 
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PS1 has been shown to play a γ-secretase independent role in protein and organelle 
trafficking within the cell [Khandelwal et al 2007; Naruse et al 1998; Lazarov et al 
2007]. These data suggests that the intracellular loop of PS1 may play a role in 
regulating this function by interacting with the cytoskeleton and cytoskeleton 
interacting proteins. The GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets 
both contained proteins that are known to be involved in the regulation of cellular 
trafficking, some of which were common between both datasets [myosin 9 and 10, 
tubulin beta-4B and tubulin beta-6 (Table 5.5)]. Other proteins, such as Ran in the 
GST-PS1-Loop dataset and NSF or Dynatin subunit 1 in the GST-PS1-Loop 
FP/VS/AA dataset, were unique to a particular dataset. This suggests the PS1 CUE 
domain may play some role regulating PS1’s role in protein and organelle 
trafficking. The PS1 CUE domain may help distinguish between different PS1 
interacting proteins involved in different cellular trafficking pathways. The exact 








6.1 Overall Summary 
The presenilins are best characterised as subunits of the γ-secretase protease 
complexes where they are involved in the regulated intramembrane proteolysis of 
over 100 different type 1 transmembrane proteins [Haapasalo et al 2012]. In addition 
to their role in the γ-secretase complexes the presenilins are involved in a number of 
γ-secretase-independent functions such as apoptosis [Zeng et al 2015], protein 
trafficking [Khandelwal et al 2007] and calcium homeostasis [Tu et al 2006]. In 
addition to the other members of the γ-secretase complexes, the presenilins are 
known to interact with over 100 other proteins that are involved in a variety of 
cellular processes and cell signalling pathways (Table 4.1) [McCarthy et al 2009; 
Soler-Lopez et al 2011].  
The presenilins contain an intracellular loop domain between TMDs 6 and 7 that is 
the site of endoproteolysis [Oh and Turner 2005] and the site of some of the protein-
protein interactions of the presenilins [Dumanchin et al 1999; Smith et al 2000]. 
Bioinformatic analysis of the PS1 intracellular loop sequence has shown the 
presence of GSK3β [Kirschenbaum et al 2001] and TRAF6 [Powell et al 2009] 
binding motifs. As a result of these interactions the presenilins are known to undergo 
GSK3β-mediated phosphorylation [Kirschenbaum et al 2001] and TRAF6-mediated 
K63-linked polyubiquitination [Yan et al 2013; Gudey et al 2014]. The TRAF6-
mediated K63-linked polyubiquitination of PS1 leads to an increased stability of the 
PS1 holoprotein [Yan et al 2013]. Activity of the γ-secretase complexes has been 
shown to be modulated by the TRAF6-mediated K63-linked polyubiquitination of 
the γ-secretase substrates IL-1R1 [Elzinga et al 2009], P75
NTR
 [Powell et al 2009] 
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and TGFβ Type 1 Receptor (TβR1) [Gudey et al 2014]. In addition to TRAF6 the 
presenilins are known to interact with and be ubiquitinated by the F-box containing 
protein SEL-10 in C. elegans, which regulates the degradation of the presenilin C. 
elegans homolog SEL-12 [Li et al 2002]. 
Further bioinformatics analysis of the primary sequence of the intracellular loops of 
the presenilins showed some similarity with an ubiquitin binding domain called 
coupling of ubiquitin to endoplasmic reticulum degradation (CUE) [Ponting 2000; 
Duggan et al 2015]. Ubiquitin molecules are bound to lysine residues and can be 
formed into polyubiquitin chains through any of the 7 lysine residues or the terminal 
glycine residue of ubiquitin [Komander and Rape 2012]. Ubiquitin binding domains 
can regulate protein function by binding to ubiquitin in either mono- or 
polyubiquitinated form and transmit the ubiquitination signal to regulate downstream 
cellular signalling [Chen and Sun 2009]. CUE domains are typically 40-45 residues 
in length and form a three helix secondary structure [Hurley et al 2006]. CUE 
domains contain a highly conserved phenylalanine-proline (FP) and less well 
conserved di-leucine motifs [Ponting 2000] and have been shown to bind to both 
monoubiquitin [Shih et al 2003] and polyubiquitin [Donaldson et al 2003; Liu et al 
2014]. CUE domains have been shown to be involved in regulating ubiquitination 
[Liu et al 2014], autophagy [Lu et al 2014], protein turnover [Rego et al 2012] and 
cell signalling [Kishida et al 2005]. 
In this study the presenilins are shown to contain putative ubiquitin binding CUE 
domains in the intracellular loops between TMDs 6 and 7 (residues 270-314 in PS1 
and 277-320 in PS2). This putative PS1 CUE domain contains the highly conserved 
FP motif at residues F283/P284 and in place of the di-leucine motif it has the 
V309/S310 motif. Using an ubiquitin binding assay PS1 and PS2 are shown to bind 
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preferentially to K63-linked polyubiquitin over K48-linked polyubiquitin; deletion 
of the CUE domains of the presenilins abolishes the ubiquitin binding functions of 
these proteins (Figure 3.3 and Figure 3.5). Mutation of V309/S310 motif, but not 
the F283/P284 motif, was shown to abolish PS1 CUE domain function using both in 
vivo and in vitro ubiquitin binding assays (Figure 3.4 and Figure 3.10). Next the 
PS1 CUE domain was shown to be dispensable for PS1 endoproteolysis in PS1 
knockout MEF cells (Figure 3.11). Deletion of the PS1 CUE domain or mutation of 
the conserved F283/P284 and V309/S310 motifs was then shown to have no effect 
on the γ-secretase mediated cleavage of APP (Figure 3.12 and Figure 3.13), Notch 
(Figure 3.14) and IL-1R1 (Figure 3.15). These data demonstrated that the PS1 CUE 
domain was not involved in γ-secretase activity and suggested a γ-secretase 
independent role for the PS1 CUE domain. We hypothesised that the PS1 CUE 
domain was involved in regulating PS1 intermolecular protein-protein interactions or 
regulating intramolecular PS1:PS1 interactions. 
To investigate the function of PS1 CUE domain a list of PS1 interacting proteins and 
their published ubiquitination status was compiled (Table 4.1) and then restricted to 
PS1 interacting protein known to undergo K63-linked polyubiquitination (Table 
4.2). P75
NTR
 and IL1-R1, which are known to undergo K63-linked 
polyubiquitination, were not shown to interact with the PS1 holoprotein or the PS1 
ΔCUE mutant (Figure 4.1 and Figure 4.2). The PS1 CUE domain was shown to be 
dispensable for the interaction between PS1 and TRAF2 (Figure 4.8) and RIP1 
(Figure 4.9). The E3 function of TRAF6 was shown to be required for the 
interaction between PS1 and TRAF6, while deletion of the PS1 CUE domain had no 
effect on this interaction (Figure 4.3). While deletion of the PS1 CUE domain had 
no effect on the PS1-TRAF6 interaction, mutation of both the conserved F283/P284 
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and V309/S310 motifs in tandem reduced this interaction (Figure 4.4) but did not 
affect the TRAF6 mediated increased stability of the PS1 holoprotein (Figure 4.5). 
To further investigate the function of the PS1 CUE domain a mass spectrometry-
based proteomics approach was used. The PS1 CUE domain containing GST-PS1-
Loop recombinant protein or the GST-PS1-Loop FP/VS/AA CUE domain mutant 
were incubated with lysate from HEK293T cells and PS1 interacting proteins were 
purified using affinity chromatography (Figure 5.5) and then identified using mass 
spectrometry. Proteins that bound to both the GST-PS1-Loop and GST-PS1-Loop 
FP/VS/AA were compiled into Table 5.2 while proteins that bound to either GST-
PS1-Loop or GST-PS1-Loop FP/VS/AA alone were compiled (Table 5.3 and Table 
5.4), respectively. Bioinformatic tools were then used to decipher shared and unique 
protein functions and protein-protein interactions that existed between the proteins 
found in the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA datasets. Analysis of 
the proteins identified in the GST-PS1-Loop and GST-PS1-Loop FP/VS/AA 
demonstrated that these proteins are involved in a variety of cellular processes 
including gene transcription, cellular trafficking, cytoskeleton organisation and the 
ubiquitin proteasome system. The armadillo proteins plakophilin-4 and δ-catenin 
were identified in both the GST-PS1-Loop (and GST-PS1-Loop FP/VS/AA datasets 
(Table 5.2), while the armadillo proteins JUP and α-catenin were found solely in the 
GST-PS1-Loop dataset and β-catenin was found solely in the GST-PS1-Loop 
FP/VS/AA dataset. PS1 is known to localise at the plasma membrane where the γ-
secretase mediated cleavage of E-cadherin is known to regulate the breakdown of 
adherens junctions [Marambaud et al 2002]. No cadherin protein was identified in 
the mass spectrometry analysis of either the GST-PS1-Loop or the GST-PS1-Loop 
FP/VS/AA samples therefore the interaction between these cytoplasmic desmosome 
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proteins and PS1 may occur away from the membrane. This could suggest that PS1 
may play some additional role in regulating the function of these proteins. 
A greater number of proteins were identified solely in the GST-PS1-Loop 
FP/VS/AA dataset (31 proteins) than in the GST-PS1-Loop dataset (22 proteins). 
This may suggest that the PS1 CUE domain may play a role in downregulating a 
number of PS1’s protein-protein interactions. In other words the presence of a 
functional K63-linked polyubiquitin binding CUE domain may prevent PS1 
interacting with a number of other proteins such as the E3 ligase βTRCP2, SLN11, 
the transport protein NSF etc. (Table 5.4). Cytoskeletal proteins myosin and tubulin 
proteins were identified in both mass spectrometry datasets (Table 5.2), while two 
actin proteins were identified solely in the GST-PS1-Loop dataset (Table 5.3). NSF, 
also known as vesicle-fusing ATPase, and dynactin subunit 1 were identified solely 
in the GST-PS1-Loop FP/VS/AA dataset (Table 5.4). NSF is involved in vesicle 
transport and synaptic structure [Nunes et al 2006; Mo and Nicolson 2011] and 
dynactin subunit 1 is involved in vesicle trafficking via the microtubule network [Fu 
and Holzbaur 2014]. The GTPase Ran was identified solely in the GST-PS1-Loop 
dataset (Table 5.3) and is also involved in the regulation of nuclear transport and 
microtubule assembly [Sato and Toda 2012]. These proteins (Table 6.1) are 
involved in cellular processes such as cell signalling and transport that PS1 is known 
to be involved in and so are strong targets for future investigation.  
6.2 Future Perspectives 
To investigate the function of the PS1 CUE domain a list of PS1 interacting proteins 
known to undergo K63-linked polyubiquitination was compiled (Table 4.2). The 
necessity of the PS1 CUE domain for regulating these interactions was examined for 
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three proteins only (TRAF2, TRAF6 and RIP1). All of these proteins were shown to 
interact with PS1 by previous members of the lab [Powell unpublished, Powell et al 
2009, Harte unpublished]. As previously discussed in the discussion section of 
chapter 4 the aspartyl protease BACE1, the AICD interacting protein Fe65 and the 
AD associated protein Tau should all be looked at as a future target for studying PS1 
CUE domain function as these proteins are associated with regulated intramembrane 
proteolysis/γ-secretase activity or symptomatic of AD. While the data presented here 
strongly suggests that the PS1 CUE domain is not involved in the regulation of γ-
secretase activity, investigating the interaction of these proteins and PS1 could 
further demonstrate that this domain is involved in a γ-secretase independent PS1 
function. Alternatively this could demonstrate a role for the PS1 CUE domain in the 
regulation of BACE1 mediated ectodomaining shedding [Hebert et al 2003], 
AICD/Fe65 mediated gene transcription [Vazquez et al 2008] or the turnover of 
ubiquitinated Tau [Babu et al 2008].  
This research utilised a mass spectrometry based proteomics based approach to 
identify PS1 CUE domain interacting proteins to help decipher the function of the 
Dataset Protein Function 











PS1 CUE domain. From this approach 74 novel PS1 interacting proteins were 
identified. However, this approach has not demonstrated a clear function for the PS1 
CUE domain but has provided a number of targets for future investigation (Table 
6.1). Firstly, the proteomics approach used unstimulated HEK293T cells to identify 
PS1 CUE domain interacting proteins. This approach may have hidden any 
interactions that may be dependent on cells being stimulated by external factors such 
as cytokines or any interactions that may be particular to certain cell types. Since this 
proteomics based approach did not fully elucidate the function of the PS1 CUE 
domain alternative approaches could in future be used to investigate PS1 CUE 
domain function. During this research attempts were made to produce a MEF 
PSDKO cell line that stably expressed the PS1 F283A/P284A/V309A/S310A mutant 
but unfortunately a functional cell line was not produced. This cell line was going to 
be used to investigate whether the PS1 CUE domain was involved in a number of 
PS1 γ-secretase independent functions such as Ca
2+
 homeostasis [Tu et al 2006] or 
protein or organelle trafficking [Naruse et al 1998, Khandelwal et al 2007]. This cell 
line could also be used to determine whether the PS1 F283A/P284A/V309A/S310A 
mutant itself suffered from any disruptions in terms of localisation within the cell as 
compared to wild type PS1. The creation of a stably expressing PS1 
F283A/P284A/V309A/S310A cell line could be of great use in deciphering PS1 
CUE domain function in the future. 
The armadillo proteins can be found at adherens junctions and desmosomes where 
they interact with transmembrane adhesion proteins like the cadherins [Dusek and 
Attardi 2011]. In addition to that β-catenin, JUP and plakophilin-4 are able to 
translocate to the nucleus to regulate transcription in conjunction with the 
transcription factor TCF-4 [Dusek and Attardi 2011]. As the intracellular loop 
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domain of PS1 was shown here to interact with desmosome proteins such as δ-
catenin, plakophilin-4, desmoplakin and JUP the co-localisation of PS1 with 
desmosomes should be a target for future investigation. No cadherin proteins were 
identified in the mass spectrometry analysis of either sample suggesting that the 
interaction of PS1 and these proteins could also be involved in other armadillo 
protein function. Presenilin is also involved in the regulation of β-catenin/TCF-4 
mediated gene transcription [Raurell et al 2008] as are plakophilin-4 and δ-catenin 
[Dusek and Attardi 2011]. Previously examined CUE domains are known to regulate 
the transduction of cell signalling pathways such as the TAB2 CUE domain which is 
known to be essential for induction of NFĸB signalling by promoting the interaction 
of TRAF6 and IKKα [Kishida et al 2005]. The role of the PS1 CUE domain in the 
regulation of β-catenin/TCF-4 gene mediated transcription was not investigated here 
and should provide another route for determining the function of PS1 CUE domain.  
PS1 is known to play a role in regulating the transport of β-catenin [Noll et al 2000; 
Meredith et al 2002]. The activity and transportation of the armadillo proteins has 
also been shown to be regulated by other proteins which were identified in the GST-
PS1-Loop and GST-PS1-Loop FP/VS/AA datasets, however, the 14-3-3-θ isoform, 
which was identified only in the GST-PS1-Loop dataset, has not previously been 
shown to interact with any of the armadillo proteins identified here. 14-3-3 proteins 
have been shown to be involved in the transport of JUP to desmosomes [Sehgal et al 
2014] and β-catenin into the nucleus [Nava et al 2014]. Disruption of the 14-3-3-γ 
mediated transport of JUP leads to a reduction in desmosome formation and 
knockout of 14-3-3-γ causes sterility in male mice [Sehgal et al 2014]. The 
involvement of 14-3-3 proteins in the transport of these armadillo proteins could 
represent a future target for investigating the function of the PS1 CUE domain. As 
197 
 
other 14-3-3 isoforms are known to interact with other armadillo proteins to regulate 
their transport determining whether 14-3-3-θ interacts with any of these armadillo 
proteins should be investigated. If this 14-3-3 isoform is shown to interact with 
desmosome complex proteins it could begin to elucidate a function for PS1 and 14-
3-3-θ in the regulation of desmosome assembly. Additionally, 14-3-3-θ is known to 
be ubiquitinated within the cell though the type of ubiquitination is not known 
[Danielsen et al 2011; Wagner et al 2011; Stes et al 2014]. It should be determined 
whether 14-3-3-θ is a target of K63-linked polyubiquitination and test whether the 
interaction between PS1 and 14-3-3-θ requires the K63-linked polyubiquitination of 
14-3-3-θ. 
βTRCP2, which was identified only in the GST-PS1-Loop FP/VS/AA dataset, is an 
E3 ligase that forms part of the SCF complex that mediates the proteasomal 
degradation of proteins [Kim et al 2015]. As PS1 is known to be ubiquitinated by the 
F-box protein SEL-10 via the SCF complex in C. elegans [Li et al 2002] it should be 
investigated whether PS1 is a target for βTRCP2 mediated ubiquitination and 
proteasomal degradation. CUE domains are known to be involved in the regulation 
of polyubiquitin chain formation. The CUE domain of Vps9 is known to be required 
for the mono-ubiquitination of Vps9 [Shih et al 2003]. Additionally, since βTRCP2 
only interacted with the GST-PS1-Loop FP/VS/AA CUE domain mutant the effect 
of deletion or mutation of the PS1 CUE domain on βTRCP2 activity could be 
investigated. βTRCP2 is known to regulate the proteasomal degradation of α-catenin 
and β-catenin [Kim et al 2015] to downregulate the transcriptional activity of β-
catenin [Fuchs et al 1999]. As βTRCP2 and PS1 can have opposing effects on the 
activity of the armadillo proteins they represent another potential source for future 
investigation into the function of the PS1 CUE domain. Schlafen-11 (SLFN11) was 
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identified only in the GST-PS1-Loop FP/VS/AA dataset (Table 5.4). The function of 
SLFN11 is not well characterised at present but it is known to block HIV-1 
replication within the cell by interacting with viral tRNA [Li et al 2012]. Mass 
spectrometry analysis of Notch ICD (NICD) interacting proteins purified from 
nuclear fractions showed that SLFN11 interacts with the NICD [Yatim et al 2013]. 
The PS1 interacting protein FBXW7 was also identified in this study and is known 
to regulate Notch activity with PS1 [Li et al 2002; Rocher-Ros et al 2010]. The 
interaction between PS1 and SLFN11 might provide a novel means through which 
PS1 can modulate Notch activity and should be looked into further. 
PS1 is known to be involved in the regulation of protein and organelle trafficking 
and cytoskeleton organisation [Gandy et al 2007; Khandelwal et al 2007]. PS1 is 
also known to regulate axonal transport through modulating the activity of the 
kinesin-1 transport protein [Lazarov et al 2007] and is known to regulate the 
structure of the cytoskeletal protein filamin [Lu et al 2010]. The transport protein 
Ran is known to be ubiquitinated; high throughput ubiquitination screening has only 
provided a site of ubiquitination and not shown the ubiquitination type [Udeshi et al 
2012]. Discovering whether Ran is a target for K63-linked polyubiquitination should 
be a target for future investigation before determining whether Ran ubiquitination is 
required for its interaction with PS1. As these transport proteins were identified in 
different datasets it may begin to suggest a role for the PS1 CUE domain in 
switching between different cellular transport pathways. PS1 is involved in transport 
of both proteins [Naruse et al 1998] and organelles [Khandelwal et al 2007] and in 
the regulation of axonal transport [Dolma et al 2014]. Therefore the affect of PS1 
CUE domain deletion or mutation in the regulation of protein transport within cell 
would be a target for future investigation. As NSF regulates vesicle transport to 
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synapses [Nunes et al 2006] and Ran regulates nuclear transport [Sato and Toda 
2012] differences in the localisation of wild type PS1 compared to PS1 CUE domain 
mutants within cells may demonstrate the function of the PS1 CUE domain. If the 
PS1 CUE domain mutants show an increase in vesicle co-localisation compared to 
wild type PS1 it would demonstrate that the PS1 CUE domain is involved in 
controlling PS1 localisation via its interaction with NSF within the cell. The CUE 
domain of Vps9 is required for the localisation of Vps9 to endosomes [Shideler et al 
2015] and the CUE domain of Tollip acts in a similar manner, where binding of 
ubiquitin to its CUE domain causes Tollip to detach from membranes [Mitra et al 
2013]. Mutation of the gp78 CUE domain is known to increase mobility of gp78 
within the ER [St-Pierre et al 2011]. Therefore, both other known CUE domains and 
PS1 itself are known to be involved in the regulation of cellular trafficking and 
protein localisation. Whether the PS1 CUE domain plays a role in cellular trafficking 
remains to be determined and should be a major avenue for future investigation of 
PS1 CUE domain function. 
In conclusion, the presenilins are shown here to contain K63-linked polyubiquitin 
chain binding CUE domains. The function of the PS1 CUE domain is shown to be 
dispensable for γ-secretase activity or interaction with γ-secretase substrates known 
to undergo K63-linked polyubiquitination. This suggests that the function of the PS1 
CUE domain is involved in a γ-secretase independent role of PS1. The data 
presented here does not confirm the function of the PS1 CUE domain but the 
identification here of previously known and novel PS1 interacting proteins provides 
a number of avenue for future research into PS1 CUE domain function and the role 





Table 7.1 Total list of proteins identified in the mass spectrometry of the GST 
sample 
 
P16152 P07910 Q13283 Q9P035 P51610 Q7L014 O43324 Q9H3N1 O94925 Q9BZZ5
P21266 P21796 Q96KK5 Q06830 P35249 P12268 Q96DI7 Q13416 Q86UK7 O14681
P04264 Q9UQE7 Q04695 O94874 Q02978 O95347 P40429 P63010 Q8N5C8 Q8NE71
P09211 P31943 Q96CX2 P11177 O14929 O14979 O00429 P55084 P05109 Q15287
P13645 P11940 P42167 Q14739 Q6Y7W6 P62263 Q15758 P49643 P05386 Q8N0X7
P28161 O00571 P45880 Q96AG4 P16989 P40926 Q16181 P23919 P50395 Q92544
P35527 P13639 P17812 P26373 P05198 P61088 Q13011 P62873 Q9BTT0 O00303
P10809 P06899 P12270 P78371 P0CG48 P17987 P08865 Q6NXT2 P35250 P31350
P35908 P49768 Q7KZF4 P00338 Q8N8S7 P24539 O96013 P22102 Q96QK1 P60228
P08107 P06733 P46783 O14880 Q15269 Q9BXP5 O75390 Q2TAY7 P62249 Q9UKM9
P07437 P06748 P62937 P27816 P14678 Q02543 Q14566 P49207 Q96C36 P24666
P08670 O60814 P30050 P16615 P56192 Q8WU90 P23284 Q06203 Q8TCT9 O00746
P22626 P19338 Q8NC51 P32969 P12277 Q9NVI7 P23258 Q14165 Q9BW92 P54886
P60709 Q07065 O75533 Q01081 Q9BPW8 P09622 P83731 Q16720 Q6UXN9 Q9NUU7
P52272 Q15029 P02768 O75489 Q14152 O75534 P36578 P62857 Q9BY77 P33991
P68104 P78347 P08559 Q86VP6 O94906 P27348 P15311 P46777 O60762 Q9UHI6
P09651 Q9NZI8 Q9Y230 P18085 P62280 P48643 Q9BSD7 O00231 P15924 P81605
P09874 P06576 Q15046 O60506 P22234 O95573 P50454 Q9BYE9 P46781 Q9BU23
Q9BVA1 Q13151 P62913 Q00325 P50914 Q14980 Q9Y4P3 Q15785 Q9NRZ9 Q8WUM4
P04350 P04843 Q9BWF3 P36873 P09661 Q9NSD9 P53999 P15927 Q96CW5 Q9BYJ9
Q08211 Q13310 Q9UQ80 P28331 P35637 Q8N1F7 Q13155 Q99497 Q92878 P39748
Q14204 P42704 P29692 P55884 P62899 Q99613 Q9UMS4 P01708 Q92997 Q15363
P68363 P62829 P12004 P27708 P61513 O00461 O95782 P62826 Q14684 O60645
Q9BQE3 Q04637 Q13813 Q13765 P62906 P61026 P40227 P61254 Q12788 Q16186
P08238 P62701 P47897 P62277 O00425 P06493 Q9UNL2 P62266 P22314 P56556
O15217 P52597 P07195 P33176 P62140 O95831 Q8TCJ2 Q12874 Q13242 P62714
P35232 P12956 P50991 P62269 Q5BKZ1 Q32MZ4 O43242 Q06265 Q6P1J9 Q10471
P07900 Q15393 Q16891 P49368 Q07021 Q99729 Q9P2J5 P57678 O00483 Q8WWY3
Q00839 P46782 P18124 Q99459 Q99798 P46977 P55209 Q9BVK6 P55265 P07237
Q05639 P39656 Q15717 P55786 P31153 P56134 P35998 O43684 P08621 Q9BXT5
P13647 P31942 P43243 P62241 P49755 Q07955 Q9Y490 P84098 Q86TJ2 Q9HB71
P26641 P39019 P23246 P62081 P36542 P62195 Q09028 P05387 Q9BTV4 Q7Z2T5
P41252 Q9Y4U1 P46940 P0CW22 P27694 Q04837 P40616 P13674 O00139 P18077
P02538 Q92945 Q92499 Q92688 Q96PK6 Q99832 P08579 A8MWD9 Q09161 P04075
Q96S19 P04844 P24534 P51148 Q9Y262 Q92900 O95202 P46087 P54709 P84090
Q00610 O43390 P05141 Q8N1G4 Q9UJS0 P46779 Q6UWP7 P51531 Q6PJT7 P48735
P60842 Q15084 P27635 P55060 Q13200 Q13868 Q9H9B4 O75947 P12814 Q9H672
P07814 Q86YZ3 Q9Y265 P13010 Q14683 Q9UHB9 Q99615 Q9UBU9 Q14444 P17980
Q99623 P52292 O43143 P61353 Q14318 P46778 P48047 Q8N766 P22570 Q8N163
P26599 P38919 P11021 Q7RTS7 Q00341 Q9BTC8 P05455 Q16630 P40938 P30419
P61978 Q9Y3I0 P63244 Q9Y285 Q9H0D6 Q02790 P62750 O95292 Q5HYI8 Q9H0S4
O75643 P51991 Q9BUJ2 Q15366 Q96S52 Q15645 Q9Y295 O94905 P51812 Q9UJZ1
Q12906 P54136 O43813 O75396 P51114 P26368 P23921 P46776 P29374 Q9NVI1
P11586 P78527 Q3ZCQ8 Q01813 Q9Y3B4 Q9BSJ8 Q8WY22 P30876 Q9P0I2 P35606
P51659 P14625 P67809 Q03252 P62888 P42677 Q92643 Q9Y3E0 Q8IYB3
Q13263 P14866 P26196 P04181 Q13148 Q9NTJ3 P50402 Q9BUQ8 O14980
P49411 P50990 P61247 P00918 P25205 P62244 P18754 Q9NQ29 Q9UQ16
P25705 P23396 P23528 Q15019 P53621 P33992 P20042 Q9NPD3 O95168
P68032 P05023 P84085 Q13347 P15880 Q7Z2W4 P37837 Q9BVP2 Q9NTZ6
Q12931 P37802 P38646 Q14974 Q9NX63 O43809 Q07666 Q9P2B4 Q15006
P02533 P39023 P41091 Q13573 Q9Y237 P60866 O75306 Q8NFW8 Q96HS1
P20700 O43175 P39687 P46060 P62851 Q9Y5A9 P35268 P08243 P33993
P14868 Q01082 P00403 Q9UHX1 Q14203 P62805 O75821 O75369 P13804
P08779 P51572 P63173 P37108 O95793 P42285 P62847 Q96KR1 P34897
Q92841 P49327 P00367 P62753 Q96EP5 P35580 P62306 Q02809 Q96FZ2
P05388 P38159 P52209 Q5D862 Q7L2E3 Q00796 Q9NZT1 Q9Y6M9 P02545
P04406 Q14103 Q15233 P32119 P43897 Q52LJ0 Q15459 Q6YN16 Q8IX01
Q6P2Q9 O00148 P62495 O95232 P51570 P36507 Q9BZJ0 Q9BV38 P33240
P17844 P61204 P40222 Q9UN86 Q9Y3A5 P62318 P51149 O96000 Q12824
Q12905 P11142 Q13409 Q9Y224 Q96I24 P50213 O95104 P53396 Q01105
201 
 




P49768 Q9BUF5 P63267 Q15393 P40938 P07195 P05109 Q8IX12 P23284 P61313
P16152 Q99623 O43175 Q3ZCQ8 P40429 Q99613 Q13724 Q9Y4P3 Q9UQE7 P02768
P21266 Q96S19 P62269 Q3ZCQ8 Q92688 O75533 Q9HAV7 Q16531 Q9NTJ3 Q13547
P09211 P11142 Q9NZI8 Q14204 Q15233 P06576 Q9UJS0 Q16795 Q9BYJ9 P46779
O60716 O15217 Q6P2Q9 Q8NI60 Q07021 Q9Y3Z3 P56182 P78527 Q9P258 Q6I9Y2
P04264 P06748 P18124 P84098 O94906 P62826 P56182 P12268 Q9NSD9 P04075
P35527 P61978 O75643 P13674 P62750 Q96I99 Q9BRX2 O60762 P55081 Q96HL8
P13645 P07814 P12956 P16989 Q8N1N4 O60506 Q8IWZ3 P62888 P51570 Q5T2N8
P28161 P17844 Q15029 P63173 Q9Y2S7 Q9UMS4 Q8WY22 Q9NZ01 P61026 Q7L2E3
P35908 P07910 O76031 P35637 Q14203 Q02543 Q01082 P24390 O43684 P30419
P08107 P19338 P23246 Q9P035 Q96KR1 P08621 Q8N8S7 P11172 P60660 P17980
P68371 P62829 O43390 P26599 P17987 Q9UBB4 P62249 P15924 P46977 P62280
P07437 P41252 Q15717 P23396 Q9Y5M8 P50914 Q9BUQ8 Q15366 Q9Y5A9 P84090
P52272 Q12905 Q9P2J5 Q86Y46 Q03252 P11177 Q92499 Q9BVP2 Q96DI7 Q15019
O75828 P14868 Q12906 P05141 P62277 P04637 P0C0S5 P46087 Q96HP4 P35250
Q9BVA1 P35232 P47897 P12004 P12236 P10619 P18754 P0CG48 Q6YN16 Q13310
P26641 Q9Y4U1 P35580 P83731 P31689 Q8WUK0 Q14839 Q13813 P81605 O76061
P68104 P35579 P35580 Q02878 Q32MZ4 P08579 P39019 P27816 P07237
P68363 P24534 Q00610 Q9BUJ2 P62851 P26640 Q9H0D6 Q13045 P62917
P60709 Q9BSD7 P48047 P46778 P62851 P62195 P22087 Q13155 Q01469
P63261 O43813 P31943 P05386 Q9Y285 P25205 P26196 Q7KZF4 Q16775
P09488 P67809 Q9Y230 O43143 Q9Y285 P68431 P46781 Q9UNX3 P26368
P02533 P51659 Q02978 P11310 Q9ULV4 P08559 P60866 Q09028 P54136
P49411 P11021 Q96EY1 Q9UHX1 P60842 Q9BQ67 Q9NQT5 Q96E11 Q13765
P13647 P20700 P27635 P62753 Q14103 O75152 O60884 Q9NW13 Q01780
Q08211 P09874 P62913 P62424 Q9UKB1 P49368 Q92900 Q8NI27 Q7Z7A3
Q99569 O60814 P39023 P13637 P35221 P30050 Q15758 O95347 P14678
P22626 Q92841 Q13263 Q96AG4 P46782 P27348 P14923 P36873 Q2TAY7
P02538 P50991 P05388 Q13283 Q13200 P05198 P62263 Q9UKM9 Q9BZE4
P04259 P62805 P11586 P29692 Q13573 Q96C36 Q0VDF9 P08865 P61353
P08238 Q04695 Q00325 P35998 O15372 Q9Y224 P35269 P04843 Q01105
P25705 P43243 P51991 Q9Y3I0 Q99729 P62241 P18085 P26038 Q13409
P08670 Q9UQ80 P51991 Q07065 P62081 Q14152 O43242 Q15424 P46776
Q86YZ3 Q15046 P13646 P13010 P22695 P32322 P49207 Q9BQG0 P38919
Q00839 Q8NC51 P04406 P33993 P46777 O43324 Q5JQF8 P05455 Q7Z2W4
P08779 P52597 P32969 Q8TEB1 O00483 P41091 Q8WU68 Q6Y7W6 P42766
P09651 Q86V81 P38646 Q01813 P26373 P14866 P42677 Q92947 Q9H1K4
Q05639 Q9Y265 P12277 P55884 P62701 Q8WVI0 P14618 P15880 P50454
P10809 O00571 Q9NR30 P62906 Q04637 P35249 P18621 P34897 Q8IX03
P07900 Q13151 P04181 P38159 P36578 P42704 P30837 Q9BTT0 Q8N9F7
202 
 
Table 7.3 Total list of proteins identified in the mass spectrometry of the GST-
PS1-Loop FP/VS/AA sample 
P49768 Q9Y4U1 Q92947 P39023 Q8TEB1 Q02878 P40616 O43301 P02768
P16152 P11586 P17844 P46777 Q8NE71 P34897 O60884 P61353 Q13363
P09211 P11142 Q12905 Q7Z7L1 P51991 Q14CN4 Q13155 P61221 P41091
O60716 P20700 P04406 Q96EY1 Q15393 O15372 P04637 Q7Z7A3 P26368
P21266 P07814 Q02978 P62805 Q9BUJ2 Q03252 P62241 P36578 P18621
P13645 P61978 P51659 P22695 Q99613 Q96IX5 Q53H96 P62249 Q9Y2X7
P04264 P38646 Q99615 O75643 Q9Y5M8 P62753 Q07021 P62917 Q9BTU6
P28161 Q00610 P46782 P30837 Q12906 P12277 P14625 Q9BY77 P46778
P35527 Q99623 P31689 Q92499 P40429 Q9BRX2 Q9BPW8 P56192 P63244
P68104 P11310 Q15029 P48047 P05198 Q5JPH6 O94813 Q9UI43 Q96PK6
P35908 P07900 Q9NZI8 Q9Y285 Q01081 P0CG48 Q92621 P61619 P09543
P26641 Q9BSD7 P67809 P54136 P62269 P15924 O60282 P50914 P23919
P07437 P17987 Q8NC51 Q9UQ80 P26373 O75616 P42677 P46783 Q9UQE7
P68363 O43175 P26599 Q96C36 Q14103 P29692 P42704 Q01082 P08579
P08107 P24534 P33993 P51570 P11177 P55209 Q9UHR4 P27635 O00233
P68371 Q96S19 Q00325 Q15717 P62424 O94906 Q8N1G4 Q8IX12 Q15424
Q9BVA1 Q9Y265 P12004 P05141 P13010 Q5JTV8 Q09028 Q8IWZ3 P26196
P60709 P50991 P35579 Q96KK5 Q6UWP8 Q16775 P04844 P22830 P50990
Q05639 P06748 P35249 O00571 P78347 O75955 Q9UL03 O95831 P23284
P49411 Q6P2Q9 P04181 P62195 P62906 P81605 P62750 Q92900 P04843
P52272 P43243 P11021 P10619 Q13573 P18085 P83731 P60228 Q8IX03
Q99569 P05388 P38159 Q9NUU7 P11940 Q15120 P48735 O14980 P14678
P25705 Q96I99 P60842 P32969 P27708 Q9UN37 O43324 O15460 Q9NR30
Q08211 P62829 P13674 P35998 Q14152 Q9NTJ3 P43490 Q13765 P22087
P22626 P35232 Q3ZCQ8 P40938 O00148 Q15645 Q04726 Q92979 P13637
P10809 P31943 Q5D862 Q9HAV7 P07686 P35222 O75152 P63208 Q8WWX8
Q9BUF5 P46459 Q9Y3Z3 Q04637 P12956 Q13200 P31327 P68431 P62899
P13647 P49368 P63173 P06576 P35637 Q9H0D6 P17812 P40227 P62280
Q00839 Q9UKB1 O60762 P32322 Q16531 P27816 O00442 Q86TJ2 P15848
O43813 Q92841 P53597 P0C0S5 P23258 Q8IY67 P35269 Q86UK7 Q04656
P02538 P09874 P11172 P23396 Q13435 Q13724 Q8WVI0 Q96GC5 Q02543
P09651 Q9Y2S7 Q9P2J5 P35580 Q9Y5V3 P12236 P35250 Q96E11 Q8ND04
P08670 P19338 Q13263 Q9NZ01 Q01813 Q99729 O43837 Q9BW62 Q9P2R7
P08238 P14868 P52597 P62913 O43143 P62701 Q9H1K4 Q13151
P41252 Q15046 O43390 Q9P035 P07195 P30050 O75533 Q9BVP2
P68032 Q9Y230 Q8NI60 Q99714 P55884 P09661 P14866 Q2TAY7
Q86YZ3 P08779 P18124 P84098 Q8N4T8 O75821 P35268 Q9UBZ9
P02533 P50454 P07910 Q14204 Q52LJ0 Q8WY22 P26640 O95347
O15217 P06493 P08559 Q7Z3Y8 O43929 O60814 Q13813 P60866
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The presenilins are the catalytic subunit of themembrane-embedded tetramericγ-secretase protease complexes.
More that 90 transmembrane proteins have been reported to be γ-secretase substrates, including the widely
studied amyloid precursor protein (APP) and the Notch receptor, which are precursors for the generation of
amyloid-β peptides and biologically active APP intracellular domain (AICD) and Notch intracellular domain
(NICD). The diversity of γ-secretase substrates highlights the importance of presenilin-dependent γ-secretase
protease activities as a regulatory mechanism in a range of biological systems. However, there is also a growing
body of evidence that supports the existence of γ-secretase-independent functions for the presenilins in the reg-
ulation and progression of an array of cell signalling pathways. In this review,wewill present an overview of cur-
rent literature that proposes evolutionarily conserved presenilin functions outside of the γ-secretase complex,
with a focus on the suggested role of the presenilins in the regulation of Wnt/β-catenin signalling, protein traf-
ficking and degradation, calcium homeostasis and apoptosis.
© 2015 Elsevier Inc. All rights reserved.
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1. Presenilins and the γ-secretase protease complex
The presenilin 1 (PS1) and presenilin 2 (PS2) proteins that form the
catalytic core of the γ-secretase protease complex were initially discov-
ered in genetic screens for mutations causing early onset forms of
familial Alzheimer's disease (FAD) [1,2]. γ-Secretase is a multisubunit
transmembrane proteolytic complex belonging to the family of
intramembrane cleaving proteases (ICliPs) of which there are four
classes; the serineproteases of the rhomboid class, themetalloproteases
in the Site-2-proteases (S2P) class and the GXGD aspartyl proteases, sig-
nal peptide peptidases (SPP) andγ-secretase [3]. Of all the ICliPs studied
to date γ-secretase is unique as it is a four-protein complex, consisting
of the presenilins, anterior pharynx-defective 1 (Aph-1), presenilin en-
hancer 2 (Pen-2) and Nicastrin, which is only found in multicellular or-
ganisms [3,4]. In humans, two forms of presenilin (PS1 and PS2) and
two forms of Aph-1 have been identified, one of the Aph-1 homologues
is also expressed in two isoforms via alternative splicing, leading to the
possible existence of at least six different γ-secretase complexes that
may have tissue- or cell type specificity [5]. The presenilins are highly
conserved transmembrane proteins that are synthesized as 50 kDa
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holoproteins that undergo endoproteolysis to generate heterodimeric
presenilin N-terminal and C-terminal fragments (NTF/CTF), a required
activation step in their role as the catalytic subunit of the γ-secretase
protease complex [6]. The structure of the PS1-γ-secretase protease
complex has revealed the intricate interaction between each subunit
and an overall horseshoe-shaped structure composed of the 20 trans-
membrane domains of presenilin, Pen2, Aph1 and nicastrin [7,8]. To
datemore than 90γ-secretase substrates have been identified including
APP and a large number of cell surface receptors and adhesion mole-
cules such as Notch, ErbB4, CD44 and E-cadherin [9,10]. The sequential
proteolysis of APP culminating in intramembrane cleavage by γ-
secretase now serves as a model for the regulated intramembrane pro-
teolysis of numerous transmembrane proteins (Fig. 1) [3,11]. Cleavage
of APP by α-secretase or β-secretase results in the release of respective
soluble ectodomains (sAPPα or sAPPβ), generation of the APP intracel-
lular domain (AICD) and P3 or Aβ peptides that represent the remaining
transmembrane domain of APP [13]. The sAPPα and sAPPβ fragments
have been shown to promote neurite growth in cortical neurons in
rats and mice and to regulate cell signalling pathways [11,12,14,15],
while the AICD fragment has been shown to have a number of cellular
functions such as regulating Wnt signalling, gene transcription and
apoptosis [16,17].
In general substrates that undergo regulated intramembrane
proteolysis are initially cleaved in the extracellular domain by
sheddases such as TACE (TNFα converting enzyme) or ADAM (a
disintegrin and metalloproteinase domain)/α-secretase, or by
aspartyl proteases, such as BACE/β-secretase, before cleavage by
the I-CLiP family of proteases [3]. Recently, cleavage of peripheral
membrane proteins and proteolysis within substrate ectodomains
and luminal loop has been described [18–20]. Furthermore, it has
been reported that prerequisite ectodomain shedding may not be
required for subsequent cleavage by γ-secretase for some sub-
strates [21]. For several substrates γ-secretase cleavage plays an es-
sential role in a signalling paradigm whereby generation of
intracellular domains (ICDs) allows for the spatial segregation of
divergent signalling pathways or as is the case for Notch, allows
for the translocation of ICDs to the nucleus where they enable tran-
scriptional activation activity [22]. Indeed, Psen1 knockout animals
display a predominant Notch loss-of function phenotype resulting
from loss of γ-secretase cleavage of Notch, highlighting the impor-
tance of γ-secretase in Notch signalling [23–25]. Cleavage can also
be used as a signal for degradation of transmembrane protein frag-
ments and the maintenance of so-called ‘membrane proteostasis’
[26]. Given the diversity of known γ-secretase substrates the
presenilins are proposed to be critically involved in regulating sev-
eral cell signalling pathways mediated by these molecules, a thor-
ough presentation of which have been reviewed elsewhere [9,10,
22,27–29].
Beyond their role in γ-secretase protease complexes, it has been
proposed and in some cases demonstrated that the presenilins have
many highly conserved γ-secretase independent regulatory functions
in cellular processes and cell signalling, includingWnt signalling, endo-
plasmic reticulum (ER) calcium homeostasis, as well as lysosomal func-
tion and autophagy [29–40]. Evolutionarily many ICliPs are conserved
from prokaryotes through to multicellular eukaryotes. Homologues of
rhomboids, S2Ps, SPP and γ-secretase have all been identified in ani-
mals, plants (Arabidopsis thaliana and Physcomitrella patens) and proto-
zoa (Dictyostelium discoideum) [27,41–44]. Genetic evidence from
presenilin-deficient mice supports this proposal, where mice deficient
in Psen1 and Psen2 have a more severe phenotype than seen in animals
deficient in other γ-secretase components, Aph-1, Pen-2 or Nicastrin
[45–49]. Similarly, reconstitution studies in P. patens revealed that loss
of presenilins was associated with distinct phenotypes that could be
fully rescued by catalytically inactive presenilin and human presenilin
[41], supporting the existence of conserved γ-secretase independent
functions for presenilins from plants to humans. This review will focus
on current evidence for the existence of γ-secretase independent func-
tions for the presenilins in a diversity of cellular processes; including the
regulation of Wnt/β-catenin signalling, calcium homeostasis, cell sur-
vival, protein trafficking and degradation.
Fig. 1. Regulated intramembrane proteolysis of amyloid precursor protein (APP). In thismodel theprogressive proteolytic cleavage of amyloid precursor protein (APP) is illustrated. Firstly,
in the non-amyloidogenic pathway, cleavage in the APP ectodomain by α-secretase produces a soluble ectodomain (sAPPα) and the membrane-anchored APP C83 carboxyl-terminal
domain. Next, the γ-secretase complex is recruited to APP-derived C83 and cleaves to generate the P3 fragment and liberate the biologically active APP intracellular domain (AICD).
Alternatively, in the amylodiogenic pathway, cleavage of APP by β-secretase produces a soluble ectodomain (sAPPβ) and the membrane-anchored APP C99 carboxyl-terminal domain.
Next γ-secretase cleavage of APP C99 liberates the APP intracellular domain (AICD) and generates amyloid-β (Aβ) peptide fragments.
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2. Post-translational modification of the presenilins
Compelling evidence for a role for the presenilins in a diversity of γ-
secretase-dependent and -independent cell signalling events come
from the study of presenilin post-translational modification and from
the identification of distinct protein binding domains with the amino
acid sequence of the presenilins (Fig. 2). The presenilins undergo
endoproteolysis, caspase cleavage, phosphorylation, and ubiquitination,
which regulate presenilin function and interaction with numerous pro-
teins [50–52]. Early studies showed that PS1 is phosphorylated by
Fig. 2. Presenilin structure, functional domains and post-translational modification. (A), Schematic representation of presenilin-1 (PS1) structure. PS1 contains ten hydrophobic domains
arranged in a predominant nine-transmembrane domain [TMD] topologywith a large hydrophilic loopdomain betweenTMD six and seven. The protease activity ofγ-secretase complexes
is mediated by two aspartyl protease active site motifs [YD and GXGD] located in the centre of adjacent TMD 6 and TMD 7 with reverse orientation, and the PALmotifs located in TMD 9.
The cytosolic loop contains the presenilinase and caspase cleavage sites, and ubiquitin-binding coupling of ubiquitin conjugation to endoplasmic reticulum degradation (CUE) domain
mapped as indicated. (B), Previously described covalent post-translational modifications of human presenilins, PS1 and PS2. PS1 contains three GSK3β phosphorylation sites [underlined]
whereas PS2 contains none. PS1 and PS2 are subject to serine/threonine phosphorylation by PKA [●], PKC [○], CDK5 [■], GSK3β [□], JNK [◊] AND CK1/2 [⁎] and mapped to specific indi-
vidual residues. PS1 is also ubiquitinated by Fbw7/Sel-10 and TRAF6 but the site(s) have not been mapped to individual residues. The TRAF6-binding domain (boxed in grey) and the
endoproteolysis and caspase cleavage sites are also indicated [arrows]. (C) Sequence alignment of the amino acid sequence of presenilins with several known coupling of ubiquitin con-
jugation to endoplasmic reticulum degradation (CUE) domains [67]. Residues highlighted in black are identical; residues in dark grey are similar; boxed residues are weakly similar. Con-
sensus sequence is shown below the alignment and position of CUE domain FP and LL motifs are indicated with asterisks. The Jnet bioinformatics tool predicted that the putative CUE
domains of PS1 and PS2 contain three consecutive α-helices, indicated above sequence alignment. Alignments were carried out with AlignX software.
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protein kinase A (PKA) [53], protein kinase C (PKC) [54], glycogen syn-
thase kinase 3β (GSK3β) [55], c-Jun. N-terminal kinases (JNK) [56] and
cyclin dependent kinase 5 (CDK5) [53,57] (Fig. 2B), resulting in a variety
of biological responses including alterations in γ-secretase activity, [56]
Wnt/β-catenin signalling, [58] caspase-3 cleavage of PS1 and PS2 [54],
and presenilin stability [57].
It has also been demonstrated that PS1 is ubiquitinated by
Caenorhabditis elegans SEL-10 [52], Fbw7 the mammalian homologue
of SEL-10 [38], andmore recently by tumour necrosis factor receptor as-
sociated factor 6 (TRAF6), which facilitates Lysine-63 (K63)-linked
polyubiquitination of PS1 [50,51]. The ubiquitination of PS1 by
C. elegans SEL-10 targets PS1 for degradation through theubiquitin–pro-
teasome system and antagonizes the signalling activity of Notch [52].
Consistent with this, PS1 and Fbw7 interact and regulate the stability
and activity of the epidermal growth factor receptor (EGFR) and the
Notch ICD (NICD) [38]. The presenilins contain a conserved TRAF6-
binding domain [59,60] and undergo TRAF6-mediated K63-linked
polyubiquitination, [50,51] which increases PS1 holoprotein stability
and function in the regulation of calcium homeostasis, independent of
γ-secretase protease activity [50]. Furthermore, the interaction be-
tween TRAF6 and PS1 has been shown to promote γ-secretase cleavage
of p75 neurotrophin receptor (p75NTR) [60], while the loss of TRAF6 E3
ligase activity reduces γ-secretase cleavage of p75NTR, TGFβ Type 1 Re-
ceptor (TβR1) and interleukin-1 receptor, type 1 (IL-1R1) [51,61].
These data suggests that the interaction between TRAF6, PS1 and γ-
secretase substrates plays a role in modulating γ-secretase activity.
However, given that TRAF6 can ubiquitinate both PS1 and some γ-
secretase substrates, the exact role-played by TRAF6 mediated
ubiquitination of PS1 remains to be fully elucidated. What is clear is
that thesemodifications are not only important for the protease assem-
bly and activity of γ-secretase complexes, but are also essential for the
stability and activation of presenilins.
The recognition of ubiquitin and polyubiquitin chains by ubiquitin-
binding domains (UBDs) is critical for determining the outcome of
ubiquitination and subsequent ubiquitin-mediated signalling pathways
[62]. To date approximately 20 different UBDs have been identified,
including ubiquitin interacting motifs (UIMs), ubiquitin associated
domains (UBAs) and the related coupling of ubiquitin conjugation to
endoplasmic reticulum degradation (CUE) domains [63]. In keeping
with a role for ubiquitination in the regulation of presenilin activities,
the UBA of ubiquilin is necessary for the binding of ubiquilin to PS1
and PS2 [64], which reduces the formation of NTF/CTF heterodimers
by stabilizing presenilin holoproteins within the cell [65]. Ubiquilin
transcript variants (TV) 1 and 3 have been shown to cause the
accumulation of higher molecular weight forms of PS1 (HMW-PS1)
[66]. Ubiquilin is hypothesised to act as a shuttle between ubiquitinated
proteins and the proteasome and it has been suggested that the accu-
mulation of HMW-PS1 is a result of weak interactions between
Ubiquilin-1 TV3 and the proteasome [66]. PS1 has recently been
shown to contain a functional ubiquitin-binding CUE domain (Fig. 2C),
which preferentially binds to K63-linked polyubiquitin chains [67].
Interestingly, missense CUE mutants that prevented binding to ubiqui-
tin, do not affect endoproteolysis of PS1, signifying that formation of
PS1NTF/CTF heterodimers does not require an intact CUE domain, but
suggesting that the presence of the CUE domain may be important for
a γ-secretase-independent PS1 holoprotein function. Furthermore,
mutation of the CUE domain does not alter PS1-dependent γ-
secretase cleave of APP or Notch, nor generation of Aβ40/42 peptides,
advocating that the PS1 CUE domain is not necessary for γ-secretase
activity [67]. Taken together, these results highlight a function for
non-covalent ubiquitin signalling in the regulation of the presenilins
and their role in both the γ-secretase-dependent and -independent
functions. Further studies will no doubt define the precise regulatory
role of post-translational modification in presenilin biology and
functions, independent of and dependent upon its role as the catalytic
subunit of γ-secretase.
3. Learning from our ancestors
As mentioned earlier, homologues of all γ-secretase components
have been identified in plants and protozoans, some of which have
emerged as model systems for the study of γ-secretase independent
functions of the presenilins [27]. The moss P. patens was the first plant
species in which conservation of γ-secretase complex components
and a γ-secretase independent function for the presenilin homologue
(PpPS) and nicastrin was demonstrated [41]. A more recent study in A.
thaliana similarly showed the conservation of γ-secretase complex
components in another plant species [42,43]. Importantly, certain high-
ly conserved amino acidmotifs crucial for γ-secretase proteolytic activ-
ity, substrate recognition and complex assembly in mammals are
similarly conserved in plant species [68]. However, phylogenetic analy-
sis of presenilins indicates that plant and animal homologues fall into
two divergent clades [43]. Interestingly, P. patens genome contains
only one copy of presenilin (PpPS) and does not possess homologues
of several mammalian γ-secretase substrates including APP and Notch
[41]. In reconstitution studies PpPS was defective in cleavage of a
Notch1-based substrate in PS-deficient mouse embryonic fibroblasts
(MEFs), but was able to restore normal proliferation rates in PS-
deficient MEFs, a function thought to be independent of γ-secretase
proteolytic activity [41]. In the phenotypic characterization of a nullmu-
tant of presenilin (Ppps), P. patens displayed abnormal growth pattern,
impaired chloroplast movement and decreased endocytosis [41]. In
this regard, in Arabidopsis studies employing exogenous expression of
γ-secretase subunits impairment of vacuole trafficking was observed
[43]. Together this data from two plant species intimates that the pre-
dominant function of presenilin in plants is not related to γ-secretase
protease activity but perhaps points to an ancestral role for presenilins
and the γ-secretase complex in protein endocytosis and trafficking.
Consistent with this hypothesis, γ-secretase is present and active in
the slime mould D. discoideum, [44] where the presenilins have been
shown to be essential for Dictyostelium cell fate determination and the
regulation of phagocytosis. However, in contrast to plants,Dictyostelium
γ-secretase was still proteolytically active against animal substrates
[44]. Again, this suggests an ancestral role for presenilins that extends
well beyond what is known about γ-secretase protease activity from
predominantly animal studies.
Nevertheless, fromanimal studies there is also a growing body of ev-
idence showing that the presenilins and γ-secretasemay be involved in
the regulation of endocytosis, protein trafficking and degradation
[69–71], leading to the proposal that signalling functions associated
with γ-secretase proteolytic activity and substrate cleavage arose later
in evolution [26,44]. In keeping with this, while there are over 90 re-
ported γ-secretase substrates no biological function has been attributed
to the majority of these γ-secretase-generated ICDs [10,22]. However,
many substrate-derived ICDs are rapidly degraded and support the pro-
posal that the predominant function attributed to γ-secretase would be
to facilitate the removal and degradation of membrane bound protein
fragments subsequent to ectodomain shedding, thereby acting as a
‘membrane proteasome’ [72]. Furthermore, mice deficient in Notch sig-
nalling or deficient in either of the γ-secretase components, Aph-1, Pen-
2 or Nicastrin, are able to generate anterior somites, whereas Psen1 and
Psen2 double-deficient animals are not, suggesting that the presenilins
contribute to the generation of anterior somites, independent of their
role in γ-secretase [73]. In summary, from an evolutionary perspective,
data supports the proposal that presenilins have an important regulato-
ry role in protein endocytosis, trafficking and degradation, which pre-
ceded signalling functions associated with γ-secretase substrate
cleavage and proteolytic activities.
4. Presenilins in protein trafficking, proteolysis and degradation
An obvious explanation for the role of presenilins and γ-secretase in
protein trafficking and degradation is that many reported γ-secretase
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substrates are functionally involved in protein transport. For example,
members of the mammalian Vsp10p sorting receptor family including
sortilin-related receptor with A-type repeat SorLA (also known as
SORL1, LR11), Sortilin and SorCS1b are reported to be γ-substrates
[74,75]. However, data from several other groups support the proposal
that the presenilins can also affect trafficking independent of γ-
secretase proteolysis activity. It has been shown that PS1 interacts
with Rab11 [76], a small GTPase involved in the regulation of vesicular
transport and several other Rab proteins have been reported to be in-
volved in PS1-mediated protein trafficking, such as Rab6 and Rab GDP
dissociation inhibitor [77,78]. Consistent with this the presenilins have
also been shown to regulate the trafficking and turnover of a number
of proteins. For example, presenilin-deficient neurons have been
shown to have reduced trafficking of TrkB and EphB receptors to the
plasma membrane and diminished neuroprotective qualities of the
EphB ligand, efnB [79,80]. Interestingly, this efnB-associated neuropro-
tection is maintained in cells treated with γ-secretase inhibitors, sug-
gesting a γ-secretase independent function of the presenilins [80]. By
contrast PS knockout cells showed an increase in integrin β1 trafficking
to the cell surface and an increase in integrinβ1 post-translationalmod-
ification andmaturation [81]. These results indicate that the presenilins
play a role in chaperoning proteins through the endoplasmic reticulum
(ER) to the Golgi independent of presenilins γ-secretase function.
PS1 has also been shown tomediate epidermal growth factor recep-
tor (EGFR) turnover via the endosomal/lysosomal system and as such
regulates EGFR signalling [70]. Abnormal EGFR signalling in PS-
deficient cells involves γ-secretase independent transcriptional down
regulation of the E3 ligase Fbw7 and by affecting a proteasome-
dependent ubiquitination step essential for constitutive degradation
and stability of EGFR [38]. Additionally, a more recent study has report-
ed that PS1 is necessary for cell-specific transcriptional regulation of
EGFR expression and neuroprotection, in a γ-secretase independent
manner [82]. The neuronal cell adhesion protein telencephalin also
interacts with PS1 and has been shown to increase in half-life and
accumulate in autophagic vacuoles in PS-deficient neurons [83].
Telencephalin trafficking was rescued by expression of wild type or
catalytically inactive PS1 aspartate mutant and was not affected by γ-
secretase inhibitors, demonstrating that this is a γ-secretase indepen-
dent function of presenilins. Additionally, presenilins have been
shown to regulate axonal transport via interactions with GSK-3β thus
influencing kinesin-1 and dynein activity and role in transport [84], an
activity that was insensitive to γ-secretase inhibitors [85]. Consistent
with this, cells expressing PS1 FADmutations and presenilin conditional
knockout (PScDKO) mice show reduced kinesin-1 activity and reduced
fast axonal transport (FAT) of type 1 transmembrane receptors [86,87].
Filamin is a protein that is involved in regulating neuronal migration,
and overexpression of the PS1 FAD M146L mutant alters filamin distri-
bution within the cell from the cell periphery to the cytoplasm; this al-
teration is not changed by treatment with a γ-secretase inhibitor [88],
suggesting that PS1 regulates filamin localization in a γ-secretase inde-
pendent manner [89]. Collectively, these observations suggest that the
presenilins play an important role in maintaining axonal transport
within neurons and in regulating neuronal migration.
PS1 deletion or PS1 FAD mutations have also been shown to
disrupt lysosomal acidification and proteolysis, which inhibits
autophagy (Fig. 3), a lysosomal degradative pathway for recycling
damaged or obsolete organelles and misfolded or aggregated proteins
[31,32,83,90–92]. This function is again independent of presenilins'
role as the catalytic subunit of γ-secretase [6,31,93]. It has been pro-
posed that PS1 holoprotein serves as a chaperone in the ER for the
vATPase V0a1 subunit, a transmembrane component of the proton
pump responsible for the acidification of lysosomes [31]. Binding of
PS1 in the ER is proposed to stabilize vATPase V0a1 and facilitate its gly-
cosylation, a prerequisite for ER exit [31,94,95]. Oligosaccharyltransferase
(OST), amultimeric complex located at themembrane of the ER, transfers
a preassembled oligosaccharide to selected asparagine residues within
Fig. 3. Presenilins, lysosomal acidification and lysosomal calcium homeostasis. Loss of PS1 or PS1 FAD mutations disturbs lysosomal acidification and proteolysis, which culminate in in-
hibition of autophagy. Oligosaccharyltransferase (OST), amultimeric complex located at themembrane of the ER, transfers a preassembled oligosaccharide to selected asparagine residues
within the consensus sequence asparagine-X-serine/threonine. It is suggested that defects in PS1 leads to compromised glycosylation of vATPase V0a1 subunit by OST, resulting in
misfolding and proteasome degradation of the V0a1 subunit, and incomplete lysosomal vATPase assembly and function. Arising from this, disruption to lysosomal acidification (higher
lysosomal pH) and degradation occurs leading to cytosolic accumulation of autolysosomes. Defects in PS1 and lysosomal acidification also lead to elevated lysosomal calcium efflux, me-
diated by pH-regulated transient receptor potential (TRP) cation channel mucoplin subfamily member 1 (TRPML1), and increased cytosolic calcium levels [97]. Increased lysosomal pH
also leads to a failure of the endolysosomal NAADP-regulated Ca2+ channels, two-pore channel (TPC2), to dissociate from NAADP, rendering the channel inactive and preventing Ca2+
efflux from the endolysosomal stores.
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the consensus sequence asparagine-X-serine/threonine. In PS1-deficient
cells the vATPase V01a subunit is poorly glycosylated and unstable,
which prevents proper assembly and function of the multisubunit
vATPase pump, resulting in reduced acidification of lysosomes and defec-
tive autophagy [31,33]. Consistent with this proposal several lysosome
acidification defects and disrupted autophagy have been associates with
loss of presenilin or FAD mutations [33,95]. Interestingly, pharmacologi-
cal inhibition of vATPase induces AD-related autophagy dysfunction
and pathologies, while pharmacological normalization of lysosomal acid-
ification in PS1-deficient cells reverses PS1-related defects [96]. In con-
trast to these studies, others have proposed an alternative model
for presenilin function in autophagy, whereby it is proposed that
N-glycosylation may not be necessary for the proper trafficking and
function of vATPase V0a1 subunit but rather defective glycosylation
of the vATPase V0a1 subunit and lysosomal acidification may arise
due to disruption in lysosomal calcium storage and release [30].
However, a recent study has demonstrated that disruption in lysosomal
calcium storage and release is secondary to dysfunctional lysosomal
acidification in PS1-deficient cells [97]. It was demonstrated that abnor-
mal calcium efflux from lysosomes in PS1-deficient cells are caused by a
pH-sensitive activation of the endolysosomal calciumchannel, transient
receptor potential (TRP) cation channel mucoplin subfamily member 1
(TRPML1), which causes elevated cytosolic calcium. Collectively, these
data indicate that PS1 deletion or PS1 FAD mutations cause lysosomal
and autophagy deficits that contribute to abnormal cellular calcium ho-
meostasis, thereby linking two AD-related pathogenic processes
through a single molecular mechanism.
Therefore as it stands, presenilin has a γ-secretase-independent role
in regulating protein trafficking, proteolysis and degradation, however
given that inhibition of γ-secretase activity can have a negative effect
on protein trafficking [69,98], we cannot exclude the possibility that
some of the trafficking defects seen in cells with compromised PS1 ex-
pression of activity may be attributed to loss or reduced cleavage of
Vsp10p sorting receptors or other substrates.
5. Presenilins and calcium homeostasis
Additional to the proposed secondary effects of PS1 on lysosomal
calcium storage and homeostasis outlined above, another proposed
ancestral role for presenilins relates to the formation of ER calcium
leak channels and the regulation of intracellular calcium homeostasis
(Fig. 4) [99,100]. Disrupted calcium signalling has been reported to pre-
cede the classic AD pathologies, neurofibrillary tangles and Aβ plaques,
and is proposed to contribute to neuronal cell death during AD [101].
Similarly, in numerous mouse models of AD increased basal levels of
Ca2+ have been observed and presenilin FAD mutations have been ob-
served to cause changes in Ca2+ levels [93,100,102,103]. There are sev-
eral lines of evidence supporting a role for presenilins in the regulation
of calcium homeostasis of intracellular stores, which appear to be inde-
pendent of γ-secretase protease activities (Fig. 4). First, the presenilins
interact with several proteins functionally involved in calcium signal-
ling, including sorcin, calmodulin, calsenilin, calmyrin and calpain
[104–106]. It was next proposed that presenilin holoproteins act as pas-
sive Ca2+ channels in the ER and those PS FAD mutations alter channel
conductance [93]. In an elegant mutagenesis study it was subsequently
demonstrated that the hydrophilic catalytic cavity of PS1 facilitates the
formation of a calcium leak conductance pore [107]. In parallel, the
presenilins have been shown to regulate Ca2+ levels through
interactions with and activation of Ca2+ channels such the sarco/ER
Ca2+-ATPase (SERCA) pump [108], the inositol triphosphate receptor
(InsP3R) [109], and the Ryanodine receptor (RyR) [110,111]. More
recently the presenilins have also been reported to modulate
phosphatidylinositol-4,5-bisphosphate (PIP2)-mediated regulation of
the transition receptor potential of melastatin related 7 (TRPM7)
[112]. Finally, the presenilins have also been proposed to increase the
number of contact sites between the ER and mitochondria, thereby
facilitating movement of Ca2+ from the ER to the mitochondria [113].
Further indicating aγ-secretase-independent role for the presenilins
in regulating calcium homeostasis, presenilin-deficient MEFs show a
Fig. 4. PS1 and γ-secretase regulate Wnt and calcium signalling within the cell. (A) The γ-secretase cleavage of E-cadherins, facilitates dissociation of β-catenin and α-catenin from the
cytoskeleton, thus promoting disassembly of the E-cadherin–catenin adhesion complex. Furthermore, this cleavage releases the E-cadherin ICD to the cytosol and increases the cytosolic
pool ofβ-catenin, a key regulator of theWnt signalling pathway. PS1 interactswithβ-catenin and is a negativemodulator ofβ-catenin/Tcf-4 gene transcription activity, thereby negatively
regulatingWnt signalling. This signalling pathway is negatively regulated by the GSK3β phosphorylation of PS1 but is also down regulated by PS1 FADmutations. (B) The presenilins reg-
ulate Ca2+ levels within the ER by interacting with the Ca2+ channels such as InsP3R or SERCA. Presenilin FADmutations have also been shown to increase the level of cytoplasmic Ca2+
concentration. The presenilins have also been proposed to act as passive Ca2+ channels that release Ca2+ from the ER.
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decrease in ER Ca2+ concentration, which may be as a result of the
presenilins regulating InsP3R levels [114] or SERCA pump levels leading
to increased ER [Ca2+] [108], which in both cases normal Ca2+ levels
can be rescued by overexpression of presenilin holoproteins. Mouse
models expressing PS1 FAD mutants show constitutive activation of
cAMP response element binding (CREB) gene expression,which is elim-
inated by inhibition of InsP3R [115]. Furthermore, PS1 FADM146Vmu-
tant knock-in hippocampal cells showed reduced synaptic plasticity and
defects in long-termpotentiation (LTP),which can be rescued by inhibi-
tion of the RyR [99]. Conditional knockout of presenilins or expression of
the PS1 FAD M146V mutant in mouse hippocampal cells has also been
shown to increase ER Ca2+ levels and enhance susceptibility to induced
Ca2+ release [100]. These cells also showed an increase in ER RyR levels,
which the authors suggest, maybe a result of the decreased presenilin
leak channel function, leading to the increased ER Ca2+ levels and
thus a need for an increase in ER Ca2+ channel expression. Additionally,
downregulation of PS1 via inhibition of JNK or P53 has been shown to
decrease ER Ca2+ leakage without altering InsP3R expression [116].
Consistent with these mammalian studies and supportive of an evolu-
tionary conserved function, X-ray crystallography studies of a presenilin
archaeal homologue PSH have shown the presence of a hole that passes
through the protein formed from TMD2, TMD3, TMD5 and TMD7,
separate to the catalytic core of the enzyme, that is large enough to
allow small ions to pass through [117]. Despite all of these studies,
some controversies have been raised by reports of the direct measure-
ment of Ca2+ ER release from primary neurons, fibroblasts, B-cells and
hippocampal neurons [118,119], which showed no difference in ER
Ca2+ dynamics between cells expressing PS1WT and PS1 FADmutants
and that any change in ER [Ca2+] in presenilin-deficient cells was not
due to increased ER filling [118]. Therefore, while the presenilins have
been shown to be important in regulating intracellular Ca2+ via several
proposed mechanisms, as it stands the Ca2+ leak channel function
theory of the presenilins remains controversial.
6. Presenilins and Wnt/β-catenin signalling
Several groups have provided substantial data indicating that PS1
acts as a negative modulator of the transcriptional activity of the β-
catenin/Tcf-4 complex (Fig. 4) [120–122]. β-Catenin is amultifunctional
protein that was first described as a mediator of cadherin-dependent
cell adhesion. In adherens junctions β-catenin and the related protein
γ-catenin (plakoglobin) are required for recruiting the actin cytoskele-
ton. In addition to its function in cell adhesion, β-catenin is also central
to the Wnt signalling pathway. Therefore, β-catenin is a signalling
protein that links transmembrane adhesion proteins, such as the γ-
secretase substrate E-cadherin [123], with intracellular signalling path-
ways and is involved in regulating transcription in a number of anti-
apoptotic/survival pathways [124]. When released from the junction
complex β-catenin can accumulate in the cytosol and translocate to
the nucleus, where it interacts with the Tcf-family of transcription fac-
tors and positively regulates expression of several genes involved in de-
velopment and tumorigenesis. The translocation of β-catenin to the
nucleus is controlled by a GSK-3β contained protein complex that regu-
lates the phosphorylation, ubiquitination and degradation of β-catenin
[125]. Wnt signalling antagonizes the activity of the degradation com-
plex, which promotes the stabilization and nuclear translocation of β-
catenin [126,127]. Early studies identified the presenilins as binding
partners for GSK-3β and subsequent works identified three conserved
GSK-3β consensus phosphorylation sequences in PS1 and characterized
PS1 as an unprimed substrate of GSK-3β [128]. Phosphorylation of
PS1 at one of these GSK3β sites (amino acids 353–357) located regu-
lates the interaction between PS1 and β-catenin and phosphorylation
at a second site (amino acids 397–401) modulated the stability and
degradation of PS1 CTF [129,130]. Phosphorylation by GSK-3β at
Ser353 and Ser357 has also been shown to reduce the association of
PS1, N-cadherin and β-catenin and a decrease in this association
negatively affects Akt signalling [58].
While extensive biochemical data exists supporting a role for
presenilins in Wnt/β-catenin signalling, research have proposed nu-
merous mechanisms to support this role, including the interaction of
PS1 with E- and N-cadherin and β-catenin and γ-secretase activity
[120,131]. It was not until recently that PS1 has been conclusively
shown to have both γ-secretase-dependent and -independent roles in
β-catenin mediated transcription, where the PS1 holoprotein and the
processed PS1NTF/CTFheterodimers have contrasting roles inmodulat-
ing β-catenin/Tcf-4 gene transcription [37]. Earlier studies had shown
that PS1 FAD mutants inhibit Wnt signalling by increasing β-catenin
phosphorylation and degradation [132], and to induce apoptosis in neu-
ronal cells [34]. Additionally, defects in neurite growth observed in FAD
murine cells can be reduced by inhibition of β-catenin mediated gene
transcription [133]. Others demonstrated that Drosophila presenilin
(DPS) negatively regulatedWnt signalling [122], and that loss of DPS ex-
pression resulted in cytosolic accumulation of armadillo/β-catenin
[134]. Consistentwith this, conditional knockout of PS1 in keratinocytes
resulted in enhanced β-catenin/Tcf signalling and skin tumorigenesis
[121]. Some researchers proposed that the enhanced β-catenin/Tcf sig-
nalling in presenilin-deficient cells resulted from the delocalization of
GSK-3β from the cytoplasm to the endosome [94]. In subsequent stud-
ies it has been demonstrated that the inhibitor effect of PS1 holoprotein
on β-catenin signalling does not depend on the proteolytic activity of
PS1/γ-secretase or on the destabilization of β-catenin [135], but rather
a physical interaction between PS1 holoprotein and γ-catenin
(plakoglobin) and Tcf-4. Furthermore it was demonstrated that nega-
tive effect of PS1 NTF/CTF heterodimers on β-catenin/Tcf-4 transcrip-
tion was dependent upon γ-secretase activity and proteolysis of E- or
N-cadherin and the generation of ICDs, which resulted in destabilization
of the β-catenin transcriptional cofactor CBP [37]. In summary, exten-
sive evidence exists to support a γ-secretase independent role for
presenilins in Wnt/catenin signalling, however, given that presenilins
not only associates with cadherin/catenin complexes, but γ-secretase
also cleaves E-cadherin and N-cadherin adds complexity to deciphering
the precise regulatory role of presenilins in Wnt signalling [123,131].
7. Presenilins and apoptosis
Apoptosis, also known as programmed cell death, has a critically
important role in tissue homeostasis, development, normal ageing and
the pathogenesis of several diseases, including cancer and neurological
disorders. The presenilins were first linked to apoptosis when cells ex-
pressing PS1 FAD mutants were shown to have increased susceptibility
to apoptotic stimuli [136–139]. Similarly, expression of PS1 and PS2 in
HeLa cells has been shown to cause cell cycle arrest and apoptosis, a pro-
cess that is increased with the expression of PS1 and PS2 FAD mutants
[140–142]. However, primary cortical neurons from PS1 FAD P264L
mutant knock-in mice did not show increased neuron degeneration,
suggesting that not all FAD mutations promote apoptosis [143,144].
Cells undergo apoptosis through two converging pathways [145]: the
extrinsic pathway, mediated by cell surface death receptors, and the in-
trinsic pathway, which depends upon the release of pro-apoptotic
cytochrome-c from the mitochondria (Fig. 5). In the extrinsic pathway,
following ligand binding and activation of a death receptor, such as FAS
or TNFR1, recruitment of the adaptor Fas-associated protein with death
domain (FADD) and pro-caspase-8 leads to the formation of the death-
inducing signalling complex (DISC), culminating in the activation of
caspase-8, which in turn leads to the activation of effector caspase-3
and caspase-7, resulting in DNA fragmentation and programmed cell
death. In the intrinsic pathway, extracellular and intracellular stresses
lead to the activation and translocation of the pro-apoptotic Bcl-2 family
member Bax to the mitochondria. Bax thereby initiates the release of
apoptogenic factors, such as cytochrome-c, resulting in the formation
of the cytoplasmic apoptosome, consisting of Apaf-1, pro-caspase-9
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and cytochrome-c. Once activated, caspase-9 leads to the activation of
caspase-3 and caspase-7. Both pathways can converge through
caspase-8-mediated activation of Bid, which subsequently promotes
translocation of Bax to the mitochondria. Consistent with a role in cell
survival the presenilin proteins are cleaved by caspase-3 during apopto-
sis to presumably form inactive alternative NTF and CTF fragments for
each protein [54,146]. Furthermore, the presenilins have been reported
to interact with the anti-apoptotic proteins Bcl-2 and Bcl-XL and with
other apoptosis related proteins such as PS1-associated protein
(PSAP), FKBP38, Omi/HtrAS and PARL, though the physiological
relevance of these reported interactions remains to be determined
[147].
Other studies have demonstrated that increased resistance to apo-
ptosis parallels loss of PS1 expression, while murine B-cells deficient
in PS2 show an increased susceptibility to induced apoptosis [148]. Con-
sistent with this, overexpression of PS1 is able to reduce p53-mediated
apoptosis in the LTR6 mouse leukaemia cell line [149], while PS2 ex-
pression enhances apoptosis via p53 where it increases Bax expression
and reduces Bcl-2 expression [150]. This increase in apoptosis ismediat-
ed by the PS2 CTF,which increases p53mediated gene transcription in a
γ-secretase independentmanner [151]. The presenilin proteins can also
affect p53 activity in a γ-secretase dependent manner in that the pro-
duction of the APP ICD leads to increased p53 expression [152]. Recently
efforts were made to define the molecular pathways that mediate the
apoptotic effects of PS1, whereby it has been shown that PS1 regulates
apoptosis in both γ-secretase-dependent and -independent ways via
cellular-FLICE-like inhibitory protein (c-FLIP) and the PS1 associated
protein (PSAP), respectively [153]. PSAP has been shown to regulate ap-
optosis via the intrinsic apoptosis pathway, by controlling the release of
cytochrome-c from the mitochondria (Fig. 5) [154]. Silencing of Bax re-
pressed this γ-secretase-independent apoptotic pathway [153], sug-
gesting that the interaction between PS1 and PSAP plays a γ-secretase
independent role in regulating the mitochondrial apoptotic pathway.
The FKBP38 protein modulates this presenilin-mediated apoptosis, as
FKBP38 knockout cells alter Bcl-2 cell localization protecting them
from presenilin-mediated apoptosis [155]. Therefore, both presenilin
proteins can be seen to play distinct roles in regulating apoptosis,
however presenilins may indirectly regulate apoptosis through their
association with calcium homeostasis, protein degradation and
other pathways, of which the underlying molecular mechanisms are
emerging.
8. Concluding remarks
The presenilins are essential parts of the γ-secretase enzyme com-
plex and as such control the regulated intramembrane proteolysis of
over 90 transmembrane proteins. These cleavage events play important
roles in cellular differentiation, gene transcription and disease progres-
sion. In addition to its γ-secretase-dependent functions the presenilins
have a number of γ-secretase independent roles in Wnt signalling,
calcium homeostasis, protein trafficking and degradation. These γ-
secretase independent roles allow the presenilins another means to
regulate cell signalling and gene transcription through pathways such
as theβ-catenin or Akt pathways and also to affect apoptosis and the in-
flammatory response. Our understanding of the apparent broad func-
tion of presenilins and γ-secretase in biological processes has grown
significantly in the past decade and further studies will no doubt define
the precise role of presenilins, independent of and dependent upon its
role as the catalytic subunit of γ-secretase.
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a b s t r a c t
The presenilins (PS1 and PS2) are the catalytic component of the c-secretase intramembrane pro-
tease complex, involved in the regulated intramembrane proteolysis of numerous type I transmem-
brane proteins, including amyloid precursor protein (APP) and Notch. Herein, we describe the
identification and characterization of a CUE (coupling of ubiquitin conjugation to endoplasmic
reticulum degradation) ubiquitin-binding domain (UBD) in PS1, and demonstrate that the CUE
domain of PS1 mediates non-covalent binding to Lysine 63-linked polyubiquitin chains. Our results
highlight a c-secretase-independent function for non-covalent ubiquitin signaling in the regulation
of PS1, and add new insights into the structure and function of the presenilin proteins.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
The reversible covalent attachment of the 8kDa protein ubiqui-
tin (Ub) to cellular proteins, predominantly to primary amines (e-
amino groups of Lys and to the N termini of proteins) targets pro-
teins for proteasomal degradation and also facilitates several non-
proteasomal functions in the assembly, amplification and trans-
mission of intracellular signals [1–4]. Protein ubiquitination is
the culmination of a multistep process involving three classes of
enzymes, known as ubiquitin-activating enzymes (E1), ubiquitin-
conjugating enzymes (E2s), and substrate-specific ubiquitin pro-
tein ligases (E3) [4]. Proteins may be ubiquitinated on a single
lysine, resulting in monoubiquitination or on several lysine resi-
dues resulting in multiubiquitination. In addition, some E2/E3
combinations can then use lysines on the substrate-conjugated
ubiquitin to act as acceptors during sequential rounds of ubiquiti-
nation, resulting in substrate polyubiquitination [5]. Ub contains
seven lysines, which can be utilized during polyubiquitin chain
formation and depending on which of the seven lysines act as
the acceptor, the ubiquitin chains will have different types of link-
ages with diverse conformations and create a diversity of molecu-
larly distinct signals in the cell [4,6]. The range of substrate-
ubiquitin structures is important for the targeting of ubiquitinated
substrates to different fates. For example, K11- and K48-linked
polyubiquitin chains generally target proteins for proteasomal
degradation [7], while K63-linked chains can regulate kinase
activation, DNA damage tolerance, signal transduction, and endo-
cytosis [8,9].
Modulation of protein–protein interactions is an important
mechanism involved in the assembly, amplification and transmis-
sion of intracellular signals. The recognition of ubiquitin and
polyubiquitin chains by ubiquitin-binding domains (UBDs) is criti-
cal for determining the outcome of ubiquitination and subsequent
ubiquitin-mediated signaling pathways [2]. To date, approximately
20 different UBDs have been identified, including ubiquitin inter-
acting motifs (UIMs), ubiquitin associated domains (UBAs) and
the related coupling of ubiquitin conjugation to endoplasmic
reticulum degradation (CUE) domains [10–12]. The UBA and CUE
domains are similar in size, approximately 40 residues, and show
a common structural homology consisting of a three helical bundle
[10]. The CUE domain was initially characterized as an ubiquitin-
binding motif and named for the yeast Cue1p protein, which is
essential for the targeting of ubiquitinated protein to degradation
pathways [13–15]. Functional studies subsequently revealed that
CUE domains promote the ubiquitination of the proteins that
http://dx.doi.org/10.1016/j.febslet.2015.03.008
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contain it [15]. Since then, CUE domains have also been reported to
contribute to the stability and specificity of the CUE–ubiquitin
complex, and moreover that CUE domain containing proteins play
an important role in stabilizing its binding partner [16,17]. The CUE
domain of other proteins has been shown to mediate interactions
between ubiquitin and CUE domain containing proteins, which
facilitates their monoubiquitination [18–20].
The presenilins, PS1 and PS2, are highly conserved transmem-
brane proteins that are synthesised as 50kDa holoproteins that
undergo endoproteolysis to generate heterodimeric presenilin N-
terminal and C-terminal fragments (NTF/CTF) that form the cat-
alytic subunit of the c-secretase protease complex. Initially
characterized as a protease responsible for the cleavage of amyloid
precursor protein (APP) and the generation of amyloid-b peptides,
the c-secretase protease is now known to be responsible for the
cleavage of numerous type I transmembrane proteins associated
with several developmental and cellular processes, including the
Notch receptor, ErbB4, Cadherins, Insulin-like growth factor recep-
tor (IGFR1) [21] and the interleukin-1 receptors, IL-1RI [22,23] and
IL-1RII [24]. In addition to the well-researched role of presenilins
as the catalytic core of the c-secretase protease, the involvement
of presenilin holoproteins in the regulation of intracellular calcium
homeostasis has become a focus of presenilin and Alzheimer’s dis-
ease research [25–28].
Critical to the complexity of presenilin-associated activities, PS1
and PS2 are differentially controlled by post-translational mod-
ifications including endoproteolysis, caspase cleavage, phospho-
rylation and ubiquitination [29]. These modifications determine
subcellular localisation [30], selectivity of binding-partners, rate
of protein turnover [31] and c-secretase protease activity [32,33].
PS1 is ubiquitinated by SEL-10 and tumor necrosis factor receptor
associated factor 6 (TRAF6), which regulate c-secretase activity
and calcium homeostasis [34], respectively. Here we report the
identification and characterization of a ubiquitin binding CUE
domain in PS1, which facilitates the binding of PS1 to K63-linked
polyubiquitin chains.
2. Materials and methods
2.1. Cell culture and transfection
HEK293T and presenilin-deficient murine embryonic fibrob-
lasts (MEFs) cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM-21) supplemented 10% fetal bovine serum at
37 C. Transfection of HEK293T and MEFs was performed using
the calcium phosphate precipitation method and TurboFect™
(BioRad Laboratories), respectively.
2.2. Expression vectors construction
The pcDNA3.1-PS1 expression construct was described pre-
viously [35,36]. PS1DCUE, PS1F283A/P284A and PS1V309A/
S310A, were generated by site-directed mutagenesis using
QuickChange Site Directed Mutagenesis Kit (Stratagene) and the
following primers: PS1DCUE: GATTTAGTGGCTTATAATGCAGAA
AGCACAGAA (sense) and TTCTGCATTATAAGCCACTAAATCATATAC
TGA (antisense); PS1: CGGGGTACCGCCATGACAGAGTTACCTGCA
CCGTTGTCC (sense) and CCGGAATTCCTAGATATAAAATTGATGGA
ATGCTAATTG (antisense); PS1F283A/P284A: GAGAAATGAAACGCT




of mutated sites are underlined. GST-fusion proteins, GST-PS1
loop domain (residues 265–380), GST-PS1F283A/P284A and
GST-PS1V309A/S310A loop domain mutants were amplified by
PCR (KOD polymerase, Novagen) using CGGGGATCCGCCGTTTT
GTGTCCGAAAGGT (sense) and CCGGAATTCCTATTTTACTCCCCTTT
CCTC (antisense) and subcloned into pGEX-6P-1 GST expression
vector (GE Healthcare). HA-ubiquitin, HA-ubiquitin K48only and
HA-ubiquitin K63only were a generous gift from Dr. R. Carmody
(University of Glasgow). HA-P62 was a gift from Prof. Jorge
Moscat & Dr. Marie Wooten (Sanford Burnham Medical research
Institute, CA), and the HA-P62 F406V mutant was generated by
site-directed mutagenesis using previously published primer pairs
[37]. The NEXT (Notch extracellular truncation) expression plasmid
was a gift from Raphael Kopan (Washington University) [38].
APP-CT100 was a gift from Scios Inc.
2.3. Western blot analysis
Total or immunoprecipitated protein extracts were obtained
from cells 24–48 h after transfection with specific plasmids. Cells
were lysed (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.1%
Nonidet P-40, 1 mM sodium orthovanadate and protease inhibitor
mixture (Complete™, Roche Molecular Biochemicals)) and protein
concentrations in the extracts were measured with a bicinchoninic
acid assay (Pierce). Equal amounts of extracts were resolved on 6%,
10%, 12% or 15% SDS–PAGE and transferred to nitrocellulose mem-
brane. Immunoblot analysis was performed with anti-PS1 NTF
[39], anti-PS1-NTF (Chemicon), anti-HA (Covance), anti-APP
(Sigma Aldrich), anti-Ubiquitin (P4D1, Santa Cruz Biotechnology),
anti-b-actin (Sigma Aldrich) and anti-cleaved Notch 1 (Val 1744)
(Cell Signaling Technology) antibodies, followed by incubation
with secondary horseradish peroxidase-labeled anti-mouse, anti-
rabbit (Dako), or infrared secondary antibodies IRDye 800 Goat
Anti-Rabbit IgG or IRDye 800CW Goat Anti-Mouse IgG (Licor
Biosciences).
2.4. In vitro ubiquitin binding assay
For the whole-cell ubiquitin binding studies, cells expressing
the indicated proteins were lysed under stringent denaturing con-
ditions and immunopurified with anti-P62, or PS1 antibodies and
protein G-sepharose beads (Invitrogen) and subsequently washed
3 times with covalent buffer (50 mM Tris (pH 8.0), 150 mM NaCl,
1% Triton, 0.1% SDS, 0.5% sodium deoxycholate, 15 mM NEM and
protease inhibitors) and once with binding buffer (20 mM Tris–
HCl (pH 7.6), 50 mM NaCl, 0.1% NP40, 0.5 mM dithiothreitol,
1 mM phenylmethylsulfonyl fluoride). Samples were incubated
overnight at 4 C in binding buffer with 5 lg of polyubiquitin
(K48- or K63-linked) (Boston Biochem), washed with binding buf-
fer and loaded onto a 10% SDS–PAGE, recombinant polyubiquitin
(K48- or K63-linked) (1 lg) was used as a positive control, fol-
lowed by Western blotting analysis using an antibody directed
against ubiquitin (P4D1, Santa Cruz Biotechnology).
For the in vitro ubiquitin binding assays, recombinant (20 lg)
GST-PS1 loop domain, GST-PS1F283A/P284A or GST-PS1V309A/
S310A loop domain mutants were immobilized onto glutathione
agarose beads (Sigma Aldrich) and incubated with 800 lg total
protein extracted from HEK293T cells, either non-transfected or
overexpressing HA-Ub-K48only or HA-Ub-K63only lysed in binding
buffer. Samples were incubated overnight at 4 C, washed in bind-
ing buffer and loaded onto SDS–PAGE followed by Western blot-
ting analysis with an antibody directed against ubiquitin (P4D1,
Santa Cruz Biotechnology).
2.5. Expression and purification of GST-tagged recombinant proteins
The pGEX-6P-1 GST-PS1 loop domain (residues 265-380),
pGEX-6P-1 GST-PS1F283A/P284A and pGEX-6P-1 GST-PS1V309A/
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S310A loop domain mutant expression plasmids were introduced
into the Escherichia coli strain BL21-CodonPlus (DE3)-RIL
(Stratagene) for recombinant protein expression. Induction of
expression, glutathione agarose affinity chromatography and puri-
fication of the recombinant proteins was performed using pre-
viously established methods [40]. The purity and molecular
weight of the recombinant protein samples were analyzed by
SDS–PAGE. The protein concentration was determined from UV
absorbance at 280 nm.
2.6. ELISA for Ab40 and Ab42
HEK293T cells were transfected by calcium phosphate precip-
itation with indicated constructs. Thirty-six hours after transfec-
tion, cell culture medium was collected for ELISA analysis and
cells were subjected to Western blotting. ELISA kits for Ab40
and Ab42 were purchased from Invitrogen (#KHB3481 and
#KHB3441). ELISA analyses were carried out according to the
manufacturer’s protocol.
2.7. Statistical analysis
Microsoft Excel was used for the statistical analysis. Data are
shown as means + standard error (S.E.M.) of replicate samples in
at least three independent experiments. Student’s t-test was used
to test comparisons between two groups. A value of p < 0.05 was
considered statistically significant.
3. Results
3.1. Presenilins contain a highly conserved putative CUE ubiquitin-
binding domain
To further examine the posttranslational modification of prese-
nilins, the amino acid sequences of PS1 and PS2 hydrophilic loop
domains were analyzed by sequence analysis. This revealed a
low-homology between the hydrophilic loop domain of PS1 and
the CUE ubiquitin-binding domain of several proteins (Fig. 1). A
sequence alignment of the hydrophilic loop domain of PS1 and
PS2 with several known CUE domains revealed a high conservation
of a methionine–phenylalanine–proline and to a lesser extent a di-
leucine motif, characteristic of CUE ubiquitin-binding domains, as
well as a number of other hydrophobic residues thought to be
important for non-covalent interaction with ubiquitin (Fig. 1B). A
sequence alignment of this region of PS1 among several species
demonstrates strong evolutionary conservation of the sequence
surrounding and including the phenylalanine–proline motif and a
weaker conservation of the sequence containing the PS1 valine–
serine sequence which corresponds to the position of the di-leucine
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Presenilinase cleavage: PS1 M292/V293




Human      PS1 (271-314)    LVETAQERNETLFPALIYSSTMVWLVNMAEGDPEAQRRVSKNSK 
Zebrafish  PS1 (260-303)    LVETAQERNEAIFPALIYSSTMVWLFNMADSAETRNNSSHPVPQ 
Drosophila PS1 (293-336)    LVETAQERNEQIFPALIYSSTVVYALVNTVTPQQSQATASSSPS 
C. elegans Sel12 (240-283)  LVETAQERNEPIFPALIYSSGVIYPYVLVTAVENTTDPREPTSS 
X. laevis  PS1 (237-280)    LVETAQERNETLFPALIYSSTMIWLVNMADGDPGLKQSASTKTY 


























Fig. 1. Presenilins contain a putative CUE ubiquitin-binding domain. (A) Schematic of the Presenilin-1 (PS1) protein indicating the proposed transmembrane domains,
hydrophilic loop domain and putative CUE domain. (B) A sequence alignment of the amino acid sequence of presenilins with several known CUE domains. Residues
highlighted in black are identical; residues in dark gray are similar; boxed residues are weakly similar. Consensus sequence is shown below the alignment and position of CUE
domain FP and LL motifs are indicated with asterisks. The JNet bioinformatics tool predicted that the putative CUE domains of PS1 and PS2 contain three consecutive a-
helices, indicated above sequence alignment. (C) A sequence alignment of the hydrophilic loop domain of PS1 from several species demonstrates high conservation of this
region. Highly conserved amino acid residues known to be important for non-covalent interaction with ubiquitin are highlighted. Alignments were carried out with AlignX
software.
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domain is structurally related to the ubiquitin binding UBA domain
and is comprised of a three-helix bundle. Using JNET, www.comp-
bio.dundee.ac.uk [41], secondary protein structure prediction soft-
ware, the putative CUE domains of PS1 and PS2 were predicted to
contain three consecutive a-helices, with the conserved methion-
ine–phenylalanine–proline residues located close to a-helix 1 and
the PS1 valine–serine sequence residing in ahelix 3 (Fig. 1B).
Given that this sequence conservation and predicted structural
arrangement are shared by the putative CUE domain of presenilins
and several other CUE domains, it supports our hypothesis that the
newly identified CUE domain in presenilins may mediate interac-
tions between presenilins and ubiquitinated substrates.
3.2. Presenilins non-covalently interact with K63-linked polyubiquitin
To determine whether presenilins interact non-covalently with
ubiquitin and contain functional CUE ubiquitin-binding domains,
HEK293T cells were transfected with pcDNA3.1, pcDNA3.1-PS1 or
pcDNA3.1-PS1DCUE (Fig. 2A), and 24 h post-transfection cells
were harvested under denaturing conditions and the cell lysates
were immunoprecipitated with an anti-PS1 antibody. The
immunoprecipitates were then incubated overnight with recombi-
nant lysine 63 (K63)-linked or lysine 48 (K48)-linked polyubiquitin
and after stringent washing ubiquitin-binding was determined by
western blotting. Our data demonstrates that PS1 has a preference
for binding K63-linked over K48-linked polyubiquitin chains
(Fig. 2A). In contrast, no binding to K63-linked polyubiquitin to
PS1 was observed in the PS1DCUE mutant. Loading control for
recombinant lysine 63 (K63)-linked or lysine 48 (K48)-linked
polyubiquitin used in experiment is indicated (Fig. 2A, right panel).
To validate the in vitro ubiquitin-binding assay employed in these
studies, the ability of PS1 to bind polyubiquitin was compared to
that of P62/sequestosome 1, which contains a functional UBA
domain that binds to K63-linked polyubiquitin [42]. A single point
mutation within the UBA domain of P62, P62F406V, abolishes ubi-
quitin binding to the P62 UBA domain. Consistent with previous
studies, wild type P62 but not P62F406V bound to K63-linked
polyubiquitin (Fig. 2B). Loading control for recombinant lysine 63
(K63)-linked polyubiquitin used in experiment is indicated
(Fig. 2B, right panel). Together these results demonstrate that PS1
contains a functional ubiquitin-binding domain that has a prefer-
ence for binding K63-linked polyubiquitin.
Based on sequences predicted to be important for ubiquitin
binding to other CUE domains, we used a site-directed mutagene-
sis approach to generate mammalian expression constructs of the
PS1 CUE missense mutants PS1F283A/P284A and PS1V309A/
S310A. Previous studies demonstrated that mutation of the con-
served methionine–phenylalanine–proline and di-leucine motifs
reduce the ability of the CUE domain of specific proteins to interact
with ubiquitin [43]. JNet secondary structure prediction analysis
revealed that the triple helical super-secondary structure of the
CUE domain should not be disrupted by these mutations (data
not shown). HEK293T cells were transiently transfected with equal
quantities of pcDNA3.1 (Vector), wild type PS1, PS1DCUE,
PS1F283A/P284A or PS1V309A/S310A. The PS1 proteins were iso-
lated using immunoprecipitation and were then incubated with
recombinant K63-linked polyubiquitin (Fig. 3A). Western blotting
analysis revealed that wild-type PS1 and the PS1 F283A/P284A
mutant bound to ubiquitin, while in contrast the PS1DCUE and
PS1V309A/S310A mutants had reduced interaction with K63-
linked polyubiquitin (Fig. 3A). These results suggest that the K63-
linked polyubiquitin binding capability of the putative CUE of
PS1 is mediated by the VS sequence, while the FP motif does not
appear to be as important in PS1 binding to K63-linked polyu-
biquitin as it shows a similar level of ubiquitin-binding as wild-
type PS1.
To further examine the ubiquitin binding ability of the PS1 CUE
domain, three GST-tagged recombinant proteins were created: a
GST-PS1 loop domain protein (residues 265–280) containing the
CUE domain, GST-PS1F283A/P284A and GST-PS1V309A/S310A
loop domain mutants. The recombinant proteins were bound to
glutathione agarose beads and then incubated with cell lysate from
cells overexpressing HA-ubiquitin K63only, a ubiquitin mutant that
can only form K63-linked polyubiquitin chains within cells [44].
GST protein was used as negative control for this experiment.
The resulting samples were run on a 10% SDS–PAGE gel and the
presence of bound ubiquitin was detected by immunoblotting for
HA. Consistent with data presented (Fig. 3A), the GST-PS1 loop
domain fusion protein and GST-PS1F283A/P284A mutant bound
to K63-linked polyubiquitin, while the GST-PS1V309A/S310A loop
domain mutant lost the ability to bind K63-linked polyubiquitin
(Fig. 3B). To verify PS1 selectivity for binding to K63-linked ubiqui-
tin in our in vitro assay, next, recombinant GST-PS1 loop domain
protein and GST-PS1V309A/S310A mutant were bound to glu-
tathione agarose beads and then incubated with cell lysate from
cells overexpressing ubiquitin K48only or ubiquitin K63only,
(Fig. 3C). Again, the GST-PS1 loop domain fusion protein selectively
bound to K63-linked polyubiquitin and not K48-linked polyu-
biquitin, while the GST-PS1V309A/S310A mutant lost the ability









































































Fig. 2. Presenilins selectively interact with K63-linked polyubiquitin. HEK293T
cells expressing wild type or mutant (A) PS1 (B) P62 were lysed under stringent
denaturing condition, immunopurified and incubated with 5 lg of recombinant
K48-linked or K63-linked polyubiquitin, and bound proteins resolved by SDS–PAGE
and immunoblotted with antibodies against ubiquitin (PD41), PS1 or P62. Loading
control for recombinant lysine 63 (K63)-linked (1 lg) or lysine 48 (K48)-linked
polyubiquitin (1 lg) used in experiments is also indicated (right panels). IP,
immunoprecipitated; WB, Western blot; HC, IgG heavy chain; LC, IgG light chain.
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3.3. Presenilins CUE domain is dispensable for c-secretase activity
Next we determined if the CUE domain was required for prese-
nilin endoproteolysis and c-secretase activity. Given that the CUE
domain (residues 271–314) of PS1 is located within the large
hydrophilic loop domain and spans the sites of presenilin
endoproteolysis (PS1 Met292/Val293) [32,45], we examined the
possible involvement of the putative CUE domain in endoproteoly-
sis of PS1 by deletion of the entire CUE domain from PS1
(PS1DCUE) and mutagenesis of the two conserved motifs within
the PS1 CUE domain (PS1F283A/P284A and PS1V309A/S310A).
Presenilin double knockout murine embryonic fibroblasts were
transfected with expression constructs directing the synthesis of
wild-type PS1, catalytically inactive PS1D257A/D385A (PS1DAsp)
mutant, CUE domain deletion mutant PS1DCUE, or CUE domain
point mutants PS1F283A/P284A or PS1V309A/S310A. Cell lysates
were immunoblotted with anti-PS1 NTF antibody (Fig. 4A). As
anticipated, expression of the catalytically inactive PS1D257A/
D385A (PS1DAsp) mutant, or deletion of PS1 CUE domain pre-
vented the endoproteolysis of PS1, and abolished the formation
of PS1 endoproteolytic NTF fragment (Fig. 4A). However, expres-
sion of the PS1 CUE domain point mutants PS1F283A/P284A and
PS1V309A/S310A had no effect on PS1 endoproteolysis and forma-
tion of PS1 NTF fragment.
Presenilin holoprotein undergoes endoproteolysis into NTF/CTF
heterodimers and has been predominantly studied as a component
of the c-secretase protease complex involved in the regulated
intramembrane proteolysis of APP, Notch and several other type I
integral membrane proteins [46]. We next measured c-secretase
activity in cells expressing CUE mutants by studying the cleavage
of a truncated APP mutation (APP CT100-FLAG), which corresponds
to the b-secretase generated APP C99 C-terminus fragment, which
is a constitutive substrate for c-secretase protease. First, HEK293T
cells, were transiently transfected with APP CT100-FLAG plasmid
and co-transfected with pcDNA3.1 (Vector), PS1, PS1DCUE
PS1F283A/P284A or PS1V309A/S310A and cell lysates were sub-
jected to Western blot analysis with an anti-APP C-terminus-speci-
fic antibody (Fig. 4B). In cells expressing PS1, overexpressed APP
C99-FLAG fragment is clearly detected (Fig. 4B, lane 3). In cells
expressing PS1 and treated with the c-secretase inhibitor,
Compound E, accumulation of overexpressed APP C99-FLAG and
endogenous APP C99 fragments are clearly detected (Fig. 4B, lane
4). In contrast, expression of PS1 CUE mutants did not alter levels
of exogenous APP C99-FLAG nor endogenous APP C99 C-terminal
fragment, which indicates that CUE domain deletion does not
induce a major change in c-secretase activity (Fig. 4B). To further
confirm the result with a more sensitive method, cell culture med-
ium was collected after transfection and tested using ELISA to mea-
sure the concentration of Ab40 and Ab42 (Fig. 4C). Results showed
that CUE domain deletion or mutagenesis does not induce signifi-
cant change in the generation of soluble Ab40 and Ab42. To further
validate this observation, PS1-deficient MEFs were transiently
transfected with pcDNA3 (Vector), PS1, PS1DCUE PS1F283A/
P284A or PS1V309A/S310A and cell lysates were analyzed for
endogenous APP C99, by Western blotting with an APP C-termi-
nus-specific antibody (Fig. 4D). Again, expression of the CUE
mutants had no effect on levels of endogenous APP C99, whereas
treatment with the c-secretase inhibitor Compound E (lane 3)
caused the accumulation of the APP C99 fragment, again demon-
strating that loss of or mutagenesis of the PS1 CUE domain does
not significantly alter c-secretase cleavage of APP.
To further examine the functionality of the PS1 CUE domain in
the cleavage of c-secretase substates. HEK293T cells, were tran-
siently transfected with NEXT, a Notch construct that is con-
stitutively cleaved by c-secretase, and co-transfected with
pcDNA3 (Vector), wild-type PS1, PS1DCUE, PS1F283A/P284A or
PS1V309A/S310A. Twenty-four hours post-transfection cell lysates
were prepared and subjected to Western blot analysis with an anti-
cleaved Notch 1 specific antibody (Fig. 4E). In cells expressing PS1,
robust generation of NICD was evident (Fig. 4E, lane 3), while in
cells treated with the c-secretase inhibitor, compound E (CpdE)
(Fig. 4E, lane 4) formation of NICD was inhibited. In contrast, in
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Fig. 3. Disruption of the PS1 CUE domain impairs binding to K63-linked polyu-
biquitin. (A) HEK293T cells expressing pcDNA3.1 (Vector), wild type PS1, PS1DCUE,
PS1F283A/P284A or PS1V309A/S310A were lysed under stringent denaturing
conditions, immunopurified with an anti-PS1 antibody and incubated with 5 lg
of recombinant K63-linked polyubiquitin, and bound proteins resolved by SDS–
PAGE and immunoblotted with antibodies against ubiquitin (PD41) or PS1. (B)
Bacterially purified recombinant GST, GST-PS1 (loop domain), GST-PS1F283A/
P284A and GST-PS1V309A/S310A were conjugated to glutathione agarose beads
and incubated with cell lysates from HEK293 cells transiently expressing HA-Ub-
K63only expression plasmid. Bound proteins were resolved by SDS–PAGE and
immunoblotted with antibodies against HA or PS1. (C) Bacterially purified
recombinant GST, GST-PS1 (loop domain) and GST-PS1V309A/S310A mutant were
conjugated to glutathione–agarose beads and incubated with HEK293 cell lysates
from cells transiently expressing either HA-Ub-K48only or HA-Ub-K63only expression
plasmid. Bound proteins were resolved by SDS–PAGE and immunoblotted with
antibodies against HA or PS1. IP, Immunoprecipitated; WB, Western blot; HC, IgG
heavy chain.
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NICD formation is still observed. This data shows that deletion of
the CUE domain of PS1 or mutagenesis of key motifs within the
PS1 CUE domain has no effect on the c-secretase mediated cleav-
age of Notch.
4. Discussion
Here we describe the presence of a CUE ubiquitin-binding
domain in the hydrophilic loop domain of presenilins, which facili-
tates an interaction between PS1 and K63-linked polyubiquitin
chains. Despite the significant importance of presenilins as the
catalytic component of c-secretase protease complexes, its struc-
ture and posttranslational regulation are poorly understood. In
addition to endoproteolysis, presenilins are also regulated by
diverse posttranslational modifications including phosphorylation
[39,47,48] and ubiquitination [31,34], which alter the functions
of presenilins and their interaction with other proteins [29].
These modifications are not only essential for the stability and
activation of presenilins, but are also important for the protease
assembly and activity of c-secretase complexes. For instance,
SEL-10, a member of the SCF (Skp1-Cdc53/CUL1-F-box protein)






























+ ++ - - --



























































































































































+ ++ - - --








Fig. 4. Presenilins CUE domain is dispensable for c-secretase activity. (A) Western blot analysis of total cell lysates from presenilin-deficient MEFs transiently expressing
pcDNA3.1 (Vector) wild type PS1, catalytically inactive PS1D257A/D385A (PS1DAsp) mutant, PS1DCUE, PS1F283A/P284A or PS1S310A/V309A. (B) HEK293T cells were
transfected with APP CT100-FLAG and co-transfected with pcDNA3.1 (Vector) wild type PS1, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A. Twelve hours after transfection,
selected cell cultures were treated with Compound E (50 nM) as indicated. Cells were harvested 24 h after transfection and lysates were subjected to western blot analysis
with anti-APP, anti-PS1 and anti-b-actin antibodies. (C) Culture medium was collected from HEK293T cells transfected with APP CT100-FLAG and co-transfected with
pcDNA3.1 (Vector) wild type PS1, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A, and subjected to ELISA for Ab40 and Ab42. Data is presented by means ± S.E.M. of three
independent experiments. p < 0.05 was considered statistically significant. (D) Western blot analysis of cell lysates from presenilin-deficient MEFs transiently expressing
pcDNA3.1 (Vector) wild type PS1, PS1D257A/D385A, PS1DCUE, PS1F283A/P284A or PS1S310A/V309A. (E) HEK293T cells were transfected with NEXT expression plasmid and
co-transfected with pcDNA3.1 (Vector) wild type PS1, PS1D257A/D385A, PS1DCUE, PS1F283A/P284A or PS1V309A/S310A. Twelve hours after transfection selected cell
cultures were treated with Compound E (50 nM) as indicated. Cells were harvested 24 h after transfection. Lysates were subjected to SDS–PAGE and immunoblotted with
anti-cleaved Notch, anti-PS1 and anti-b-actin antibodies.
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enhance PS1 ubiquitination, and alter the cellular levels of PS1
holoprotein and its NTF/CTF heterodimers [34]. In contrast, we
have also reported the ubiquitination of PS1 and PS2 by another
E3 ligase, tumor necrosis factor receptor-associated factor 6
(TRAF6) [35], which alters the stability of PS1 holoprotein and its
function in the regulation of calcium homeostasis, independent
of c-secretase protease activity.
Thus, the identification of a CUE domain represents an impor-
tant advancement in the understanding of the posttranslational
activity in these biologically and therapeutically important pro-
teins. The CUE domain is structurally related to the ubiquitin-bind-
ing UBA domain and is strictly comprised of a three-helix bundle
structure (Fig. 1). However, the amino acid sequence of CUE
domains does differ from the consensus amino acid sequence, sug-
gesting that the structural integrity of the CUE domain rather that
amino acids sequence is the primary determinant for interaction
with different ubiquitin modifications. Within the CUE domain, a
conserved MFP motif in a-helix1 and a less conserved LL motif in
a-helix 3 have been shown to enable interaction with the con-
served hydrophobic patch of ubiquitin. While deletion of the entire
PS1 CUE domain abolished binding to ubiquitin, mutation of the
MFP motif in PS1 did not significantly disrupt interaction with ubi-
quitin. However, mutagenesis of the PS1 VS sequences that corre-
sponds to the LL motif in a-helix 3 did disrupt binding to ubiquitin.
It was surprising that mutation of the MFP motif in PS1 did not dis-
rupt interaction with ubiquitin, as is the case for many published
CUE domain-containing proteins. These discrepancies suggest that
the PS1 CUE domain may bind to ubiquitin in a different manner.
Site-directed mutagenesis and deletion of residues predicted to
have an important role in non-covalent ubiquitin binding [43]
revealed and highlight the biological importance of this domain
in presenilins. First, using the CUE domain deletion and missense
CUE mutants demonstrated loss in ability of PS1 to selectively bind
to K63-linked polyubiquitin chains. Second, missense CUE mutants
that prevented binding to ubiquitin, did not affect endoproteolysis
of PS1, suggesting that formation of PS1NTF/CTF heterodimers does
not require an intact CUE domain, but suggest that the presence of
the CUE domain may be important for a PS1 holoprotein function.
Third, mutation of the CUE domain did not alter PS1-dependent c-
secretase cleave of APP or Notch, nor generation of Ab40/42 pep-
tides, suggesting that the PS1 CUE domain is not necessary for c-
secretase activity.
Recognition of ubiquitin and polyubiquitin chains by ubiquitin-
binding domains (UBDs) is vital for ubiquitin-mediated signaling
pathways [9]. The presenilins regulate critical proteins and bio-
logical functions via c-secretase dependent and independent
mechanisms [49]. Based on other studies that have elucidated
the function of CUE domains on other proteins, the presence of
the CUE domain in presenilins leads to at least three possible func-
tions of this CUE domain; ubiquitination of presenilin enables the
CUE domain to recognize and non-covalently interact with prese-
nilin itself (intraprotein interaction); ubiquitination of presenilin
leads to the formation of a presenilin homodimer enabled by inter-
action between the CUE domain and ubiquitinated presenilin on
an adjacent holoprotein, or the CUE domain of presenilins facili-
tates its interaction with other ubiquitin-modified proteins (inter-
protein interaction).
Taken together our results highlight a function for non-covalent
ubiquitin signaling in the regulation of the presenilins, add new
insight into the structure and function of the presenilins and have
important implications for cell signaling and Alzheimer’s disease.
Acknowledgements
This work was supported and funded by grants from the Irish
Research Council for Science, Engineering and Technology (RS/
2009/1245) and (RS/2012/407) and Science Foundation Ireland
(09/IN.1/B2624). We thank B. de Strooper (KU Leuven, Belgium)
for the PS deficient MEFs, R. Carmody (University of Glasgow),
Prof. Jorge Moscat & Dr. Marie Wooten (Sanford Burnham
Medical research Institute, CA), Prof. Raphael Kopan (Washington
University) and Scios Inc. for plasmids. We thank members of the
Signal Transduction Laboratory for experimental assistance and
helpful discussion.
References
[1] Dikic, I. and Dotsch, V. (2009) Ubiquitin linkages make a difference. Nat. Struct.
Mol. Biol. 16, 1209–1210.
[2] Grabbe, C. and Dikic, I. (2009) Functional roles of ubiquitin-like domain (ULD)
and ubiquitin-binding domain (UBD) containing proteins. Chem. Rev. 109,
1481–1494.
[3] Kulathu, Y., Akutsu, M., Bremm, A., Hofmann, K. and Komander, D. (2009) Two-
sided ubiquitin binding explains specificity of the TAB2 NZF domain. Nat.
Struct. Mol. Biol. 16, 1328–1330.
[4] Komander, D. and Rape, M. (2012) The ubiquitin code. Annu. Rev. Biochem. 81,
203–229.
[5] Nagy, V. and Dikic, I. (2010) Ubiquitin ligase complexes: from substrate
selectivity to conjugational specificity. Biol. Chem. 391, 163–169.
[6] Komander, D. (2009) The emerging complexity of protein ubiquitination.
Biochem. Soc. Trans. 37, 937–953.
[7] Thrower, J.S., Hoffman, L., Rechsteiner, M. and Pickart, C.M. (2000) Recognition
of the polyubiquitin proteolytic signal. EMBO J. 19, 94–102.
[8] Passmore, L.A. and Barford, D. (2004) Getting into position: the catalytic
mechanisms of protein ubiquitylation. Biochem. J. 379, 513–525.
[9] Chen, Z.J. and Sun, L.J. (2009) Nonproteolytic functions of ubiquitin in cell
signaling. Mol. Cell 33, 275–286.
[10] Hurley, J.H., Lee, S. and Prag, G. (2006) Ubiquitin-binding domains. Biochem. J.
399, 361–372.
[11] Ikeda, F. and Dikic, I. (2008) Atypical ubiquitin chains: new molecular signals.
‘Protein modifications: beyond the usual suspects’ review series. EMBO Rep. 9,
536–542.
[12] Winget, J.M. and Mayor, T. (2010) The diversity of ubiquitin recognition: hot
spots and varied specificity. Mol. Cell 38, 627–635.
[13] Ponting, C.P. (2000) Proteins of the endoplasmic-reticulum-associated
degradation pathway: domain detection and function prediction. Biochem. J.
351 (Pt 2), 527–535.
[14] Biederer, T., Volkwein, C. and Sommer, T. (1997) Role of Cue1p in
ubiquitination and degradation at the ER surface. Science 278, 1806–1809.
[15] Shih, S.C., Prag, G., Francis, S.A., Sutanto, M.A., Hurley, J.H. and Hicke, L. (2003)
A ubiquitin-binding motif required for intramolecular monoubiquitylation,
the CUE domain. EMBO J. 22, 1273–1281.
[16] Kang, R.S., Daniels, C.M., Francis, S.A., Shih, S.C., Salerno, W.J., Hicke, L. and
Radhakrishnan, I. (2003) Solution structure of a CUE-ubiquitin complex
reveals a conserved mode of ubiquitin binding. Cell 113, 621–630.
[17] Zhang, P.J., Zhao, J., Li, H.Y., Man, J.H., He, K., Zhou, T., Pan, X., Li, A.L., Gong,
W.L., Jin, B.F., Xia, Q., Yu, M., Shen, B.F. and Zhang, X.M. (2007) CUE domain
containing 2 regulates degradation of progesterone receptor by ubiquitin-
proteasome. EMBO J. 26, 1831–1842.
[18] Davies, B.A., Topp, J.D., Sfeir, A.J., Katzmann, D.J., Carney, D.S., Tall, G.G.,
Friedberg, A.S., Deng, L., Chen, Z. and Horazdovsky, B.F. (2003) Vps9p CUE
domain ubiquitin binding is required for efficient endocytic protein traffic. J.
Biol. Chem. 278, 19826–19833.
[19] Shih, S.C., Prag, G., Francis, S.A., Sutanto, M.A., Hurley, J.H. and Hicke, L. (2003)
A ubiquitin-binding motif required for intramolecular monoubiquitylation,
the CUE domain. EMBO J. 22, 1273–1281.
[20] Chen, B., Mariano, J., Tsai, Y.C., Chan, A.H., Cohen, M. and Weissman, A.M.
(2006) The activity of a human endoplasmic reticulum-associated degradation
E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc.
Natl. Acad. Sci. U.S.A. 103, 341–346.
[21] McElroy, B., Powell, J.C. and McCarthy, J.V. (2007) The insulin-like growth
factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated
intramembrane proteolysis. Biochem. Biophys. Res. Commun. 358, 1136–
1141.
[22] Elzinga, B.M., Twomey, C., Powell, J.C., Harte, F. and McCarthy, J.V. (2009)
Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent
regulated intramembrane proteolysis. J. Biol. Chem. 284, 1394–1409.
[23] Twomey, C., Qian, S. and McCarthy, J.V. (2009) TRAF6 promotes ubiquitination
and regulated intramembrane proteolysis of IL-1R1. Biochem. Biophys. Res.
Commun. 381, 418–423.
[24] Kuhn, P.H., Marjaux, E., Imhof, A., De Strooper, B., Haass, C. and Lichtenthaler,
S.F. (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor
II by alpha-, beta-, and gamma-secretase. J. Biol. Chem. 282, 11982–11995.
[25] Honarnejad, K. and Herms, J. (2012) Presenilins: role in calcium homeostasis.
Int. J. Biochem. Cell Biol. 44, 1983–1986.
[26] Honarnejad, K., Jung, C.K., Lammich, S., Arzberger, T., Kretzschmar, H. and
Herms, J. (2013) Involvement of presenilin holoprotein upregulation in
calcium dyshomeostasis of Alzheimer’s disease. J. Cell Mol. Med. 17, 293–302.
S.P. Duggan et al. / FEBS Letters 589 (2015) 1001–1008 1007
[27] Supnet, C. and Bezprozvanny, I. (2010) The dysregulation of intracellular
calcium in Alzheimer disease. Cell Calcium 47, 183–189.
[28] Zhang, H., Sun, S., Herreman, A., De Strooper, B. and Bezprozvanny, I. (2010)
Role of presenilins in neuronal calcium homeostasis. J. Neurosci. J. Soc.
Neurosci. 30, 8566–8580.
[29] Yan, R. and McCarthy, J.V.. (2010) Presenilin and c-secretase activity: a viable
therapeutic target For Alzheimer’s disease? Curr. Signal Transduct. Ther. 5,
128–140.
[30] Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Ando, K., Shimohama, S. and
Kinoshita, A. (2007) GSK3beta activity modifies the localization and function
of presenilin 1. J. Biol. Chem. 282, 15823–15832.
[31] Massey, L.K., Mah, A.L. and Monteiro, M.J. (2005) Ubiquilin regulates
presenilin endoproteolysis and modulates gamma-secretase components,
Pen-2 and nicastrin. Biochem. J. 391, 513–525.
[32] Jacobsen, H., Reinhardt, D., Brockhaus, M., Bur, D., Kocyba, C., Kurt, H., Grim,
M.G., Baumeister, R. and Loetscher, H. (1999) The influence of endoproteolytic
processing of familial Alzheimer’s disease presenilin 2 on abeta42 amyloid
peptide formation. J. Biol. Chem. 274, 35233–35239.
[33] Wolfe, M.S., Xia, W., Ostaszewski, B.L., Diehl, T.S., Kimberly, W.T. and Selkoe,
D.J. (1999) Two transmembrane aspartates in presenilin-1 required for
presenilin endoproteolysis and gamma-secretase activity. Nature 398, 513–
517.
[34] Li, J., Pauley, A.M., Myers, R.L., Shuang, R., Brashler, J.R., Yan, R., Buhl, A.E.,
Ruble, C. and Gurney, M.E. (2002) SEL-10 interacts with presenilin 1, facilitates
its ubiquitination, and alters A-beta peptide production. J. Neurochem. 82,
1540–1548.
[35] Powell, J.C., Twomey, C., Jain, R. and McCarthy, J.V. (2009) Association between
presenilin-1 and TRAF6 modulates regulated intramembrane proteolysis of
the p75NTR neurotrophin receptor. J. Neurochem. 108, 216–230.
[36] Elzinga, B.M., Twomey, C., Powell, J.C., Harte, F. and McCarthy, J.V. (2009)
Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent
regulated intramembrane proteolysis. J. Biol. Chem. 284, 1394–1409.
[37] Wooten, M.W., Geetha, T., Seibenhener, M.L., Babu, J.R., Diaz-Meco, M.T. and
Moscat, J. (2005) The p62 scaffold regulates nerve growth factor-induced NF-
kappaB activation by influencing TRAF6 polyubiquitination. J. Biol. Chem. 280,
35625–35629.
[38] Mumm, J.S., Schroeter, E.H., Saxena, M.T., Griesemer, A., Tian, X., Pan, D.J., Ray,
W.J. and Kopan, R. (2000) A ligand-induced extracellular cleavage regulates
gamma-secretase-like proteolytic activation of Notch1. Mol. Cell 5, 197–206.
[39] Kirschenbaum, F., Hsu, S.C., Cordell, B. and McCarthy, J.V. (2001) Glycogen
synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels. J.
Biol. Chem. 276, 30701–30707.
[40] Jagoe, W.N., Jackson, S.R., Lindsay, A.J., McCaffrey, M.W. and Khan, A.R. (2006)
Purification, crystallization and preliminary X-ray diffraction studies of Rab11
in complex with Rab11-FIP2. Acta Crystallogr. F Struct. Biol. Cryst. Commun.
62, 692–694.
[41] Cole, C., Barber, J.D. and Barton, G.J. (2008) The Jpred 3 secondary structure
prediction server. Nucleic Acids Res. 36, W197–201.
[42] Seibenhener, M.L., Babu, J.R., Geetha, T., Wong, H.C., Krishna, N.R. and Wooten,
M.W. (2004) Sequestosome 1/p62 is a polyubiquitin chain binding protein
involved in ubiquitin proteasome degradation. Mol. Cell. Biol. 24, 8055–8068.
[43] Prag, G., Misra, S., Jones, E.A., Ghirlando, R., Davies, B.A., Horazdovsky, B.F. and
Hurley, J.H. (2003) Mechanism of ubiquitin recognition by the CUE domain of
Vps9p. Cell 113, 609–620.
[44] Kang, E.L., Cameron, A.N., Piazza, F., Walker, K.R. and Tesco, G. (2010) Ubiquitin
regulates GGA3-mediated degradation of BACE1. J. Biol. Chem. 285, 24108–
24119.
[45] Thinakaran, G., Borchelt, D.R., Lee, M.K., Slunt, H.H., Spitzer, L., Kim, G.,
Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A.I.,
Gandy, S.E., Jenkins, N.A., Copeland, N.G., Price, D.L. and Sisodia, S.S. (1996)
Endoproteolysis of presenilin 1 and accumulation of processed derivatives
in vivo. Neuron 17, 181–190.
[46] McCarthy, J.V., Twomey, C. and Wujek, P. (2009) Presenilin-dependent
regulated intramembrane proteolysis and gamma-secretase activity. Cell.
Mol. Life Sci. 66, 1534–1555.
[47] Twomey, C. and McCarthy, J.V. (2006) Presenilin-1 is an unprimed glycogen
synthase kinase-3beta substrate. FEBS Lett. 580, 4015–4020.
[48] Kirschenbaum, F., Hsu, S.C., Cordell, B. and McCarthy, J.V. (2001) Substitution
of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1
separates presenilin function from beta-catenin signaling. J. Biol. Chem. 276,
7366–7375.
[49] Zhang, X., Li, Y., Xu, H. and Zhang, Y.W. (2014) The gamma-secretase complex:
from structure to function. Front. Cell. Neurosci. 8, 427.
1008 S.P. Duggan et al. / FEBS Letters 589 (2015) 1001–1008
